<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput xmlns:ns2="local"><serviceExecutionTime>403</serviceExecutionTime><Trial id="103687"><TitleDisplay>Safety Study of Endobronchial Transplantation of Autologous Mesenchymal Stem Cells (MSCs) in Emphysema Patients</TitleDisplay><TitleOfficial>Safety Study of Endobronchial Transplantation of Autologous Mesenchymal Stem Cells Derived Bone Marrow in Patients With Emphysema</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">f-91-135</Identifier><Identifier type="NCT">NCT01758055</Identifier></Identifiers><Indications><Indication id="111">Emphysema</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="213" role="Therapeutic effect marker" type="Biochemical">Creatinine</BiomarkerName><BiomarkerName id="1211" role="Therapeutic effect marker" type="Genomic;Proteomic">Alanine transaminase</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="1912" role="Therapeutic effect marker" type="Physiological">Forced Vital Capacity</BiomarkerName><BiomarkerName id="1913" role="Therapeutic effect marker" type="Physiological">Arterial oxygen saturation</BiomarkerName><BiomarkerName id="2358" role="Therapeutic effect marker" type="Biochemical">Urea nitrogen</BiomarkerName><BiomarkerName id="2527" role="Therapeutic effect marker" type="Genomic;Proteomic">Aspartate aminotransferase</BiomarkerName><BiomarkerName id="2689" role="Therapeutic effect marker" type="Physiological">Partial pressure of oxygen</BiomarkerName><BiomarkerName id="2699" role="Therapeutic effect marker" type="Physiological">Partial pressure of carbon dioxide</BiomarkerName><BiomarkerName id="2713" role="Therapeutic effect marker" type="Physiological">Forced expiratory volume</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Autologous mesenchymal stem cells</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1041557" type="Company"><TargetEntity id="5035563982" type="organizationId">Royan Institute</TargetEntity></SourceEntity><SourceEntity id="1061107" type="Company"><TargetEntity id="5035552918" type="organizationId">Shahid Beheshti University</TargetEntity></SourceEntity><SourceEntity id="1072869" type="Company"><TargetEntity id="5037843962" type="organizationId">Masih Daneshvari Hospital</TargetEntity></SourceEntity><SourceEntity id="111" type="ciIndication"><TargetEntity id="J43" type="ICD10"></TargetEntity><TargetEntity id="492" type="ICD9"></TargetEntity><TargetEntity id="10014561" type="MEDDRA"></TargetEntity><TargetEntity id="D004646" type="MeSH"></TargetEntity><TargetEntity id="-1329111132" type="omicsDisease"></TargetEntity><TargetEntity id="282" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1061107">Shahid Beheshti University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1041557">Royan Institute</Company><Company id="1072869">Masih Daneshvari Hospital</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>12</PatientCountEnrollment><DateStart>2012-12-31T00:00:00Z</DateStart><DateEnd type="estimated">2014-01-31T00:00:00Z</DateEnd><DateChangeLast>2013-09-25T10:23:49Z</DateChangeLast><DateAdded>2013-01-08T12:54:21Z</DateAdded><Contacts><Contact type="Public contact"><Email>Kiani@nritld.ac.ir</Email><Name>Arda Kiani, MD,PULMONO</Name><Phone>0098-021-27122171</Phone></Contact><Contact type="Public contact"><Email>nasser.aghdami@royaninstitute.org</Email><Name>Naser Aghdami, MD, PHD</Name><Phone>0098-021-22172330</Phone></Contact><Contact type="Scientific contact"><Affiliation>Tracheal Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation><Name>Arda Kiani, MD, pulmono</Name></Contact><Contact type="Scientific contact"><Affiliation>Department of Regenerative Biomedicine and cell therapy,Cell science Research Center,Royan Institute for Stem Cell Biology and Technology,ACER,Tehran,Iran</Affiliation><Name>Naser Aghdami, MD,PHD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with moderate to severe emphysema that has a FEV1&amp;lt;/= 50% (approved by
                  HRCT)&lt;/li&gt;&lt;li&gt;Aged&amp;lt; 70 years
&lt;/li&gt;&lt;li&gt;No tobacco use for at least 12 months before the protocol application&lt;/li&gt;&lt;li&gt;No serious coronaropathy and/or ventricular dysfunction&lt;/li&gt;&lt;li&gt;No significant renal illness and/or hepatitis&lt;/li&gt;&lt;li&gt;EF(ejection fraction)&amp;gt; 50%
&lt;/li&gt;&lt;li&gt;Creatinine&amp;lt; 2
&lt;/li&gt;&lt;li&gt;AST, ALT&amp;lt;/= 10 times of its normal basis
&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Detected immunosuppressive illnesses&lt;/li&gt;&lt;li&gt;Carrier of known neoplasias&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Limitation in daily physical activities&lt;/li&gt;&lt;li&gt;Known case of diabetic disorders&lt;/li&gt;&lt;li&gt;Modifying in his/her medical treatment regime in the past year&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Forced vital capacity (FVC), forced expiratory volume (FEV1), FEV1/FVC: a pulmonary function test that measures the volume and speed of inhaled air. A pulmonary function test that measures the volume and speed of exhaled air</Description><Timeframe>Baseline and one year after procedure</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>6 min walk test: a 6 min walk test with treadmills</Description><Timeframe>Baseline and one year after procedure</Timeframe></Measure><Measure><Description>Oxygen saturation: an oximeter test for evaluating the oxygen saturation</Description><Timeframe>Baseline and one year after procedure</Timeframe></Measure><Measure><Description>Quality of life: a SF36 quality of life questioner for evaluating the quality of life</Description><Timeframe>Baseline and one year after procedure</Timeframe></Measure><Measure><Description>DLCO (diffusion capacity of lung for carbon monoxide): body box device for evaluating diffusing capacity of the lung for carbon monoxide</Description><Timeframe>Baseline and one year after procedure</Timeframe></Measure><Measure><Description>CT scan: a CT scan for evaluating the changes</Description><Timeframe>Baseline and one year after procedure</Timeframe></Measure><Measure><Description>Dyspnea score: a MMRC (modified medical research council) scale for evaluating the dyspnea score</Description><Timeframe>Baseline and one year after procedure</Timeframe></Measure><Measure><Description>Atrial blood gases test-PaO2 (partial pressure of oxygen in blood), PaCO2 (partial pressure of carbon dioxide in blood): presence of oxygen in blood gases, presence of carbon dioxide in blood gases</Description><Timeframe>Baseline and one year after procedure</Timeframe></Measure><Measure><Description>Infection: a CBC test for evaluating the infection</Description><Timeframe>Baseline and one year after procedure</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to evaluate the safety of endobronchial transplantation of
      autologous mesenchymal stem cells derived bone marrow  in patients with emphysema.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this clinical trial, patients will be taken to the operating room, placed in a prone position and administered a spinal anesthesia. Approximately, 120 ml of bone marrow will be aspirated from each puncture and after preparation about 60 million autologous mesenchymal stem cells will be transplanted by bronchoscopy into the endobronchial of these patients. Patients will be administered with intrabronchial injection  of autologous mesenchymal stem cells at a dose of 60 million cells.&lt;br/&gt;&lt;/para&gt;&lt;para&gt;Â &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Masih-Daneshvari Hospital</Name><Address1>Tehran</Address1><Address3>021</Address3><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>KIANI@NRITLD.AC.IR</Email><Name>ARDA KIANI, MD,PULMONO</Name><Phone>0098-021-27122171</Phone></Contact><Contact type="Facility contact backup"><Email>PARITASH_T@YAHOO.COM</Email><Name>PARITASH TAHMASEB POUR, MD</Name><Phone>0098-09125037861</Phone></Contact><Contact type="Facility investigator"><Name>Paritash Tahmaseb pour, MD</Name></Contact><Contact type="Facility investigator"><Name>Hoda Madani, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Chronic obstructive pulmonary disease</Disease><PatientSegments><PatientSegment><PatientSegment id="554">Subjects with Emphysema</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Stem cell transplantation</Disease><PatientSegments><PatientSegment><PatientSegment id="10729">Subjects with comorbid conditions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01758055</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="4288"><Endpoint>Assessment of Forced Vital Capacity (FVC)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Stem cell transplantation" id="17451"><Endpoint>Assessment of Pulmonary Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4501"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4502">Six-minute walk test (6MWT)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stem cell transplantation" id="17451"><Endpoint>Assessment of Pulmonary Function</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Chronic obstructive pulmonary disease" id="4336"><Endpoint>Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4337">Assessment of partial pressure of O2(PaO2) </SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4338">Partial pressure of carbon dioxide (PaCO2)</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4344">Assessment of oxygen saturation (SaO2/SpO2)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Chronic obstructive pulmonary disease" id="4409"><Endpoint>Imaging/Radiological Assessments</Endpoint></OtherEndpoint><OtherEndpoint disease="Chronic obstructive pulmonary disease" id="4432"><Endpoint>Assessment of Dyspnea</Endpoint></OtherEndpoint><OtherEndpoint disease="Chronic obstructive pulmonary disease" id="4437"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="30222">Assessment of quality of life</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Chronic obstructive pulmonary disease" id="4483"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Chronic obstructive pulmonary disease" id="4604"><Endpoint>Assessment of Pulmonary Function</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4357">Carbon monoxide diffusing capacity (DLCO)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Stem cell transplantation" id="17422"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Stem cell transplantation" id="17431">Assessment by imaging techniques</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Stem cell transplantation" id="17443"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Stem cell transplantation" id="17446">Assessment by SF-36/SF-12</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Stem cell transplantation" id="17451"><Endpoint>Assessment of Pulmonary Function</Endpoint></OtherEndpoint><OtherEndpoint disease="Stem cell transplantation" id="17460"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Stem cell transplantation" id="17463">Assessment of infections</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Chronic obstructive pulmonary disease" id="2060"><Criterion>Subjects with Diagnosis of COPD</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="2061">Subjects with emphysema</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stem cell transplantation" id="17877"><Criterion>Subjects with Systemic Disorders Indicated for SCT</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="17882">Subjects with pulmonary diseases/disorders indicated for SCT</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stem cell transplantation" id="32562"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="17932">Subjects with normal/acceptable cardiac function</SubCriterion><SubCriterion disease="Stem cell transplantation" id="17934">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stem cell transplantation" id="33969"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="17933">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Chronic obstructive pulmonary disease" id="3076"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3093"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3095"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3111"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3239"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Stem cell transplantation" id="15721"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Stem cell transplantation" id="15729"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="20272"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2013-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2012-11-18T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-01-08T12:54:21Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="119156"><TitleDisplay>The bronchodilator effect of ultrafine particles of salbutamol</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN89168782</Identifier><Identifier type="Secondary Organisational">N0265126517</Identifier></Identifiers><Indications><Indication id="31">Asthma</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>salbutamol</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1036776" type="Company"><TargetEntity id="5001408738" type="organizationId">University Hospitals Birmingham NHS Foundation Trust</TargetEntity></SourceEntity><SourceEntity id="1081323" type="Company"><TargetEntity id="4298440772" type="organizationId">Department Of Health</TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1036776">University Hospital Birmingham NHS Foundation Trust</Company><Company id="1081323">Department of Health</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>8</PatientCountEnrollment><DateStart>2003-09-05T00:00:00Z</DateStart><DateEnd type="estimated">2004-09-05T00:00:00Z</DateEnd><DateChangeLast>2015-03-19T06:39:56Z</DateChangeLast><DateAdded>2013-04-05T11:26:29Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Respiratory MedicineSelly Oak Hospital, Birmingham, B29 6JD, United Kingdom</Affiliation><Name>W. Tunnicliffe</Name><Phone>44 (0)121 627 1627</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Aged 18 years or older&lt;/li&gt;&lt;li&gt;The presence of mild to moderate asthma&lt;/li&gt;&lt;li&gt;Willingness and ability to give written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;The use of&amp;gt; 1000 microg beclomethasone (or equivalent) per day&lt;/li&gt;&lt;li&gt;Unstable asthma&lt;/li&gt;&lt;li&gt;Inability or unwillingness to discontinue long acting and oral bronchodilators for 24 h, and all short acting bronchodilators for 4 h prior to each study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this double-blind, randomized,  placebo-controlled  study was to prove whether ultrafine particles of inhaled salbutamol generated from a standard nebulized dose (2.5 mg) could cause measurable bronchodilation in patients with asthma.	This was a accumulative dose response study based on the hypothesis that wether ultrafine particles of inhaled salbutamol generated from a standard nebulised dose (2.5 mg) would cause measurable bronchodilation in patients with asthma [&lt;ulink linkType="Reference" linkID="1399323"&gt;1399323&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients (n = 8) would be randomized to receive either	standard nebulized dose (2.5 mg) of 	ultrafine particles of  salbutamol to be inhaled or a placebo of ultrafine particles of 0.9% saline, generated in an identical way to the active (salbutamol) aerosol [&lt;ulink linkType="Reference" linkID="1399323"&gt;1399323&lt;/ulink&gt;].Â &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Contacts></Contacts></Site><Site><Name>Addenbrooke s Hospital</Name><Address1>Cambridge</Address1><Address3> CB2 0QQ</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Asthma</Disease><PatientSegments><PatientSegment><PatientSegment id="11959">Subjects with Persistent Asthma</PatientSegment><SubSegments><SubSegment id="11960">Subjects with mild persistent asthma</SubSegment><SubSegment id="11961">Subjects with moderate persistent asthma</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN89168782</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Asthma" id="6074"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Asthma" id="6078">Efficacy</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Asthma" id="22363"><Criterion>Subjects with Persistent Asthma</Criterion><SubCriteria><SubCriterion disease="Asthma" id="22364">Subjects with mild persistent asthma</SubCriterion><SubCriterion disease="Asthma" id="22365">Subjects with moderate persistent asthma</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Asthma" id="3832"><Criterion>Subjects with specific disease</Criterion></Exclusion><Exclusion disease="Asthma" id="20248"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Asthma" id="20249">Subjects with history of/scheduled for asthma drugs</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-05T11:26:29Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="123218"><TitleDisplay>Prospective Clinical Study of the Therapeutic Effects of Prostaglandin in Patients With Combined Lumbar Spinal Stenosis and Arteriosclerosis Obliterans Showing Intermittent Claudication</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000005959</Identifier></Identifiers><Indications><Indication id="3137">Spinal stenosis</Indication><Indication id="540">Arteriosclerosis</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>alprostadil (penile injection), Pfizer</Name><Drug id="2485">alprostadil (penile injection), Pfizer</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2485">alprostadil (penile injection), Pfizer</Drug><IndicationsPioneer><Indication id="3137">Spinal stenosis</Indication><Indication id="540">Arteriosclerosis</Indication></IndicationsPioneer><Companies><Company><Company id="21273">Tokai University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2485" type="Drug"><TargetEntity id="91363" type="siDrug">Alprostadil</TargetEntity></SourceEntity><SourceEntity id="21273" type="Company"><TargetEntity id="5035523932" type="organizationId">Tokai University</TargetEntity></SourceEntity><SourceEntity id="3137" type="ciIndication"><TargetEntity id="M48.0" type="ICD10"></TargetEntity><TargetEntity id="10041540" type="MEDDRA"></TargetEntity><TargetEntity id="D013130" type="MeSH"></TargetEntity><TargetEntity id="-286867296" type="omicsDisease"></TargetEntity><TargetEntity id="1177" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="540" type="ciIndication"><TargetEntity id="10003210" type="MEDDRA"></TargetEntity><TargetEntity id="D001161" type="MeSH"></TargetEntity><TargetEntity id="-1473236367" type="omicsDisease"></TargetEntity><TargetEntity id="207" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21273">Tokai University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="321">PGE1 agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="312">Platelet aggregation inhibitor</Class><Class id="388">Vasodilator</Class></Class><Technologies><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="596">Injectable formulation</Technology><Technology id="764">Local formulation unspecified</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>300</PatientCountEnrollment><DateStart>2010-11-01T00:00:00Z</DateStart><DateChangeLast>2014-01-02T10:28:46Z</DateChangeLast><DateAdded>2013-04-26T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Tokai University School of Medicine, Department of Orthopaedic Surgery;  143,Shimokasuya,Isehara,Kanagawa,259-1193,Japan</Affiliation><Email>sato-m@is.icc.u-tokai.ac.jp</Email><Name>Masato Sato</Name><Phone>0463-93-1121</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;The subjects are patients who meet all of the following inclusion criteria and are able to provide informed consent:&lt;ul&gt;&lt;li&gt;Male and female patients aged 20 years or older&lt;/li&gt;&lt;li&gt;Patients who are diagnosed with lumbar spinal stenosis based on X-ray and MRI findings and are undergoing conservative treatment&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients who are diagnosed with arteriosclerosis obliterans (peripheral arterial disease) Fontaine classification I or II&lt;/li&gt;&lt;li&gt;Patients who understand the objectives of this study and provide informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who have ethical difficulties due to special consideration required for them or their family&lt;/li&gt;&lt;li&gt;Patients with diabetes, chronic renal failure, etc, who are suspected to have a complication of peripheral nerve disorder or circulatory disorder&lt;/li&gt;&lt;li&gt;Patients who are receiving administration of anticoagulant, etc&lt;/li&gt;&lt;li&gt;Patients who have a history of surgical treatment for the spine/spinal cord&lt;/li&gt;&lt;li&gt;Patients who have problematic infection&lt;/li&gt;&lt;li&gt;Patients who do not understand the objectives of this study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The Japanese Orthopaedic Association (JOA) score</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Age, sex, affected period, biochemical examination of blood, details of treatment (number and frequency of infusions, concomitant drug therapy, block therapy, and other conservative therapies)</Description></Measure><Measure><Description>SF-36</Description></Measure><Measure><Description>VAS</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial was  to evaluate the therapeutic effects of prostaglandin (&lt;ulink linkType="Drug" linkID="2485"&gt;alprostadil&lt;/ulink&gt;) from the viewpoint of administration method and duration by administering the drug to patients with combined lumbar spinal stenosis and arteriosclerosis obliterans (peripheral arterial disease) who exhibit intermittent claudication, which tends to increase in aging society [&lt;ulink linkType="Reference" linkID="1407826"&gt;1407826&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would consist of three arms.&lt;br/&gt;Arm 1: patients would receive prostaglandin for injection (&lt;ulink linkType="Drug" linkID="2485"&gt;alprostadil&lt;/ulink&gt;),  60 microg, iv, once a week or more. This therapy would be  repeated ten times or more.  &lt;br/&gt;Arm 2:  patients would receive ripple injection (&lt;ulink linkType="Drug" linkID="2485"&gt;alprostadil&lt;/ulink&gt; injection) 10 microg, iv  once a week or more. This treatment would be repeated ten times or more.&lt;br/&gt;Arm 3:   patients would receive conventional treatment  [&lt;ulink linkType="Reference" linkID="1407826"&gt;1407826&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Peripheral vascular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="10141">Subjects with Intermittent Claudication</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000005959</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Peripheral vascular disease" id="21783"><Endpoint>Clinical Evaluation of Treated Ischemic Leg</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Peripheral vascular disease" id="21800"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="26275">Assessment by Short Form Health Survey (SF-36)</SubEndpoint><SubEndpoint disease="Peripheral vascular disease" id="26295">Pain scores</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Peripheral vascular disease" id="19212"><Criterion>Subjects with Inclusion Based On Rutherford"s Classification</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19215">Subjects with rutherford 1-3</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peripheral vascular disease" id="19226"><Criterion>Subjects with Inclusion Based On Location/Anatomy of Vessel</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19232">Stenosis/Occlusion of the artery/lesion</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Peripheral vascular disease" id="15458"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="15980"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="15981"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="15986"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15987">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="16021"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16026">Subjects with history of anticoagulant medications</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="135762"><TitleDisplay>Efficacy of Human Atrial Natriuretic Peptide for the Patients with Severe Sepsis: Impact on Prevention against Acute Kidney Injury</TitleDisplay><TitleOfficial>Efficacy of human atrial natriuretic peptide for the patients with severe sepsis; Impact on prevention against acute kidney injury</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000003821</Identifier></Identifiers><Indications><Indication id="114">Sepsis</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>human atrial natriuretic peptide (hANP)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1084263" type="Company"><TargetEntity id="5039931473" type="organizationId">Tosei General Hospital</TargetEntity></SourceEntity><SourceEntity id="114" type="ciIndication"><TargetEntity id="10040047" type="MEDDRA"></TargetEntity><TargetEntity id="D018805" type="MeSH"></TargetEntity><TargetEntity id="-200243460" type="omicsDisease"></TargetEntity><TargetEntity id="953" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1084263">Tosei General Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2010-06-01T00:00:00Z</DateStart><DateChangeLast>2018-10-13T03:02:00Z</DateChangeLast><DateAdded>2013-05-30T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Tosei General Hospital Department of Emergency and Intensive Care Medicine , 160 Nishioiwake-cho, Seto, Aichi, 489-8642, Japan</Affiliation><Name>Ryuichi Hasegawa</Name></Contact><Contact type="Public contact"><Affiliation>Tosei General Hospital, Department of Emergency and Intensive Care Medicine; 160 Nishioiwake-cho, Seto, Aichi, 489-8642, Japan</Affiliation><Email>niwatake1227@yahoo.co.jp</Email><Name>Takehiro Niwa</Name><Phone>+81-561-82-5101</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age older 16 years and the presence of severe sepsis or septic shock&lt;/li&gt;&lt;li&gt;Patients who have renal failure according to RIFLE category or are dependent on mechanical ventilation including non-invasive ventilation, are enrolled&lt;/li&gt;&lt;li&gt;All patients are needed to have written informed consent before enrolment in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients are excluded:&lt;ul&gt;&lt;li&gt;If they have already introduced maintenance HD before admission&lt;/li&gt;&lt;li&gt;Have got abdominal surgery for perforation of digestive tract&lt;/li&gt;&lt;li&gt;Have fallen in sepsis for &gt; 48 h before the start of antibiotic therapy&lt;/li&gt;&lt;li&gt;Can't get out of septic shock within 72 h after the start of antibiotic therapy&lt;/li&gt;&lt;li&gt;Have severe chronic heart failure as NYHA III or IV&lt;/li&gt;&lt;li&gt;Known pregnancy&lt;/li&gt;&lt;li&gt;Expected stay in the intensive care unit of&amp;lt; 3 days&lt;/li&gt;&lt;li&gt;Poor chance of survival&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>A 30-day mortality</Description><Timeframe>30 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Renal function</Description></Measure><Measure><Description>Introduction of maintenance haemodialysis (HD)</Description></Measure><Measure><Description>Ventilator free days</Description></Measure><Measure><Description>A 90-day mortality</Description><Timeframe>90 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial was  to examine the efficacy of human atrial natriuretic peptide (hANP) in mortality and renal function for the patients with severe sepsis [&lt;ulink linkType="Reference" linkID="1430563"&gt;1430563&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be randomly assigned to receive hANP or distilled water (placebo) for continuous infusion. HANP would be started if catecholamine index was &amp;lt; 50 and mean arterial pressure keeps &amp;gt; 65 mmHg without vasopressin. HANP would be administered 1000 to 4000 microg/day as much as possible. In addition, hANP would be administered until patients were discharged from ICU or for 14 days in ICU stay  [&lt;ulink linkType="Reference" linkID="1430563"&gt;1430563&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Renal failure</Disease><PatientSegments><PatientSegment><PatientSegment id="8107">Subjects with Prerenal Causes for Acute Renal Failure(ARF)</PatientSegment><SubSegments><SubSegment id="8110">Subjects with infections</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11494">Subjects with Acute Renal Failure(ARF)</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Sepsis</Disease><PatientSegments><PatientSegment><PatientSegment id="10568">Subjects with Sepsis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10573">Subjects with Severe Sepsis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10579">Subjects with Septic Shock</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000003821</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Sepsis" id="16033"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Renal failure" id="23008"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Sepsis" id="16016"><Endpoint>Assessment of Disease Progression</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Sepsis" id="16032"><Endpoint>Assessment of Morbidity</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Sepsis" id="16033"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Sepsis" id="16042"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Sepsis" id="16041">Renal function tests</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Renal failure" id="22985"><Endpoint>Assessment of Renal Replacement Therapy(RRT)</Endpoint><SubEndpoints><SubEndpoint disease="Renal failure" id="22986">Assessment of filtration/dialysis</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Sepsis" id="14997"><Criterion>Subjects with Sepsis</Criterion></Inclusion><Inclusion disease="Sepsis" id="15003"><Criterion>Subjects with Severe Sepsis</Criterion><SubCriteria><SubCriterion disease="Sepsis" id="15006">Subjects with renal dysfunction</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Sepsis" id="15009"><Criterion>Subjects with Septic Shock</Criterion></Inclusion><Inclusion disease="Renal failure" id="20154"><Criterion>Subjects with Prerenal Causes for Acute Renal Failure(ARF)</Criterion><SubCriteria><SubCriterion disease="Renal failure" id="20156">Subjects with sepsis/infection</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Renal failure" id="20175"><Criterion>Subjects with Acute Renal Failure(ARF)</Criterion></Inclusion><Inclusion disease="Renal failure" id="20190"><Criterion>Hospitalized/ICU Subjects</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Sepsis" id="12404"><Criterion>Subjects with Sepsis</Criterion><SubCriteria><SubCriterion disease="Sepsis" id="12409">Subjects with septic shock</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Sepsis" id="12411"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Sepsis" id="12418"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Sepsis" id="12421">Surgical subjects</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Sepsis" id="12425"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Renal failure" id="17906"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Renal failure" id="17908"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Renal failure" id="17918"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Renal failure" id="17920">Subjects co-morbid with sepsis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Renal failure" id="17939"><Criterion>Subjects with History of Renal Replacement Therapy(RRT)</Criterion><SubCriteria><SubCriterion disease="Renal failure" id="17940">Subjects with history of/scheduled for dialysis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Renal failure" id="17947"><Criterion>Subjects with History Other Surgery</Criterion></Exclusion><Exclusion disease="Renal failure" id="17950"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-05-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="136383"><TitleDisplay>HD13 for Early Stage Hodgkin's Disease: Quality Assurance Protocol for Reduction of Toxicity in the First-line Treatment of Early Stage Hodgkin's Disease (HD)</TitleDisplay><TitleOfficial>HD13 for Early Stage Hodgkin's Disease: Quality Assurance Protocol for Reduction of Toxicity in the First-line Treatment of Early Stage Hodgkin's Disease (HD)</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN63474366</Identifier><Identifier type="Trial Acronym">HD13</Identifier></Identifiers><Indications><Indication id="161">Hodgkins disease</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Involved field radiotherapy (IF-RT) 30 Gy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>bleomycin</Name></Intervention><Intervention type="InterventionPrimary"><Name>dacarbazine</Name></Intervention><Intervention type="InterventionPrimary"><Name>doxorubicin</Name></Intervention><Intervention type="InterventionPrimary"><Name>vinblastine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1041768" type="Company"><TargetEntity id="5035543999" type="organizationId">Deutsche Krebshilfe eV</TargetEntity></SourceEntity><SourceEntity id="1049527" type="Company"><TargetEntity id="5035547700" type="organizationId">German Hodgkins Lymphoma Study Group</TargetEntity></SourceEntity><SourceEntity id="161" type="ciIndication"><TargetEntity id="C81" type="ICD10"></TargetEntity><TargetEntity id="201" type="ICD9"></TargetEntity><TargetEntity id="10020206" type="MEDDRA"></TargetEntity><TargetEntity id="D006689" type="MeSH"></TargetEntity><TargetEntity id="98293" type="ORPHANET"></TargetEntity><TargetEntity id="-1008729809" type="omicsDisease"></TargetEntity><TargetEntity id="701" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1049527">German Hodgkin's Lymphoma Study Group</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1041768">Deutsche Krebshilfe eV</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>1250</PatientCountEnrollment><PatientCountEvaluable>1502</PatientCountEvaluable><DateStart>2003-01-01T00:00:00Z</DateStart><DateEnd type="actual">2008-01-01T00:00:00Z</DateEnd><DateChangeLast>2018-11-08T07:46:11Z</DateChangeLast><DateAdded>2013-06-04T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>German Hodgkins Lymphoma Study Group,Herderstr. 52-54, Cologne, 50924, Germany</Affiliation><Email>dhsg@biometrie.uni-koeln.de</Email><Name>Volker Diehl</Name><Phone>49 (0)221 478-3557 (-3558)</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Histologically confirmed Hodgkin's disease&lt;/li&gt;&lt;li&gt;Stages IA (not lympocyte predominant HD), IB, IIA, and IIB without the following risk factors:&lt;ul&gt;&lt;li&gt;Massive mediastinal involvement (tumor one third or more of the maximum intrathoracic diameter&lt;/li&gt;&lt;li&gt;Extranodal involvement&lt;/li&gt;&lt;li&gt;High Erythrocyte Sedimentation Rate (ESR) (&gt;/= 50 mm; &gt;/=  30 mm with B symptoms)&lt;/li&gt;&lt;li&gt;Three or more involved lymph node areas&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;No prior therapy for Hodgkin's disease&lt;/li&gt;&lt;li&gt;Aged 18  to  75 years&lt;/li&gt;&lt;li&gt;No major organ dysfunction&lt;/li&gt;&lt;li&gt;Life expectancy &gt; 3 months&lt;/li&gt;&lt;li&gt;Written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Incomplete staging&lt;/li&gt;&lt;li&gt;Major organ dysfunction (Chronic Obstructive Pulmonary Disease [COPD] with respiratory insufficiency, symptomatic Coronary Heart Disease [CHD], cardiomyopathy or heart failure [ejection fraction &amp;lt;  50%], severe hypertension, non-treatable infections, white blood count &amp;lt;   3000/mm(3) or platelets &amp;lt; 100,000/mm(3), creatinine clearance &amp;lt; 60 ml/min, bilirubin &gt; 2 mg/dl, Glutamic-Oxaloacetic Transaminase [GOT]/aspartate aminotransferase [AST] &gt; 100 U/l, Glutamic-Pyruvic Transaminase [GPT]/alanine aminotransferase [ALT] &gt;  100 U/l, Human Immunodeficiency Virus [HIV]-infection)&lt;/li&gt;&lt;li&gt;Composite lymphoma&lt;/li&gt;&lt;li&gt;Prior chemotherapy or radiotherapy&lt;/li&gt;&lt;li&gt;Any history of another malignancy in the last five years (except for cervical carcinoma in situ and fully resected melanoma TNMpT1)&lt;/li&gt;&lt;li&gt;Pregnancy or breastfeeding&lt;/li&gt;&lt;li&gt;World Health Organization (WHO) performance status &gt; 2&lt;/li&gt;&lt;li&gt;Long term use of corticosteroids (eg,  for arthritis) or antineoplastic substances (eg,  methotrexate)&lt;/li&gt;&lt;li&gt;Expected non compliance&lt;/li&gt;&lt;li&gt;Current therapy for epilepsy&lt;/li&gt;&lt;li&gt;Intolerabilities against study drugs&lt;/li&gt;&lt;li&gt;Inability to give truly informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Freedom From Treatment Failure (FFTF)</Description></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In April 2015, results were published. Results showed that, compared with 28, 26 and 26% of patients in ABV, AVD and AV groups, respectively, 33% of the patients in ABVD group had WHO grade III or toxicity. The most common event was leucopenia, and was highest in the groups receiving bleomycin [&lt;ulink linkType="Reference" linkID="1652863"&gt;1652863&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, results were pooled results from &lt;ulink linkType="Protocol" linkID="139340"&gt;HD10&lt;/ulink&gt; and HD13 trials were published. Similar grade 3 to 4 adverse events were observed in patients receiving 2 x AVD and 2 x ABVD (40 and 39%, respectively), but considerably higher in patients receiving 4 x ABVD (65%). Bleomycin-induced lung toxicity occurred in 10% of patients randomized to 4 x ABVD, with three lethal events, but was rare in patients receiving 2 x ABVD/AVD [&lt;ulink linkType="Reference" linkID="1783691"&gt;1783691&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial was to study if there would be reduction of toxicity through de-escalation of chemotherapy while maintaining high freedom from treatment failure (FFTF) and overall survival rates [&lt;ulink linkType="Reference" linkID="1432781"&gt;1432781&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In April 2015, results were published. Results showed that, for ABVD, ABV, AVD, and AV, respectively, five-year FFTF were 3.1, 81.4, 89.2, and 77.1%, respectively. Compared with ABVD, inferiority of the dacarbazine-deleted variants was detected with five year differences of -11.5 and -15.2%   for ABV and  AV, respectively. Non-inferiority of AVD compared with ABVD could also not be detected (five year difference -3.9%, HR 1.50) [&lt;ulink linkType="Reference" linkID="1652863"&gt;1652863&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2018, pooled results of two studies (ISRCTN63474366 and &lt;ulink linkType="Protocol" linkID="154440"&gt;ISRCTN04761296&lt;/ulink&gt;) were published. The aim was to perform a risk factor analysis to focus on isolated nodal infradiaphragmatic disease in patients treated within the German Hodgkin Study Group trials. After a median follow-up time of 51 months, in patients with infradiaphragmatic disease, PFS and OS were significantly worseÂ (five year PFS and OS, 80.1 and 91.5 versus 91.2 and 97.6% in patients with supradiaphragmatic disease; each p &amp;lt; 0.001). In multivariable analyses,Â in terms of PFS and OS, Hodgkin lymphoma (HL) remained as a significant risk factor (hazard ratio [HR], 1.5 and 2.0;Â p = 0.03 and 0.01). However,Â among those patients treated with the more intensive chemotherapy, inferior PFS and OS could not be observed (two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine [ABVD] in HD13, and two cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone [BEACOPP escalated] plus two cycles of ABVD in HD14; all patients received 30 Gy of involved-field radiotherapy) [&lt;ulink linkType="Reference" linkID="2091337"&gt;2091337&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Th study design would consist of four treatment arms: &lt;br/&gt;Arm A:  patients would receive 2 x doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) and 30 Gray (Gy)  involved field radiotherapy (IF-RT).&lt;br/&gt;Arm B:  patients would receive  2 x doxorubicin, bleomycin, vinblastine (ABV) and 30 Gy IF-RT.&lt;br/&gt;Arm C:  patients would receive  2 x doxorubicin, vinblastine, dacarbazine (AVD) and 30 Gy IF-RT.&lt;br/&gt;Arm D: patients would receive 2 x doxorubicin, vinblastine (AV) and 30 Gy IF-RT [&lt;ulink linkType="Reference" linkID="1432781"&gt;1432781&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1545148"&gt;1545148&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized to receive ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine), ABV (doxorubicin, bleomycin, and vinblastine), AVD (doxorubicin, vinblastine, and dacarbazine), or AV (doxorubicin and vinblastine) [&lt;ulink linkType="Reference" linkID="1652863"&gt;1652863&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>German Hodgkin's Lymphoma Study Group</Name><Address1>Hamburg</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lymphoma</Disease><PatientSegments><PatientSegment><PatientSegment id="3467">Subjects with Hodgkin's Lymphoma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="23733">Subjects with specific Ann Arbor stage</PatientSegment><SubSegments><SubSegment id="3495">Subjects with Ann Arbor Stage I Lymphoma</SubSegment><SubSegment id="3496">Subjects with Ann Arbor Stage II Lymphoma</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN63474366</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lymphoma" id="7625"><Endpoint>Assessment of Clinical Response</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7630">Assessment of freedom from treatment failure</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lymphoma" id="3442"><Criterion>Subjects with Hodgkin's Lymphoma</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3469"><Criterion>Subjects with Specific (Ann Arbor) Stage of Lymphoma</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3470">Subjects with stage I lymphoma</SubCriterion><SubCriterion disease="Lymphoma" id="3471">Subjects with stage II lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3528"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3548"><Criterion>Subjects Diagnosed Based on Histo-Pathological Examination</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3621"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lymphoma" id="4668"><Criterion>Subjects with Specific (Ann Arbor) Stage of Lymphoma</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4681"><Criterion>Subjects with Lymphoma-Related Complications</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4686"><Criterion>Subjects with Other Lymphoid Malignancies</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4692"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4702"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4724"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4725">Subjects with specific ECOG/WHO/Zubrod performance status</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4729"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4733">Subjects with abnormal hematological tests</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4742"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4756">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4761"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4762">Subject with history of radiotherapy</SubCriterion><SubCriterion disease="Lymphoma" id="4769">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4810"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Lymphoma" id="6766"><Criterion>Lymphoma Subjects with Advanced Disease</Criterion></Exclusion><Exclusion disease="Lymphoma" id="26332"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4730">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Lymphoma" id="4731">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2008-11-01T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>70.03 Months</EnrollmentPeriod><EnrollmentRate>17.85 Patients/Month</EnrollmentRate><FundersType><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-06-04T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2016-05-26T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="137993"><TitleDisplay>Kumamoto-PrevEntioN cilosTazol Acute proGressiON Stroke</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000004016</Identifier></Identifiers><Indications><Indication id="65">Stroke</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>aspirin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>cilostazol</Name><Drug id="13482">cilostazol</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="13482">cilostazol</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1082911">The Clinical Research Promotion Foundation</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21328">Kumamoto University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="13482" type="Drug"><TargetEntity id="90133" type="siDrug">Cilostazol</TargetEntity></SourceEntity><SourceEntity id="1082911" type="Company"><TargetEntity id="5039708438" type="organizationId">Clinical Research Promotion Foundation</TargetEntity></SourceEntity><SourceEntity id="21328" type="Company"><TargetEntity id="4296761268" type="organizationId">Kumamoto University</TargetEntity></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"></TargetEntity><TargetEntity id="-1815339002" type="omicsDisease"></TargetEntity><TargetEntity id="93" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="302" type="Action"><TargetEntity id="469" type="Mechanism">Phosphodiesterase PDE3 Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21328">Kumamoto University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1082911">The Clinical Research Promotion Foundation</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="302">PDE 3 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="312">Platelet aggregation inhibitor</Class><Class id="388">Vasodilator</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="898">Formulation powder</Technology><Technology id="585">Oral formulation</Technology><Technology id="660">Oral sustained release formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2009-08-01T00:00:00Z</DateStart><DateChangeLast>2016-08-24T14:30:15Z</DateChangeLast><DateAdded>2013-06-07T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Kumamoto University, Department of Neurology;  1-1-1 Honjo, Kumamoto</Affiliation><Email>terry07@kumamoto-u.ac.jp</Email><Name>Teruyuki Hirano</Name><Phone>+81-96-373-5896</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Non-cardioembolic brain infarction&lt;/li&gt;&lt;li&gt;First or recurrent stroke&lt;/li&gt;&lt;li&gt;Within 48 h after the onset&lt;/li&gt;&lt;li&gt;Patients who develop symptoms within 48 h before starting the administration of the investigational drugs&lt;/li&gt;&lt;li&gt;Stable general condition&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Cardioembolic brain infarction&lt;/li&gt;&lt;li&gt;Contraindications to aspirin or&lt;ulink linkType="Drug" linkID="13482"&gt;cilostazol&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Patients with hemorrhagic disease&lt;/li&gt;&lt;li&gt;Patients with congestive heart failure&lt;/li&gt;&lt;li&gt;Patients known hypersensitivity to aspirin or&lt;ulink linkType="Drug" linkID="13482"&gt;cilostazol&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Patients with pregnancy or potential pregnancy&lt;/li&gt;&lt;li&gt;Patients with active peptic ulcer&lt;/li&gt;&lt;li&gt;Patients with aspirin-induced asthma&lt;/li&gt;&lt;li&gt;Low birth weight infant, newborn and infant&lt;/li&gt;&lt;li&gt;Patients who should be treated with rt-PA&lt;/li&gt;&lt;li&gt;Patient who is taking aspirin or&lt;ulink linkType="Drug" linkID="13482"&gt;cilostazol&lt;/ulink&gt; at the time of admission &lt;/li&gt;&lt;li&gt;Patients who are considered unsuitable for inclusion in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Incidence of the progressing stroke (worsening of the NIHSS score by 2 point or more)</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Proportion of the patients with mRS score 0, 1 or 2 at 3 months follow-up</Description></Measure><Measure><Description>Incidence of cardiovascular events</Description></Measure><Measure><Description>Incidence of adverse events (without hemorrhagic stroke)</Description></Measure><Measure><Description>Incidence of hemorrhagic adverse events</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study was to evaluate the efficacy and safety of aspirin versus &lt;ulink linkType="Drug" linkID="13482"&gt;cilostazol&lt;/ulink&gt; in the prevention of acute progressing stroke [&lt;ulink linkType="Reference" linkID="1435176"&gt;1435176&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive either aspirin or &lt;ulink linkType="Drug" linkID="13482"&gt;cilostazol&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1435176"&gt;1435176&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Stroke</Disease><PatientSegments><PatientSegment><PatientSegment id="11635">Subjects with First Stroke</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11637">Subjects with Other Types of Stroke</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000004016</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Stroke" id="24189"><Endpoint>Assessment of Stroke</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Stroke" id="24223"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="27540">Assessment by National Institute of Health Stroke Scale (NIHSS)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Stroke" id="24180"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stroke" id="24185"><Endpoint>Assessment of Cardiovascular Events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stroke" id="24197"><Endpoint>Assessment of Hemorrhagic Complications</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stroke" id="24223"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="24091">Assessment by Modified Rankin Scale (MRS) Score</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Stroke" id="20941"><Criterion>Subjects with Other Types of Stroke</Criterion><SubCriteria><SubCriterion disease="Stroke" id="20942">Subjects with first stroke</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stroke" id="20957"><Criterion>Inclusion Based on Time Post Stroke</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Stroke" id="18634"><Criterion>Subjects with Specified Type of Stroke</Criterion></Exclusion><Exclusion disease="Stroke" id="18664"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18665">Subjects co-morbid with asthma</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stroke" id="18679"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18680">Subjects co-morbid with peptic ulcer disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stroke" id="18681"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion><Exclusion disease="Stroke" id="18692"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Stroke" id="18693"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18694">Subjects with a history/current use of protocol prohibited anti-coagulants</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stroke" id="25988"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18653">Subjects co-morbid with heart failure</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-06-07T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="147338"><TitleDisplay>L-Thyroxine Augmentation of Serotonergic Antidepressants in Female Patients With Refractory Depression</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="93">Depression</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>L-thyroxin</Name></Intervention><Intervention type="InterventionPrimary"><Name>clomipramine</Name></Intervention><Intervention type="InterventionPrimary"><Name>fluoxetine hydrochloride</Name><Drug id="17558">fluoxetine hydrochloride</Drug></Intervention><Intervention type="InterventionPrimary"><Name>paroxetine hydrochloride</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="17558">fluoxetine hydrochloride</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1039575">Poznan University of Medical Sciences</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="17558" type="Drug"><TargetEntity id="131699" type="siDrug">Fluoxetine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1039575" type="Company"><TargetEntity id="4298452495" type="organizationId">Uniwersytet Medyczny im Karola Marcinkowskiego w Poznaniu</TargetEntity></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="D003863" type="MeSH"></TargetEntity><TargetEntity id="-508468160" type="omicsDisease"></TargetEntity><TargetEntity id="53" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1039575">Poznan University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="2941">Antidepressant</Class><Class id="2942">Anxiolytic</Class><Class id="3">5-HT uptake inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="641">Controlled release formulation</Technology><Technology id="590">Enteric coated formulation</Technology><Technology id="894">Liquid formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="742">Pellet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>17</PatientCountEnrollment><PatientCountEvaluable>17</PatientCountEvaluable><DateChangeLast>2014-01-24T11:59:02Z</DateChangeLast><DateAdded>2013-07-24T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Female patients with treatment-resistant depressive episode in the course of unipolar or bipolar mood disorder&lt;/li&gt;&lt;li&gt;Age 30 to 60 years&lt;/li&gt;&lt;li&gt;No history of thyroid axis disturbances&lt;/li&gt;&lt;li&gt;T3, T4, and thyroid-stimulating hormone (TSH) values within the normal range&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Efficacy</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this trial was to evaluate the efficacy of addition of moderate dose of L-thyroxine (T4) to serotonergic antidepressants in refractory depression [&lt;ulink linkType="Reference" linkID="1455868"&gt;1455868&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In November 2007, results were published. After 4 weeks of L-thyroxine augmentation, the remission, assessed as &amp;lt;/= 7  points on Hamilton Depression Rating Scale (HDRS) was observed in 11 patients (64.7%). A total of five other patients (29.5%) had responded (reduction &amp;gt; 50% on HDRS) and one patient did not show an improvement. The efficacy of augmentation was observed to not show any correlation with laboratory tests' results performed before (T3, T4, TSH and TSH stimulation test) as well as with any clinical factors (age, diagnosis, duration of illness, duration of episode)  [&lt;ulink linkType="Reference" linkID="1455868"&gt;1455868&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients (n = 17) on  serotonergic antidepressants (clomipramine [n =  11], paroxetine [n = 5], &lt;ulink linkType="Drug" linkID="17558"&gt;fluoxetine&lt;/ulink&gt;  [n = 1]) received    L-thyroxine (100 microm daily for 4 weeks) [&lt;ulink linkType="Reference" linkID="1455868"&gt;1455868&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Bipolar disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="7299">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms><SecondaryEndpoints><SecondaryEndpoint disease="Bipolar disorder" id="10031"><Endpoint>Assessment of Remission</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="10032">Assessment of remission rate</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Bipolar disorder" id="9921"><Endpoint>Assessment of Bipolar Disorder Symptoms</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9925">Assessment of time to new episode</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="9934"><Endpoint>Assessment of Depression Severity by Specific Criteria</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9940">Assessment by Hamilton Depression Rating Scale (HDRS)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10001"><Endpoint>Assessment of Co-morbidity</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9922">Assessment of depression</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10012"><Endpoint>Assessment of thyroid function</Endpoint></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10028"><Endpoint>Assessment of Response Rates (RR)</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Bipolar disorder" id="5787"><Criterion>Subjects with Bipolar Disorder</Criterion></Inclusion><Inclusion disease="Bipolar disorder" id="5822"><Criterion>Subjects co-morbid with psychiatric disease/disorders</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="5823">Subjects co-morbid with unipolar depression</SubCriterion><SubCriterion disease="Bipolar disorder" id="5824">Subjects with depressive disorders</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bipolar disorder" id="5851"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion></Inclusion><Inclusion disease="Bipolar disorder" id="5886"><Criterion>Subjects with Treatment Resistant Disease</Criterion></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-07-24T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="152049"><TitleDisplay>Evaluation of Translymphatic Chemotherapy Targeting Sentinel Lymph Nodes of Patients with Oral Cancer Using Intra-Arterial Chemotherapy</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000007038</Identifier></Identifiers><Indications><Indication id="793">Mouth tumor</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>cisplatin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="DOL1000061" type="Company"><TargetEntity id="4298184040" type="organizationId">Juntendo University</TargetEntity></SourceEntity><SourceEntity id="793" type="ciIndication"><TargetEntity id="10061325" type="MEDDRA"></TargetEntity><TargetEntity id="D009062" type="MeSH"></TargetEntity><TargetEntity id="-538098431" type="omicsDisease"></TargetEntity><TargetEntity id="625" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1084225">Juntendo University, Graduate School of Medicine</Company><Company id="DOL1000061">Juntendo University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>7</PatientCountEnrollment><PatientCountEvaluable>7</PatientCountEvaluable><DateStart>2011-05-01T00:00:00Z</DateStart><DateChangeLast>2014-02-19T11:16:29Z</DateChangeLast><DateAdded>2013-08-26T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Juntendo University school of medicine, Department of Otolaryngology, head and neck surgery; 2-1-1, Hongo, Bunkyou-ku, Tokyo Japan</Affiliation><Email>shin709@juntendo.ac.jp</Email><Name>Shin Ito</Name></Contact><Contact type="Public contact"><Affiliation>Juntendo University school of medicine, Department of Otolaryngology, head and neck surgery; 2-1-1, Hongo, Bunkyou-ku, Tokyo</Affiliation><Name>Junkichi Yokoyama</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Untreated oral squamous cell carcinoma (T2 orT3) patients with small neck metastasis (about 1 cm)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Distant metastasis&lt;/li&gt;&lt;li&gt;Previously treated patients&lt;/li&gt;&lt;li&gt;A history of radiation therapy for the neck&lt;/li&gt;&lt;li&gt;Pregnancy or lactating women or women with suspected pregnancy&lt;/li&gt;&lt;li&gt;Patients judged by the investigator to be unfit to be enrolled into the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Evaluate CDDP concentration in SNL</Description></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate the efficacy of translymphatic chemotherapy targeting sentinel lymph nodes (SNL) of patients with oral cancer using intra-arterial chemotherapy by measuring the cisplatin (CDDP) concentration in SNL [&lt;ulink linkType="Reference" linkID="1469380"&gt;1469380&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In September 2012, results were published. The mean CDDP concentrations in the metastasis and non-SLNs were 2.35 and 1.08 mg/g, respectively (p = 0.034). Of 27 metastatic nodes, 24 (89%) were identified by ICG fluorescence imaging; however, only 18 (67%) were identified by the conventional method (p = 0.043). Of 22 measurable metastatic nodes, partial response was observed in 8 and 14 did not respond (stable disease). Apoptosis was detected in all metastatic nodes [&lt;ulink linkType="Reference" linkID="1469385"&gt;1469385&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would undergo intra-arterial chemotherapy using cisplatin [&lt;ulink linkType="Reference" linkID="1469380"&gt;1469380&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received  intra-arterial chemotherapy using cis-diamminedichloroplatinum (CDDP) 75 mg/m2  biw [&lt;ulink linkType="Reference" linkID="1469385"&gt;1469385&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="345750">cisplatin</Intervention><Treatments><Treatment><Dose>75 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Head and neck tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3777">Subjects with Specific Histological Sub-type of HNC</PatientSegment><SubSegments><SubSegment id="3778">Subjects with squamous cell carcinoma</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7278">Subjects with Oral Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10290">Subjects with TNM Stage IV Head and Neck Cancer</PatientSegment><SubSegments><SubSegment id="10291">Subjects with TNM stage IVa HNC</SubSegment><SubSegment id="10292">Subjects with TNM stage IVb HNC</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000007038</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Head and neck tumor" id="7340"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Head and neck tumor" id="7263"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Head and neck tumor" id="9140">Assessment of Partial Response (PR)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Head and neck tumor" id="7285"><Endpoint>Imaging/Radiological Assessments</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Head and neck tumor" id="4359"><Criterion>Subjects with Oral Cancer</Criterion></Inclusion><Inclusion disease="Head and neck tumor" id="4386"><Criterion>Subjects with TNM Stage IV Head and Neck Cancer</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4387">Subjects with TNM stage IV A HNC</SubCriterion><SubCriterion disease="Head and neck tumor" id="4388">Subjects with TNM stage IV B HNC</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Head and neck tumor" id="4793"><Criterion>Subjects with Specific Histological Sub-type of Head and Neck Cancer</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="4794">Subjects with squamous cell head and neck carcinoma</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Head and neck tumor" id="5712"><Criterion>Subjects with TNM Stage IV Head and Neck Cancer</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5715">Subjects with TNM stage IV C HNC</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Head and neck tumor" id="5777"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Head and neck tumor" id="5781">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-08-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="153747"><TitleDisplay>A Double-blind, Randomised, Placebo-controlled, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Two Oral Doses of GR-43175C Separated by 2 h</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">WHP:88:35</Identifier></Identifiers><Indications></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sumatriptan</Name><Drug id="4491">sumatriptan</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4491">sumatriptan</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="28355">GlaxoSmithKline plc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="10" type="Action"><TargetEntity id="222" type="Mechanism">5-HT1D Agonists</TargetEntity></SourceEntity><SourceEntity id="8" type="Action"><TargetEntity id="221" type="Mechanism">5-HT1B Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="10">5-HT 1d receptor agonist</Action><Action id="8">5-HT 1b receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2946">Analgesic</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="605">Nasal systemic formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="661">Oral quick release formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>6</PatientCountEnrollment><PatientCountEvaluable>6</PatientCountEvaluable><DateStart>1989-01-26T00:00:00Z</DateStart><DateEnd type="actual">1989-03-15T00:00:00Z</DateEnd><DateChangeLast>2013-09-10T08:35:17Z</DateChangeLast><DateAdded>2013-09-10T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Males and nonpregnant females using adequate contraception  if they were at least 18 years of age and were free from significant cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, hematological and psychiatric diseases&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects were excluded if they had received a regular course of medication in the 4 weeks prior to the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>To determine the safety and tolerability of sumatriptan and plasma concentrations of sumatriptan achieved in healthy subjects</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, double-blind,  placebo-controlled, crossover trial was to determine the safety and tolerability of &lt;ulink linkType="Drug" linkID="4491"&gt;sumatriptan&lt;/ulink&gt; and plasma concentrations of &lt;ulink linkType="Drug" linkID="4491"&gt;sumatriptan&lt;/ulink&gt; achieved in healthy subjects after a single oral dose of 200 mg &lt;ulink linkType="Drug" linkID="4491"&gt;sumatriptan&lt;/ulink&gt; followed by a further 200 mg dose 2 h later [&lt;ulink linkType="Reference" linkID="1474947"&gt;1474947&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results published in September 2005 showed that,	geometric mean of Cmax was 188.9 ng/ml. Similarly the tmax was 3.5 h and AUC(zero to 8 hpost-dose) was 	795 ng/h/ml  [&lt;ulink linkType="Reference" linkID="1474947"&gt;1474947&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Subjects were randomized to receive either 2 x 100 mg &lt;ulink linkType="Drug" linkID="4491"&gt;sumatriptan&lt;/ulink&gt; tablets followed by a further 2 x 100 mg tablets 2 h later, or placebo  [&lt;ulink linkType="Reference" linkID="1474947"&gt;1474947&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="349278">sumatriptan</Intervention><Treatments><Treatment><Dose>200 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Contacts></Contacts></Site><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="26032"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="37190"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="34745"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22260">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="25794"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20154">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-09-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="170392"><TitleDisplay>Vitamin D Receptor Polymorphisms and Efficacy of Vitamin D-Fortified Yogurt Drink in Patients With Type 2 Diabetes</TitleDisplay><TitleOfficial>Determination of VDR Single Nucleotide Polymorphisms (SNPs) and Their Roles in Efficacy of Vitamin D-fortified Yogurt Drink on the Metabolic, Inflammatory and Oxidative Stress Parameters in Type 2 Diabetic Patients</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01236846</Identifier><Identifier type="Organisational Study">ABT-1236-RV</Identifier><Identifier type="Trial Acronym">-</Identifier></Identifiers><Indications><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="342" role="Disease marker" type="Genomic;Proteomic">Vitamin D3 receptor</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="14767" role="Therapeutic effect marker" type="Biochemical">Lipids</BiomarkerName><BiomarkerName id="28020" role="Therapeutic effect marker" type="Biochemical">24,25-Dihydroxyvitamin D 3</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Plain yogurt drink</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Vitamin D-fortified yogurt drink</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1043016" type="Company"><TargetEntity id="5035525669" type="organizationId">Tehran University of Medical Sciences and Health Services</TargetEntity></SourceEntity><SourceEntity id="1079099" type="Company"><TargetEntity id="5038068181" type="organizationId">National Nutrition and Food Technology Research Institute</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="1079099">National Nutrition and Food Technology Institute</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1043016">Tehran University of Medical Sciences</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>180</PatientCountEnrollment><DateStart>2009-10-31T00:00:00Z</DateStart><DateEnd type="actual">2011-04-30T00:00:00Z</DateEnd><DateChangeLast>2019-02-08T11:15:31Z</DateChangeLast><DateAdded>2014-01-31T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Tehran University of Medical Sciences</Affiliation><Name>Abolghasem Djazayeri, Professor</Name></Contact><Contact type="Scientific contact"><Affiliation>Tehran University of Medical Sciences</Affiliation><Name>Sakineh Shab-Bidar, M.Sc.</Name></Contact><Contact type="Scientific contact"><Affiliation>National Nutrition &amp; Food technology Research institute, P.O. Box 19395-4741</Affiliation><Name>Tirang R. Neyestani, Ph.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Type 2 diabetes&lt;/li&gt;&lt;li&gt;Informed consent&lt;/li&gt;&lt;li&gt;BMI between 25 to 35 kg/m2&lt;/li&gt;&lt;li&gt;Age: 30 to 45 years old&lt;/li&gt;&lt;li&gt;Willingness to maintain current body weight for the duration of the study&lt;/li&gt;&lt;li&gt;Willingness to maintain baseline lifestyle activities and routines for the duration of the study&lt;/li&gt;&lt;li&gt;Willingness to avoid the use of all over-the-counter or prescription vitamins, dietary supplements, and herbal products during the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;History of cardiovascular, gastrointestinal, renal disease and any other endocrinological disorders&lt;/li&gt;&lt;li&gt;Patients receiving vitamin D or omega-3 supplement&lt;/li&gt;&lt;li&gt;Pregnancy, or lactation within the study period&lt;/li&gt;&lt;li&gt;Treatment with insulin&lt;/li&gt;&lt;li&gt;Treatment for weight reduction&lt;/li&gt;&lt;li&gt;Treatment for reducing serum lipids&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Serum 25-hydroxyvitamin D</Description><Timeframe>3 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Blood pressure</Description><Timeframe>3 months</Timeframe></Measure><Measure><Description>Glycemic control</Description><Timeframe>3 months</Timeframe></Measure><Measure><Description>Inflammatory markers</Description><Timeframe>3 nonths</Timeframe></Measure><Measure><Description>Lipid profiles</Description><Timeframe>3 nonths</Timeframe></Measure><Measure><Description>Oxidative stress markers</Description><Timeframe>3 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was  to examine the possible      effects of  vitamin D receptor gene polymorphisms on the metabolic, inflammatory and      oxidative stress markers in type 2 diabetic subjects upon vitamin D-fortified yogurt drink      intake.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would consist of  three polymorphic variant groups (genotype aa, AA, Aa) which receives vitamin D-fortified yogurt drink and one control group which receives plain yogurt      drink for a total of 12 weeks.In treatment groups, all subjects would receive 500 ml  per      day of low-fat (1%) yogurt drink fortified with approximately 500 IU of vitamin D3. Control      group would receive 500 ml per day of plain (unfortified) yogurt drink. Metabolic, inflammatory      and oxidative stress markers would be  evaluated at the beginning and in the end of the      interventional period.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Address1>Tehran</Address1><Contacts></Contacts></Site><Site><Name>National Nutrition and Food Technology Research Institute</Name><Address1>Tehran</Address1><Address3>19395-4741</Address3><Contacts></Contacts></Site><Site><Name>National Nutrition and Food Technology Research Institute</Name><Address1>Tehran</Address1><Address3>1981619573</Address3><Contacts></Contacts></Site><Site><Name>Tirang Neyestani</Name><Address1>Tehran</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="104">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="108">Subjects with obesity</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="13324">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-1265278377" id="21839">VDR_HUMAN_Mutation</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01236846</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1423"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1451"><Endpoint>Assessment of lipid profiles</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1514"><Endpoint>Glycemic Control Analysis</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1580"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="608"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="609">Overweight subjects (Grade 1 obesity, BMI= 25 to 29.9)</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="610">Obese subjects (Grade 2 obesity, BMI= 30 to 39.9)</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="837"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="891"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="932"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="946"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="957">Subjects on/treated with insulin</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="963"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="5063">Subjects on/treated with dietary supplements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5070"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="26284"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="5059">Subject is on a weight loss program</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2011-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2010-08-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-01-31T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="added"><Date>2019-02-07T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change><Change type="added"><Date>2019-02-07T00:00:00Z</Date><Reason id="320">Trial Biomarker Added</Reason></Change></ChangeHistory></Trial><Trial id="178464"><TitleDisplay>Reducing Reconsolidation of Trauma Memories With Propranolol</TitleDisplay><TitleOfficial>Reduction of the Reconsolidation of the Trauma Memory With Propranolol</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01349439</Identifier><Identifier type="Organisational Study">08-44</Identifier></Identifiers><Indications><Indication id="1935">Post traumatic stress disorder</Indication></Indications><BiomarkerNames><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>memory reactivation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>propranolol</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1034426" type="Company"><TargetEntity id="5000817453" type="organizationId">Canadian Institutes of Health Research</TargetEntity></SourceEntity><SourceEntity id="1053977" type="Company"><TargetEntity id="5035549616" type="organizationId">Douglas Mental Health University Institute</TargetEntity></SourceEntity><SourceEntity id="1935" type="ciIndication"><TargetEntity id="F43.1" type="ICD10"></TargetEntity><TargetEntity id="10036316" type="MEDDRA"></TargetEntity><TargetEntity id="D013313" type="MeSH"></TargetEntity><TargetEntity id="-1731993138" type="omicsDisease"></TargetEntity><TargetEntity id="38" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1053977">Douglas Mental Health University Institute</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1034426">Canadian Institutes of Health Research</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>76</PatientCountEnrollment><PatientCountEvaluable>41</PatientCountEvaluable><DateStart>2011-03-31T00:00:00Z</DateStart><DateChangeLast>2017-04-21T16:00:18Z</DateChangeLast><DateAdded>2014-04-09T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>alain.brunet@mcgill.ca</Email><Extension>4348</Extension><Name>Alain R Brunet, Ph.D.</Name><Phone>514-761-6131</Phone></Contact><Contact type="Scientific contact"><Affiliation>Douglas Institute Research Centre</Affiliation><Name>Alain Brunet, Ph.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Suffer from chronic PTSD for at least 6 consecutive months&lt;/li&gt;&lt;li&gt;Obtain a score of &gt;/= 33 on the Impact of events scale-revised&lt;/li&gt;&lt;li&gt;For participants aged 40 years: accept to undergo an electrocardiogram assessment. The results of the electrocardiogram must be normal&lt;/li&gt;&lt;li&gt;Accept to not commence taking new medications on a regular basis during the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Hypotension&lt;/li&gt;&lt;li&gt;Cardiac rhythm&amp;lt; 55 beats/min&lt;/li&gt;&lt;li&gt;Medical conditions that contraindicates the administration of propranolol&lt;/li&gt;&lt;li&gt;Previous adverse reaction to, or non-compliance with, beta-blockers&lt;/li&gt;&lt;li&gt;Current use of medication that may involve potentially dangerous interactions with propranolol&lt;/li&gt;&lt;li&gt;Any medication that can have an impact on cardiac rhythm&lt;/li&gt;&lt;li&gt;Women who are breast feeding&lt;/li&gt;&lt;li&gt;Past or present bipolar disorder or psychosis&lt;/li&gt;&lt;li&gt;Present substance abuse or dependence, suicidal ideation&lt;/li&gt;&lt;li&gt;Participating in psychotherapy other than support psychotherapy&lt;/li&gt;&lt;li&gt;An average score &gt; 20 on the dissociative experience scale&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Electromyogram</Description><Timeframe>2 weeks post-treatment</Timeframe></Measure><Measure><Description>Heart rate</Description><Timeframe>2 weeks post-treatment</Timeframe></Measure><Measure><Description>Skin conductance</Description><Timeframe>2 weeks post-treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Wechsler Adult Intelligence Scale third edition (WAIS-III)</Description></Measure><Measure><Description>Memory experience: the memory experiences questionnaire will be administered from 2 to 26 weeks following randomization</Description><Timeframe>2 to 26 weeks</Timeframe></Measure><Measure><Description>PTSD symptom levels: PTSD symptom levels will be assessed 2 to 26 weeks after randomization by the Impact of Event Scale Revised (IES-R)</Description><Timeframe>2 to 26 weeks; 1 week before and after treatment</Timeframe></Measure><Measure><Description>Psychophysiological assessments: psychophysiological assessments will be repeated 26 weeks following randomization</Description><Timeframe>26 weeks</Timeframe></Measure><Measure><Description>Quality of life: quality of life assessments will be conducted 2 to 26 weeks following randomization</Description><Timeframe>2 to 26 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to test whether propranolol was capable of reducing subsequent      physiological trauma-related conditioned responses, as well as self-reported post-traumatic      stress disorder (PTSD) symptoms. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In March 2016, results were published. Compared to the placebo group, the propranolol group performed significantly better on the Processing Speed composite measure. Within the propranolol group, greater heart rate decreases were associated with higher Perceptual Organization performance [&lt;ulink linkType="Reference" linkID="1748655"&gt;1748655&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study would be divided into five arms:&lt;br/&gt;Arm 1: this arm involves recalling the traumatic event (memory reactivation) after administration of propranolol (1 mg/kg).&lt;br/&gt;Arm 2: this arm involves memory reactivation after administration of  placebo (1 mg/kg).&lt;br/&gt;Arm 3: this arm involves administration of  placebo (1 mg/kg) without memory reactivation.&lt;br/&gt;Arm 4: this arm involves administration of propranolol (1 mg/kg) without memory reactivation.&lt;br/&gt;Arm 5 (open-label): patients  would receive short acting propranolol 1 mg/kg  plus long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation for 6 weeks. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized to receive a single dose of 1 mg/kg of propranolol (n = 20) or placebo (n = 21) [&lt;ulink linkType="Reference" linkID="1748655"&gt;1748655&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="406407">propranolol</Intervention><Treatments><Treatment><Dose>1 milligram/kg</Dose><Route></Route></Treatment><Treatment><Dose>1.5 milligram/kg</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Douglas Mental Health University Institute</Name><Address1>Verdun</Address1><Address2>Quebec</Address2><Address3>H4H 1R3</Address3><CountrySubDivision>Quebec</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>andrea.ashbaugh@douglas.mcgill.ca</Email><Extension>4341</Extension><Name>Andrea Ashbaugh, Ph.D.</Name><Phone>514-761-6131</Phone></Contact><Contact type="Facility investigator"><Name>Alain Brunet, Ph.D.</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Anxiety disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="7478">Subjects with Post Traumatic Stress Disorder</PatientSegment><SubSegments><SubSegment id="7481">Subjects with chronic post traumatic stress disorder</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01349439</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Anxiety disorder" id="10385"><Endpoint>Assessment of the Symptoms of Anxiety Disorder</Endpoint><SubEndpoints><SubEndpoint disease="Anxiety disorder" id="10387">Assessment of autonomic and visceral symptoms</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Anxiety disorder" id="10483"><Endpoint>Assessment of Vital Signs</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Anxiety disorder" id="10490"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Anxiety disorder" id="10420"><Endpoint>Assessment of Symptoms of Post Traumatic Stress Disorder</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Anxiety disorder" id="10437"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Anxiety disorder" id="31634">Assessment of quality of life(unspecified)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anxiety disorder" id="10452"><Endpoint>Assessment of Neuropsychological Function</Endpoint><SubEndpoints><SubEndpoint disease="Anxiety disorder" id="10454">Assessment of memory</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Anxiety disorder" id="6531"><Criterion>Subjects with a Specific Anxiety Disorder</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6539">Subjects with post traumatic stress disorder[PTSD]</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anxiety disorder" id="6546"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6549">Subjects with severe anxiety disorders</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anxiety disorder" id="6553"><Criterion>Subjects with Specific Forms of Post Traumatic Stress Disorder</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6555">Subjects with chronic post traumatic stress disorder</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anxiety disorder" id="6599"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion></Inclusion><Inclusion disease="Anxiety disorder" id="33345"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6602">Subjects with normal/acceptable cardiac function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Anxiety disorder" id="8173"><Criterion>Subjects with Protocol Specified Clinical Manifestations</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8177">Subjects with suicidal ideation/suicide attempts</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="8179"><Criterion>Protocol Specified Scales of Anxiety Disorders Symptom Assessment</Criterion></Exclusion><Exclusion disease="Anxiety disorder" id="8183"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8184">Subjects with mood disorders</SubCriterion><SubCriterion disease="Anxiety disorder" id="8185">Subjects co-morbid with psychotic disorders</SubCriterion><SubCriterion disease="Anxiety disorder" id="8187">Subjects co-morbid with substance abuse disorders</SubCriterion><SubCriterion disease="Anxiety disorder" id="8192">Subjects with Axis II disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="8194"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Anxiety disorder" id="8197"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Anxiety disorder" id="8216"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8222">Hypersensitivity/Contraindication to sympatholytics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="8226"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8235">Subjects with history of psychotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="26306"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8209">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2015-01-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2011-03-31T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-04-09T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-04-06T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="181270"><TitleDisplay>(18F) Flourothymidine (FLT) PET/CT Imaging for Gynecological Cancers</TitleDisplay><TitleOfficial>(18F) Flourothymidine (FLT)PET/CT Imaging for Gynecological Cancers</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02108457</Identifier><Identifier type="Organisational Study">UPCC 28813</Identifier></Identifiers><Indications><Indication id="438">Gynecological disorder</Indication><Indication id="651">Cancer</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>(18F) fluorothymidine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>PET/CT imaging</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1053899" type="Company"><TargetEntity id="5035549880" type="organizationId">Abramson Cancer Center Of The University Of Pennsylvania</TargetEntity></SourceEntity><SourceEntity id="438" type="ciIndication"><TargetEntity id="538" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1053899">Abramson Cancer Center of the University of Pennsylvania</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Diagnosis</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>15</PatientCountEnrollment><DateStart>2014-02-28T00:00:00Z</DateStart><DateEnd type="actual">2016-12-21T00:00:00Z</DateEnd><DateChangeLast>2019-04-25T06:59:05Z</DateChangeLast><DateAdded>2014-04-18T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Abramson Cancer Center of the University of Pennsylvania</Affiliation><Name>Lilie Lin, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Participants will be &gt;/= 18 years of age&lt;/li&gt;&lt;li&gt;History of gynecological cancer&lt;/li&gt;&lt;li&gt;Recommended to undergo IMRT or PBT of the pelvis with concurrent chemotherapy&lt;/li&gt;&lt;li&gt;Female participants of child-bearing potential must have a negative urine or serum pregnancy test at the time of the screening visit&lt;/li&gt;&lt;li&gt;Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study specific procedures&lt;/li&gt;&lt;li&gt;Participants must be willing and able to comply with scheduled visits and imaging procedures in the opinion of the investigator or treating physician&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Females who are pregnant or breast feeding at the time of screening will not be eligible for this study&lt;/li&gt;&lt;li&gt;Inability to tolerate imaging procedures in the opinion of the investigator or treating physician&lt;/li&gt;&lt;li&gt;Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subjects safety or successful participation in the study&lt;/li&gt;&lt;li&gt;Unwilling or unable to provide informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of adverse events</Description><Timeframe>Up to 5 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to determine the effect of specific bone marrow maps developed      with18F flourothymidine (FLT) PET/CT imaging on the ability to spare proliferating bone marrow using proton      beam radiotherapy compared to IMRT. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Proton or IMRT subjects would undergo three (18F) fluorothymidine  -PET scans (one before treatment,      one during the course of RT, and one 2 to 5 weeks after initiation of RT). Scans would take      place in the department of radiation oncology.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Abramson Cancer Center of the University of Pennsylvania</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3>19104</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02108457</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Ovary tumor" id="10900"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Ovary tumor" id="10901">Assessment of frequency and severity of adverse events (AE) &amp; serious adverse events (SAEs) </SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Uterine cervix tumor" id="12737"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Uterine cervix tumor" id="7723"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Uterine cervix tumor" id="7726">Subjects with gynecological cancers</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8288"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8290">Subjects with other gynecological cancers</SubCriterion></SubCriteria></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-12-21T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2014-04-07T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-04-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-02-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-04-25T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-04-25T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-04-25T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="204983"><TitleDisplay>Effect of Iron-fortified TPN on Preterm Infants Anemia</TitleDisplay><TitleOfficial>Effect of Iron-fortified TPN on Preterm Infants Anemia</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01813682</Identifier><Identifier type="Organisational Study">EOITOPIA</Identifier></Identifiers><Indications><Indication id="17">Anemia</Indication></Indications><BiomarkerNames><BiomarkerName id="442" role="Therapeutic effect marker" type="Biochemical">Malondialdehyde</BiomarkerName><BiomarkerName id="6839" role="Therapeutic effect marker" type="Biochemical">2,3-Dinor-8-iso-prostaglandin-F(2alpha)</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>iron</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1060344" type="Company"><TargetEntity id="5035552725" type="organizationId">Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</TargetEntity></SourceEntity><SourceEntity id="17" type="ciIndication"><TargetEntity id="10002034" type="MEDDRA"></TargetEntity><TargetEntity id="D000740" type="MeSH"></TargetEntity><TargetEntity id="-201701473" type="omicsDisease"></TargetEntity><TargetEntity id="988" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1060344">Xinhua Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Factorial Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>118</PatientCountEnrollment><DateStart>2012-09-30T00:00:00Z</DateStart><DateEnd type="estimated">2014-06-30T00:00:00Z</DateEnd><DateChangeLast>2014-07-22T16:01:17Z</DateChangeLast><DateAdded>2014-07-22T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Shanghai jiaotong university affiliated xinhua hospital</Affiliation><Email>tangqingya@163.com</Email><Name>qingya tang, M.D.</Name><Phone>+8613761184818</Phone></Contact><Contact type="Public contact"><Affiliation>Xinhua Hospital; Shanghai; Shanghai; 200092; China</Affiliation><Email>taoyexuan@hotmail.com</Email><Name>Yexuan Tao</Name><Phone>8613818334664</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Preterm infants with birth weight&amp;lt; 2 kg &lt;/li&gt;&lt;li&gt;Have parenteral nutrition indication With written informed consent of parents or guardian&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Have already used TPN before randomization&lt;/li&gt;&lt;li&gt;Kidney and liver function abnormal&lt;/li&gt;&lt;li&gt;Have hemolytic disease&lt;/li&gt;&lt;li&gt;Have hemorrhagic disease&lt;/li&gt;&lt;li&gt;Have serious congenital malformation&lt;/li&gt;&lt;li&gt;Have septicemia&lt;/li&gt;&lt;li&gt;Have plethora&lt;/li&gt;&lt;li&gt;Newborn use TPN&amp;lt; 10 days&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Anemia rate: compare the anemia rate of three groups and identify the effect of iron-fortified TPN for preterm infants</Description><Timeframe>Upto 2 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Iron status: serum iron, iron protein and total iron binding force are parameters used to test the effectiveness of iron-fortified TPN used for preterm infants</Description><Timeframe>Baseline and &gt; 10 days</Timeframe></Measure><Measure><Description>Oxidative stress parameters: MDA, 8-iso-prostaglandin F2alpha as the oxidative stress parameters to identify the safety of iron-fortified TPN used in preterm infants</Description><Timeframe>Baseline and &gt; 10 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to determine whether iron-fortified total parenteral nutrition (TPN) is effective in the      preventative and treatment of preterm infants. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Study will include the following arms:&lt;br/&gt;Arm A: infants will receive iron-free TPN for &amp;gt; 10 days.&lt;br/&gt;Arm B: infants will receive iron supplementation 200 microg/kg/day for &amp;gt; 10 days (highest concentration      of iron is &amp;lt;/= 0.8 g/100ml TPN).&lt;br/&gt;Arm C: infants will receive iron supplementation 400 microg/kg/day for &amp;gt; 10 days.&lt;/para&gt;&lt;para&gt;For three      groups, complete blood counts, differential counts, and reticulocyte counts will be measured      weekly in samples obtained, serum iron, iron protein, total iron binding force were measured      at baseline and after 2 weeks.  Malondialdehyde (MDA) and 8-iso-prostaglandin F2-alpha (8-iso-PGF2alpha) will also be evaluated.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Xinhua Hospital</Name><Address1>Shanghai</Address1><Address2>Shanghai</Address2><Address3>200092</Address3><CountrySubDivision>Shanghai</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>taoyexuan@hotmail.com</Email><Name>yexuan tao, PH.D.</Name><Phone>+8613818334664</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Anemia</Disease><PatientSegments><PatientSegment><PatientSegment id="7649">Subjects at risk of developing disease</PatientSegment><SubSegments><SubSegment id="7651">Infants/children</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01813682</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Anemia" id="17197"><Endpoint>Assessment of Incidence/Prevalence of Anemia</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Anemia" id="17205"><Endpoint>Assessment of iron status</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17207">Assessment of serum iron</SubEndpoint><SubEndpoint disease="Anemia" id="17208">Assessment of total iron binding capacity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="17319"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17324">Assessment of efficacy</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Anemia" id="45041"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17322">Assessment of oxidative stress</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Anemia" id="14357"><Criterion>Subjects at Risk of Developing Disease</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14358">Infants/children</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Anemia" id="11806"><Criterion>Subjects with Other Forms of Anemia</Criterion></Exclusion><Exclusion disease="Anemia" id="11815"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11825">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11819"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Anemia" id="11821"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Anemia" id="11824"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Anemia" id="11855"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Anemia" id="25384"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11793">Subjects with Hemolytic Anemia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="26067"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11820">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="26321"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11843">Subjects with abnormal/unacceptable lung function</SubCriterion><SubCriterion disease="Anemia" id="11844">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Anemia" id="11845">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="27098"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11818">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2013-12-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-07-22T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="206496"><TitleDisplay>A randomized, double-blind clinical trial on the treatment of knee osteoarthritis evaluating the efficacy of polynucleotides compared to standard hyaluronian viscosupplementation</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="245">Osteoarthritis</Indication></Indications><BiomarkerNames><BiomarkerName id="579" role="Therapeutic effect marker" type="Genomic;Proteomic">Cartilage oligomeric matrix protein</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>hyaluronic acid</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>polynucleotides</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20625" type="Company"><TargetEntity id="5001202589" type="organizationId">Universita degli Studi di Milano</TargetEntity></SourceEntity><SourceEntity id="245" type="ciIndication"><TargetEntity id="10031161" type="MEDDRA"></TargetEntity><TargetEntity id="D010003" type="MeSH"></TargetEntity><TargetEntity id="-478836143" type="omicsDisease"></TargetEntity><TargetEntity id="747" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="20625">Universita degli Studi di Milano</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>72</PatientCountEnrollment><PatientCountEvaluable>75</PatientCountEvaluable><DateChangeLast>2017-07-19T16:10:00Z</DateChangeLast><DateAdded>2014-07-25T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients affected by knee OAÂ &lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The determination of COMP serum levels</Description><Timeframe>At T0, T6 and T26 weeks</Timeframe></Measure><Measure><Description>KOOS and pain level at rest, at weight-bearing and during physical activity</Description><Timeframe>At baseline (T0) and after one (T1), two (T2), six (T6), ten (T10), and 26 (T26) weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results were published in June 2014. Significant adverse events were not reported [&lt;ulink linkType="Reference" linkID="1580168"&gt;1580168&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, double-blind, parallel-group clinical trial was to assess the equivalence of intra-articular polynucleotides compared to standard hyaluronic acid (HA) viscosupplementation in the treatment of knee osteoarthritis (OA) [&lt;ulink linkType="Reference" linkID="1580168"&gt;1580168&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in June, 2014. For both treatments, the reduction of pain and the increase of KOOS values from baseline were statistically significant. For parameter KOOS symptoms the treatment with Condrotide showed significant results already after two weeks (at T2 p = 0.003) while the results obtained with Hyalubrix became significant only after 18 weeks (at T18 p = 0.01) [&lt;ulink linkType="Reference" linkID="1580168"&gt;1580168&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized to receive either intra-articular polynucleotides (Condrotide) or hyaluronic acid. Patients were treated with  three intra-articular injections of condrotide or hyalubrix with an interval of 1Â week [&lt;ulink linkType="Reference" linkID="1580168"&gt;1580168&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-07-25T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="221760"><TitleDisplay>Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2</TitleDisplay><TitleOfficial>A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After Radical Gastrectomy With D2</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02356276</Identifier><Identifier type="Organisational Study">20150129</Identifier><Identifier type="Other">HIPEC-01</Identifier><Identifier type="Trial Acronym">EHTLAGCRGD2</Identifier></Identifiers><Indications><Indication id="3666">Metastatic stomach cancer</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>D2 lymphadenectomy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>hyperthermic intraperitoneal chemotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>capecitabine</Name><Drug id="12205">capecitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>oxaliplatin</Name><Drug id="3792">oxaliplatin</Drug></Intervention><Intervention type="InterventionPrimary"><Name>paclitaxel</Name><Drug id="3803">paclitaxel</Drug></Intervention><Intervention type="InterventionPrimary"><Name>tegafur + gimeracil + oteracil potassium</Name><Drug id="10084">tegafur + gimeracil + oteracil potassium</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="10084">tegafur + gimeracil + oteracil potassium</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1004360">Sun Yat-Sen University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1012056">Nanfang Hospital First Medical University of PLA</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1021685">Chinese PLA General Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1033512">Central South University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1038712">Guangdong Provincial People's Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1039331">Hebei Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1043327">Harbin Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1045085">Zhejiang Cancer Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1049793">Tianjin Medical University Cancer Institute and Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1058888">Henan Province Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1059121">Wuhan Union Hospital, China</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1074103">Guangdong Provincial Hospital of Chinese Medicine</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1095713">Guangzhou Medical University Cancer Institute and Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12205">capecitabine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1004360">Sun Yat-Sen University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1012056">Nanfang Hospital First Medical University of PLA</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1021685">Chinese PLA General Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1033512">Central South University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1038712">Guangdong Provincial People's Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1039331">Hebei Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1043327">Harbin Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1045085">Zhejiang Cancer Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1049793">Tianjin Medical University Cancer Institute and Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1058888">Henan Province Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1059121">Wuhan Union Hospital, China</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1074103">Guangdong Provincial Hospital of Chinese Medicine</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1095713">Guangzhou Medical University Cancer Institute and Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3792">oxaliplatin</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1004360">Sun Yat-Sen University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1012056">Nanfang Hospital First Medical University of PLA</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1021685">Chinese PLA General Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1033512">Central South University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1038712">Guangdong Provincial People's Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1039331">Hebei Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1043327">Harbin Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1045085">Zhejiang Cancer Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1049793">Tianjin Medical University Cancer Institute and Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1058888">Henan Province Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1059121">Wuhan Union Hospital, China</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1074103">Guangdong Provincial Hospital of Chinese Medicine</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1095713">Guangzhou Medical University Cancer Institute and Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3803">paclitaxel</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1004360">Sun Yat-Sen University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1012056">Nanfang Hospital First Medical University of PLA</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1021685">Chinese PLA General Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1033512">Central South University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1038712">Guangdong Provincial People's Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1039331">Hebei Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1043327">Harbin Medical University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1045085">Zhejiang Cancer Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1049793">Tianjin Medical University Cancer Institute and Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1058888">Henan Province Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1059121">Wuhan Union Hospital, China</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1074103">Guangdong Provincial Hospital of Chinese Medicine</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1095713">Guangzhou Medical University Cancer Institute and Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3803" type="Drug"><TargetEntity id="101438" type="siDrug">Paclitaxel</TargetEntity></SourceEntity><SourceEntity id="3792" type="Drug"><TargetEntity id="108094" type="siDrug">Oxaliplatin</TargetEntity></SourceEntity><SourceEntity id="10084" type="Drug"><TargetEntity id="203364" type="siDrug">Tegafur/gimeracil/oteracil</TargetEntity><TargetEntity id="217985" type="siDrug">TS1</TargetEntity></SourceEntity><SourceEntity id="12205" type="Drug"><TargetEntity id="211639" type="siDrug">Capecitabine</TargetEntity></SourceEntity><SourceEntity id="1004360" type="Company"><TargetEntity id="4297781695" type="organizationId">Sun Yat-sen University</TargetEntity></SourceEntity><SourceEntity id="1012056" type="Company"><TargetEntity id="5035557358" type="organizationId">Nanfang Hospital First Medical University Of Pla</TargetEntity></SourceEntity><SourceEntity id="1021685" type="Company"><TargetEntity id="5035558113" type="organizationId">Chinese Pla General Hospital</TargetEntity></SourceEntity><SourceEntity id="1033512" type="Company"><TargetEntity id="5035525210" type="organizationId">Central South University</TargetEntity></SourceEntity><SourceEntity id="1038712" type="Company"><TargetEntity id="5035559590" type="organizationId">Guangdong Provincial Peoples Hospital</TargetEntity></SourceEntity><SourceEntity id="1039331" type="Company"><TargetEntity id="5035542400" type="organizationId">Hebei Medical University</TargetEntity></SourceEntity><SourceEntity id="1043327" type="Company"><TargetEntity id="5035544747" type="organizationId">Harbin medical university</TargetEntity></SourceEntity><SourceEntity id="1045085" type="Company"><TargetEntity id="5035545224" type="organizationId">Zhejiang Cancer Hospital</TargetEntity></SourceEntity><SourceEntity id="1049793" type="Company"><TargetEntity id="5035547448" type="organizationId">Tianjin Medical University Cancer Institute &amp; Hospital</TargetEntity></SourceEntity><SourceEntity id="1058888" type="Company"><TargetEntity id="5035564988" type="organizationId">Henan Provincial Hospital</TargetEntity></SourceEntity><SourceEntity id="1059121" type="Company"><TargetEntity id="5035560635" type="organizationId">Wuhan Union Hospital  China</TargetEntity></SourceEntity><SourceEntity id="1074103" type="Company"><TargetEntity id="5037930211" type="organizationId">Guangdong Provincial Hospital of Chinese Medicine</TargetEntity></SourceEntity><SourceEntity id="1095713" type="Company"><TargetEntity id="5042373333" type="organizationId">Cancer Center of Guangzhou Medical University</TargetEntity></SourceEntity><SourceEntity id="3666" type="ciIndication"><TargetEntity id="10063916" type="MEDDRA"></TargetEntity><TargetEntity id="647" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="372" type="Action"><TargetEntity id="505" type="Mechanism">Thymidylate Synthase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="782" type="Action"><TargetEntity id="512" type="Mechanism">Uracil Dehydrogenase Inhibitors</TargetEntity><TargetEntity id="2868" type="Mechanism">Dihydropyrimidine Dehydrogenase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>14</NumberOfSites><CompaniesSponsor><Company id="1033512">Central South University</Company><Company id="1049793">Tianjin Medical University Cancer Institute and Hospital</Company><Company id="1095713">Guangzhou Medical University Cancer Institute and Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1004360">Sun Yat-Sen University</Company><Company id="1012056">Nanfang Hospital First Medical University of PLA</Company><Company id="1021685">Chinese PLA General Hospital</Company><Company id="1038712">Guangdong Provincial People's Hospital</Company><Company id="1039331">Hebei Medical University</Company><Company id="1043327">Harbin Medical University</Company><Company id="1045085">Zhejiang Cancer Hospital</Company><Company id="1058888">Henan Province Hospital</Company><Company id="1059121">Wuhan Union Hospital, China</Company><Company id="1074103">Guangdong Provincial Hospital of Chinese Medicine</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="372">Thymidylate synthase inhibitor</Action><Action id="6661">Orotate phosphoribosyltransferase inhibitor</Action><Action id="782">Dihydropyrimidine dehydrogenase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="2576">Microtubule stabilizer</Class><Class id="2660">Vasoprotectant</Class><Class id="50">Anticancer alkylating agent</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="175">Drug combination</Technology><Technology id="751">Film coating</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="1647">Natural product</Technology><Technology id="102">Nucleotide and derivatives</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>584</PatientCountEnrollment><DateStart>2015-05-11T00:00:00Z</DateStart><DateEnd type="estimated">2022-01-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T16:50:41Z</DateChangeLast><DateAdded>2015-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Affiliated Tumor Hospital of Guangzhou Medical University Recruiting</Affiliation><Name>shuzhong cui, M.D</Name></Contact><Contact type="Public contact"><Email>cuishuzhong@126.com</Email><Name>shuzhong cui, M.D</Name><Phone>0086-138-0251-3800</Phone></Contact><Contact type="Public contact"><Email>7097359@qq.com</Email><Name>Xian-Zi Yang, M.M</Name><Phone>0086-188-9853-4167</Phone></Contact><Contact type="Public contact"><Affiliation>Chinese PLA General Hospital</Affiliation><Name>Zheng Peng</Name></Contact><Contact type="Public contact"><Affiliation>Sun Yat-sen University Cancer Center</Affiliation><Name>Zhi-Wei Zhou</Name></Contact><Contact type="Public contact"><Affiliation>Guangdong General Hospital</Affiliation><Name>Yong Li</Name></Contact><Contact type="Public contact"><Affiliation>Affiliated Tumor Hospital of Guangzhou Medical University</Affiliation><Name>shuzhong cui</Name></Contact><Contact type="Public contact"><Affiliation>Guangdong Provincial Hospital of Traditional Chinese Medicine</Affiliation><Name>Jin Wang</Name></Contact><Contact type="Public contact"><Affiliation>Nanfang Hospital of Southern Medical University</Affiliation><Name>Guo-Xin Li</Name></Contact><Contact type="Public contact"><Affiliation>The Second Hospital of Hebei Medical University</Affiliation><Name>Bao-Jun Zhou</Name></Contact><Contact type="Public contact"><Affiliation>Hebei Medical University Fourth Hospital</Affiliation><Name>Yong Li</Name></Contact><Contact type="Public contact"><Affiliation>Harbin Medical University Cancer Hospital</Affiliation><Name>Kuan Wang</Name></Contact><Contact type="Public contact"><Affiliation>Henan Cancer Hospital</Affiliation><Name>Guang-Sen Han</Name></Contact><Contact type="Public contact"><Affiliation>Wuhan Union Hospital, China</Affiliation><Name>Kai-Xiong Tao</Name></Contact><Contact type="Public contact"><Affiliation>The second Xiangya Hospital of Central South University</Affiliation><Name>Hong-Liang Yao</Name></Contact><Contact type="Public contact"><Affiliation>Tianjin Medical University Cancer Institute and Hospital</Affiliation><Name>Han Liang</Name></Contact><Contact type="Public contact"><Affiliation>Zhejiang Cancer Hospital</Affiliation><Name>Xin-Bao Wang</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age &gt; 18&amp;lt; and &amp;lt;/=  70 years old&lt;/li&gt;&lt;li&gt;Male or non-pregnant female&lt;/li&gt;&lt;li&gt;The Eastern Cooperative Oncology Group (ECOG) status 0 to 1&lt;/li&gt;&lt;li&gt;A T3 or T4 gastric adenocarcinoma (visual determination according to AJCC 2010 seventh edition)&lt;/li&gt;&lt;li&gt;No distance metastasis, eligible for D2 lymphadenectomy&lt;/li&gt;&lt;li&gt;Have not received cytotoxic chemotherapy, radiotherapy or immunotherapy&lt;/li&gt;&lt;li&gt;White blood cells&amp;gt; 4000/mm3&lt;/li&gt;&lt;li&gt;Neutrophils &gt;/=  1500/mm3&lt;/li&gt;&lt;li&gt;Platelets &gt;/=  100,000/mm3&lt;/li&gt;&lt;li&gt;Hemoglobin&amp;gt; 9 g/l&lt;/li&gt;&lt;li&gt;Alanine transaminase (ALT) and aspartate aminotransferase (AST)&amp;lt;/= 2.5 x upper limit of nominal (ULN)&lt;/li&gt;&lt;li&gt;Total bilirubin (TBIL)&amp;lt; 1.5 x ULN&lt;/li&gt;&lt;li&gt;Serum creatinine&amp;lt; 1 x ULN&lt;/li&gt;&lt;li&gt;Having given written informed consent prior to any procedure related to the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Have other cancer within five years&lt;/li&gt;&lt;li&gt;Existence of distance metastasis during surgey (M1)&lt;/li&gt;&lt;li&gt;Prior malignant tumors with detectable signs of recurrence or distant metastasis&lt;/li&gt;&lt;li&gt;Poorly controlled disease eg, atrial fibrillation, stenocardia, cardiac insufficiency, persistent hypertension despite medicinal treatment, ejection fraction&amp;lt; 50%&lt;/li&gt;&lt;li&gt;Epileptic seizures patients need medicine control&lt;/li&gt;&lt;li&gt;Uncontroled mental disease or mental disorder&lt;/li&gt;&lt;li&gt;Drug abuse or psychological or social factors affect the judgment of results&lt;/li&gt;&lt;li&gt;Contraindication to any therapy contained in this regimen specific to the study&lt;/li&gt;&lt;li&gt;Receiving other chemotherapy, radiotherapy or immunotherapy&lt;/li&gt;&lt;li&gt;Without given written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Five-year overall survival: assess overall survival during five years in both study arms</Description><Timeframe>Five years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>CEA mRNA expression of peritoneal lavage fluid: Quantitative RT-PCR is used to analyze CEA mRNA expression of peritoneal lavage fluid before and after D2 lymphadenectomy between two arms</Description><Timeframe>Through study completion, an average of three year</Timeframe></Measure><Measure><Description>Liver metastatic rate: calculate the percent of liver metastatic in both two arms during five years</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>Local recurrence rate: calculate the percent of local recurrence in both two arms during five years</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>Five-year progression-free survival: assess progression-free survival rate during five years in both study arms</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>Side effects: determine percent of adverse events or side effects according to NCI criteria, Common Terminology Criteria for AE (CTCAE 4.0)</Description><Timeframe>Five years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, multicenter, phase III study is to study the efficacy of hyperthermic intraperitoneal      chemotherapy (HIPEC) in the treatment of patients with locally advanced gastric cancer after radical      gastrectomy with D2 lymphadenectomy.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomized into two arms:&lt;br/&gt;Arm 1 (experimental arm): postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is performed after radical surgery, followed by six to eight cycles of systemic chemotherapy. The first HIPEC is conducted within 48 h after surgery: Paclitaxel 75 mg/m2, 43degC, 60 min. The second HIPEC is performed after 24 h of the first HIPEC. The regimens are Paclitaxel 100 mg/m2, 43degC, 60 min. XELOX regimen: Oxaliplatin: 130 mg/m2, IV, d1; Capecitabine: 1 g/m2 bid, days 1 to 14, every 3 weeks for a total of six to eight cycles. If XELOX regimen is not conducted in some collaborators, SOX regimen is also permitted. The regimen is Oxaliplatin: 130 mg/m2, IV, d1; &lt;ulink linkType="Drug" linkID="10084"&gt;S-1&lt;/ulink&gt;, 40 to 60 mg/m^2 bid, po, day 1 to 14, every 3 weeks for a total of 6 to 8 cycles.&lt;br/&gt;Arm 2: control group:   six to eight cycles of systemic chemotherapy (XELOX or SOX regimens) will be  performed after radical gastrectomy with D2 lymphadenectomy. XELOX regimen includes Oxaliplatin: 130 mg/m2, iv, d1; Capecitabine: 1 g/m2 bid, days 1 to 14, q3w for a total of six to eight cycles. If XELOX regimen is not conducted in some collaborators, SOX regimen as comment systemic chemotherapy in Asia is also permitted to treat the patients. The treatment bundles are listed as follows: Oxaliplatin: 130 mg/m2, iv, d1; S-1, 40 to 60 mg/m2 bid (S-1: BSA &amp;lt; 1.25m2, 40mg bid, 1.25m2 &amp;lt;/= BSA &amp;lt;/= 1.5m2, 50 mg bid, BSA &amp;gt; 1.5m2, 60 mg bid), po, day 1 to 14, q3w for a total of six to eight cycles.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Affiliated Tumor Hospital of Guangzhou Medical University</Name><Address1>Guangzhou</Address1><Address2>Guangdong</Address2><Address3>510095</Address3><CountrySubDivision>Guangdong</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>cuishuzhong@126.com</Email><Name>shuzhong cui, M.D</Name><Phone>0086-138-0251-3800</Phone></Contact><Contact type="Facility contact backup"><Email>57932181@qq.com</Email><Name>Zhen Tang, M.M</Name><Phone>0086-159-2081-9128</Phone></Contact><Contact type="Facility investigator"><Name>shuzhong cui, M.D</Name></Contact></Contacts></Site><Site><Name>Chinese PLA General Hospital</Name><Address1>Beijing</Address1><Address2>Beijing</Address2><Address3>100853</Address3><CountrySubDivision>Beijing</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>pengzheng301@sina.com</Email><Name>Zheng Peng, M.D</Name><Phone>0086-137-0132-3669</Phone></Contact><Contact type="Facility investigator"><Name>Zheng Peng, M.D</Name></Contact></Contacts></Site><Site><Name>Guangdong General Hospital</Name><Address1>Guangzhou</Address1><Address2>Guangdong</Address2><Address3>510080</Address3><CountrySubDivision>Guangdong</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>yuan821007@126.com</Email><Name>Yong Li, M.D</Name><Phone>0086-138-2217-7479</Phone></Contact><Contact type="Facility contact backup"><Email>648593454@qq.com</Email><Name>Ze-Jian Lv, M.M</Name><Phone>0086-137-9819-1490</Phone></Contact><Contact type="Facility investigator"><Name>Yong Li, M.D</Name></Contact></Contacts></Site><Site><Name>Guangdong Provincial Hospital of Traditional Chinese Medicine</Name><Address1>Guangzhou</Address1><Address2>Guangdong</Address2><Address3>510120</Address3><CountrySubDivision>Guangdong</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>gdphtcmwanjin@163.com</Email><Name>Jin Wang, M.D</Name><Phone>0086-136-0283-8202</Phone></Contact><Contact type="Facility contact backup"><Email>xiongwj1988@163.com</Email><Name>Wen-Jun Xiong, M.M</Name><Phone>0086-159-2055-3177</Phone></Contact><Contact type="Facility investigator"><Name>Jin Wang, M.D</Name></Contact></Contacts></Site><Site><Name>Harbin Medical University Cancer Hospital</Name><Address1>Harbin</Address1><Address2>Heilongjiang</Address2><Address3>150081</Address3><CountrySubDivision>Heilongjiang</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>88008008@sina.com</Email><Name>Kuan Wang, M.D</Name><Phone>0086-139-3624-3918</Phone></Contact><Contact type="Facility contact backup"><Email>zhuguanyu001@163.com</Email><Name>Guan-Yu Zhu, M.D</Name><Phone>0086-187-4612-6777</Phone></Contact><Contact type="Facility investigator"><Name>Kuan Wang, M.D</Name></Contact></Contacts></Site><Site><Name>Hebei Medical University Fourth Hospital</Name><Address1>Shijiazhuang</Address1><Address2>Hebei</Address2><Address3>050011</Address3><CountrySubDivision>Hebei</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>li_yong_hbth@126.com</Email><Name>Yong Li, M.D</Name><Phone>0086-311-8609-5678</Phone></Contact><Contact type="Facility contact backup"><Email>liuqingwei_10@163.com</Email><Name>Qing-Wei Liu, M.M</Name><Phone>0086-159-3105-9506</Phone></Contact><Contact type="Facility investigator"><Name>Yong Li, M.D</Name></Contact></Contacts></Site><Site><Name>Henan Cancer Hospital</Name><Address1>Zhengzhou</Address1><Address2>Henan</Address2><Address3>450008</Address3><CountrySubDivision>Henan</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>hnhanguangsen@126.com</Email><Name>Guang-Sen Han</Name><Phone>0086-138-0381-8006</Phone></Contact><Contact type="Facility contact backup"><Email>294859420@qq.com</Email><Name>Wei Yang, M.M</Name><Phone>0086-151-3893-9753</Phone></Contact><Contact type="Facility investigator"><Name>Guang-Sen Han</Name></Contact></Contacts></Site><Site><Name>Nanfang Hospital of Southern Medical University</Name><Address1>Guangzhou</Address1><Address2>Guangdong</Address2><Address3>510515</Address3><CountrySubDivision>Guangdong</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>gzliguoxin@163.com</Email><Name>Guo-Xin Li, M.D</Name><Phone>0086-138-0277-1450</Phone></Contact><Contact type="Facility contact backup"><Email>liuhaofbi@163.com</Email><Name>Hao Liu, M.D</Name><Phone>0086-138-2215-8578</Phone></Contact><Contact type="Facility investigator"><Name>Guo-Xin Li, M.D</Name></Contact></Contacts></Site><Site><Name>Sun Yat-sen University Cancer Center</Name><Address1>Guangzhou</Address1><Address2>Guangdong</Address2><Address3>510060</Address3><CountrySubDivision>Guangdong</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>zhouzhw@sysucc.org.cn</Email><Name>Zhi-Wei Zhou, M.D</Name><Phone>0086-139-0222-2859</Phone></Contact><Contact type="Facility contact backup"><Email>zhuxx@sysucc.org.cn</Email><Name>Xiao-Xi Zhu, M.B</Name><Phone>0086-138-0881-5489</Phone></Contact><Contact type="Facility investigator"><Name>Zhi-Wei Zhou, M.D</Name></Contact></Contacts></Site><Site><Name>The Second Hospital of Hebei Medical University</Name><Address1>Shijiazhuang</Address1><Address2>Hebei</Address2><Address3>050000</Address3><CountrySubDivision>Hebei</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>zhoubaojun67@hotmail.com</Email><Name>Bao-Jun Zhou, M.M</Name><Phone>0086-136-0311-7586</Phone></Contact><Contact type="Facility contact backup"><Email>13733314055@163.com</Email><Name>Shao-Wei Ma, M.M</Name><Phone>0086-137-3331-4055</Phone></Contact><Contact type="Facility investigator"><Name>Bao-Jun Zhou, M.M</Name></Contact></Contacts></Site><Site><Name>The second Xiangya Hospital of Central South University</Name><Address1>Changsha</Address1><Address2>Hunan</Address2><Address3>410011</Address3><CountrySubDivision>Hunan</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>Yaohl0326@163.com</Email><Name>Hong-Liang Yao, M.D</Name><Phone>0086-138-0845-2603</Phone></Contact><Contact type="Facility contact backup"><Email>13974991477@163.com</Email><Name>San-Lin Lei, M.D</Name><Phone>0086-139-7499-1477</Phone></Contact><Contact type="Facility investigator"><Name>Hong-Liang Yao, M.D</Name></Contact></Contacts></Site><Site><Name>Tianjin Medical University Cancer Institute and Hospital</Name><Address1>Tianjin</Address1><Address2>Tianjin</Address2><Address3>300060</Address3><CountrySubDivision>Tianjin</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>tjlianghan@126.com</Email><Name>Han Liang, M.M</Name><Phone>0086-130-1138-3125</Phone></Contact><Contact type="Facility contact backup"><Email>wxjsimon@163.com</Email><Name>Xue-Jun Wang, M.D</Name><Phone>0086-</Phone></Contact><Contact type="Facility investigator"><Name>Han Liang, M.M</Name></Contact></Contacts></Site><Site><Name>Wuhan Union Hospital, China</Name><Address1>Wuhan</Address1><Address2>Hubei</Address2><Address3>430030</Address3><CountrySubDivision>Hubei</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>tao_kaixiong@163.com</Email><Name>Kai-Xiong Tao, M.D</Name><Phone>0086-135-0715-5452</Phone></Contact><Contact type="Facility contact backup"><Email>wuke201288@126.com</Email><Name>Ke Wu, M.D</Name><Phone>0086-135-4524-8289</Phone></Contact><Contact type="Facility investigator"><Name>Kai-Xiong Tao, M.D</Name></Contact></Contacts></Site><Site><Name>Zhejiang Cancer Hospital</Name><Address1>Hanzhou</Address1><Address2>Zhejiang</Address2><Address3>310022</Address3><CountrySubDivision>Zhejiang</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>wangxb@zjcc.org.cn</Email><Name>Xin-Bao Wang, M.D</Name><Phone>0086-139-0652-3036</Phone></Contact><Contact type="Facility contact backup"><Email>huchao1987pj@126.com</Email><Name>Chao Hu, M.D</Name><Phone>0086-137-3589-3334</Phone></Contact><Contact type="Facility investigator"><Name>Xin-Bao Wang, M.D</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Stomach tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8008">Subjects with Locally Advanced Gastric Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8025">Subjects with adenocarcinoma of the gastroesophageal junction</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02356276</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Stomach tumor" id="12152"><Endpoint>Assessment of Survival</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Stomach tumor" id="12151"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12200"><Endpoint>Assessment of Disease Relapse/Recurrence</Endpoint><SubEndpoints><SubEndpoint disease="Stomach tumor" id="12202">Assessment of recurrence rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12207"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12222"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Stomach tumor" id="7912"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Stomach tumor" id="7934"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7935">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Stomach tumor" id="7936">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7943"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7949">Subjects with history of surgery/procedure for gastric cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7953"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7954">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Stomach tumor" id="7958">Subjects with normal/acceptable pulmonary function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7960"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7969">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="7981"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Stomach tumor" id="22491"><Criterion>Subjects with Adenocarcinoma of the Gastroesophageal Junction</Criterion></Inclusion><Inclusion disease="Stomach tumor" id="34019"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7956">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stomach tumor" id="34411"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7964">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Stomach tumor" id="9483"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="9484"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="9503"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="9511"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9512">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Stomach tumor" id="9516">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="25503"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9527">Subjects with inability/unwillingness to provide informed consent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="29406"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9538">Subjects with history of drug/substance abuse</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2022-01-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2015-01-29T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="24058"><TitleDisplay>FR-901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma</TitleDisplay><TitleOfficial>A Pilot Study Of FR-901228, Or Depsipeptide (NSC-630176) For Adult Patients With Advanced Hematological Cancers</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CDR0000069473</Identifier><Identifier type="NCT">NCT00042822</Identifier><Identifier type="Secondary Organisational">MSKCC-00116</Identifier><Identifier type="Secondary Organisational">NCI-1715</Identifier></Identifiers><Indications><Indication id="1272">Myelodysplastic syndrome</Indication><Indication id="1731">Acute myelogenous leukemia</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication></Indications><BiomarkerNames><BiomarkerName id="9345" role="Disease marker" type="Genomic;Proteomic">Histone H4</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>romidepsin</Name><Drug id="8023">romidepsin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8023">romidepsin</Drug><IndicationsPioneer><Indication id="1272">Myelodysplastic syndrome</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication></IndicationsPioneer><Companies><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="8023" type="Drug"><TargetEntity id="158963" type="siDrug">Romidepsin</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="22122" type="Company"><TargetEntity id="4296508772" type="organizationId">Memorial Sloan-Kettering Cancer Center</TargetEntity></SourceEntity><SourceEntity id="1272" type="ciIndication"><TargetEntity id="D46" type="ICD10"></TargetEntity><TargetEntity id="10028533" type="MEDDRA"></TargetEntity><TargetEntity id="D011289" type="MeSH"></TargetEntity><TargetEntity id="-376765165" type="omicsDisease"></TargetEntity><TargetEntity id="711" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1731" type="ciIndication"><TargetEntity id="D015470" type="MeSH"></TargetEntity><TargetEntity id="519" type="ORPHANET"></TargetEntity><TargetEntity id="-1550871001" type="omicsDisease"></TargetEntity><TargetEntity id="686" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="319" type="ciIndication"><TargetEntity id="10029547" type="MEDDRA"></TargetEntity><TargetEntity id="D008228" type="MeSH"></TargetEntity><TargetEntity id="547" type="ORPHANET"></TargetEntity><TargetEntity id="-1008757452" type="omicsDisease"></TargetEntity><TargetEntity id="703" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2574" type="Action"><TargetEntity id="1213" type="Mechanism">Histone Deacetylase (HDAC) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="22122">Memorial Sloan-Kettering Cancer Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20519">National Cancer Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="2574">Histone deacetylase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class><Class id="7293">Synergist</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="1647">Natural product</Technology><Technology id="80">Peptide</Technology><Technology id="1652">Prodrug</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>12</PatientCountEnrollment><PatientCountEvaluable>12</PatientCountEvaluable><DateStart>2002-05-31T00:00:00Z</DateStart><DateEnd type="actual">2005-03-01T00:00:00Z</DateEnd><DateChangeLast>2017-03-31T22:04:20Z</DateChangeLast><DateAdded>2008-09-03T11:46:20Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Memorial Sloan-Kettering Cancer Center</Affiliation><Name>Virginia Klimek</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Disease characteristics:&lt;ul&gt;&lt;li&gt;Histologically confirmed refractory or relapsed acute myeloid leukemia (AML)&lt;/li&gt;&lt;li&gt;Failed anthracycline-based chemotherapy&lt;/li&gt;&lt;li&gt;Ineligible for or refused allogeneic stem cell transplantation&lt;/li&gt;&lt;li&gt;Elderly patients with newly diagnosed AML&lt;/li&gt;&lt;li&gt;Ineligible for or refused standard chemotherapy&lt;/li&gt;&lt;li&gt;Histologically confirmed high-risk myelodysplastic syndromes&lt;/li&gt;&lt;li&gt;Eligible subtypes include:&lt;ul&gt;&lt;li&gt;Refractory anemia with excess blasts (RAEB)&lt;/li&gt;&lt;li&gt;RAEB in transformation&lt;/li&gt;&lt;li&gt;Chronic myelomonocytic leukemia&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Ineligible for or refused allogeneic bone marrow transplantation&lt;/li&gt;&lt;li&gt;Histologically confirmed intermediate-grade non-Hodgkin's lymphoma (NHL)&lt;/li&gt;&lt;li&gt;Relapsed after high-dose therapy or&lt;/li&gt;&lt;li&gt;Ineligible for allogeneic or autologous stem cell transplantation&lt;/li&gt;&lt;li&gt;Evaluable lesions by radiologic study or physical examination&lt;/li&gt;&lt;li&gt;Histologically confirmed follicular NHL&lt;/li&gt;&lt;li&gt;Progressed after anthracycline-based chemotherapy and rituximab&lt;/li&gt;&lt;li&gt;Evaluable lesions by radiologic study or physical examination&lt;/li&gt;&lt;li&gt;A new classification scheme for adult non-Hodgkin's lymphoma (NHL) has been adopted by PDQ. The terminology of indolent and aggressive lymphoma will replace the former terminology of low and intermediate or high grade lymphoma. However, this protocol uses the former terminology&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patient characteristics:&lt;ul&gt;&lt;li&gt;Age
18 years and over&lt;/li&gt;&lt;li&gt;Performance status:
Karnofsky 60 to 100%&lt;/li&gt;&lt;li&gt;Life expectancy:
not specified&lt;/li&gt;&lt;li&gt;Hematopoietic:
not specified&lt;/li&gt;&lt;li&gt;Hepatic:&lt;ul&gt;&lt;li&gt;Bilirubin no &gt; 1.5 mg/dl (unless due to Gilbert's syndrome)&lt;/li&gt;&lt;li&gt;SGOT and SGPT&amp;lt; 2 times upper limit of normal
&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Renal:&lt;ul&gt;&lt;li&gt;Creatinine no &gt; 1.5 mg/dl&lt;/li&gt;&lt;li&gt;Creatinine clearance at least 60 ml/min&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Cardiovascular:&lt;ul&gt;&lt;li&gt;Cardiac ejection fraction &gt; 50%&lt;/li&gt;&lt;li&gt;No cardiac hypertrophy&lt;/li&gt;&lt;li&gt;No known conduction heart disease&lt;/li&gt;&lt;li&gt;No New York Heart Association class III or IV heart disease that would make it difficult to assess patient during study participation&lt;/li&gt;&lt;li&gt;No significant prior heart disease&lt;/li&gt;&lt;li&gt;No significant prior secondary or tertiary heart block&lt;/li&gt;&lt;li&gt;No significant prior atrial or ventricular arrhythmia requiring therapeutic intervention or antiarrhythmics for rate control&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Pulmonary:&lt;ul&gt;&lt;li&gt;No severe debilitating pulmonary disease that would make it difficult to assess patient during study participation&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Other:&lt;ul&gt;&lt;li&gt;Not pregnant or nursing&lt;/li&gt;&lt;li&gt;Negative pregnancy test&lt;/li&gt;&lt;li&gt;Fertile patients must use effective contraception during and for 1 month after study participation&lt;/li&gt;&lt;li&gt;Potassium &gt;/= 4.0 mmol/l (supplementation allowed)&lt;/li&gt;&lt;li&gt;Magnesium &gt;/= 2.0 mg/dl (supplementation allowed)&lt;/li&gt;&lt;li&gt;No other concurrent active malignancy except basal cell skin cancer&lt;/li&gt;&lt;li&gt;No other concurrent significant co-morbidity that would make it difficult to assess patient during study participation&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Prior concurrent therapy:&lt;ul&gt;&lt;li&gt;Biological therapy:&lt;ul&gt;&lt;li&gt;See disease characteristics&lt;/li&gt;&lt;li&gt;At least 2 weeks since prior epoetin alfa or filgrastim (G-CSF)&lt;/li&gt;&lt;li&gt;At least 4 weeks since prior cytokines&lt;/li&gt;&lt;li&gt;No concurrent immunotherapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Chemotherapy:&lt;ul&gt;&lt;li&gt;See disease characteristics&lt;/li&gt;&lt;li&gt;At least 4 weeks since prior systemic chemotherapy&lt;/li&gt;&lt;li&gt;No other concurrent chemotherapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Endocrine therapy: not specified&lt;/li&gt;&lt;li&gt;Radiotherapy:&lt;ul&gt;&lt;li&gt;At least 4 weeks since prior radiotherapy&lt;/li&gt;&lt;li&gt;No concurrent radiotherapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Surgery: not specified&lt;/li&gt;&lt;li&gt;Other:&lt;ul&gt;&lt;li&gt;No other concurrent investigational agents&lt;/li&gt;&lt;li&gt;No concurrent drugs that may prolong the QTc interval&lt;/li&gt;&lt;li&gt;&lt;ulink linkType="Drug" linkID="8023"&gt;FR-901228&lt;/ulink&gt; may be administered after a five half lives washout period following the use of these drugs&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pharmacokinetics</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure><Measure><Description>Determine the disease response</Description></Measure><Measure><Description>Determine the pattern of adverse clinical experience in patients with myelodysplastic syndrome, acute myeloid leukemia, or intermediate-grade or follicular non-Hodgkin's lymphoma</Description></Measure><Measure><Description>Pharmacodynamics</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results were published in February 2008. The most common grade 3/4 toxicities were febrile neutropenia/infection (n = 5), neutropenia/thrombocytopenia (n = 9), nausea (n = 9), and asymptomatic hypophosphatemia (n = 3). Clinically significant cardiac toxicity was not observed [&lt;ulink linkType="Reference" linkID="1488018"&gt;1488018&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this phase II trial was   to study the effectiveness of &lt;ulink linkType="Drug" linkID="8023"/&gt;&lt;ulink linkType="Drug" linkID="8023"&gt;romidepsin&lt;/ulink&gt; in treating patients with myelodysplastic syndrome, acute myeloid leukemia, or non-Hodgkin's lymphoma.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results published in February 2008, showed that, 12 patients (9 with AML, 3 with MDS) received one to five cycles of &lt;ulink linkType="Drug" linkID="8023"&gt;romidepsin&lt;/ulink&gt;. Out of 11 patients assessed, best response was one complete remission in a patient with AML, stable disease in six patients, and progression of disease in four patients. Exploratory laboratory studies were performed, which showed that increases in apoptosis, were modest but rapid. Changes in myeloid maturation marker expression were also seen. Consistent changes were not observed in Histone H3 and H4 acetylation levels (n = 5) [&lt;ulink linkType="Reference" linkID="1488018"&gt;1488018&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Objectives of this study were to:
&lt;br/&gt;Determine the pattern of adverse clinical experience in patients with myelodysplastic syndrome, acute myeloid leukemia, or intermediate-grade or follicular non-Hodgkin's lymphoma treated with &lt;ulink linkType="Drug" linkID="8023"/&gt;&lt;ulink linkType="Drug" linkID="8023"&gt;romidepsin&lt;/ulink&gt;.
&lt;br/&gt;Determine the disease response in patients treated with &lt;ulink linkType="Drug" linkID="8023"/&gt;&lt;ulink linkType="Drug" linkID="8023"&gt;romidepsin&lt;/ulink&gt;.
&lt;br/&gt;Determine the pharmacokinetic and pharmacodynamic correlates of &lt;ulink linkType="Drug" linkID="8023"/&gt;&lt;ulink linkType="Drug" linkID="8023"&gt;romidepsin&lt;/ulink&gt;, including measurement of serum plasma levels, H3 and H4 acetylation, apoptosis induction, differentiation, and multidrug-resistant (MDR) phenotype expression in these patients.
&lt;/para&gt;&lt;para&gt;Patients would receive &lt;ulink linkType="Drug" linkID="8023"/&gt;&lt;ulink linkType="Drug" linkID="8023"&gt;romidepsin&lt;/ulink&gt; iv over 4 h on days 1 and 5. Courses would repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients were followed monthly.
A total of 12 patients would be accrued for this study within one year.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received a phase I dose of &lt;ulink linkType="Drug" linkID="8023"&gt;romidepsin&lt;/ulink&gt; (18 mg/m2, iv) on days 1 and 5 every 3 weeks [&lt;ulink linkType="Reference" linkID="1488018"&gt;1488018&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>romidepsin</Name><Drug id="8023">romidepsin</Drug><Dose unit="milligram/m2 dose">18.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="1280">Hypophosphatemia</Indication><CountPatientsTotal>12</CountPatientsTotal><CountPatientsAffected>3</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="1991">Neutropenia</Indication></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsTotal>12</CountPatientsTotal><CountPatientsAffected>9</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="324">Thrombocytopenia</Indication></AdverseEvent><AdverseEvent><Indication id="3795">Febrile neutropenia</Indication></AdverseEvent><AdverseEvent><Indication id="746">Infectious disease</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="359223">romidepsin</Intervention><Treatments><Treatment><Dose>18 milligram/m2</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Memorial Sloan-Kettering Cancer Center</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10021</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lymphoma</Disease><PatientSegments><PatientSegment><PatientSegment id="3489">Subjects with B Cell Non Hodgkin's Lymphoma</PatientSegment><SubSegments><SubSegment id="3473">Subjects with follicular lymphoma</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3490">Subjects with T Cell Non Hodgkin's Lymphoma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3525">Subjects with Relapse/Recurrent Lymphoma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="23734">Subjects with Specific Grade of Lymphoma</PatientSegment><SubSegments><SubSegment id="3500">Subjects with Indolent (slow-growing, low grade) Lymphoma</SubSegment><SubSegment id="3501">Subjects with Moderately Aggressive (intermediate grade) Lymphoma</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Leukemia</Disease><PatientSegments><PatientSegment><PatientSegment id="3973">Subjects at risk of developing disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3975">Subjects with Acute Leukemia Unspecified Type</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3977">Subjects with Acute Myeloid Leukemia (AML)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3999">Subjects with Treatment Resistant Disease</PatientSegment><SubSegments><SubSegment id="4000">Subjects with chemotherapy resistant disease</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="4003">Subjects with Relapsed/Recurrent Leukemia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Anemia</Disease><PatientSegments><PatientSegment><PatientSegment id="7541">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19884">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="7512">Subjects with Cancer/Cancer Chemotherapy Induced Anemia</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Myelodysplastic syndrome</Disease><PatientSegments><PatientSegment><PatientSegment id="8709">Subjects with Refractory Anemia (RA)</PatientSegment><SubSegments><SubSegment id="8713">Subjects with Refractory Anemia with Excess Blasts in Transformation (RAEB-T)</SubSegment><SubSegment id="8767">Subjects with Refractory Anemia with Excess Blasts (RAEB)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8720">Subjects with Chronic Myelomonocytic Leukemia (CMML)</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Myeloproliferative disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="8754">Subjects with Chronic Myelogenous Leukemia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00042822</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Leukemia" id="7981"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8078"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8136"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8140">Assessment of Clinical Efficacy</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Myeloproliferative disorder" id="14204"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Myeloproliferative disorder" id="14207">Assessment of Complete Response</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Myeloproliferative disorder" id="14240"><Endpoint>Assessment of Markers of Tumor Growth and Progression</Endpoint><SubEndpoints><SubEndpoint disease="Myeloproliferative disorder" id="14241">Assessment of markers of apoptosis</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Myeloproliferative disorder" id="14254"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Myeloproliferative disorder" id="14283"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Anemia" id="17297"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17306">Assessment of disease response</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Anemia" id="17334"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Anemia" id="17356"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Myeloproliferative disorder" id="14280"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Myeloproliferative disorder" id="14282">Assessment of toxicity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anemia" id="17353"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Anemia" id="17355">Assessment of toxicity</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Lymphoma" id="7604"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7573">Assessment of therapeutic response</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Lymphoma" id="7680"><Endpoint>Assessment of adverse events</Endpoint></OtherEndpoint><OtherEndpoint disease="Lymphoma" id="7739"><Endpoint>Assessment of Markers of Tumor Growth and Progression</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7730">Assessment of apoptosis markers</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Lymphoma" id="7775"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7784">Assessment of plasma drug concentrations</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Lymphoma" id="7788"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7790">Assessment of histone acetylation</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Leukemia" id="7906"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7908">Assessment of Complete Response</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Leukemia" id="7935"><Endpoint>Assessment of Disease Progression</Endpoint></OtherEndpoint><OtherEndpoint disease="Leukemia" id="7988"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint><OtherEndpoint disease="Leukemia" id="8036"><Endpoint>Assessment of Markers of Tumor Growth and Progression</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8041">Assessment of markers of apoptosis</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Leukemia" id="8049"><Endpoint>Assessment of Biomarkers</Endpoint></OtherEndpoint><OtherEndpoint disease="Leukemia" id="8071"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8072">Assessment of gene expression profile/signature</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Leukemia" id="8077"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Leukemia" id="8084"><Endpoint>Assessment of Cardiovascular Events</Endpoint></OtherEndpoint><OtherEndpoint disease="Myelodysplastic syndrome" id="11820"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Myelodysplastic syndrome" id="11827">Assessment of tumor response rate (Duration of response)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Myelodysplastic syndrome" id="11882"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lymphoma" id="3464"><Criterion>Subjects with B Cell Non Hodgkin's Lymphoma</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3448">Subjects with follicular lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3465"><Criterion>Subjects with T Cell Non Hodgkin's Lymphoma</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3474"><Criterion>Subjects with Specific Grade of Lymphoma</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3475">Subjects with indolent (slow-growing, low grade) lymphoma</SubCriterion><SubCriterion disease="Lymphoma" id="3476">Subjects with moderately aggressive (intermediate grade) lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3497"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3501">Subjects with disease measurable by imaging techniques</SubCriterion><SubCriterion disease="Lymphoma" id="3502">Subjects with disease measurable by physical examination</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3509"><Criterion>Subjects co-morbid with malignancy/tumor</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3518"><Criterion>Subjects with other hematological malignancies</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3519"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3536"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3542">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3548"><Criterion>Subjects Diagnosed Based on Histo-Pathological Examination</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3609"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="3614"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3615">Subjects with progressive/refractory lymphoma to chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3621"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3622">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Lymphoma" id="3633">Subjects with normal/acceptable cardiac function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3652"><Criterion>Subjects with Specific Biochemical Status</Criterion></Inclusion><Inclusion disease="Leukemia" id="4961"><Criterion>Subjects at Risk of Developing Disease</Criterion></Inclusion><Inclusion disease="Leukemia" id="4973"><Criterion>Subjects with Acute Leukemia Unspecified Type</Criterion></Inclusion><Inclusion disease="Leukemia" id="4980"><Criterion>Subjects with Myeloid Leukemia Unspecified Type</Criterion></Inclusion><Inclusion disease="Leukemia" id="4981"><Criterion>Subjects with Acute Myeloid Leukemia (AML)</Criterion></Inclusion><Inclusion disease="Leukemia" id="5031"><Criterion>Subjects with Other Bone Marrow Disorders</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5032">Subjects with myelodysplastic syndromes</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5036"><Criterion>Subjects co-morbid with malignancy/tumor</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5043">Subjects with non-hodgkin's lymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5063"><Criterion>Subjects Diagnosed by Specific Methods</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5065">Subjects with histo-pathologically confirmed leukemia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5071"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5073">Subjects with normal/adequate liver function</SubCriterion><SubCriterion disease="Leukemia" id="5075">Subjects with normal/acceptable cardiac function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5085"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5093">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5164"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5165">Subjects with progressive/refractory leukemia to chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5173"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Lymphoma" id="7083"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3561">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Lymphoma" id="3569">Subjects with history of anti-cancer biological therapy</SubCriterion><SubCriterion disease="Lymphoma" id="3576">Subject with history of treatment with any investigational agent</SubCriterion><SubCriterion disease="Lymphoma" id="3578">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="7092"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5102">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Leukemia" id="5120">Subjects with history of anti-cancer biological therapy</SubCriterion><SubCriterion disease="Leukemia" id="5125">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7583"><Criterion>Subjects with Refractory Anemia (RA)</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7585">Subjects with Refractory Anemia with Excess Blasts (RAEB)</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="7586">Subjects with Refractory Anemia with Excess Blasts in Transformation (RAEB-T)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7591"><Criterion>Subjects with Chronic Myelomonocytic Leukemia (CMML)</Criterion></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7612"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7619">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7631"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7633">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="7635">Subjects with normal/acceptable cardiac function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7637"><Criterion>Subjects with Specific Biochemical Status</Criterion></Inclusion><Inclusion disease="Myeloproliferative disorder" id="8741"><Criterion>Subjects with Chronic Myelogenous Leukemia</Criterion></Inclusion><Inclusion disease="Myeloproliferative disorder" id="8750"><Criterion>Subjects co-morbid with malignancy/tumor</Criterion></Inclusion><Inclusion disease="Myeloproliferative disorder" id="8751"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="8752">Subjects with disease measurable by physical examination</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="8753">Subjects with disease measurable by imaging techniques</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myeloproliferative disorder" id="8754"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Myeloproliferative disorder" id="8762"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="8769">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myeloproliferative disorder" id="8771"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion></Inclusion><Inclusion disease="Myeloproliferative disorder" id="8781"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="8784">Subjects with history of biological therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myeloproliferative disorder" id="8790"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Myeloproliferative disorder" id="13442"><Criterion>Subjects with Specific Eligibility for Stem Cell Therapy</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="13444">Myeloproliferative disorder subjects not eligible for stem cell therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="14364"><Criterion>Subjects with Cancer/Cancer Chemotherapy Induced Anemia</Criterion></Inclusion><Inclusion disease="Anemia" id="14406"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14414">Subjects co-morbid with premalignant/malignant condition</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="14418"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Anemia" id="14421">Subjects with specific Karnofsky performance status</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="14431"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Anemia" id="14435"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14436">Subjects with history of rHuEPO therapy</SubCriterion><SubCriterion disease="Anemia" id="15527">Subjects with history of biological therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="14451"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Anemia" id="14473"><Criterion>Subjects with Refractory Anemia</Criterion></Inclusion><Inclusion disease="Myeloproliferative disorder" id="33320"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="8774">Subjects with normal/acceptable cardiac function</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="8776">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="33342"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14428">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myeloproliferative disorder" id="33353"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="8782">Subjects with history of anti-cancer chemotherapy</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="8786">Subjects with history of anti-cancer radiotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anemia" id="33976"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Anemia" id="14429">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myeloproliferative disorder" id="33998"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="8777">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="34012"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3628">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34013"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5074">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="34033"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7634">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lymphoma" id="4692"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4702"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4761"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4762">Subject with history of radiotherapy</SubCriterion><SubCriterion disease="Lymphoma" id="4769">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Lymphoma" id="4777">Subject with history of biologics therapy</SubCriterion><SubCriterion disease="Lymphoma" id="4783">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="4810"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Leukemia" id="6534"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Leukemia" id="6554"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Leukemia" id="6660"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Leukemia" id="8709"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6618">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9160"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9161"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9188"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="9189">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="9193">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="9195">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9196"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10302"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="10310">Subjects with premalignant/malignant condition</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10304"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10335"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="10336">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="10340">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="10342">Subjects with history of/scheduled to receive an investigational drug</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="10945">Patient with history of immunotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10343"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Anemia" id="11815"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11823">Subjects with premalignant/malignant condition</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11817"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Anemia" id="11855"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Anemia" id="12934">Subjects with history of immunotherapy</SubCriterion><SubCriterion disease="Anemia" id="12936">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="11871"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Leukemia" id="26844"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6639">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myeloproliferative disorder" id="27083"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="10305">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anemia" id="27098"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Anemia" id="11818">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2005-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2002-08-05T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-09-03T11:46:20Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-06-20T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="264497"><TitleDisplay>Daily Sodium Intake in Anuric Hemodialysis Patients and Interdialytic Weight Gain</TitleDisplay><TitleOfficial>Daily Sodium Intake in Anuric Hemodialysis Patients and Interdialytic Weight Gain</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02792530</Identifier><Identifier type="Organisational Study">0654-15-RMC</Identifier></Identifiers><Indications><Indication id="2954">Weight gain</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sodium</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1012209" type="Company"><TargetEntity id="5035524657" type="organizationId">Rabin Medical Center</TargetEntity></SourceEntity><SourceEntity id="2954" type="ciIndication"><TargetEntity id="10000188" type="MEDDRA"></TargetEntity><TargetEntity id="D015430" type="MeSH"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1012209">Rabin Medical Center</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2016-08-31T00:00:00Z</DateStart><DateChangeLast>2016-09-03T16:02:54Z</DateChangeLast><DateAdded>2016-07-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>bnaiar@clalit.org.il</Email><Name>Benaya Rozen Zvi,., Ph.D</Name><Phone>972-50-8773766</Phone></Contact><Contact type="Public contact"><Email>merav.j.n@gmail.com</Email><Name>Merav Jacobson Naftali</Name><Phone>972-50-7778369</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Adults&amp;gt;18 years providing signed informed consent&lt;/li&gt;&lt;li&gt;Any patient more than 3 months in hemodialysis who reach his assigned dry weight&lt;/li&gt;&lt;li&gt;Intradialytic weight gain of more than 2.5 l or 4% of dry body weight in two mid-week sessions&lt;/li&gt;&lt;li&gt;Residual renal function of less than 200 ml per 24 h&lt;/li&gt;&lt;li&gt;Expected to stay on hemodialysis for at least 6 month&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Malnutrition as assessed by SGA: score C&lt;/li&gt;&lt;li&gt;Dementia&lt;/li&gt;&lt;li&gt;Active malignancy&lt;/li&gt;&lt;li&gt;Active infection&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Reduction in intradialytic weight gain (IDWG): reduction in the weight gain at two subsequent hemodialysis in kg</Description><Timeframe>Between baseline and 6 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in CRP values</Description><Timeframe>Between baseline and 6 weeks</Timeframe></Measure><Measure><Description>Changes in quality of life: assessed by SF 36</Description><Timeframe>Between baseline and 6 weeks</Timeframe></Measure><Measure><Description>Changes in subjective global assesment (SGA): SGA is a nutritional assesment measure</Description><Timeframe>Between baseline and 6 weeks</Timeframe></Measure><Measure><Description>Change in predialysis blood pressure</Description><Timeframe>Between baseline and 6 weeks</Timeframe></Measure><Measure><Description>Dietary sodium intake : as measured by food recall assesment</Description><Timeframe>At baseline and 6 weeks</Timeframe></Measure><Measure><Description>Number of hypotensive episode during dialysis: define as drop of &gt; 20 mm hg systolic blood pressure from baseline</Description><Timeframe>At baseline and 6 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study will evaluate the efficiency of dietary intervention on intradialytic weight      gain. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Uniric hemodialysis patients without serious dietary complications, who accumulate      above 2.5 kg (or above 4%) of their dry weight, will undergo a series of dietary      consultations for sodium restriction. Dietary consultation for sodium restriction to decrease dietary intake to 2 g/day less than the patients consume currently. Their intradialytic      weight accumulation will be measured   after 1 month of  intervention. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02792530</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="End stage renal disease" id="22570"><Endpoint>Assessment of dialysis</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="44909"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="45206"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="End stage renal disease" id="22539"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22540">Assessment of blood pressure</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22555"><Endpoint>Assessment of Fluid Balance</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22558">Assessment of hypotensive events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22559"><Endpoint>Assessment of Nutritional Status</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22570"><Endpoint>Assessment of dialysis</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22574">Assessment of dialytic complications</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22578"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22579">Quality of life(QOL)</SubEndpoint><SubEndpoint disease="End stage renal disease" id="22583">Assessment by Subject Global Assessment (SGA) Questionnaire</SubEndpoint><SubEndpoint disease="End stage renal disease" id="29426">Assessment by SF-36/SF-12</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22598"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="43820"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="44909"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="45223"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="End stage renal disease" id="17690"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Inclusion><Inclusion disease="End stage renal disease" id="17700"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="End stage renal disease" id="17518"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17531"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17533"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17535"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17534">Subjects co-morbid with malnutrition</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17555"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2017-05-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-07-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="265464"><TitleDisplay>Safety and Optimal Neuroprotection of Neu-2000 in Ischemic Stroke With Endovascular Recanalizion</TitleDisplay><TitleOfficial>A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess Efficacy and Safety of Neu-2000KWL in Patients With Acute Ischemic Stroke Receiving Endovascular Therapy</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02831088</Identifier><Identifier type="Organisational Study">NEU2000KWL-P01</Identifier><Identifier type="Trial Acronym">SONIC</Identifier></Identifiers><Indications><Indication id="3676">Ischemic stroke</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Neu-2000</Name><Drug id="56512">Neu-2000</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>endovascular therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>endovascular therapy</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="56512">Neu-2000</Drug><IndicationsPioneer><Indication id="3676">Ischemic stroke</Indication></IndicationsPioneer><Companies><Company><Company id="28073">GNT Pharma Co Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="56512" type="Drug"><TargetEntity id="384921" type="siDrug">Neu-2000</TargetEntity></SourceEntity><SourceEntity id="28073" type="Company"><TargetEntity id="5000069950" type="organizationId">GNT Pharma Co Ltd</TargetEntity></SourceEntity><SourceEntity id="3676" type="ciIndication"><TargetEntity id="10061256" type="MEDDRA"></TargetEntity><TargetEntity id="96" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>6</NumberOfSites><CompaniesSponsor><Company id="28073">GNT Pharma Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="17877">NMDA receptor epsilon 2 subunit inhibitor</Action><Action id="283">Noncompetitive NMDA antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1615">Neuroprotectant</Class><Class id="170">Free radical scavenger</Class><Class id="449">Antiarrhythmic agent</Class><Class id="659">Coagulation inhibitor</Class><Class id="7292">Vulnerary agent</Class><Class id="74">Antioxidant agent</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>210</PatientCountEnrollment><DateStart>2016-07-31T00:00:00Z</DateStart><DateEnd type="estimated">2018-12-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T22:34:31Z</DateChangeLast><DateAdded>2016-07-18T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>csan@gntpharma.com</Email><Name>Chun San An</Name><Phone>82-31-8005-9910</Phone></Contact><Contact type="Public contact"><Email>sicho@gntpharma.com</Email><Name>Sung Ig Cho</Name><Phone>82-31-8005-9910</Phone></Contact><Contact type="Scientific contact"><Affiliation>Ajou University Medical Centre</Affiliation><Name>Ji Man Hong, MD, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Adults  &gt;/= 19 years&lt;/li&gt;&lt;li&gt;Patients who were presented to hospitals after onset of brain ischemic symptoms from the base of last normal state and can start  endovascular therapy in accordance with standard practice guidelines within 8 h after the symptom onset&lt;/li&gt;&lt;li&gt;NIHSS scores on screening time point (admission) &gt;/=  8 points&lt;/li&gt;&lt;li&gt;Patients whose activity is possible without the help of others in the gen-eral condition 1 day before the ischemic stroke onset. and whose Barthel index scores exceed 90 points&lt;/li&gt;&lt;li&gt;Patients whose brain CT and CT angiography imaging confirmed acute ischemic stroke and symptomatic intracranial occlusion at screening and whose occlusion site considered the cause of acute ischemic stroke meets the following conditions:&lt;ul&gt;&lt;li&gt;Carotid T or L type occlusion&lt;/li&gt;&lt;li&gt;M1 MCA&lt;/li&gt;&lt;li&gt;M1-MCA equivalent (two or more M2-MCAs) However, anterior temporal artery is not regarded M2&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients with ASPECTS on Brain CT without early imaging hyper-enhancement  &gt;/= 6&lt;/li&gt;&lt;li&gt;Patients who spontaneously submitted a written informed consent to participation on this clinical study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;A medical history of hypersensitivity against aspirin (salicylates), sulfasalazine or (5-ASA) at screening&lt;/li&gt;&lt;li&gt;Patients who meets the exclusion criteria on imaging in intra-arterial re-canalization therapy&lt;ul&gt;&lt;li&gt;CTA patients whose imaging shows that the site of occlusion considered the cause of acute ischemic stroke meets the following conditions:&lt;ul&gt;&lt;li&gt;MCA + PCA or MCA + ACA occlusion in carotid T/L&lt;/li&gt;&lt;li&gt;Occlusion of a bilateral large artery&lt;/li&gt;&lt;li&gt;Simultaneous infiltration of anterior and posterior circulation&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Absence of the collateral circulation corresponding to one of the followings:&lt;ul&gt;&lt;li&gt;On CT angiography (MIP-CTA) imaging, absence or minimal collateral circulation at &gt;/= 50% of MCA territories, compared with pial filling of contralateral side of the lesion&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients whose heart diseases corresponding to following conditions were confirmed at screening:&lt;ul&gt;&lt;li&gt;Patients who were diagnosed with myocardial infarction within 6 months at screening&lt;/li&gt;&lt;li&gt;Patients who had severe arrhythmia evoking clinical symptoms (respiratory difficulties, tachycardia etc.) within 6 months at screening. Patients whose ECG measured at the stable state at emergency room confirmed the following results:&lt;ul&gt;&lt;li&gt;Pulse rate&amp;lt; 50 or &amp;gt; 120 beats per min&lt;/li&gt;&lt;li&gt;Second and third degree AV block is confirmed&lt;/li&gt;&lt;li&gt;Congenital or acquired QT syndrome is confirmed&lt;/li&gt;&lt;li&gt;Ventricular pre-excitation syndrome is confirmed&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients who were diagnosed with heart failure â¥ class II according to heart failure classification by NYHA (New York Heart Association) before screening. Heart failure classification by NYHA (New York Heart Association) Class I: patients with no limitation of activities; they suffer no symptoms from ordinary activities. Class II: patients with slight, mild limitation of activity; they are comfortable with rest or with mild exertion. Class III: patients with marked limitation of activity; they are comfortable only at rest. Class IV: patients who should be at complete rest, confined to bed or chair; any physical activity brings on&lt;/li&gt;&lt;li&gt;Patients who have contraindication to contrast media for brain imaging&lt;/li&gt;&lt;li&gt;Patients who are receiving renal replacement therapy such as dialysis, due to acute or chronic renal failure, nephropathy, etc. at screening&lt;/li&gt;&lt;li&gt;Patients who were diagnosed with cancer or received cancer therapy within 6 months at screening or have recurrent or transitional cancer&lt;/li&gt;&lt;li&gt;Patients who show high body temperature of 38 deg or more or who need antibiotic therapy due to medical opinion of infectious diseases at screening&lt;/li&gt;&lt;li&gt;Patients who take pharmacotherapy due to liver diseases such as hepatitis, liver cirrhosis etc. at screening&lt;/li&gt;&lt;li&gt;Patients who are pregnant or lactating. However, in case of a woman of child-bearing potential, only patients whose non-pregnancy was confirmed can participate in this clinical study&lt;/li&gt;&lt;li&gt;Patients who participated in other clinical studies within past 3 months at the screening time as a base. However, in case of participation in an observatory study without medication, the patients can participate in this clinical study&lt;/li&gt;&lt;li&gt;Patients who were determined unsuitable for participation in this clinical study due to other reasons&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Proportional Ratios of study subjects with mRS 0 to 2 scores at 12 weeks after Neu2000KWL treatment</Description><Timeframe>12 weeks</Timeframe></Measure><Measure><Description>Occurrence rate of cerebral hemorrhagic transformation occurring within 48 h based on parenchymal hematoma (PH) criteria by ECASS (European Co-operative Acute Stroke Study)-I and II</Description><Timeframe>12 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Distribution changes of mRS scores at 1, 4 and 12 weeks versus baseline (shift analysis)</Description><Timeframe>1, 4  and 12 weeks</Timeframe></Measure><Measure><Description>Occurrence rate of cerebral hemorrhagical transformation occurring within day 4 or  5 (day of the last treatment of the study drug): based on parenchymal hematoma (PH) criteria by ECASS (European Co-operative Acute Stroke Study)-I and II</Description><Timeframe>4 to 5 days</Timeframe></Measure><Measure><Description>Occurrence rate of symptomatic intracranial hemorrhage (SICH) described and defined by this study protocol occurring within day 4 or 5 (day of the last treatment of the study drug): It is defined as SICH of intracranial hemorrhage by brain imaging is confirmed and any one of the following conditions is accompanied: in case that NIHSS scores become worse two points or more, in case that NIHSS scores become worse one point or more, accompanying decreased consciousness C. in case that neurological deficits persist &gt;/= 24 h (and), in case of recurrence of stroke and progress deterioration, or in case that other medical causes are not related</Description><Timeframe>4 to 5 days</Timeframe></Measure><Measure><Description>Ratios of Barthel index &gt; 90 (&gt;/=  95) at 1, 4 and 12 weeks versus baseline</Description><Timeframe>1, 4  and 12 weeks</Timeframe></Measure><Measure><Description>Ratios of NIHSS 0 to 2 scores at 1, 4 and 12 weeks versus  baseline</Description><Timeframe>1, 4  and 12 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The &lt;ulink linkType="Drug" linkID="56512"&gt;Neu-2000&lt;/ulink&gt;,  was  investigated in acute      ischemic stroke patients receiving endovascular treatment to remove clot within 8 h      following stroke onset.&lt;br/&gt;The aim of this proof of concept, phase II, double-blinded, randomized, placebo-controlled, multicenter study  was to examine efficacy and safety of Neu-2000 in      acute ischemic stroke patients receiving endovascular thrombectomy within 8 h of stroke      onset [&lt;ulink linkType="Reference" linkID="1762992"&gt;1762992&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2077284"&gt;2077284&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Neu-2000  would  be administered before endovascular treatment. Patients would  receive placebo or Neu-2000 infusion 750 (high-dose) or 500 (low-dose) mg within 8 h following ischemic stroke onset followed by nine consecutive infusions of 500 or 250 mg at intervals of 12 h  [&lt;ulink linkType="Reference" linkID="2077284"&gt;2077284&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients would be randomly assigned to receive twice-daily doses of Neu-2000 or placebo for 5 days [&lt;ulink linkType="Reference" linkID="1762992"&gt;1762992&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="2077284"&gt;2077284&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="South Korea"><Sites><Site><Name>Ajou University Hospital</Name><Address1>Seoul</Address1><Address3>16499</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Chosun University Hospital</Name><Address1>Gwangju</Address1><Address3>61453</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Chungbuk National University Hospital</Name><Address1>Cheongju</Address1><Address3>28644</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Gachon University Gil Medical Center</Name><Address1>Incheon</Address1><Address3>21565</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Keimyung University Dongsan Medical Center</Name><Address1>Daegu</Address1><Address3>41931</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Kyungpook National University Hospital</Name><Address1>Daegu</Address1><Address3>41944</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Stroke</Disease><PatientSegments><PatientSegment><PatientSegment id="11631">Subjects with Ischemic Stroke</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11632">Subjects with Acute Stroke</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02831088</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Stroke" id="24223"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="24091">Assessment by Modified Rankin Scale (MRS) Score</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Stroke" id="24197"><Endpoint>Assessment of Hemorrhagic Complications</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="24198">Assessment of intracranial hemorrhage</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stroke" id="24200"><Endpoint>Assessment of Cerebrovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="24191">Assessment of hemorrhagic stroke</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stroke" id="24223"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Stroke" id="24090">Assessment by Barthel Activities of Daily Living Index</SubEndpoint><SubEndpoint disease="Stroke" id="24091">Assessment by Modified Rankin Scale (MRS) Score</SubEndpoint><SubEndpoint disease="Stroke" id="27540">Assessment by National Institute of Health Stroke Scale (NIHSS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stroke" id="24269"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Stroke" id="24179"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Stroke" id="20936"><Criterion>Stroke Subjects</Criterion><SubCriteria><SubCriterion disease="Stroke" id="20938">Subjects with ischemic stroke</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stroke" id="20939"><Criterion>Subjects with Acute Stroke</Criterion></Inclusion><Inclusion disease="Stroke" id="20973"><Criterion>Inclusion Based on Angiographic Criteria</Criterion><SubCriteria><SubCriterion disease="Stroke" id="20976">Acceptable vessel occlusion</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stroke" id="20984"><Criterion>Inclusion Based on CT Findings</Criterion></Inclusion><Inclusion disease="Stroke" id="20985"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Stroke" id="20986">Inclusion based on barthel index</SubCriterion><SubCriterion disease="Stroke" id="20988">Inclusion based on NIHSS</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stroke" id="21015"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion></Inclusion><Inclusion disease="Stroke" id="21016"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Stroke" id="21022">Subjects receiving/scheduled to receive stable medication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stroke" id="34168"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion><Inclusion disease="Stroke" id="34326"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Stroke" id="21025">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Stroke" id="18642"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Stroke" id="18650"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18656">Subjects co-morbid with myocardial infarction</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stroke" id="18651"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion></Exclusion><Exclusion disease="Stroke" id="18654"><Criterion>Subjects with history of cardiac surgery/intervention</Criterion></Exclusion><Exclusion disease="Stroke" id="18662"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Stroke" id="18692"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Stroke" id="18693"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Stroke" id="18695"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18700">Not suitable to take part in the trial as per the physician/investigator</SubCriterion><SubCriterion disease="Stroke" id="18701">Participating in another trial/administration of any investigational drug before wash out period</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stroke" id="25765"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18698">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stroke" id="25988"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18653">Subjects co-morbid with heart failure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stroke" id="28228"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18721">Subjects with unstable vital sign</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stroke" id="28258"><Criterion>Subjects co-morbid with Hepatic Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Stroke" id="18644">Subjects co-morbid with hepatitis</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-12-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-07-03T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-07-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-07-08T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="267612"><TitleDisplay>Airway Clearance By Exercising In Mild Cystic Fibrosis (ACE-CF): A Feasibility Study</TitleDisplay><TitleOfficial>Exercise Alone Versus Exercise And Positive Expiratory Pressure As A Form Of Airway Secretion Clearance In Adults With Mild Cystic Fibrosis-Related Respiratory Disease - A Feasibility Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">ACTRN12615001361594</Identifier><Identifier type="Secondary Organisational">ANZCTR369700</Identifier><Identifier type="Secondary Organisational">HREC/15/RAH/518 (R20151132)</Identifier><Identifier type="Trial Acronym">ACE-CF</Identifier></Identifiers><Indications><Indication id="711">Respiratory disease</Indication><Indication id="88">Cystic fibrosis</Indication></Indications><BiomarkerNames><BiomarkerName id="661" role="Disease marker" type="Genomic;Proteomic">Cystic fibrosis transmembrane conductance regulator</BiomarkerName><BiomarkerName id="1912" role="Therapeutic effect marker" type="Physiological">Forced Vital Capacity</BiomarkerName><BiomarkerName id="2029" role="Therapeutic effect marker" type="Physiological">Forced expiratory flow </BiomarkerName><BiomarkerName id="2713" role="Therapeutic effect marker" type="Physiological">Forced expiratory volume</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Fitbit Charge HR device</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>PariPEP S device</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>exercise</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>positive expiratory pressure therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>exercise</Name></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>positive expiratory pressure therapy</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1040687" type="Company"><TargetEntity id="5037969488" type="organizationId">Central Adelaide Local Health Network Inc</TargetEntity></SourceEntity><SourceEntity id="21852" type="Company"><TargetEntity id="4296055231" type="organizationId">La Trobe University</TargetEntity></SourceEntity><SourceEntity id="711" type="ciIndication"><TargetEntity id="J98.9" type="ICD10"></TargetEntity><TargetEntity id="10038683" type="MEDDRA"></TargetEntity><TargetEntity id="D012140" type="MeSH"></TargetEntity><TargetEntity id="-2143937119" type="omicsDisease"></TargetEntity><TargetEntity id="269" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="88" type="ciIndication"><TargetEntity id="E84" type="ICD10"></TargetEntity><TargetEntity id="10011762" type="MEDDRA"></TargetEntity><TargetEntity id="D003550" type="MeSH"></TargetEntity><TargetEntity id="586" type="ORPHANET"></TargetEntity><TargetEntity id="-1447400656" type="omicsDisease"></TargetEntity><TargetEntity id="288" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1040687">Central Adelaide Local Health Network Inc</Company><Company id="21852">La Trobe University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2016-03-23T00:00:00Z</DateStart><DateChangeLast>2018-08-17T06:37:45Z</DateChangeLast><DateAdded>2016-08-10T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Royal Adelaide Hospital</Affiliation><Email>nathan.ward2@sa.gov.au</Email><Name>Nathan Ward</Name><Phone>+61882225574</Phone></Contact><Contact type="Scientific contact"><Affiliation>Royal Adelaide Hospital</Affiliation><Email>nathan.ward2@sa.gov.au</Email><Name>Nathan Ward</Name><Phone>+61882225574</Phone></Contact><Contact type="Scientific contact"><Affiliation>Royal Adelaide Hospital</Affiliation><Email>nathan.ward2@sa.gov.au</Email><Name>Nathan Ward</Name><Phone>+61882225574</Phone></Contact><Contact type="Public contact"><Affiliation>Royal Adelaide Hospital</Affiliation><Email>nathan.ward2@sa.gov.au</Email><Name>Nathan Ward</Name><Phone>+61882225574</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosis of cystic fibrosis confirmed by positive sweat or identification of 2 CF-causing genetic mutations&lt;/li&gt;&lt;li&gt;FEV1&amp;gt; 69% at baseline&lt;/li&gt;&lt;li&gt;An active patient of the Royal Adelaide CF Service&lt;/li&gt;&lt;li&gt;Clinically stable (no new medications for 4 weeks, FEV1 within 10% of most recent value at time of baseline, upper respiratory tract infection free for 2 weeks)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Lacking capacity to provide informed consent&lt;/li&gt;&lt;li&gt;Post-lung transplant&lt;/li&gt;&lt;li&gt;Unwilling to participate&lt;/li&gt;&lt;li&gt;Current participation in another interventional study&lt;/li&gt;&lt;li&gt;Pregnant&lt;/li&gt;&lt;li&gt;Inability to understand written English&lt;/li&gt;&lt;li&gt;Pneumothorax in the last 6 months&lt;/li&gt;&lt;li&gt;Hemoptysis&amp;gt; 20 ml in the 4 weeks prior to baseline assessment&lt;/li&gt;&lt;li&gt;Positive culture for Burkholderia cepacia within the last year&lt;/li&gt;&lt;li&gt;Ative treatment for non-tuberculosis mycobacteria&lt;/li&gt;&lt;li&gt;Presence of a condition or abnormality that, in the opinion of the treating CF physician&lt;/li&gt;&lt;li&gt;Compromises the safety of the patient or would otherwise make them unsuitable for this study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Feasibility, by the ability to recruit at least 30% of identified eligible patients</Description><Timeframe>End of 12 months recruitment period</Timeframe></Measure><Measure><Description>Feasibility, by at least 80% of participants being adherent with the protocol at the end of the wash-in period and therefore eligible for randomization</Description><Timeframe>End of 4 weeks wash-in period</Timeframe></Measure><Measure><Description>Feasibility, by at least 80% of randomized participants completing the intervention phase and follow-up measurements</Description><Timeframe>End of 3 months intervention period</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Cough-related quality of life as assessed by the Leicester Cough Questionnaire</Description><Timeframe>End of wash-in and intervention periods</Timeframe></Measure><Measure><Description>Lung function as measured by spirometry (FEV1, FVC, FEF25 to 75)</Description><Timeframe>End of wash-in and intervention periods</Timeframe></Measure><Measure><Description>Respiratory symptom and treatment burden-related quality of life as assessed by the Cystic Fibrosis Questionnaire (revised)</Description><Timeframe>End of wash-in and intervention periods</Timeframe></Measure><Measure><Description>Acute respiratory exacerbation rate as measured by additional medications commenced for an increase in respiratory symptoms recorded on a purpose = specific event form</Description><Timeframe>End of wash-in and intervention periods</Timeframe></Measure><Measure><Description>Adverse events including but not limited to: hemoptysis, pneumothorax, new colonization of Pseudomonas aeruginosa/Burkholderia cepacia/non-tuberculosis mycobacteria, distal intestinal obstruction syndrome, new or significantly increased chest pain, new or significantly increased musculoskeletal pain, other. These will all be assessed by participant self-reporting to the investigators and casenote review (eg, for sputum results)</Description><Timeframe>End of wash-in and intervention periods</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study is to evaluate the effect of exercise alone versus exercise and positive expiratory pressure as a form of airway secretion clearance in participants with mild cystic fibrosis-related respiratory disease.&lt;/para&gt;&lt;para&gt;Participants will do 4  weeks of 'usual' care involving daily breathing exercises (PEP) and walking, running or step ups. After 4 weeks, those who will have adhered to these requirements will be randomly allocated to either continue this routine or to stop the PEP and to just continue with the walking, running or step ups for 3 months. Participants will be assessed before and after the 4 weeks of usual care and at the end of the 3 months intervention phase.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;All participants will initially undertake a  4 weeks wash-in period consisting of the control condition of exercise and positive expiratory pressure therapy (PEP). The exercise will consists of walking/running for 30 min or step-ups 6 x  5 min on a daily basis, with participants able to select which type of exercise they will do based on personal preference and external factors (eg, weather conditions). Intensity for all exercise = 3 to 5 on the Borg RPE scale.&lt;/para&gt;&lt;para&gt;Participants will be encouraged to huff/cough every 4 to 5 min during walking/running or at the end of the 5 min bout of step-ups. Rest time between step-ups will be of a duration sufficient to allow performance of these huffs/coughs. These sessions will be done independently at a location (eg,. home, local park) at the choosing of the participants. PEP will consist of six cycles of 15 breaths in a seated position through a PariPEP S device. The expiration will be slightly active, achieving a target pressure of 10 to 20 cm H2O.&lt;/para&gt;&lt;para&gt;Participants will be encouraged to perform two to three  huffs, to cough as needed and to then will have 1 to 2 min of relaxed breathing between each cycle. PEP will be performed at least once per day. Timing of PEP to exercise will be at the discretion of the participant. Participants reporting adherence with the regimen will then be eligible for randomization to either the control or intervention groups.&lt;/para&gt;&lt;para&gt;The intervention group will cease PEP and only perform the exercise regimen as outlined above. The intervention period will runs for 3 months. Adherence will be assessed by participant report at the face-to-face assessments and also by telephone calls from an investigator 1 and 2 months into the intervention period. Fitbit Charge HR devices will also be used to assess adherence based on active min recorded.   &lt;/para&gt;&lt;para&gt;After the wash-in period, as outlined in the intervention description, participants will be randomized to the control group  and will continue the same regimen used in the wash-in period of exercise and PEP for the 3 months intervention period. Adherence will be assessed by participant report at the face-to-face assessments and also by telephone calls from an investigator 1 and 2 months into the intervention period.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Australia"><Sites><Site><Name>The Royal Adelaide Hospital</Name><Address1>Adelaide</Address1><Address2>South Australia</Address2><Address3>5000 - Adelaide</Address3><CountrySubDivision>South Australia</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cystic fibrosis</Disease><PatientSegments><PatientSegment><PatientSegment id="9555">Subjects with Diagnosis of Cystic Fibrosis</PatientSegment><SubSegments><SubSegment id="9556">Subjects with mutation in the gene for CFTR protein</SubSegment><SubSegment id="9557">Subjects with abnormal sweat test (sweat chloride &gt;60 mEq/liter)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="9559">Cystic Fibrosis Subjects with Lung Manifestation</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9567">Subjects with H/O or Scheduled For Treatment of Cystic Fibrosis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12798">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-1050276350" id="19370">CFTR_HUMAN_Mutation</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1011">Australian New Zealand Clinical Trials Registry (ANZCTR)</Name><Identifiers><Identifier type="Secondary Organisational">ACTRN12615001361594</Identifier><Identifier type="Secondary Organisational">ANZCTR369700</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Cystic fibrosis" id="14151"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Cystic fibrosis" id="14049"><Endpoint>Assessment of Forced Expiratory Volume in One Second (FEV1)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cystic fibrosis" id="14052"><Endpoint>Assessment of Forced Vital Capacity (FVC)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cystic fibrosis" id="14074"><Endpoint>Assessment of Respiratory System/Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cystic fibrosis" id="14076"><Endpoint>Assessment of Exacerbations</Endpoint><SubEndpoints><SubEndpoint disease="Cystic fibrosis" id="14077">Assessment by Frequency/duration of exacerbations</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cystic fibrosis" id="14087"><Endpoint>Assessment of Clinical Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cystic fibrosis" id="14105"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Cystic fibrosis" id="29662">Cystic fibrosis questionnaire (CFQ)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cystic fibrosis" id="14117"><Endpoint>Assessment of Sputum</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cystic fibrosis" id="14130"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Cystic fibrosis" id="14131">Assessment of adverse events/treatment emergent adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cystic fibrosis" id="45072"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cystic fibrosis" id="46080"><Endpoint>Assessment of Forced Expiratory Flow (FEF)</Endpoint><SubEndpoints><SubEndpoint disease="Cystic fibrosis" id="14070">Forced expiratory flow 25-75%</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Cystic fibrosis" id="16426"><Criterion>Clinically Stable CF Subjects</Criterion></Inclusion><Inclusion disease="Cystic fibrosis" id="16427"><Criterion>Subjects with Confirmed Diagnosis of Cystic Fibrosis</Criterion><SubCriteria><SubCriterion disease="Cystic fibrosis" id="16428">Subjects with abnormal sweat test </SubCriterion><SubCriterion disease="Cystic fibrosis" id="16429">Subjects enrolled based on genetic analysis for CFTR mutation</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cystic fibrosis" id="16433"><Criterion>Subjects with Sino-Pulmonary Manifestations</Criterion></Inclusion><Inclusion disease="Cystic fibrosis" id="16447"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Inclusion><Inclusion disease="Cystic fibrosis" id="16461"><Criterion>Subjects with Abnormal Pulmonary Function Parameters</Criterion><SubCriteria><SubCriterion disease="Cystic fibrosis" id="16462">Subjects with abnormal/required FEV1 levels</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Cystic fibrosis" id="13603"><Criterion>Subjects with Complications of Cystic Fibrosis</Criterion><SubCriteria><SubCriterion disease="Cystic fibrosis" id="13605">Subjects colonized with burkholderia cepacia species</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cystic fibrosis" id="13607"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Cystic fibrosis" id="13616"><Criterion>Subjects with/Predisposed to Local/Systemic Infections</Criterion><SubCriteria><SubCriterion disease="Cystic fibrosis" id="13619">Subjects with/predisposed to tuberculosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cystic fibrosis" id="13620"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Cystic fibrosis" id="13633"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Cystic fibrosis" id="13634">Subjects history of/requiring lung transplant</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cystic fibrosis" id="13637"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cystic fibrosis" id="13639">Subjects unwilling/unable to provide informed consent</SubCriterion><SubCriterion disease="Cystic fibrosis" id="13641">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cystic fibrosis" id="25472"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Cystic fibrosis" id="13640">Subjects not suitable to participate as per investigator's discretion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cystic fibrosis" id="26487"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Cystic fibrosis" id="27797"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Cystic fibrosis" id="13638">Subjects unable/unwilling to comply with protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-08-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="26937"><TitleDisplay>Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure</TitleDisplay><TitleOfficial>A Phase II Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">M01-366</Identifier><Identifier type="NCT">NCT00038662</Identifier><Identifier type="NCT Alias">NCT00084994</Identifier></Identifiers><Indications><Indication id="3246">Hormone refractory prostate cancer</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>atrasentan</Name><Drug id="12151">atrasentan</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12151">atrasentan</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="13601">Abbott Laboratories</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="12151" type="Drug"><TargetEntity id="226636" type="siDrug">Atrasentan</TargetEntity></SourceEntity><SourceEntity id="13601" type="Company"><TargetEntity id="4295903265" type="organizationId">Abbott Laboratories</TargetEntity></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="770" type="Action"><TargetEntity id="141" type="Mechanism">Endothelin ETA Receptor Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>40</NumberOfSites><CompaniesSponsor><Company id="13601">Abbott Laboratories</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="770">Endothelin ET-A receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2657">Antihypertensive</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2002-05-31T00:00:00Z</DateStart><DateChangeLast>2013-12-02T16:18:04Z</DateChangeLast><DateAdded>2008-09-17T05:51:46Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Abbott</Affiliation><Name>Darryl Sleep, M.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Prostate adenocarcinoma&lt;/li&gt;&lt;li&gt;Radical prostatectomy&lt;/li&gt;&lt;li&gt;PSA between 0.4 and 5 ng/ml&lt;/li&gt;&lt;li&gt;PSADT&amp;lt; 1 year
&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Previous hormonal therapy&lt;/li&gt;&lt;li&gt;Salvage therapy to the pelvis within 3 months prior to randomization&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects, as measured by the rate of rise in PSA</Description></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study was to evaluate the safety and efficacy of 10 mg &lt;ulink linkType="Drug" linkID="12151"&gt;atrasentan&lt;/ulink&gt; in hormone naive subjects as measured by rate of rise in the PSA (primary objective).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Chuq Pavillon Hotel-Dieu</Name><Address1>Quebec</Address1><Address3>G1R 2J6</Address3><Contacts></Contacts></Site><Site><Name>Cross Cancer Institute</Name><Address1>Edmonton</Address1><Address2>Alberta</Address2><Address3>T6G1Z2</Address3><CountrySubDivision>Alberta</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Cal Andreou, MD</Name><Address1>Surrey</Address1><Address2>British Columbia</Address2><Address3>V3V 1N1</Address3><CountrySubDivision>British Columbia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Can-Med Medical Research Inc</Name><Address1>Victoria</Address1><Address2>British Columbia</Address2><CountrySubDivision>British Columbia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Bruce W. Palmer Urology Inc.</Name><Address1>Kentville</Address1><Address2>Nova Scotia</Address2><Address3>B4N4K9</Address3><CountrySubDivision>Nova Scotia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Jack Barkin, MD</Name><Address1>North York</Address1><Address2>Ontario</Address2><Address3>M6A 3B5</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Burlington Professional Centre</Name><Address1>Burlington</Address1><Address2>Ontario</Address2><Address3>L7N 3V2</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site><Site><Name>London Health Sciences Centre</Name><Address1>London</Address1><Address2>Ontario</Address2><Address3>N6A 4G5</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site><Site><Name>The Male Health Centres</Name><Address1>Barrie</Address1><Address2>Ontario</Address2><Address3>L4M 4S5</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site><Site><Name>The Male Health Centres</Name><Address1>Oakville</Address1><Address2>Ontario</Address2><Address3>L6H 3P1</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Quest Clinical Trials</Name><Address1>Markham</Address1><Address2>Ontario</Address2><Address3>L6B1A1</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Guardian Medical Arts Bldg.</Name><Address1>North Bay</Address1><Address2>Ontario</Address2><Address3>P1B4Z2</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Sunnybrook &amp;Women's College Health Sciens Center</Name><Address1>Toronto</Address1><Address2>Ontario</Address2><Address3>M4N 3M5</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Hopital Notre-Dame</Name><Address1>Montreal</Address1><Address2>Quebec</Address2><Address3>H2L 4M1</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Tom Baker Cancer Center</Name><Address1>Calgary,</Address1><Address2>Alberta</Address2><Address3>T2N 4N2</Address3><CountrySubDivision>Alberta</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Hamilton &amp; District Urology Association</Name><Address1>Hamilton,</Address1><Address2>Ontario</Address2><Address3>L8N 1T8</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Alaska Clinical Research Center, LLC</Name><Address1>Anchorage</Address1><Address2>Alaska</Address2><Address3>99508</Address3><CountrySubDivision code="AK">Alaska</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Arkansas Urologial Associates, PA</Name><Address1>Little Rock</Address1><Address2>Arkansas</Address2><Address3>72205</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>San Diego Urology Center</Name><Address1>La Mesa</Address1><Address2>California</Address2><Address3>91942</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Western Clinical Research Inc</Name><Address1>Torrance</Address1><Address2>California</Address2><Address3>90505</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Georgetown University Medical Center</Name><Address1>Washington</Address1><Address2>District of Columbia</Address2><Address3>20007</Address3><CountrySubDivision code="DC">District of Columbia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Southeastern Urological Center, PA</Name><Address1>Tallahassee</Address1><Address2>Florida</Address2><Address3>32308</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Northwestern University</Name><Address1>Chicago</Address1><Address2>Illinois</Address2><Address3>60611</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Johns Hopkins Oncology Center</Name><Address1>Baltimore</Address1><Address2>Maryland</Address2><Address3>21231-1000</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Sheldon Freedman MD</Name><Address1>Las Vegas</Address1><Address2>Nevada</Address2><Address3>89109</Address3><CountrySubDivision code="NV">Nevada</CountrySubDivision><Contacts></Contacts></Site><Site><Name>VA Medical Center(111)</Name><Address1>Reno</Address1><Address2>Nevada</Address2><Address3>89502</Address3><CountrySubDivision code="NV">Nevada</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Nevada Urology Associates</Name><Address1>Reno</Address1><Address2>Nevada</Address2><Address3>89511</Address3><CountrySubDivision code="NV">Nevada</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Cleveland Clinic Foundation</Name><Address1>Cleveland</Address1><Address2>Ohio</Address2><Address3>44195</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Oregon Urology Specialists</Name><Address1>Eugene</Address1><Address2>Oregon</Address2><Address3>97401</Address3><CountrySubDivision code="OR">Oregon</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University Of Pittsburgh</Name><Address1>Pittsburgh</Address1><Address2>Pennsylvania</Address2><Address3>15232</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Urological Assoc. of Lancaster</Name><Address1>Lancaster</Address1><Address2>Pennsylvania</Address2><Address3>17604-3200</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Ntouch Research Corporation</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75230</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Salt Lake Research</Name><Address1>Salt Lake City</Address1><Address2>Utah</Address2><Address3>84124</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Washington Medical Center</Name><Address1>Seattle</Address1><Address2>Washington</Address2><Address3>98195</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Urology Centers Of Alabama</Name><Address1>Homewood,</Address1><Address2>Alabama</Address2><Address3>35205</Address3><CountrySubDivision code="AL">Alabama</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Clinical Physiology Associates</Name><Address1>FORT MYERS</Address1><Address2>Florida</Address2><Address3>33916</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Carolinas Medical Centre</Name><Address1>Charlotte,</Address1><Address2>North Carolina</Address2><Address3>28204</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Urologic Specialists Of Oklahoma, Inc.</Name><Address1>Tulsa,</Address1><Address2>Oklahoma</Address2><Address3>74104-5433</Address3><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Center for Urologic Care</Name><Address1>West Reading,</Address1><Address2>Pennsylvania</Address2><Address3>19611</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Jeffrey Frankel, M.D.</Name><Address1>Seattle,</Address1><Address2>Washington</Address2><Address3>98166-3059</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Prostate tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="12018">Subjects with adenocarcinoma of prostate</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00038662</Identifier><Identifier type="NCT Alias">NCT00084994</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate tumor" id="7129"><Endpoint>Assessment of Prostate Specific Antigen(PSA) Dependent Variables</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Prostate tumor" id="7152"><Endpoint>Assessment of Other Prostate Specific Markers</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Prostate tumor" id="7189"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Prostate tumor" id="7129"><Endpoint>Assessment of Prostate Specific Antigen(PSA) Dependent Variables</Endpoint></OtherEndpoint><OtherEndpoint disease="Prostate tumor" id="7152"><Endpoint>Assessment of Other Prostate Specific Markers</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Prostate tumor" id="3714"><Criterion>Subjects with Histologically/Cytologically Confirmed Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3715">Subjects with adenocarcinoma of prostate</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3716"><Criterion>Subjects with Prostate Specific Laboratory Values</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3719">Subjects with specified PSA levels</SubCriterion><SubCriterion disease="Prostate tumor" id="3722">Subjects with specified PSA doubling time</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3745"><Criterion>Subjects on Prior/Concurrent Therapy for Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3749">Subjects with prior/concurrent surgery</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Prostate tumor" id="4965"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4966">Subjects with history of/scheduled to receive hormone therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4975"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-09-17T05:51:46Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="270875"><TitleDisplay>Non-neoplastic Epithelial Disorders of Vulva and High Intensity Focused Ultrasound</TitleDisplay><TitleOfficial>Treatment of Non-neoplastic Epithelial Disorders of Skin and Mucosa of Vulva With High Intensity Focused Ultrasound</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02890277</Identifier><Identifier type="Organisational Study">JNJQ201408</Identifier></Identifiers><Indications><Indication id="2232">Vulva disease</Indication><Indication id="95">Dermatological disease</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>high intensity focused ultrasound</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>Fu Tiankang disposable vaginal filling suppository</Name></Intervention><Intervention type="InterventionPrimary"><Name>albothyl (policresulen solution)</Name></Intervention><Intervention type="InterventionPrimary"><Name>chitosan gel</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1079250" type="Company"><TargetEntity id="5038070966" type="organizationId">JiNan Military General Hospital</TargetEntity></SourceEntity><SourceEntity id="2232" type="ciIndication"><TargetEntity id="10047754" type="MEDDRA"></TargetEntity><TargetEntity id="D014845" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="95" type="ciIndication"><TargetEntity id="10040831" type="MEDDRA"></TargetEntity><TargetEntity id="D012871" type="MeSH"></TargetEntity><TargetEntity id="-57728907" type="omicsDisease"></TargetEntity><TargetEntity id="442" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1079250">Chinese PLA General Hospital of Jinan Military Command</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>120</PatientCountEnrollment><DateStart>2016-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2017-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-05-11T08:18:20Z</DateChangeLast><DateAdded>2016-09-14T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>ygpwylll@hotmail.com</Email><Name>Geping Yin, M.D.</Name><Phone>86-0531-51666230</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with clinically and biopsy confirmed non-neoplastic lesions of genital skin and mucous membrane (non-neoplasia epithelial disorders of skin and mucosa of vulva). Symptoms include repeated itching, discoloration, rhagades, loss of skin elasticity and dyspareunia that affect the patients' quality of life&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Atypical hyperplasia or vulvar cancer confirmed by biopsy of genital lesions&lt;/li&gt;&lt;li&gt;Vulvovaginal or other gynecological trauma, acute inflammatory diseases and other acute illness in need of urgent care&lt;/li&gt;&lt;li&gt;Combined with other serious gynecological diseases (symptomatic hysteromyoma, ovarian tumor, etc), and/or severe organ diseases (such as heart, lung, brain and renal disease/failure) that need immediate treatment&lt;/li&gt;&lt;li&gt;Other type of cancers that require urgent care&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Grading changes of nonneoplastic epithelial disorders from colposcopy and biopsy pathology: the data from colposcopy and biopsy pathology were collected before and after treatment to create the objective identifying degree of the disease by with 'grading methods' and evaluate the treatment effect</Description><Timeframe>1 month before treatment and 2, 4, 6 weeks and 2, 6, 12, 24 months after treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;In this study, the investigators combined the      technology of high intensity focused ultrasound (HIFU) (ultrasound device made by Mianyang      Sonic electronic LLC, Mianyang China, registration number: 2005-2230099) with special drug      to treat.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The data from colposcopy and biopsy pathology will be collected before and after      treatment to create the objective identifying degree of the disease by with 'grading      methods' and evaluate the treatment effect. At the meantime, the standardized treatment      procedure, methods and efficacy criterion will be all stipulated to achieve satisfactory      results, which will be used to clinical treatments. Patients will receive the high intensity focused ultrasound (Mianyang Sonic electronic LLC) and drugs: Fu Tiankang disposable vaginal filling suppository, albothyl (policresulen solution) , and the gynecological medical antimicrobial dressing gel (chitosan gel).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Jinan Military General Hospital</Name><Address1>Jinan</Address1><Address2>Shandong</Address2><Address3>250031</Address3><CountrySubDivision>Shandong</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>ygpwylll@hotmail.com</Email><Name>Geping Yin, M.D.</Name><Phone>86-0531-51666230</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other genitourinary disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18253">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="17361">Subjects with vulvar disease</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02890277</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other genitourinary disease" id="43587"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other genitourinary disease" id="33052"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other genitourinary disease" id="24057"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other genitourinary disease" id="24603">Subjects with comorbid cervical/uterine diseases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other genitourinary disease" id="24302"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2017-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2015-02-14T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-09-14T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="273409"><TitleDisplay>Safety and Efficacy Adipose-Derived Stem Cell Injection Partial Thickness Rotator Cuff Tears</TitleDisplay><TitleOfficial>Safety and Efficacy of Adult Adipose-Derived Stem Cell Injections Into Partial Thickness Rotator Cuff Tears</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02918136</Identifier><Identifier type="Organisational Study">RTC-001</Identifier></Identifiers><Indications><Indication id="3361">Tendon injury</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>adipose tissue-derived autologous stem cell therapy (cartilage repair, osteoarthritis, tendon injury, knee injury), InGeneron</Name><Drug id="85945">adipose tissue-derived autologous stem cell therapy (cartilage repair, osteoarthritis, tendon injury, knee injury), InGeneron</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>cortisone</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="85945">adipose tissue-derived autologous stem cell therapy (cartilage repair, osteoarthritis, tendon injury, knee injury), InGeneron</Drug><IndicationsPioneer><Indication id="3361">Tendon injury</Indication></IndicationsPioneer><Companies><Company><Company id="1047965">InGeneron Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1047965" type="Company"><TargetEntity id="5014532127" type="organizationId">InGeneron Inc</TargetEntity></SourceEntity><SourceEntity id="3361" type="ciIndication"><TargetEntity id="10043242" type="MEDDRA"></TargetEntity><TargetEntity id="D013708" type="MeSH"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1047965">InGeneron Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="6195">Collagen modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class><Class id="7292">Vulnerary agent</Class></Class><Technologies><Technology id="878">Adipose stem cell therapy</Technology><Technology id="856">Autologous stem cell therapy</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="596">Injectable formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>18</PatientCountEnrollment><DateStart>2016-12-31T00:00:00Z</DateStart><DateEnd type="actual">2018-12-13T00:00:00Z</DateEnd><DateChangeLast>2018-12-18T08:46:24Z</DateChangeLast><DateAdded>2016-11-10T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Sanford Orthopedics &amp; Sports Medicine - Sioux Falls, SD</Affiliation><Name>Jason Hurd, M.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Males and females 30 to 75 years of age&lt;/li&gt;&lt;li&gt;Clinical symptoms consistent with a rotator cuff lesion including but not limited to pain, muscle weakness, or active-limited range of motion (AROM)&lt;/li&gt;&lt;li&gt;Subjects who have not responded to physical therapy treatments for at least 6 weeks&lt;/li&gt;&lt;li&gt;Subjects with&amp;gt; 70% passive range of motion (PROM)&lt;/li&gt;&lt;li&gt;Diagnosed with&amp;gt; 50% tear to supraspinatus muscle or &amp;lt; 5 mm separation assessed by MRI&lt;/li&gt;&lt;li&gt;Diagnosed with a partial-thickness rotator cuff tear&lt;/li&gt;&lt;li&gt;The ability of subjects to give appropriate consent or have an appropriate representative available&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;lt; 30 or &amp;gt; 75 years&lt;/li&gt;&lt;li&gt;Insufficient amount of subcutaneous tissue to allow recovery of 50 cc of lipoaspirate&lt;/li&gt;&lt;li&gt;History of systemic malignant neoplasms within last five years&lt;/li&gt;&lt;li&gt;History of local neoplasm within the last 6 months and any history of local neoplasm at site of administration&lt;/li&gt;&lt;li&gt;Subject is receiving immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (eg, human immunodeficiency virus, systemic lupus erythematosus, etc)&lt;/li&gt;&lt;li&gt;Subjects who are known to be HIV positive&lt;/li&gt;&lt;li&gt;Patients who have received a corticosteroid injection in rotator cuff site within last 3 months&lt;/li&gt;&lt;li&gt;Severe arthrosis of the glenohumeral or acromioclavicular joint&lt;/li&gt;&lt;li&gt;Irreparable rotator cuff tear (including rotator cuff tear arthropathy)&lt;/li&gt;&lt;li&gt;Fatty atrophy above grade 2 in affected shoulder&lt;/li&gt;&lt;li&gt;Previous shoulder surgeries in affected shoulder&lt;/li&gt;&lt;li&gt;History of tobacco use within the last 3 months&lt;/li&gt;&lt;li&gt;Any contraindications to MRI scan according to MRI guidelines, or unwillingness to undergo MRI procedures&lt;/li&gt;&lt;li&gt;Patients on an active regimen of chemotherapy&lt;/li&gt;&lt;li&gt;Patients with a documented history of liver disease or an ALT value&amp;gt; 400&lt;/li&gt;&lt;li&gt;Allergy to sodium citrate of any 'caine' type of local anesthetic&lt;/li&gt;&lt;li&gt;Patients pregnant or breast feeding&lt;/li&gt;&lt;li&gt;Subject is in the opinion of the Investigator or designee, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason. This includes completion of Patient Reported Outcome instruments&lt;/li&gt;&lt;li&gt;Subject is currently participating in another clinical trial that has not yet completed its primary endpoint&lt;/li&gt;&lt;li&gt;Subject is part of a vulnerable population who, in the judgment of the investigator, is unable to give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include: Individuals with mental disability, persons in nursing homes, children, impoverished persons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention&lt;/li&gt;&lt;li&gt;Uncooperative patients or those with neurological/psychiatric disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Safety evaluation as indicated by collection of adverse events</Description><Timeframe>Enrollment through 12 months of follow-up</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this prospective, randomized, multi-site study was to evaluate the safety and efficacy of adult adipose-derived stem cell injections (&lt;ulink linkType="Drug" linkID="85945"&gt;adipose tissue-derived autologous stem cell&lt;/ulink&gt;) in subjects with      rotator cuff injuries.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would fall into two categories: treatment group (12 subjects) and non-treatment or      control group (six subjects). The treatment group would undergo a small liposuction procedure      and receive rotator cuff repair treatment with an ultrasound-guided injection of 5 cc      adipose-derived stem cells (ADSCs) into the point of injury. The control group would receive      a 5 cc cortisone injection into the point of injury.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Sanford Orthopedics and Sports Medicine - Fargo</Name><Address1>Fargo</Address1><Address2>North Dakota</Address2><Address3>58103</Address3><CountrySubDivision code="ND">North Dakota</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Sanford orthopedics and Sports Medicine - Sioux Falls</Name><Address1>Sioux Falls</Address1><Address2>South Dakota</Address2><Address3>57104</Address3><CountrySubDivision code="SD">South Dakota</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other musculoskeletal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18266">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16578"> Subjects with Tendinopathy</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02918136</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other musculoskeletal disease" id="43042"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other musculoskeletal disease" id="34307"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="32740">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other musculoskeletal disease" id="24093"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24173"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="24176">Subjects with elevated Alanine aminotransferase (ALT)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24183"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24962"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="24090">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other musculoskeletal disease" id="25891"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="24182">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-07-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2017-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>6.03 Months</EnrollmentPeriod><EnrollmentRate>2.99 Patients/Month</EnrollmentRate><DateFirstReceived>2016-09-26T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-11-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-01-11T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-07-08T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="275222"><TitleDisplay>Validation of portable sleep monitoring device in sleep breathing disorder patients</TitleDisplay><TitleOfficial>Validation of portable sleep monitoring device in sleep breathing disorder patients</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">KCT0002098</Identifier><Identifier type="Other">AJIRB-DEV-DE2-14-102</Identifier></Identifiers><Indications><Indication id="1490">Sleep apnea</Indication></Indications><BiomarkerNames><BiomarkerName id="257" role="Therapeutic effect marker" type="Physiological">Oxygen desaturation index</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ApneaLink Plus</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1079166" type="Company"><TargetEntity id="5050990734" type="organizationId">Ajou University Hospital</TargetEntity></SourceEntity><SourceEntity id="1117997" type="Company"><TargetEntity id="5048817971" type="organizationId">National Evidence-based Healthcare Collaborating Agency</TargetEntity></SourceEntity><SourceEntity id="1490" type="ciIndication"><TargetEntity id="G47.3" type="ICD10"></TargetEntity><TargetEntity id="327.2" type="ICD9"></TargetEntity><TargetEntity id="10040979" type="MEDDRA"></TargetEntity><TargetEntity id="D012891" type="MeSH"></TargetEntity><TargetEntity id="-1599540692" type="omicsDisease"></TargetEntity><TargetEntity id="79" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1117997">NECA â National Evidence-based healthcare Collaborating Agency</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1079166">Ajou University Hospital</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2014-07-23T00:00:00Z</DateStart><DateEnd type="actual">2016-05-31T00:00:00Z</DateEnd><DateChangeLast>2016-10-27T05:28:16Z</DateChangeLast><DateAdded>2016-10-27T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Ajou University Hospital</Affiliation><Name>Kim Hyun Jun</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients aged 4 years or older who took sleep test for sleep related breathing disorder such as snoring or apnea&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with severe diseases such as congenital malformation disorder&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Apnea-hypopnea index</Description><Timeframe>After scoring of sleep test</Timeframe></Measure><Measure><Description>Risk Indicator</Description><Timeframe>After scoring of sleep test</Timeframe></Measure><Measure><Description>Unclassified Apnea Index</Description><Timeframe>After scoring of sleep test</Timeframe></Measure><Measure><Description>Obstructive Apnea Index</Description><Timeframe>After scoring of sleep test</Timeframe></Measure><Measure><Description>Central Apnea Index</Description><Timeframe>After scoring of sleep test</Timeframe></Measure><Measure><Description>Mixed Apnea Index</Description><Timeframe>After scoring of sleep test</Timeframe></Measure><Measure><Description>Oxygen desaturation index</Description><Timeframe>After scoring of sleep test</Timeframe></Measure><Measure><Description>snoring event</Description><Timeframe>After scoring of sleep test</Timeframe></Measure><Measure><Description>Respiratory disturbance index</Description><Timeframe>After scoring of sleep test</Timeframe></Measure><Measure><Description>snoring time</Description><Timeframe>After scoring of sleep test</Timeframe></Measure><Measure><Description>hypopnea index</Description><Timeframe>After scoring of sleep test</Timeframe></Measure><Measure><Description>flow limitation</Description><Timeframe>After scoring of sleep test</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;There are few devices that can precisely differentiate central apnea from obstructive apnea yet. ResMed from Australia developed and started to provide a portable device named ApneaLink Plus which can distinguish between central and obstructive apnea but there are no studies on the effectiveness or accuracy of it. Therefore, in this research, we will study on the effectiveness or accuracy of the ApneaLink Plus.Compare and analyze between the results from ApneaLink Plus simultaneously tested with formal polysomnography and from ApneaLink Plus tested at home. Â &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will execute formal polysomnography and ApneaLink Plus device simultaneously and in addition, test with ApneaLink only home and compare and analyze the results respectively&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="South Korea"><Sites><Site><Name>Ajou University Hospital</Name><Address1>Suwon</Address1><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Sleep apnea</Disease><PatientSegments><PatientSegment><PatientSegment id="11209">Subjects with Snoring Due to Sleep Apnea</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1010">Korea Clinical Research Information Service (CRiS)</Name><Identifiers><Identifier></Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Sleep apnea" id="25070"><Endpoint>Assessment of Clinical Symptoms</Endpoint><SubEndpoints><SubEndpoint disease="Sleep apnea" id="25074">Assessment of snoring</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Sleep apnea" id="25079"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Sleep apnea" id="25080">Assessment by apnea-hypopnea index [AHI]</SubEndpoint><SubEndpoint disease="Sleep apnea" id="25081">Assesment by apnea index [AI]</SubEndpoint><SubEndpoint disease="Sleep apnea" id="25082">Assesment by hypopnea index [HI]</SubEndpoint><SubEndpoint disease="Sleep apnea" id="25083">Assessment by obstructive apnea index</SubEndpoint><SubEndpoint disease="Sleep apnea" id="25084">Assessment by central apnea index</SubEndpoint><SubEndpoint disease="Sleep apnea" id="25085">Assessment by mixed apnea index</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Sleep apnea" id="25143"><Endpoint>Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Sleep apnea" id="25149">Assessment of oxygen desaturation</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Sleep apnea" id="25206"><Endpoint>Assessment of Risk Factors</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Sleep apnea" id="20795"><Criterion>Subjects with Diagnosis of Sleep Apnea</Criterion></Inclusion><Inclusion disease="Sleep apnea" id="20810"><Criterion>Subjects with Symptomatic Disease</Criterion><SubCriteria><SubCriterion disease="Sleep apnea" id="20813">Subjects with snoring</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Sleep apnea" id="18927"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-10-27T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="287344"><TitleDisplay>Japanese Idiopathic Interstitial Pneumonias Registry</TitleDisplay><TitleOfficial>Japanese Idiopathic Interstitial Pneumonias Registry</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03041623</Identifier><Identifier type="Organisational Study">NEJ030</Identifier><Identifier type="Trial Acronym">JIPS</Identifier></Identifiers><Indications><Indication id="360">Pneumonia</Indication><Indication id="3771">Idiopathic pulmonary fibrosis</Indication></Indications><BiomarkerNames><BiomarkerName id="1912" role="Disease marker" type="Physiological">Forced Vital Capacity</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1082745" type="Company"><TargetEntity id="5039682527" type="organizationId">NPO North East Japan Study Group</TargetEntity></SourceEntity><SourceEntity id="14881" type="Company"><TargetEntity id="4298428312" type="organizationId">Boehringer Ingelheim International GmbH</TargetEntity></SourceEntity><SourceEntity id="360" type="ciIndication"><TargetEntity id="10035664" type="MEDDRA"></TargetEntity><TargetEntity id="D011014" type="MeSH"></TargetEntity><TargetEntity id="-104071315" type="omicsDisease"></TargetEntity><TargetEntity id="4597" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3771" type="ciIndication"><TargetEntity id="J84.112" type="ICD10"></TargetEntity><TargetEntity id="10021240" type="MEDDRA"></TargetEntity><TargetEntity id="D054990" type="MeSH"></TargetEntity><TargetEntity id="2032" type="ORPHANET"></TargetEntity><TargetEntity id="-1110748304" type="omicsDisease"></TargetEntity><TargetEntity id="289" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>86</NumberOfSites><CompaniesSponsor><Company id="1082745">North East Japan Study Group</Company></CompaniesSponsor><CompaniesCollaborator><Company id="14881">Boehringer Ingelheim International GmbH</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>800</PatientCountEnrollment><DateStart>2016-12-31T00:00:00Z</DateStart><DateEnd type="estimated">2021-03-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T15:37:28Z</DateChangeLast><DateAdded>2017-02-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>b980013@yahoo.co.jp</Email><Name>Ryo Okuda, MD</Name><Phone>+81-45-701-9581</Phone></Contact><Contact type="Scientific contact"><Affiliation>Kanagawa Cardiovascular and Respiratory Center</Affiliation><Name>Takashi Ogura, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients aged between 20 and 84 years&lt;/li&gt;&lt;li&gt;Patients with idiopathic pulmonary fibrosis (IPF) and other IIPs diagnosis within 6 months before registration at each facility&lt;/li&gt;&lt;li&gt;Patients from whom written informed consent has been obtained regarding participation in this study and follow-up observation&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients for whom the tests (such as the lung function test) conducted in this study could not be performed&lt;/li&gt;&lt;li&gt;Patients who underwent pulmonary resection&lt;/li&gt;&lt;li&gt;Patients undergoing dialysis&lt;/li&gt;&lt;li&gt;Patients with cancer treated at the time of registration or those planning to receive treatment in the future&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Data on current practice patterns for diagnosis of IIPs: describe the frequency of surgical lung biopsy, bronchoalveolar lavage</Description><Timeframe>Three to four years</Timeframe></Measure><Measure><Description>Prevalence of each categorized IIPs: investigate the prevalence of each categorized IIPs by using a recent guideline</Description><Timeframe>Three to four years</Timeframe></Measure><Measure><Description>Natural history of each categorized IIPs: describe the natural history of each categorized IIPs, focusing on CT findings, FVC changes, medications, and causes of death</Description><Timeframe>Three to four years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Hospital admission for acute exacerbations of IIPs: to evaluate incidences, therapy and prognosis of acute respiratory deterioration in patients with IIPs</Description><Timeframe>Three to four years</Timeframe></Measure><Measure><Description>Mean change of patient-reported outcome (Saint George Respiratory Questionnaire, COPD assessment test, and Dyspnea-12) every12 months from baseline</Description><Timeframe>Three to four years</Timeframe></Measure><Measure><Description>Progression-free survival by category of IIPs</Description><Timeframe>Three to four years</Timeframe></Measure><Measure><Description>Quantitative evaluation of CT findings</Description><Timeframe>Three to four years</Timeframe></Measure><Measure><Description>Validation of second multidisciplinary discussion: multidisciplinary discussion (MDD) held by independent central reviewers will be conducted twice at the time of registration and final observation using questionnaire. Concordance rate for diagnosis and disease behavior in each case between the time of registration and final observation will be evaluated</Description><Timeframe>Three to four years</Timeframe></Measure><Measure><Description>Validation of new guideline: if there are changes in IIPs diagnostic guidelines or severity classification during this study, these changes will be verified</Description><Timeframe>Three to four years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;An objective of JIPS Registry is to examine disease behavior  of idiopathic interstitial      pneumonias (IIPs), considering classification, background, and diagnostic methods based on      American Thoracic Society (ATS)/European Respiratory Society(ERS)/Japanese Respiratory      Society (JRS)/Latin American Thoracic Association (ALAT) guidelines for diagnosis and the      ATS/ERS classification of 2002 and 2013.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;JIPS Registry is a multisite, non-interventional, prospective observation study of patients      with newly diagnosed IIPs in Japan. At least 600 patients will be registered for 16 months      at approximately 80 sites in Japan.&lt;/para&gt;&lt;para&gt;Primary research question is to determine the natural history of each category of IIPs at      registration, patient background and diagnosis methods will be considered. Furthermore, the      present treatment patterns and disease behavior (CT and forced vital capacity (FVC) changes,      as well as changes in interstitial pneumonia markers, etc) will also be investigated.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Asahikawa Medical University Hospital</Name><Address1>Asahikawa</Address1><Address2>Hokkaido</Address2><Address3>078-8510</Address3><CountrySubDivision>Hokkaido</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yoshinori Minami, MD</Name><Phone>+81-166-69-3290</Phone></Contact><Contact type="Facility investigator"><Name>Yoshinobu Osaki, MD</Name></Contact></Contacts></Site><Site><Name>Aso Iizuka Hospital</Name><Address1>Iizuka</Address1><Address2>Fukuoka</Address2><Address3>820-8505</Address3><CountrySubDivision>Fukuoka</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Kosuke Tsuruno, MD</Name><Phone>+81-948-22-3800</Phone></Contact><Contact type="Facility investigator"><Name>Kazunori Tobino, MD</Name></Contact></Contacts></Site><Site><Name>Chiba University Hospital</Name><Address1>Chiba</Address1><Address3>260-8677</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Mitsuhiro Abe, MD</Name><Phone>+81-43-222-7171</Phone></Contact><Contact type="Facility investigator"><Name>Koichiro Tatsumi, MD</Name></Contact></Contacts></Site><Site><Name>Dokkyo Medical University Hospital</Name><Address1>Tochigi</Address1><Address3>321-0293</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yasuo Shimizu, MD</Name><Phone>+81-282-87-2151</Phone></Contact><Contact type="Facility investigator"><Name>Yoshiki Ishi, MD</Name></Contact></Contacts></Site><Site><Name>Dokkyo Medical University Koshigaya Hospital</Name><Address1>Koshigaya</Address1><Address2>Saitama</Address2><Address3>343-8555</Address3><CountrySubDivision>Saitama</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yasutsugu Fukushima, MD</Name><Phone>+81-48-965-1111</Phone></Contact><Contact type="Facility investigator"><Name>Yasutsugu Fukushima, MD</Name></Contact></Contacts></Site><Site><Name>Ehime Prefectural Central Hospital</Name><Address1>Matsuyama</Address1><Address2>Ehime</Address2><Address3>790-0024</Address3><CountrySubDivision>Ehime</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Tomoya Katsuta, MD</Name><Phone>+81-89-947-1111</Phone></Contact><Contact type="Facility investigator"><Name>Norihiko Nakanishi, MD</Name></Contact></Contacts></Site><Site><Name>Fujita Health University Hospital</Name><Address1>Toyoake</Address1><Address2>Aichi</Address2><Address3>470-1192</Address3><CountrySubDivision>Aichi</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Kazuyoshi Imaizumi, MD</Name><Phone>+81-562-93-9241</Phone></Contact><Contact type="Facility investigator"><Name>Kazuyoshi Imaizumi, MD</Name></Contact></Contacts></Site><Site><Name>Fukuoka University Chikushi Hospital</Name><Address1>Chikushino</Address1><Address2>Fukuoka</Address2><Address3>818-8502</Address3><CountrySubDivision>Fukuoka</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yuji Yoshida, MD</Name><Phone>+81-92-921-1011</Phone></Contact><Contact type="Facility investigator"><Name>Nobuhiko Nagata, MD</Name></Contact></Contacts></Site><Site><Name>Fukuoka University Hospital</Name><Address1>Fukuoka</Address1><Address3>814-0180</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Hiroshi Ishii, MD</Name><Phone>+81-92-801-1011</Phone></Contact><Contact type="Facility investigator"><Name>Kentaro Watanabe, MD</Name></Contact></Contacts></Site><Site><Name>Fukushima Medical University Hospital</Name><Address1>Fukushima</Address1><Address3>960-1295</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Takefumi Nikaido, MD</Name><Phone>+81-24-547-1360</Phone></Contact><Contact type="Facility investigator"><Name>Yoshinori Tanino, MD</Name></Contact></Contacts></Site><Site><Name>Gunma University Hospital</Name><Address1>Maebashi</Address1><Address2>Gunma</Address2><Address3>371-8511</Address3><CountrySubDivision>Gunma</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yasuhiko Koga, MD</Name><Phone>+81-27-220-8123</Phone></Contact><Contact type="Facility investigator"><Name>Yasuhiko Koga, MD</Name></Contact></Contacts></Site><Site><Name>Hamamatsu Rosai Hospital</Name><Address1>Hamamatsu</Address1><Address2>Shizuoka</Address2><Address3>430-8525</Address3><CountrySubDivision>Shizuoka</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Mikio Toyoshima, MD</Name><Phone>+81-53-462-1211</Phone></Contact><Contact type="Facility investigator"><Name>Mikio Toyoshima, MD</Name></Contact></Contacts></Site><Site><Name>Hamamatsu University Hospital</Name><Address1>Hamamatsu</Address1><Address2>Shizuoka</Address2><Address3>431-3126</Address3><CountrySubDivision>Shizuoka</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>suda@hama-med.ac.jp</Email><Name>Tomoyuki Fujisawa, MD</Name><Phone>+81-53-435-2111</Phone></Contact><Contact type="Facility investigator"><Name>Takafumi Suda, MD</Name></Contact></Contacts></Site><Site><Name>Haruhi Respiratory Medical Hospital</Name><Address1>Kiyosu</Address1><Address2>Aichi</Address2><Address3>452-0962</Address3><CountrySubDivision>Aichi</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yasuo Kohashi, MD</Name><Phone>+81-52-400-7111</Phone></Contact><Contact type="Facility investigator"><Name>Yuji Saito, MD</Name></Contact></Contacts></Site><Site><Name>Hirosaki University Hospital</Name><Address1>Hirosaki</Address1><Address2>Aomori</Address2><Address3>036-8562</Address3><CountrySubDivision>Aomori</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Kageaki Taima, MD</Name><Phone>+81-172-39-5469</Phone></Contact><Contact type="Facility investigator"><Name>Sadatomo Tasaka, MD</Name></Contact></Contacts></Site><Site><Name>Hiroshima Prefectural Hospital</Name><Address1>Hiroshima</Address1><Address3>734-8530</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Nobuhisa Ishikawa, MD</Name><Phone>+81-82-254-1818</Phone></Contact><Contact type="Facility investigator"><Name>Nobuhisa Ishikawa, MD</Name></Contact></Contacts></Site><Site><Name>Hiroshima University Hospital</Name><Address1>Hiroshima</Address1><Address3>734-8551</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yasushi Horimasu, MD</Name><Phone>+81-82-257-5196</Phone></Contact><Contact type="Facility contact backup"><Name>Masako Watanabe, MD</Name></Contact><Contact type="Facility investigator"><Name>Noboru Hattori, MD</Name></Contact></Contacts></Site><Site><Name>Ibarakihigashi National Hospital</Name><Address1>Naka</Address1><Address2>Ibaraki</Address2><Address3>319-1113</Address3><CountrySubDivision>Ibaraki</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Naoki Arai, MD</Name><Phone>+81-29-282-1151</Phone></Contact><Contact type="Facility investigator"><Name>Takefumi Saito, MD</Name></Contact></Contacts></Site><Site><Name>Iwate Prefectural Central Hospital</Name><Address1>Morioka</Address1><Address2>Iwate</Address2><Address3>020-0066</Address3><CountrySubDivision>Iwate</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yoshiaki Mori, MD</Name><Phone>+81-19-653-1151</Phone></Contact><Contact type="Facility investigator"><Name>Yoshiaki Mori, MD</Name></Contact></Contacts></Site><Site><Name>JR Tokyo General Hospital</Name><Address1>Tokyo</Address1><Address3>151-8528</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Mizuki Fukuoka, MD</Name><Phone>+81-3-3320-2200</Phone></Contact><Contact type="Facility investigator"><Name>Yoshihito Yamada, MD</Name></Contact></Contacts></Site><Site><Name>Japanese Red Cross Ise Hospital</Name><Address1>Ise</Address1><Address2>Mie</Address2><Address3>516-8512</Address3><CountrySubDivision>Mie</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Hajime Sasano, MD</Name><Phone>+81-596-28-2171</Phone></Contact><Contact type="Facility investigator"><Name>Motoaki Tanigawa, MD</Name></Contact></Contacts></Site><Site><Name>Japanese Red Cross Medical Center</Name><Address1>Tokyo</Address1><Address3>150-8935</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Takehiro Izumo, MD</Name><Phone>+81-3-3400-1311</Phone></Contact><Contact type="Facility investigator"><Name>Takehiro Izumo, MD</Name></Contact></Contacts></Site><Site><Name>Japanese Red Cross Saitama Hospital</Name><Address1>Saitama</Address1><Address3>330-8553</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Shintaro Sato, MD</Name><Phone>+81-48-852-1111</Phone></Contact><Contact type="Facility investigator"><Name>Hidekazu Matsushima, MD</Name></Contact></Contacts></Site><Site><Name>Jichi Medical University</Name><Address1>Shimotsuke</Address1><Address2>Tochigi</Address2><Address3>329-0498</Address3><CountrySubDivision>Tochigi</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Hiroyoshi Yamauchi, MD</Name><Phone>+81-285-58-7350</Phone></Contact><Contact type="Facility investigator"><Name>Masashi Bando, MD</Name></Contact></Contacts></Site><Site><Name>Juntendo University Hospital</Name><Address1>Tokyo</Address1><Address3>113-8431</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Motoyasu Kato, MD</Name><Phone>+81-3-3813-3111</Phone></Contact><Contact type="Facility investigator"><Name>Motoyasu Kato, MD</Name></Contact></Contacts></Site><Site><Name>Kagoshima University Hospital</Name><Address1>Kagoshima</Address1><Address3>890-8520</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Takuya Samukawa, MD</Name><Phone>+81-99-275-6481</Phone></Contact><Contact type="Facility investigator"><Name>Hiromasa Inoue, MD</Name></Contact></Contacts></Site><Site><Name>Kameda Medical Center</Name><Address1>Kamogawa</Address1><Address2>Chiba</Address2><Address3>296-8602</Address3><CountrySubDivision>Chiba</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Satoshi Noma, MD</Name><Phone>+81-4-7092-2211</Phone></Contact><Contact type="Facility investigator"><Name>Masahiro Aoshima, MD</Name></Contact></Contacts></Site><Site><Name>Kanagawa Cardiovascular and Respiratory Center</Name><Address1>Yokohama</Address1><Address2>Kanagawa</Address2><Address3>236-0051</Address3><CountrySubDivision>Kanagawa</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>b980013@yahoo.co.jp</Email><Name>Ryo Okuda, MD</Name><Phone>+81-45-701-9581</Phone></Contact><Contact type="Facility investigator"><Name>Tomohisa Baba, MD</Name></Contact><Contact type="Facility investigator"><Name>Takashi Ogura, MD</Name></Contact><Contact type="Facility investigator"><Name>Ryo Okuda, MD</Name></Contact></Contacts></Site><Site><Name>Kanazawa University Hospital</Name><Address1>Kanazawa</Address1><Address2>Ishikawa</Address2><Address3>920-8641</Address3><CountrySubDivision>Ishikawa</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Satoshi Watanabe, MD</Name><Phone>+81-76-265-2274</Phone></Contact><Contact type="Facility investigator"><Name>Kazuo Kasahara, MD</Name></Contact></Contacts></Site><Site><Name>Kinki University Hospital</Name><Address1>Osakasayama</Address1><Address2>Osaka</Address2><Address3>589-8511</Address3><CountrySubDivision>Osaka</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Osamu Nishiyama, MD</Name><Phone>+81-72-366-0221</Phone></Contact><Contact type="Facility investigator"><Name>Yuji Tohda, MD</Name></Contact></Contacts></Site><Site><Name>Kobe City Medical Center General Hospital</Name><Address1>Kobe</Address1><Address2>Hyogo</Address2><Address3>650-0047</Address3><CountrySubDivision>Hyogo</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Atsushi Nakagawa, MD</Name><Phone>+81-78-302-4321</Phone></Contact><Contact type="Facility investigator"><Name>Keisuke Tomii, MD</Name></Contact></Contacts></Site><Site><Name>Kobe City Medical Center West Hospital</Name><Address1>Kobe</Address1><Address2>Hyogo</Address2><Address3>653-0013</Address3><CountrySubDivision>Hyogo</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Hiromi Tomioka, MD</Name><Phone>+81-78-576-5251</Phone></Contact><Contact type="Facility investigator"><Name>Hiromi Tomioka, MD</Name></Contact></Contacts></Site><Site><Name>Kochi medical School Hospital</Name><Address1>Nankoku</Address1><Address2>Kochi</Address2><Address3>783-8505</Address3><CountrySubDivision>Kochi</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Kazufumi Takamatsu, MD</Name><Phone>+81-88-866-5811</Phone></Contact><Contact type="Facility investigator"><Name>Hiroshi Onishi, MD</Name></Contact></Contacts></Site><Site><Name>Kumamoto University Hospital</Name><Address1>Kumamoto</Address1><Address3>860-8556</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Kimitaka Akaike, MD</Name><Phone>+81-96-373-5012</Phone></Contact><Contact type="Facility investigator"><Name>Hidenori Ichiyasu, MD</Name></Contact></Contacts></Site><Site><Name>Kurashiki Central Hospital</Name><Address1>Kurashiki</Address1><Address2>Okayama</Address2><Address3>710-8602</Address3><CountrySubDivision>Okayama</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Reoto Takei, MD</Name><Phone>+81-86-422-0210</Phone></Contact><Contact type="Facility investigator"><Name>Machiko Arita, MD</Name></Contact></Contacts></Site><Site><Name>Kurume University Hospital</Name><Address1>Kurume</Address1><Address2>Fukuoka</Address2><Address3>830-0011</Address3><CountrySubDivision>Fukuoka</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Masaki Okamoto, MD</Name><Phone>+81-942-31-7560</Phone></Contact><Contact type="Facility investigator"><Name>Tomoaki Hoshino, MD</Name></Contact></Contacts></Site><Site><Name>Kyorin University Hospital</Name><Address1>Mitaka</Address1><Address2>Tokyo</Address2><Address3>181-8611</Address3><CountrySubDivision>Tokyo</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Kojiro Honada, MD</Name><Phone>+81-422-47-5511</Phone></Contact><Contact type="Facility investigator"><Name>Haruyuki Ishii, MD</Name></Contact></Contacts></Site><Site><Name>Kyoto University Hospital</Name><Address1>Kyoto</Address1><Address3>606-8507</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Tomohiro Handa, MD</Name><Phone>+81-75-751-3830</Phone></Contact><Contact type="Facility investigator"><Name>Tomohiro Handa, MD</Name></Contact></Contacts></Site><Site><Name>Kyushu University Hospital.</Name><Address1>Fukuoka</Address1><Address3>812-8582</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Naoki Hamada, MD</Name><Phone>+81-92-642-5378</Phone></Contact><Contact type="Facility investigator"><Name>Yoichi Nakanishi, MD</Name></Contact></Contacts></Site><Site><Name>Matsuzaka City Hospital</Name><Address1>Matsuzaka</Address1><Address2>Mie</Address2><Address3>515-8544</Address3><CountrySubDivision>Mie</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Osamu Hataji, MD</Name><Phone>+81-598-23-1515</Phone></Contact><Contact type="Facility investigator"><Name>Osamu Hataji, MD</Name></Contact></Contacts></Site><Site><Name>NTT Medical Center Tokyo</Name><Address1>Tokyo</Address1><Address3>141-8625</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Kazuhiro Usui, MD</Name><Phone>+81-3-3448-6331</Phone></Contact><Contact type="Facility investigator"><Name>Kazuhiro Usui, MD</Name></Contact></Contacts></Site><Site><Name>Nagasaki University Hospital</Name><Address1>Nagasaki</Address1><Address3>852-8510</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Hiroshi Ishimoto, MD</Name><Phone>+81-95-819-7273</Phone></Contact><Contact type="Facility investigator"><Name>Hiroshi Mukae, MD</Name></Contact></Contacts></Site><Site><Name>Nagoya City University Hospital</Name><Address1>Nagoya</Address1><Address2>Aichi</Address2><Address3>467-8601</Address3><CountrySubDivision>Aichi</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Hirotsugu Okubo, MD</Name><Phone>+81-52-853-8216</Phone></Contact><Contact type="Facility investigator"><Name>Akio Niimi, MD</Name></Contact></Contacts></Site><Site><Name>Nagoya University Hospital</Name><Address1>Nagoya</Address1><Address2>Aichi</Address2><Address3>466-8560</Address3><CountrySubDivision>Aichi</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Naozumi Hashimoto, MD</Name><Phone>+81-52-741-2111</Phone></Contact><Contact type="Facility investigator"><Name>Naozumi Hashimoto, MD</Name></Contact></Contacts></Site><Site><Name>National Center for Global Health and Medicine</Name><Address1>Tokyo</Address1><Address3>162-8655</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Keita Sakamoto, MD</Name><Phone>+81-3-3202-7181</Phone></Contact><Contact type="Facility investigator"><Name>Haruhito Sugiyama, MD</Name></Contact></Contacts></Site><Site><Name>National Hospital Organization Chiba-East-Hospital</Name><Address1>Chiba</Address1><Address3>260-8712</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Satoru Ishikawa, MD</Name><Phone>+81-43-261-5171</Phone></Contact><Contact type="Facility investigator"><Name>Satoru Ishikawa, MD</Name></Contact></Contacts></Site><Site><Name>National Hospital Organization Himeji Medical Center</Name><Address1>Himeji</Address1><Address2>Hyogo</Address2><Address3>670-8520</Address3><CountrySubDivision>Hyogo</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Tetsuji Kawamura, MD</Name><Phone>+81-79-225-3211</Phone></Contact><Contact type="Facility investigator"><Name>Tetsuji Kawamura, MD</Name></Contact></Contacts></Site><Site><Name>National Hospital Organization Kinki-chuo Chest Medical Center</Name><Address1>Sakai</Address1><Address2>Osaka</Address2><Address3>591-8555</Address3><CountrySubDivision>Osaka</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Chikatoshi Sugimoto, MD</Name><Phone>+81-72-252-3021</Phone></Contact><Contact type="Facility investigator"><Name>Yoshikazu Inoue, MD</Name></Contact></Contacts></Site><Site><Name>National Hospital Organization Matsue Medical Center</Name><Address1>Matsue</Address1><Address2>Shimane</Address2><Address3>690-8556</Address3><CountrySubDivision>Shimane</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Masahiro Kimura, MD</Name><Phone>+81-852-21-6131</Phone></Contact><Contact type="Facility investigator"><Name>Shuichi Yano, MD</Name></Contact></Contacts></Site><Site><Name>National Hospital Organization Minami-Okayama Medical Center</Name><Address1>Okayama</Address1><Address3>701-0304</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yasushi Tanimoto, MD</Name><Phone>+81-86-482-1121</Phone></Contact><Contact type="Facility investigator"><Name>Yasushi Tanimoto, MD</Name></Contact></Contacts></Site><Site><Name>National Hospital Organization Tokyo Medical Center</Name><Address1>Tokyo</Address1><Address3>152-8902</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yoshitaka Oyamada, MD</Name><Phone>+81-3-3411-0111</Phone></Contact><Contact type="Facility investigator"><Name>Yoshitaka Oyamada, MD</Name></Contact></Contacts></Site><Site><Name>National Hospital Organization Tokyo National Hospital</Name><Address1>Kiyose</Address1><Address2>Tokyo</Address2><Address3>204-8585</Address3><CountrySubDivision>Tokyo</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Osamu Narumoto, MD</Name><Phone>+81-42-491-2111</Phone></Contact><Contact type="Facility investigator"><Name>Ken Ota, MD</Name></Contact></Contacts></Site><Site><Name>National Hospital Organization Yamaguchi-Ube Medical Center</Name><Address1>Ube</Address1><Address2>Yamaguchi</Address2><Address3>755-0241</Address3><CountrySubDivision>Yamaguchi</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yoriyuki Murata, MD</Name><Phone>+81-836-58-2300</Phone></Contact><Contact type="Facility investigator"><Name>Yoriyuki Murata, MD</Name></Contact></Contacts></Site><Site><Name>Nihon University Itabashi Hospital</Name><Address1>Tokyo</Address1><Address3>173-8610</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Mari Hikichi, MD</Name><Phone>+81-3-3972-8111</Phone></Contact><Contact type="Facility investigator"><Name>Yasuhiro Gon, MD</Name></Contact></Contacts></Site><Site><Name>Niigata University Medical and Dental Hospital</Name><Address1>Niigata</Address1><Address3>951-8510</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Takuro Sakagami, MD</Name><Phone>+81-25-368-9325</Phone></Contact><Contact type="Facility investigator"><Name>Takuro Sakagami, MD</Name></Contact></Contacts></Site><Site><Name>Nippon Medical School Hospital</Name><Address1>Tokyo</Address1><Address3>113-8603</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Hiroki Hayashi, MD</Name><Phone>+81-3-3822-2131</Phone></Contact><Contact type="Facility investigator"><Name>Shinji Abe, MD</Name></Contact></Contacts></Site><Site><Name>Ogaki Municipal Hospital</Name><Address1>Ogaki</Address1><Address2>Gifu</Address2><Address3>503-8502</Address3><CountrySubDivision>Gifu</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Akira Shiraki, MD</Name><Phone>+81-584-81-3341</Phone></Contact><Contact type="Facility investigator"><Name>Joe Shindou, MD</Name></Contact></Contacts></Site><Site><Name>Okinawa Chubu Hospital</Name><Address1>Uruma</Address1><Address2>Okinawa</Address2><Address3>904-2293</Address3><CountrySubDivision>Okinawa</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yuichiro Nei, MD</Name><Phone>+81-98-973-4111</Phone></Contact><Contact type="Facility investigator"><Name>Tomoo Kishaba, MD</Name></Contact></Contacts></Site><Site><Name>Saiseikai Kumamoto Hospital</Name><Address1>Kumamoto</Address1><Address3>861-4193</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Kodai Kawamura, MD</Name><Phone>+81-96-351-8000</Phone></Contact><Contact type="Facility investigator"><Name>Kazuya Ichikado, MD</Name></Contact></Contacts></Site><Site><Name>Saku Central Hospital Advanced Care Center</Name><Address1>Saku</Address1><Address2>Nagano</Address2><Address3>385-0051</Address3><CountrySubDivision>Nagano</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Satoshi Wasamoto, MD</Name><Phone>+81-267-62-8181</Phone></Contact><Contact type="Facility investigator"><Name>Tetsuo Kimura, MD</Name></Contact></Contacts></Site><Site><Name>Sapporo Medical University Hospital</Name><Address1>Sapporo</Address1><Address2>Hokkaido</Address2><Address3>060-8543</Address3><CountrySubDivision>Hokkaido</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Hirotaka Nishikiori, MD</Name><Phone>+81-11-611-2111</Phone></Contact><Contact type="Facility investigator"><Name>Hirofumi Chiba, MD</Name></Contact></Contacts></Site><Site><Name>Seirei Hamamatsu General Hospital</Name><Address1>Hamamatsu</Address1><Address2>Shizuoka</Address2><Address3>430-8558</Address3><CountrySubDivision>Shizuoka</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Dai Hashimoto, MD</Name><Phone>+81-53-474-2222</Phone></Contact><Contact type="Facility investigator"><Name>Hidenori Nakamura, MD</Name></Contact></Contacts></Site><Site><Name>Seirei Mikatahara General Hospital</Name><Address1>Hamamatsu</Address1><Address2>Shizuoka</Address2><Address3>433-8558</Address3><CountrySubDivision>Shizuoka</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Koshi Yokomura, MD</Name><Phone>+81-53-436-1251</Phone></Contact><Contact type="Facility investigator"><Name>Koshi Yokomura, MD</Name></Contact></Contacts></Site><Site><Name>Sendai Kousei Hospital</Name><Address1>Sendai</Address1><Address2>Miyagi</Address2><Address3>980-0873</Address3><CountrySubDivision>Miyagi</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yukihiro Toi, MD</Name><Phone>+81-22-222-6181</Phone></Contact><Contact type="Facility investigator"><Name>Yuichiro Kimura, MD</Name></Contact></Contacts></Site><Site><Name>Shiga University of Medical Science Hospital</Name><Address1>Otsu</Address1><Address2>Shiga</Address2><Address3>520-2192</Address3><CountrySubDivision>Shiga</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Kentaro Fukunaga, MD</Name><Phone>+81-77-548-2111</Phone></Contact><Contact type="Facility investigator"><Name>Yasutaka Nakano, MD</Name></Contact></Contacts></Site><Site><Name>Shimane University Hospital</Name><Address1>Izumo</Address1><Address2>Shimane</Address2><Address3>693-8501</Address3><CountrySubDivision>Shimane</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Megumi Hamaguchi, MD</Name><Phone>+81-853-20-2581</Phone></Contact><Contact type="Facility investigator"><Name>Takeshi Isobe, MD</Name></Contact></Contacts></Site><Site><Name>Shinshu University Hospital</Name><Address1>Matsumoto</Address1><Address2>Nagano</Address2><Address3>390-8621</Address3><CountrySubDivision>Nagano</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Hiroshi Yamamoto, MD</Name><Phone>+81-263-37-2631</Phone></Contact><Contact type="Facility investigator"><Name>Masayuki Hanaoka, MD</Name></Contact></Contacts></Site><Site><Name>Showa University Fujigaoka Hospital</Name><Address1>Yokohama</Address1><Address2>Kanagawa</Address2><Address3>227-8501</Address3><CountrySubDivision>Kanagawa</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Daisuke Inoue, MD</Name><Phone>+81-45-971-1151</Phone></Contact><Contact type="Facility investigator"><Name>Yusuke Shikama, MD</Name></Contact></Contacts></Site><Site><Name>St. Marianna University School of Medicine Hospital</Name><Address1>Kawasaki</Address1><Address2>Kanagawa</Address2><Address3>216-8511</Address3><CountrySubDivision>Kanagawa</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Mariko Okamoto, MD</Name><Phone>+81-44-977-8111</Phone></Contact><Contact type="Facility investigator"><Name>Masamichi Mineshita, MD</Name></Contact></Contacts></Site><Site><Name>Suwa Central Hospital</Name><Address1>Chino</Address1><Address2>Nagano</Address2><Address3>391-8503</Address3><CountrySubDivision>Nagano</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Shinko Suzuki, MD</Name><Phone>+81-266-72-1000</Phone></Contact><Contact type="Facility investigator"><Name>Shinko Suzuki, MD</Name></Contact></Contacts></Site><Site><Name>Teikyo University Hospital</Name><Address1>Tokyo</Address1><Address3>173-8605</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yuta Koizumi, MD</Name><Phone>+81-3-3964-8351</Phone></Contact><Contact type="Facility investigator"><Name>Hiroyuki Nagase, MD</Name></Contact></Contacts></Site><Site><Name>Tenri Hospital</Name><Address1>Tenri</Address1><Address2>Nara</Address2><Address3>632-8552</Address3><CountrySubDivision>Nara</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Seishu Hashimoto, MD</Name><Phone>+81-743-63-5611</Phone></Contact><Contact type="Facility investigator"><Name>Yoshio Taguchi, MD</Name></Contact></Contacts></Site><Site><Name>The Jikei University Hospital</Name><Address1>Tokyo</Address1><Address3>105-8471</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Hiromichi Hara, MD</Name><Phone>+81-3-3433-1111</Phone></Contact><Contact type="Facility investigator"><Name>Kazuyoshi Kuwano, MD</Name></Contact></Contacts></Site><Site><Name>Toho University Omori Medical Center</Name><Address1>Tokyo</Address1><Address3>143-8541</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Susumu Sakamoto, MD</Name><Phone>+81-3-3762-4151</Phone></Contact><Contact type="Facility investigator"><Name>Sakae Homma, MD</Name></Contact></Contacts></Site><Site><Name>Tohoku Medical and Pharmaceutical University Hospital</Name><Address1>Sendai</Address1><Address2>Miyagi</Address2><Address3>983-8512</Address3><CountrySubDivision>Miyagi</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Masahito Ebina, MD</Name><Phone>+81-22-259-1221</Phone></Contact><Contact type="Facility investigator"><Name>Masahito Ebina, MD</Name></Contact></Contacts></Site><Site><Name>Tokai University Hospital</Name><Address1>Isehara</Address1><Address2>Kanagawa</Address2><Address3>259-1193</Address3><CountrySubDivision>Kanagawa</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Takahisa Takihara, MD</Name><Phone>+81-463-93-1121</Phone></Contact><Contact type="Facility investigator"><Name>Koichiro Asano, MD</Name></Contact></Contacts></Site><Site><Name>Tokushima University Hospital</Name><Address1>Tokushima</Address1><Address3>770-8053</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yuko Toyoda, MD</Name><Phone>+81-88-633-7127</Phone></Contact><Contact type="Facility investigator"><Name>Yasuhiko Nishioka, MD</Name></Contact></Contacts></Site><Site><Name>Tokyo Medical and Dental University</Name><Address1>Tokyo</Address1><Address3>113-8519</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yukihisa Inoue, MD</Name><Phone>+81-3-5803-5954</Phone></Contact><Contact type="Facility investigator"><Name>Yasunari Miyazaki, MD</Name></Contact></Contacts></Site><Site><Name>Tokyo University Hospital</Name><Address1>Tokyo</Address1><Address3>113-8655</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Hirokazu Urushiyama, MD</Name><Phone>+81-3-3815-5411</Phone></Contact><Contact type="Facility investigator"><Name>Takahide Nagase, MD</Name></Contact></Contacts></Site><Site><Name>Toranomon Hospital</Name><Address1>Tokyo</Address1><Address3>105-8470</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Atsushi Miyamoto, MD</Name><Phone>+81-3-3588-1111</Phone></Contact><Contact type="Facility investigator"><Name>Kazuma Kishi, MD</Name></Contact></Contacts></Site><Site><Name>Tosei General Hospital</Name><Address1>Seto</Address1><Address2>Aichi</Address2><Address3>489-8642</Address3><CountrySubDivision>Aichi</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Kensuke Kataoka, MD</Name><Phone>+81-561-82-5101</Phone></Contact><Contact type="Facility investigator"><Name>Yasuhiro Kondo, MD</Name></Contact></Contacts></Site><Site><Name>Tottori University Hospital</Name><Address1>Yonago</Address1><Address2>Tottori</Address2><Address3>683-0853</Address3><CountrySubDivision>Tottori</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Masato Morita, MD</Name><Phone>+81-859-34-8105</Phone></Contact><Contact type="Facility investigator"><Name>Masato Morita, MD</Name></Contact></Contacts></Site><Site><Name>Toyama University Hospital</Name><Address1>Toyama</Address1><Address3>930-0194</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Seisuke Okazawa, MD</Name><Phone>+81-76-434-7287</Phone></Contact><Contact type="Facility investigator"><Name>Ryuji Hayashi, MD</Name></Contact></Contacts></Site><Site><Name>University of Fukui Hospital</Name><Address1>Yoshida</Address1><Address2>Fukui</Address2><Address3>910-1193</Address3><CountrySubDivision>Fukui</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Yuko Waseda, MD</Name><Phone>+81-776-61-8355</Phone></Contact><Contact type="Facility investigator"><Name>Tamotsu Ishizuka, MD</Name></Contact></Contacts></Site><Site><Name>University of Occupational and Environmental Health Japan</Name><Address1>Kitakyushu</Address1><Address2>Hukuoka</Address2><Address3>807-8555</Address3><CountrySubDivision>Hukuoka</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Keishi Oda, MD</Name><Phone>+81-93-603-1611</Phone></Contact><Contact type="Facility investigator"><Name>Kazuhiro Yatera, MD</Name></Contact></Contacts></Site><Site><Name>Yamagata City Hospital Saiseikan</Name><Address1>Yamagata</Address1><Address3>990-8533</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Katsuyoshi Iwabuchi, MD</Name><Phone>+81-23-625-5555</Phone></Contact><Contact type="Facility investigator"><Name>Katsuyoshi Iwabuchi, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pneumonia</Disease><PatientSegments><PatientSegment><PatientSegment id="8903">Subjects with Interstitial Pneumonia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03041623</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pneumonia" id="16603"><Endpoint>Imaging/Radiological Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pneumonia" id="16607"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pneumonia" id="16616"><Endpoint>Assessment of Forced Vital Capacity (FVC)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pneumonia" id="16621"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pneumonia" id="16624"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pneumonia" id="16603"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pneumonia" id="16621"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pneumonia" id="16624"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pneumonia" id="30678"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Pneumonia" id="45888"><Endpoint>Assessment of Biomarkers</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pneumonia" id="15556"><Criterion>Subjects with Interstitial Pneumonia</Criterion></Inclusion><Inclusion disease="Pneumonia" id="15590"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Pneumonia" id="34329"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Pneumonia" id="32049">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pneumonia" id="12959"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Pneumonia" id="12961">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pneumonia" id="12978"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Pneumonia" id="12984"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2021-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-12-18T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-02-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="287794"><TitleDisplay>Gastric Cancer Registry for Epidemiology and Molecular Risk Factor</TitleDisplay><TitleOfficial>Anaylsis and Prediction of Epidemiology and Molecular Biological Risks of Gastric Cancer by Multicenter Registry</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03046745</Identifier><Identifier type="Organisational Study">KNUMC 2017-01-014</Identifier><Identifier type="Other">KNUMC 2016-07-014</Identifier><Identifier type="Other">KCT0002284</Identifier></Identifiers><Indications><Indication id="127">Stomach tumor</Indication><Indication id="2399">Adenocarcinoma</Indication></Indications><BiomarkerNames><BiomarkerName id="250" role="Disease marker" type="Proteomic">Anti-Helicobacter pylori antibodies</BiomarkerName><BiomarkerName id="318" role="Disease marker" type="Genomic;Proteomic">Trefoil factor 3</BiomarkerName><BiomarkerName id="534" role="Disease marker" type="Proteomic">Pepsinogen</BiomarkerName><BiomarkerName id="3451" role="Disease marker" type="Genomic;Proteomic">Immunoglobulin G</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1051725" type="Company"><TargetEntity id="5035526273" type="organizationId">Ministry of Healthy and Welfare</TargetEntity></SourceEntity><SourceEntity id="28011" type="Company"><TargetEntity id="5035524203" type="organizationId">Kyungpook National University</TargetEntity></SourceEntity><SourceEntity id="127" type="ciIndication"><TargetEntity id="C16" type="ICD10"></TargetEntity><TargetEntity id="151" type="ICD9"></TargetEntity><TargetEntity id="10017758" type="MEDDRA"></TargetEntity><TargetEntity id="D013274" type="MeSH"></TargetEntity><TargetEntity id="-2031094615" type="omicsDisease"></TargetEntity><TargetEntity id="646" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2399" type="ciIndication"><TargetEntity id="10001141" type="MEDDRA"></TargetEntity><TargetEntity id="D000230" type="MeSH"></TargetEntity><TargetEntity id="-1620546969" type="omicsDisease"></TargetEntity><TargetEntity id="656" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>6</NumberOfSites><CompaniesSponsor><Company id="28011">Kyungpook National University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1051725">Ministry of Health &amp; Welfare, Korea</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>18000</PatientCountEnrollment><DateStart>2016-08-31T00:00:00Z</DateStart><DateEnd type="estimated">2022-04-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-14T02:24:13Z</DateChangeLast><DateAdded>2017-02-13T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>sw-jeon@hanmail.net</Email><Name>Seong Woo Jeon, Professor</Name><Phone>+82-53-200-3089</Phone></Contact><Contact type="Scientific contact"><Affiliation>Gastric Cancer Center, Kyungpook National University Medical Center</Affiliation><Name>Seong Woo Jeon, Professor</Name></Contact><Contact type="Public contact"><Email>tear1480@hanmail.net</Email><Name>Yong Hwan Kwon, Doctor</Name><Phone>+82-53-200-2609</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;The patients who were diagnosed of primary gastric adenocarcinoma and drew up agreement for understanding and enrollment of this study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Being treated (surgery, endoscopic resection and chemoradiation) after the diagnosis of gastric cancer; metastatic gastric cancer; refusal to participation of this study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Prediction of risk factors for gastric cancer and definition of optimal endoscopic screening interval</Description><Timeframe>Up to five years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The diagnostic validity of serum biomarker (serum pepsinogen and TFF3) for detection of gastric cancer</Description><Timeframe>Up to five years</Timeframe></Measure><Measure><Description>Analysis of proportion of each treatment of gastric cancer and five year survival: should analyze the treatment patterns (endoscopic resection, surgery, chemotherapy or supportive care) of gastric cancer and assess the survival rate according to each treatment modalities</Description><Timeframe>Up to ten years</Timeframe></Measure><Measure><Description>Analysis of quality of life questionnaire after early gastric cancer between endoscopic treatment group and surgery group: should measure QOL of the enrolled patients with EORTC questionnaire and compare the changing trends in each groups, prospectively</Description><Timeframe>Up to six years</Timeframe></Measure><Measure><Description>The incidence of gastric cancer development in control group</Description><Timeframe>Up to 20 years</Timeframe></Measure><Measure><Description>The incidence of metachronous gastric neoplasm after endoscopic treatment or surgery</Description><Timeframe>Up to ten years</Timeframe></Measure><Measure><Description>Analysis of clinical differences and characteristics between positive gastric cancer family history and negative family history groups</Description><Timeframe>Up to five years</Timeframe></Measure><Measure><Description>Stage, treatment and prognosis of gastric cancer according to molecular classification</Description><Timeframe>Up to ten years</Timeframe></Measure><Measure><Description>Stage, treatment and prognosis of gastric cancer according to endoscopic screening interval</Description><Timeframe>Up to ten years</Timeframe></Measure><Measure><Description>Reservation of frozen serum for novel gastric cancer serological marker analysis</Description><Timeframe>Up to five years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;In      this present study, investigators are going to evaluate the efficacy of serum biomarker by the use of serum of      GC participants and health control group.&lt;br/&gt;The main aims of this study are:&lt;br/&gt;To evaluate the optimal interval of endoscopic screening for early detection of gastric           cancer and risk factors in Korean.&lt;br/&gt;To evaluate the diagnostic validity of serum biomarker (combining pepsinogen, H pylori           IgG Antibody, and TFF3) as a screening test for detection of GC in Korean.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this    multicenter, prospective, cohort study investigators will be planned to enroll the 6000      participants (aged  &amp;gt; 18 years) who diagnosed the primary gastric cancer and 12,000 healthy normal cohort      participants (aged  &amp;gt; 40 years) for five years. All participants who enrolled in this registry,       will be questioned by the gastric cancer survey and the serum and tissue of these participants      will be analyzed.&lt;/para&gt;&lt;para&gt;Investigators will be planned to evaluate the optimal endoscopic interval to find early gastric      cancer by use of survey between newly diagnosed GC cohort group and healthy control cohort      group. In addition, Investigators will be going to analyze the risk factors of GC in Korean (epidemiological,      diet, and clinical factors). In this study, the investigators will be going to enroll the      participants who will be diagnosed GC and normal control group people, from October 2016 to      October 2021 in multicenter, prospectively. The baseline characteristics of the      participants, H pylori status, stage of gastric cancer at diagnosis, treatment modalities,      treatment response and mortality will be analyzed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="South Korea"><Sites><Site><Name>Kyungpook National University Medical Center</Name><Address1>Daegu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>sw-jeon@hanmail.net</Email><Name>Seong Woo Jeon, Ph.D.</Name></Contact></Contacts></Site><Site><Name>Yeongnam University Medical Center</Name><Address1>Daegu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Daegu Catholic University Medical Center</Name><Address1>Daegu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Daegu Fatima Hospital</Name><Address1>Daegu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Dongguk University Gyeongju Hospital</Name><Address1>Gyeongju</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Keimyung University Dongsan Medical Center</Name><Address1>Daegu</Address1><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Stomach tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="7829">Subjects at risk of developing disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8025">Subjects with adenocarcinoma of the gastroesophageal junction</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03046745</Identifier></Identifiers></Registry><Registry><Name id="1010">Korea Clinical Research Information Service (CRiS)</Name><Identifiers><Identifier></Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Stomach tumor" id="12193"><Endpoint>Assessment of Biomarkers</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Stomach tumor" id="12218"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Stomach tumor" id="12222"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Stomach tumor" id="12223">Assessment of Efficacy</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Stomach tumor" id="12193"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12218"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="12222"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Stomach tumor" id="12227">Assessment of Resection Rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stomach tumor" id="44929"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Stomach tumor" id="12901"><Criterion>Subjects at Risk of Developing Disease</Criterion></Inclusion><Inclusion disease="Stomach tumor" id="22491"><Criterion>Subjects with Adenocarcinoma of the Gastroesophageal Junction</Criterion></Inclusion><Inclusion disease="Stomach tumor" id="34884"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="7966">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Stomach tumor" id="9473"><Criterion>Subjects with Advanced/Metastatic Gastric Cancer</Criterion></Exclusion><Exclusion disease="Stomach tumor" id="9511"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9512">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Stomach tumor" id="9516">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Stomach tumor" id="9517">Subjects with history of surgical interventions/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Stomach tumor" id="27827"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Stomach tumor" id="9528">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2021-04-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-02-05T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-02-13T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="289056"><TitleDisplay>Combining CES Alpha-Stim and InterX for Optimized Rehabilitation Following Extremity Immobilization</TitleDisplay><TitleOfficial>The Clinical Feasibility of Combining Cranial Electrotherapy Stimulation (CES Alpha-Stim) and Non-invasive Interactive Neurostimulation (InterX) for Optimized Rehabilitation Following Extremity Immobilization</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03060122</Identifier><Identifier type="Organisational Study">C.2017.026</Identifier></Identifiers><Indications><Indication id="1091">Bone injury</Indication><Indication id="1295">Neuropathic pain</Indication><Indication id="3112">Musculoskeletal injury</Indication></Indications><BiomarkerNames><BiomarkerName id="44216" role="Therapeutic effect marker" type="Physiological">Body temperature</BiomarkerName><BiomarkerName id="46234" role="Therapeutic effect marker" type="Physiological">Shoulder motion</BiomarkerName><BiomarkerName id="53387" role="Therapeutic effect marker" type="Physiological">Arm motion</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Alpha-Stim cranial electrical stimulation device</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>non-invasive interactive neurostimulation (InterX) therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>standard immobilization rehabilitation care</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1033206" type="Company"><TargetEntity id="5035540300" type="organizationId">Brooke Army Medical Center</TargetEntity></SourceEntity><SourceEntity id="1091" type="ciIndication"><TargetEntity id="10017076" type="MEDDRA"></TargetEntity><TargetEntity id="D050723" type="MeSH"></TargetEntity><TargetEntity id="-1417017400" type="omicsDisease"></TargetEntity><TargetEntity id="1166" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1295" type="ciIndication"><TargetEntity id="10029223" type="MEDDRA"></TargetEntity><TargetEntity id="D009437" type="MeSH"></TargetEntity><TargetEntity id="-533466818" type="omicsDisease"></TargetEntity><TargetEntity id="14" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1033206">Brooke Army Medical Center</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>94</PatientCountEnrollment><DateStart>2017-10-01T00:00:00Z</DateStart><DateEnd type="estimated">2020-05-01T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T22:37:53Z</DateChangeLast><DateAdded>2017-03-01T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;An orthopedic/musculoskeletal postoperative injury that required cast or splint immobilization of the joint(s) to be treated of &gt;/=  2 weeks and available for treatment and are coming in for physical or occupational therapy&lt;/li&gt;&lt;li&gt;Between the age of 18 to 65 years&lt;/li&gt;&lt;li&gt;Read and speak English well enough to provide informed consent and follow study instructions&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Active infection, open sores, or open incisions (or anything that would inhibit the application of the stim) in the affected extremity&lt;/li&gt;&lt;li&gt;Any contraindications to electrical stimulation including: any type of implanted demand type cardiac pacemakers, implanted defibrillators, or implanted functioning devices (ie, insulin pump); active cancerous tissue or are undergoing chemotherapy; known pregnancy or breastfeeding or history of epilepsy or other seizures&lt;/li&gt;&lt;li&gt;History of inflammatory skin diseases (psoriasis, dermatitis, etc)&lt;/li&gt;&lt;li&gt;Contralateral extremity involvement resulting in less than normal range of motion, muscle strength, or daily pain &gt; 1/10&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pain: an 11-point verbalize NRS will be used to assess the subject's upper or lower extremity pain the day of each assessment as well as during therapy sessions. The 0 to 10 NPS has been found to be valid and reliable in many patient populations including the musculoskeletal population and has been recommended for inclusion in the core NIH Toolbox for use with adults</Description><Timeframe>4 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Global Rating of Change (GRC): the GRC, a self-report instrument, assesses subjective perception of the efficacy of a particular treatment and the significance of that change. A 15-point Likert type scale ranging from 1 (very great deal worse) to 15 (a very great deal better) and a 6-point Likert type scale ranging from 1 (a tiny bit important) to 6 (a very great important) will be used. The GRC is used to determine the minimal clinically important differences and will be used in this study to assess the participants' perceived magnitude of changes following the 30 min combined NIN/CES treatment and again after each physical therapy or occupational therapy session for range of motion and pain</Description><Timeframe>4 months</Timeframe></Measure><Measure><Description>Lower Extremity Functional Scale(LEFS): the LEFS, originally described by Binkley et al, provides global assessment of function related specifically to the lower extremities. It is one self-report outcome measure that can capture adverse impact on function from multiple injuries or specific locations in the lower extremity. It consists of 20 questions total related to functional activities, each with a possible score ranging from 0 to 4, where 0 indicates that the activity cannot be performed at all and 4 indicates that the activity be performed with no limitations. The total maximum score is 80 points, indicating no limitations with any of the functional tasks. It has been shown to be valid, reliable, and responsive to change in various patient populations and in different body regions in the lower extremity (ankle, knee, and hip)</Description><Timeframe>4 months</Timeframe></Measure><Measure><Description>National Institutes of Health Patient Reported Outcomes Measurement Information Systems (PROMIS) 29: Emotional The PROMIS 29, a self-reported measure, assesses health-related quality of life (HRQOL) in seven domains (physical function, anxiety, depression, fatigue, sleep disturbance, social role satisfaction, pain interference, pain intensity). The instrument utilizes a 7-days recall period and consists of eight questions on a Likert-type scale, ranging from 1 to 5 , except for the pain intensity scale, which ranges from 0 to 10</Description><Timeframe>4 months</Timeframe></Measure><Measure><Description>Pain Medication: an 11-point verbalize NRS will be used to assess the subject's upper or lower extremity pain the day of each assessment as well as during therapy sessions. The 0 to 10 NPS has been found to be valid and reliable in many patient populations including the musculoskeletal population and has been recommended for inclusion in the core NIH Toolbox for use with adults</Description><Timeframe>4 months</Timeframe></Measure><Measure><Description>Quick Disabilities of the Arm, Shoulder and Hand (Quick DASH: the DASH is an 11-item self-report measure that assesses a subject's perceived ability to complete twenty-one upper extremity functional activities using a 5-point Likert scale. The cumulative Quick DASH score is scaled from 0 to 100, with higher scores indicating increased disability. The DASH is well tested and has been validated and found reliable in many different upper limb musculoskeletal disorders[45-48]. The Minimally Clinically Important Difference (MCID) for the Dash is 10.83 points, and for the QuickDash is 15.91 points.</Description><Timeframe>4 months</Timeframe></Measure><Measure><Description>Range of motion (ROM): active and/or passive ROM of the involved joints will be assessed using an electronic goniometer, and the reference of 'normal' will be the non-involved limb. A measurement will be taken, but also the result will be dichotomously categorized as within 95% of opposite side - yes or no</Description><Timeframe>4 months</Timeframe></Measure><Measure><Description>Temperature: the temperature at three locations (different for upper and lower extremity) will be recorded with an infrared thermometer (Exergen DT-1001RS Infrared Dermal Thermometer with Remote Sensor, Exergen Corp, Watertown, Massachusetts) on both the involved and uninvolved extremities</Description><Timeframe>4 months</Timeframe></Measure><Measure><Description>The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) Pain Scale: the LANNS assessment helps identify whether or not a patient exhibits neuropathic pain. The instrument consists of five self-report and two clinician administered sensory function items that assess dynamic mechanical allodynia and altered pin-prick threshold (PPT). Weighted scores for the seven items are binary (yes or no) and summed, giving a total score between 0 and 24. In terms of diagnostic validity, during the validation study this assessment yielded a sensitivity of 85% and specificity of 80%</Description><Timeframe>4 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study will be aimed at assessing the feasibility of a dual-device treatment prior to a      rehabilitation session for an orthopedic injury requiring immobilization, and its impact on      improving outcomes and decreasing the risk for development of neuropathic pain. The investigators  will      evaluate the clinical feasibility and effectiveness of incorporating the Alpha-Stim cranial electrical stimulation (CES) device and      non-invasive interactive neurostimulationÂ (Inter-X) treatment into a standard rehabilitation protocol to address risk factors associated      with the development of neuropathic pain (ie, pain, range of motion, and skin temperature)      as well as its impact on reduced pain medication.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Once patients provide consent and the investigators  have determined that they meet inclusion criteria the      process will occur as follows:&lt;br/&gt;Patients will be administered baseline demographic and standard medical history           questionnaires, including information about prescription medication use. In addition,           patients will fill out baseline self-report outcomes and be administered the (LANSS)           Pain Scale. Range of motion and temperature will also be assessed during the initial           session. Some of these measurements will be  standard of care and will  be filled out by the           patient even if they will  not be participating in the study.&lt;/para&gt;&lt;para&gt;Usual care:&lt;br/&gt;The usual care aspect of this study will be  the delivery of the pain treatment (NIN      and CES) as  commonly used at the Center for the Intrepid. The experimental aspect will be  the      combined delivery of the treatment, and the use of sham treatment as a control. The      treatment (NIN and CES) will be delivered in a pragmatic fashion, with treatment delivered      in conjunction with rehab visits and lasting approximately 4-weeks total. Each session will      last approximately 20 to 40 min long, and will most often be delivered in conjunction with      their rehab visit (physical therapy or occupational therapy) that occurs anywhere from one to      three times each week.&lt;/para&gt;&lt;para&gt;Strictly research:&lt;br/&gt;The experimental aspect of the study will be the comparison of combined treatment (NIN + CES), standard NIN with sham CES, to standard care alone. Before initiation of treatment patients will be randomized to either NIN + CES, NIN + sham CES, or standard care only immediately after the immobilization device (cast, brace, etc) has been removed. Randomization with be performed with a random number gerator. All groups will continue with their own rehabilitation as indicated throughout the entire course of the study treatment, and beyond as indicated by their therapist. The investigators will keep track of rehab appointments and visits, but not control for them.&lt;/para&gt;&lt;para&gt;At the 1-month follow-up, all patients will fill out the same self-report outcome measures from baseline, to include prescription pain medication and be administered the LANSS pain scale. Range of motion and temperature will also be assessed.&lt;/para&gt;&lt;para&gt;At the 2 and 4-months follow-up the same assessments will again be administered. If the patients has completed formal therapy prior to the 2 and 4 month follow-up time points the patients will be asked to return to the clinic to complete these assessments. Patients will  be contacted by telephone or email, if agreeable, to provide a reminder for the return appointment(s).&lt;/para&gt;&lt;para&gt;Outcomes will be compared between the three groups at each time point (ie, initial, 1, 2 and 4 months).&lt;/para&gt;&lt;para&gt;All patients will be followed out to 4 months.&lt;/para&gt;&lt;para&gt;Although every attempt will be made to collect data at these specific times, due to the      variability of patient and clinic schedules, the actual timing of collection may vary (+/- 1      week) and some of the proposed measures will  not be collected at all time points.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8390">Subjects with Neuropathic Pain</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8424">Subjects with Post-Operative Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03060122</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25875">Based on Numerical Rating Scale [NRS]</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25875">Based on Numerical Rating Scale [NRS]</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25898"><Endpoint>Assessment of Neuropathic Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25901">Based on Leeds Assessment of Neuropathic Symptoms and Signs[LNSS]</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25959"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25983"><Endpoint>Assessment of Sleep</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26009"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26014"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26041">Assessment of sensitivity/specificity</SubEndpoint><SubEndpoint disease="Pain" id="26044">Assessment of analgesic use/rescue medication</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26043"><Endpoint>Assessment of compliance/adherence</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="34798">Assessment by Health Related Quality of Life (HRQOL)</SubEndpoint><SubEndpoint disease="Pain" id="34807">Assessment by DASH scale</SubEndpoint><SubEndpoint disease="Pain" id="34985">Assessment by Likert scale</SubEndpoint><SubEndpoint disease="Pain" id="35029">Assessment by Global Rating of Change Questionnaire</SubEndpoint><SubEndpoint disease="Pain" id="35090">Assessment by Patient Reported Outcomes Measurement Information System (PROMIS)</SubEndpoint><SubEndpoint disease="Pain" id="35405">Assessment by Pain Interference Scale</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="35229"><Endpoint>Assessment of Fatigue</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Pain" id="26032"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22096"><Criterion>Subjects with Neuropathic Pain</Criterion></Inclusion><Inclusion disease="Pain" id="22142"><Criterion>Subjects with Peri-operative Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22143">Subjects with post operative pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22189"><Criterion>Conditions Associated with Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22207">Subjects with musculoskeletal disorder/injury associated pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="22269">Subjects able to communicate in the language specified in the protocol</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34371"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22263">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20075"><Criterion>Subjects Based on Pain Scale Ratings</Criterion></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion><SubCriterion disease="Pain" id="20123">Subjects with infectious disorders/disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="20186">Protocol specified exclusion criteria for women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20129">Hypersensitivity/ contraindication to investigational drug/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="25893"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Pain" id="20124">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-05-01T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-02-17T00:00:00Z</DateFirstReceived><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-03-01T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="291041"><TitleDisplay>A retrospective, monocentric study to evaluate the incidence of cumulative toxicity and its prognostic role in sunitinib-or pazopanib-treated patients with metastatic renal cell carcinoma (mRCC)</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="4250">Metastatic renal cell carcinoma</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>pazopanib</Name><Drug id="43738">pazopanib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sunitinib</Name><Drug id="12973">sunitinib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12973">sunitinib</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1033122">European Institute of Oncology</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="43738">pazopanib</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1033122">European Institute of Oncology</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="12973" type="Drug"><TargetEntity id="309144" type="siDrug">Sunitinib malate</TargetEntity></SourceEntity><SourceEntity id="43738" type="Drug"><TargetEntity id="334209" type="siDrug">Pazopanib hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1033122" type="Company"><TargetEntity id="4298234712" type="organizationId">Istituto Europeo DI Oncologia Srl</TargetEntity></SourceEntity><SourceEntity id="4250" type="ciIndication"><TargetEntity id="10050513" type="MEDDRA"></TargetEntity><TargetEntity id="3229" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3154" type="Action"><TargetEntity id="2314" type="Mechanism">CSF1R (c-FMS) Inhibitors</TargetEntity><TargetEntity id="4836" type="Mechanism">Anti-Colony Stimulating Factor 1 Receptor (CSF1R)</TargetEntity><TargetEntity id="4956" type="Mechanism">Anti-M-CSF</TargetEntity></SourceEntity><SourceEntity id="3584" type="Action"><TargetEntity id="1465" type="Mechanism">Lck Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3594" type="Action"><TargetEntity id="1669" type="Mechanism">ITK (EMT) Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3682" type="Action"><TargetEntity id="2298" type="Mechanism">FGFR1 Inhibitors</TargetEntity><TargetEntity id="4080" type="Mechanism">Anti-FGFR1</TargetEntity></SourceEntity><SourceEntity id="3688" type="Action"><TargetEntity id="1702" type="Mechanism">FGFR3 Inhibitors</TargetEntity><TargetEntity id="3639" type="Mechanism">Anti-FGFR3</TargetEntity></SourceEntity><SourceEntity id="3806" type="Action"><TargetEntity id="1628" type="Mechanism">Flt3 (FLK2/STK1) Inhibitors</TargetEntity><TargetEntity id="1910" type="Mechanism">Anti-CD135 (flt-3)</TargetEntity></SourceEntity><SourceEntity id="3808" type="Action"><TargetEntity id="1704" type="Mechanism">KIT (C-KIT) Inhibitors</TargetEntity><TargetEntity id="3405" type="Mechanism">Anti-c-KIT</TargetEntity><TargetEntity id="5665" type="Mechanism">KIT (C-KIT) (Asp816Val Mutant) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3846" type="Action"><TargetEntity id="1308" type="Mechanism">VEGFR-1 (Flt-1) Inhibitors</TargetEntity><TargetEntity id="2609" type="Mechanism">Anti-VEGFR-1 (Flt-1)</TargetEntity></SourceEntity><SourceEntity id="3848" type="Action"><TargetEntity id="1309" type="Mechanism">VEGFR-2 (FLK-1/KDR) Inhibitors</TargetEntity><TargetEntity id="1786" type="Mechanism">Anti-VEGFR-2 (KDR)</TargetEntity></SourceEntity><SourceEntity id="385" type="Action"><TargetEntity id="1069" type="Mechanism">Tyrosine Kinase Inhibitors</TargetEntity><TargetEntity id="4771" type="Mechanism">TAM Receptor Tyrosine Kinases Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3850" type="Action"><TargetEntity id="1627" type="Mechanism">VEGFR-3 (FLT4) Inhibitors</TargetEntity><TargetEntity id="2518" type="Mechanism">Anti-VEGFR-3 (FLT4)</TargetEntity></SourceEntity><SourceEntity id="48489" type="Action"><TargetEntity id="1650" type="Mechanism">PDGFRalpha Inhibitors</TargetEntity><TargetEntity id="2517" type="Mechanism">Anti-CD140a (PDGFRalpha)</TargetEntity><TargetEntity id="5666" type="Mechanism">PDGFRalpha (Asp842Val Mutant) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="48492" type="Action"><TargetEntity id="1651" type="Mechanism">PDGFRbeta Inhibitors</TargetEntity><TargetEntity id="1831" type="Mechanism">Anti-CD140b (PDGFRbeta)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1033122">European Institute of Oncology</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3154">CSF-1 antagonist</Action><Action id="3584">Lck tyrosine kinase inhibitor</Action><Action id="3594">Itk tyrosine kinase inhibitor</Action><Action id="3682">FGF1 receptor antagonist</Action><Action id="3688">FGF3 receptor antagonist</Action><Action id="3738">Ltk tyrosine kinase receptor inhibitor</Action><Action id="3806">Flt3 tyrosine kinase inhibitor</Action><Action id="3808">Kit tyrosine kinase inhibitor</Action><Action id="3816">RET tyrosine kinase receptor family inhibitor</Action><Action id="3846">VEGF-1 receptor antagonist</Action><Action id="3848">VEGF-2 receptor antagonist</Action><Action id="385">Protein tyrosine kinase inhibitor</Action><Action id="3850">VEGF-3 receptor antagonist</Action><Action id="48489">PDGF receptor alpha antagonist</Action><Action id="48492">PDGF receptor beta antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="751">Film coating</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>104</PatientCountEnrollment><PatientCountEvaluable>104</PatientCountEvaluable><DateChangeLast>2018-05-03T14:39:39Z</DateChangeLast><DateAdded>2017-03-18T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with metastatic renal cell carcinoma (mRCC)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Incidence of adverse events or cumulative toxicity: cumulative toxicity was defined as the presence of more than one selected adverse event of any grade</Description></Measure><Measure><Description>To evaluate the prognostic role by International mRCC Database Consortium criteria</Description></Measure><Measure><Description>Progression-free survival (PFS): evaluated using the Kaplan-Meier method and Cox analysis</Description></Measure><Measure><Description>Overall survival (OS): evaluated using the Kaplan-Meier method and Cox analysis</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In February 2017, results were published. Any of the selected toxicities were not experienced by 18.3% of patients. However, 26.9, 35.6 and 19.2% of patients experienced one, two and all three toxicities, respectively. Cumulative toxicity was reported by 54.8% ofÂ patients [&lt;ulink linkType="Reference" linkID="1909509"&gt;1909509&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this retrospective, monocentric study was to evaluate the incidence of cumulative toxicity and its prognostic role in &lt;ulink linkType="Drug" linkID="12973"&gt;sunitinib&lt;/ulink&gt;-or &lt;ulink linkType="Drug" linkID="43738"&gt;pazopanib&lt;/ulink&gt;-treated  patients with metastatic renal cell carcinoma (mRCC)   [&lt;ulink linkType="Reference" linkID="1909509"&gt;1909509&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In February 2017, results were published. Median duration of progression-free survival (PFS) and overall survival (OS) for patients with versus Â without cumulative toxicity wereÂ 27.6 versus 7.2 and 61.2 versus 18.7 months, respectively. After adjustment of cumulative toxicity for International mRCC Database Consortium prognostic groups, it maintained its prognostic role for both PFS (hazard ratio: 0.31; p &amp;lt; 0.001) and OS (hazard ratio: 0.27; p &amp;lt; 0.001)     [&lt;ulink linkType="Reference" linkID="1909509"&gt;1909509&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who received sunitinib or pazopanib were included and analyzed    [&lt;ulink linkType="Reference" linkID="1909509"&gt;1909509&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Italy"><Sites><Site><Name>European Institute of Oncology</Name><Address1>Milan</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><ChangeHistory><Change type="added"><Date>2017-03-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="299538"><TitleDisplay>A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer</TitleDisplay><TitleOfficial>A Study of Preoperative FOLFIRINOX For Potentially Curable Pancreatic Cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03167112</Identifier><Identifier type="Organisational Study">CODIM-MBM-17-040</Identifier></Identifiers><Indications><Indication id="2399">Adenocarcinoma</Indication><Indication id="249">Pancreas tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="70" role="Therapeutic effect marker" type="Proteomic">CA19-9 antigen</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>fluorouracil</Name></Intervention><Intervention type="InterventionPrimary"><Name>irinotecan</Name><Drug id="2871">irinotecan</Drug></Intervention><Intervention type="InterventionPrimary"><Name>leucovorin</Name></Intervention><Intervention type="InterventionPrimary"><Name>oxaliplatin</Name><Drug id="3792">oxaliplatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2871">irinotecan</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1039577">McGill University Health Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3792">oxaliplatin</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1039577">McGill University Health Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2871" type="Drug"><TargetEntity id="103766" type="siDrug">Irinotecan hydrochloride</TargetEntity></SourceEntity><SourceEntity id="3792" type="Drug"><TargetEntity id="108094" type="siDrug">Oxaliplatin</TargetEntity></SourceEntity><SourceEntity id="1039577" type="Company"><TargetEntity id="5001154939" type="organizationId">Mcgill University Health Centre</TargetEntity></SourceEntity><SourceEntity id="2399" type="ciIndication"><TargetEntity id="10001141" type="MEDDRA"></TargetEntity><TargetEntity id="D000230" type="MeSH"></TargetEntity><TargetEntity id="-1620546969" type="omicsDisease"></TargetEntity><TargetEntity id="656" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"></TargetEntity><TargetEntity id="10033609" type="MEDDRA"></TargetEntity><TargetEntity id="D010190" type="MeSH"></TargetEntity><TargetEntity id="-670361033" type="omicsDisease"></TargetEntity><TargetEntity id="630" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="141" type="Action"><TargetEntity id="418" type="Mechanism">DNA Topoisomerase I Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1039577">McGill University Health Center</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="141">Topoisomerase I inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="50">Anticancer alkylating agent</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="1647">Natural product</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2017-07-03T00:00:00Z</DateStart><DateEnd type="estimated">2018-05-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T22:31:11Z</DateChangeLast><DateAdded>2017-05-31T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>petr.kavan@mcgill.ca</Email><Extension>23460</Extension><Name>Petr Kavan, MD, PhD</Name><Phone>+1-514340-8222</Phone></Contact><Contact type="Scientific contact"><Affiliation>McGill University</Affiliation><Name>Petr Kavan, MD, PhD</Name></Contact><Contact type="Public contact"><Email>hamed.javan@mail.mcgill.ca</Email><Extension>23460</Extension><Name>Hamed Javan, MD</Name><Phone>+1-514340-8222</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Be &gt;/=  18 years of age at the time of signing the informed consent form&lt;/li&gt;&lt;li&gt;Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures conducted&lt;/li&gt;&lt;li&gt;Histologically or cytologically confirmed adenocarcinoma of the pancreas&lt;/li&gt;&lt;li&gt;Performance status or comorbidity condition not currently appropriate (but potentially reversible) for a major abdominal operation. Acceptable hematology parameters:&lt;ul&gt;&lt;li&gt;Absolute neutrophil count (ANC) &gt;/= 1500 cell/mm3&lt;/li&gt;&lt;li&gt;Platelet count &gt;/= 100,000/mm3 without transfusion support&lt;/li&gt;&lt;li&gt;Hemoglobin (Hgb) &gt;/= 9 g/dl&lt;/li&gt;&lt;li&gt;Acceptable blood chemistry levels:&lt;ul&gt;&lt;li&gt;Hepatic transaminases (ALT and AST)&amp;lt; 2.5 Ã the upper limits of normal (ULN)&lt;/li&gt;&lt;li&gt;Total bilirubin level&amp;lt; 1.5 Ã the upper limits of normal (ULN) or in patient with biliary stenting &amp;lt; 2 mg/dl&lt;/li&gt;&lt;li&gt;Serum creatinine level&amp;lt; 1.5 Ã the upper limits of normal (ULN) or creatinine clearance (Ccr) &gt;/= 40 ml/min&lt;/li&gt;&lt;li&gt;Alkaline phosphatase&amp;lt;/= 2.5 x ULN&lt;/li&gt;&lt;li&gt;Serum albumin&amp;gt; 3 g/dl&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Absence of poorly controlled comorbid conditions:&lt;ul&gt;&lt;li&gt;Congestive heart failure (CHF)&lt;/li&gt;&lt;li&gt;Chronic obstructive pulmonary disease (COPD)&lt;/li&gt;&lt;li&gt;Uncontrolled diabetes mellitus (DM)&lt;/li&gt;&lt;li&gt;Neurological disorders (not acutely related to pancreatic cancer) or limit function&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Radio-graphically suspicious but not diagnostic for extra-pancreatic disease&lt;ul&gt;&lt;li&gt;Superior mesenteric vein and portal vein confluence that can be reconstructed even if short segment venous occlusion is present (ie, a suitable portal vein above, and a suitable superior mesenteric vein below the area of occlusion)&lt;/li&gt;&lt;li&gt;Tumor abutment of the superior mesenteric artery of&amp;lt;/= 180 degree&lt;/li&gt;&lt;li&gt;Short segment encasement of the hepatic artery amenable to resection and reconstruction (this is usually at the origin of the gastroduodenal artery and reconstruction may or may not require interposition grafting with a short segment of reversed saphenous vein)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Cancer antigen 19-9 level (in absence of jaundice) &gt;/= 100 mocro/ml suggestive of disseminated disease&lt;/li&gt;&lt;li&gt;Preoperative treatment is recommended as an alternative for patients with potentially curable pancreatic cancer who meet all of the following criteria:&lt;ul&gt;&lt;li&gt;No clinical evidence for metastatic disease, a performance status and comorbidity condition appropriate for a major abdominal operation, no radiographic interface between primary tumor and mesenteric vasculature on imaging, an acceptable cancer antigen 19-9 level&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pancreatic tumors of endocrine or mixed origin&lt;/li&gt;&lt;li&gt;Prior anticancer therapy for pancreatic carcinoma&lt;/li&gt;&lt;li&gt;Presence of or history of metastatic pancreatic adenocarcinoma&lt;/li&gt;&lt;li&gt;Any other malignancy within five years prior to enrollment, with the exception of adequately treated in-situ carcinoma of the prostate (Gleason score&amp;lt;/= 7), cervix, uteri, or non-melanomatous skin cancer (all treatment of which should have been completed 6 months prior to enrollment)&lt;/li&gt;&lt;li&gt;Active bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment&lt;/li&gt;&lt;li&gt;Known infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or subject receiving immunosuppressive or myelo-suppressive medications that would, in the opinion of the Investigator, increase the risk of serious neutropenic complications&lt;/li&gt;&lt;li&gt;History of allergy or hypersensitivity to study regimen or any of their excipients&lt;/li&gt;&lt;li&gt;Peripheral sensory neuropathy grade&amp;gt; 1&lt;/li&gt;&lt;li&gt;Clinically significant ascites&lt;/li&gt;&lt;li&gt;Plastic biliary stent (metal biliary stent is allowed)&lt;/li&gt;&lt;li&gt;Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the subject's safety or the integrity of the study data. These include, but are not limited to:&lt;ul&gt;&lt;li&gt;History of connective tissue disorders (eg, lupus, scleroderma, arteritis nodosa)&lt;/li&gt;&lt;li&gt;History of interstitial lung disease, slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, or multiple allergies&lt;/li&gt;&lt;li&gt;History of the following within 6 months prior to treatment 1 day 1: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class III to IV heart failure, uncontrolled hypertension, clinically significant cardiac dysrhythmia or electrocardiogram (ECG) abnormality, cerebrovascular accident, transient ischemic attack, or seizure disorder&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Enrollment in any other clinical protocol or investigational study with an interventional agent or assessments that may interfere with study procedures&lt;/li&gt;&lt;li&gt;Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study&lt;/li&gt;&lt;li&gt;Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study&lt;/li&gt;&lt;li&gt;Any condition that confounds the ability to interpret data from the study&lt;/li&gt;&lt;li&gt;Unwillingness or inability to comply with study procedures&lt;/li&gt;&lt;li&gt;Pregnant or breast feeding&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Time to progression (TTP): time to orogression (TTP) is defined as the time from the first cycle of chemotherapy until objective tumor progression</Description><Timeframe>Through study completion, an average of one year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Overall response rate: overall response rate will be summarized based on RECIST V1.1</Description><Timeframe>Through study completion, an average of one year</Timeframe></Measure><Measure><Description>Overall survival (OS): overall survival indicates the interval between the first cycle of chemotherapy and the occurrence of death from any cause</Description><Timeframe>Through study completion, an average of one year</Timeframe></Measure><Measure><Description>Residual (R) tumor status: the R classification is based on International Union Against Cancer (UICC)</Description><Timeframe>Through study completion, an average of one year</Timeframe></Measure><Measure><Description>Incidence of Treatment related Adverse Events (safety and tolerability): safety and toxicity variable is the incidence of treatment related treatment-emergent adverse effect, serious adverse effect, laboratory abnormalities and other safety parameters</Description><Timeframe>Through study completion, an average of one year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;In this clinical trial, the primary objective is to evaluate and estimate Time to      Progression (TTP). However, the secondary objectives are to determine Overall Response Rate      (ORR), R0 and R1 Resection Rate, assessment of safety and toxicity associated with study      regimen, and finally, to investigate Overall survival (OS).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Pre-treatment procedures start with 2 weeks of comprehensive staging evaluation.      Approximately 20 eligible subjects, based on inclusion/exclusion criteria will receive study      regimen for six treatment every 2 weeks. Once six treatments have been completed, comprehensive      re-staging procedures will be repeated, and subjects without disease progression or      unacceptable toxicity will continue on their treatment contingent upon treating team      decision (surgical intervention, radiation therapy or continue chemotherapy with FOLFIRINOX      or different regimen). Subjects then follow with CT scan, cancer antigen 19-9 and physical      examination every 3 months.&lt;br/&gt;Intervention will be as follows: subjects will receive &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt; 85 mg/m2 over 2 h. Oxaliplatin will be followed by &lt;ulink linkType="Drug" linkID="2871"&gt;CPT-11&lt;/ulink&gt; (irinotecan) 180 mg/m2 over 90 min, which will be followed by leucovorin (LV) 400 mg/m2 over 2 h day1 and then followed by fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46 h continuous infusion.&lt;br/&gt;Subjects will be considered active study subjects from enrollment up to survival      follow-up period until documented disease progression, withdrawal of consent, lost to      follow-up, or death (by any cause), whichever will be earliest.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Jewish General Hospital</Name><Address1>MontrÃ©al</Address1><Address2>Quebec</Address2><Address3>H3T 1E2</Address3><CountrySubDivision>Quebec</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>petr.kavan@mcgill.ca</Email><Name>Petr Dr Kavan, MD</Name><Phone>5143408222</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pancreas tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="11424">Subjects with Adenocarcinoma of Pancreas</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03167112</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pancreas tumor" id="13354"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13351">Assessment of time to disease progression (TTP)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pancreas tumor" id="13356"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13357">Assessment of objective response rate (ORR)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pancreas tumor" id="44924"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pancreas tumor" id="13344"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13356"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13357">Assessment of objective response rate (ORR)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13433"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13434">Assessment of serious adverse events</SubEndpoint><SubEndpoint disease="Pancreas tumor" id="13444">Assessment of treatment induced toxicity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13450"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13453">Assessment of time to all cause mortality</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13457"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13463"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13470">Assessment of surgical resection rate</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pancreas tumor" id="8834"><Criterion>Subjects with Protocol Specified Performance Status </Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8845"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8850">Subjects with history of surgery/procedure for Pancreatic cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="8854"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8855">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Pancreas tumor" id="8856">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="13495"><Criterion>Subjects with Histological Subtypes of Pancreatic Cancer</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="13496">Subjects with Pancreatic adenocarcinoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="34028"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8857">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="34378"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8867">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pancreas tumor" id="10370"><Criterion>Subjects with Advanced/Metastatic/Stage IV Pancreatic Cancer</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10371"><Criterion>Subjects with Pancreatic Endocrine Tumors (PETs)</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10377"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10378"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10379"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10380">Subjects co-morbid with HIV infection</SubCriterion><SubCriterion disease="Pancreas tumor" id="10381">Subjects co-morbid with hepatitis virus infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pancreas tumor" id="10388"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10392">Subjects with abnormal pulmonary functions</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pancreas tumor" id="10397"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10402">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pancreas tumor" id="10405"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10412"><Criterion>Subjects with History of Treatment with Non-anticancer Drugs</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10416"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10419">Subjects with medical condition interfering with the study protocol</SubCriterion><SubCriterion disease="Pancreas tumor" id="10426">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pancreas tumor" id="25627"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10420">Subjects not suitable to participate as per investigator's discretion</SubCriterion><SubCriterion disease="Pancreas tumor" id="10421">Subjects with prior/current participation in any investigational study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pancreas tumor" id="26353"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10391">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pancreas tumor" id="27927"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10418">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-05-14T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-05-31T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-08-30T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="311686"><TitleDisplay>Bioequivalence study of clonazepam 0.5 mg mouth dissolving tablet</TitleDisplay><TitleOfficial>A Randomized, Open-Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover, Bioequivalence Study of Clonazepam Mouth Dissolving Tablets 0.5 mg of Abbott Healthcare Pvt ltd, With Clonazepam 0.5 mg Immediate Release Tablets of Abbott Healthcare Pvt ltd, in Normal, Healthy, Adult, Male and Female Human Subjects Under Fasting Conditions</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">CTRI/2017/08/009515</Identifier><Identifier type="Other">ARL/16/411</Identifier></Identifiers><Indications></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>clonazepam (mouth dissolving) Abbott Healthcare Pvt ltd</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>clonazepam (immediate release) Abbott Healthcare Pvt ltd</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1074842" type="Company"><TargetEntity id="5000711003" type="organizationId">Abbott Healthcare Pvt Ltd</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1074842">Abbott Healthcare Pvt Ltd</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers only</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioequivalence</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2017-08-30T00:00:00Z</DateStart><DateChangeLast>2018-03-15T22:03:38Z</DateChangeLast><DateAdded>2017-09-08T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Accutest Research Laboratories (I) Pvt. Ltd</Affiliation><Email>vandana.sahlam@accutestglobal.com</Email><Name>Dr Vandana Sahlam</Name><Phone>02227780718</Phone></Contact><Contact type="Public contact"><Affiliation>Abbott Healthcare Pvt. Ltd</Affiliation><Email>shubhangi.desai@abbott.com</Email><Name>Dr Shubhangi Desai</Name><Phone>02238160918</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male and non pregnant female human subjects, age in the range of 18 to 45 years both inclusive.&lt;/li&gt;&lt;li&gt;Body Mass Index between 18.5 tro 30 Kg / m2 extremes included&lt;/li&gt;&lt;li&gt;Subjects with normal findings as determined by baseline history, physical examination and vital sign examination (blood pressure, pulse rate, respiration rate and body temperature)&lt;/li&gt;&lt;li&gt;Subjects with clinically acceptable findings as determined by haemogram, biochemistry, urinalysis, 12 lead ECG and chest X-ray (if done)&lt;/li&gt;&lt;li&gt;Willingness to follow the protocol requirements especially abstaining from xanthine containing food or beverages (chocolates, tea, coffee or cola drinks) or grapefruit juice, any alcoholic products, the use of cigarettes and the use of tobacco products for 48.00 h prior to dosing until after the last blood sample collection in each study period and adherence to food, fluid and posture restrictions&lt;/li&gt;&lt;li&gt;No history of significant alcoholism&lt;/li&gt;&lt;li&gt;No history of drug abuse (benzodiazepines and barbiturates) for the last one month and other illegal drugs (Appendix B) for the last 06 months&lt;/li&gt;&lt;li&gt;Non smokers as evident from the history obtained will be included&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Known history of hypersensitivity to Clonazepam or related drugs&lt;/li&gt;&lt;li&gt;Requiring medication for any ailment having enzyme-modifying activity in the previous 28 days, prior to dosing day&lt;/li&gt;&lt;li&gt;Subjects who have taken prescription medications or over-the-counter products (including vitamins and minerals) within 14 days prior to administration of IMP&lt;/li&gt;&lt;li&gt;Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, bloodâforming organs etc&lt;/li&gt;&lt;li&gt;History of cardiovascular, renal, hepatic, ophthalmical, pulmonary, neurological, metabolical, hematological, gastrointestinal, endocrine, immunological or psychiatric diseases&lt;/li&gt;&lt;li&gt;Participation in a clinical drug study or bioequivalence study 90 days prior to period I dosing of the present study&lt;/li&gt;&lt;li&gt;History of malignancy or other serious diseases&lt;/li&gt;&lt;li&gt;Blood donation 90 days prior to period I dosing of the present study&lt;/li&gt;&lt;li&gt;Subjects with positive HIV tests, HBsAg or Hepatitis-C tests&lt;/li&gt;&lt;li&gt;Found positive in breath alcohol test&lt;/li&gt;&lt;li&gt;Found positive in urine test for drug abuse&lt;/li&gt;&lt;li&gt;History of problem in swallowing&lt;/li&gt;&lt;li&gt;Any contraindication to blood sampling&lt;/li&gt;&lt;li&gt;Female subjects found positive serum Beta- hCG (Human Chorionic Gonadotropin) test&lt;/li&gt;&lt;li&gt;Lactating women (currently breast feeding)&lt;/li&gt;&lt;li&gt;Female subjects not confirming to using birth control measures, from the date of screening until the completion of the study. Abstinence, barrier methods (condom, diaphragm, etc) are acceptable.&lt;/li&gt;&lt;li&gt;Use of hormonal contraceptives either oral or implants&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>To demonstrate the bioequivalence between Test Product (T): clonazepam Mouth Dissolving Tablets 0.5 mg and Reference Product (R): clonazepam 0.5 mg Immediate Release Tablet in normal, healthy, adult, male and female human subjects, under fasting conditions</Description><Timeframe>Total number of blood samples: 23 per period. Sampling hrs: Pre dose (collected within 01.00 hour prior to dosing), 00.25, 00.50, 00.75, 01.00, 01.33, 01.67, 02.00, 02.33, 02.67, 03.00, 03.33, 03.67, 04.00, 04.50, 05.00, 06.00, 08.00, 12.00, 16.00, 24.00, 48.00 and 72.00 h post dose</Timeframe></Measure><Measure><Description>To monitor the safety and tolerability of a single oral dose of investigational medicinal products (IMPs)</Description><Timeframe>Total number of blood samples: 23 per period. Sampling hrs: Pre dose (collected within 01.00 hour prior to dosing), 00.25, 00.50, 00.75, 01.00, 01.33, 01.67, 02.00, 02.33, 02.67, 03.00, 03.33, 03.67, 04.00, 04.50, 05.00, 06.00, 08.00, 12.00, 16.00, 24.00, 48.00 and 72.00 h post dose</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, open-label, balanced, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study of clonazepam mouth dissolving tablets 0.5 mg of Abbott Healthcare Pvt ltd, with clonazepam 0.5 mg immediate release tablets of Abbott Healthcare Pvt ltd., in normal, healthy, adult, male and female human subjects under fasting conditions.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomized into one of the two arms and will  receive clonazepam 0.5 mg immediate release tablet of Abbott Healthcare Pvt ltd or clonazepam 0.5 mg mouth dissolving tablets of Abbott Healthcare Pvt ltd.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>Accutest Research Laboratories (I) Pvt. Ltd</Name><Address1>Mumbai</Address1><Address2>Maharashtra</Address2><Address3>400709</Address3><CountrySubDivision>Maharashtra</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Epilepsy</Disease><PatientSegments><PatientSegment><PatientSegment id="15245">Others</PatientSegment><SubSegments><SubSegment id="18684">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier>CTRI/2017/08/009515</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Epilepsy" id="17151"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Epilepsy" id="17155"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Epilepsy" id="15306"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="15307">Subjects with normal/acceptable vital signs</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Epilepsy" id="15308"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion></Inclusion><Inclusion disease="Epilepsy" id="15316"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Epilepsy" id="15348"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="15356">Protocol specified inclusion criteria for women</SubCriterion><SubCriterion disease="Epilepsy" id="15359">Subjects with ability to take oral medications</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Epilepsy" id="33338"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="15310">Subjects with normal/acceptable cardiac function</SubCriterion><SubCriterion disease="Epilepsy" id="15313">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Epilepsy" id="33845"><Criterion>Subjects with specific cigarette smoking activity</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="15363">Non-smokers</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Epilepsy" id="33980"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="15312">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Epilepsy" id="34515"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="15347">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Epilepsy" id="34867"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="15350">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Epilepsy" id="34953"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Inclusion><Inclusion disease="Epilepsy" id="35308"><Criterion>Subjects with protocol specified imaging/radiological assessments</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Epilepsy" id="12709"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12710">Subjects with other central nervous system diseases/disorders</SubCriterion><SubCriterion disease="Epilepsy" id="12715">Subjects co-morbid with respiratory disorders/disease</SubCriterion><SubCriterion disease="Epilepsy" id="12716">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Epilepsy" id="12717">Subjects co-morbid with metabolic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12711"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Epilepsy" id="12712"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Epilepsy" id="12714"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Epilepsy" id="12718"><Criterion>Subjects co-morbid with immunological disease/disorder</Criterion></Exclusion><Exclusion disease="Epilepsy" id="12720"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Epilepsy" id="12734"><Criterion>Subjects with abnormal/unacceptable neuropsychological assessment</Criterion></Exclusion><Exclusion disease="Epilepsy" id="12736"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12738">Hypersensitivity/Contra-Indication to GABA reuptake inhibitors
</SubCriterion><SubCriterion disease="Epilepsy" id="12745">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12748"><Criterion>Subjects with History/ Scheduled to receive Anti-epileptic Therapy</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12749">Subjects with history/ scheduled to receive GABA receptor agonists</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12764"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12769">Subjects with history/ scheduled to receive enzyme altering drugs</SubCriterion><SubCriterion disease="Epilepsy" id="12773">Subjects with history/scheduled to receive hormonal therapy for other indication</SubCriterion><SubCriterion disease="Epilepsy" id="12775">Subjects with history/scheduled to receive dietary/herbal supplements for other indication</SubCriterion><SubCriterion disease="Epilepsy" id="12777">Subjects with history of/scheduled for surgery for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12784"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12787">Protocol specified exclusion criteria for females</SubCriterion><SubCriterion disease="Epilepsy" id="12789">Subjects with participation in investigational study</SubCriterion><SubCriterion disease="Epilepsy" id="12796">History/scheduled to donate blood</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="12791"><Criterion>Subjects with contraindication to imaging/diagnostic procedures</Criterion></Exclusion><Exclusion disease="Epilepsy" id="25877"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12719">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="26069"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12713">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="26310"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12732">Subjects with abnormal/unacceptable hematological functions</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Epilepsy" id="27816"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Epilepsy" id="12786">Subjects unable to comply with study/protocol requirements</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-09-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="339224"><TitleDisplay>MyT1DHero: an mHealth Intervention for Type 1 Diabetes</TitleDisplay><TitleOfficial>MyT1DHero: A Randomized, Controlled Trial of an mHealth Intervention to Improve Parent-child Communication and Adolescent Self-management of Type 1 Diabetes</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03521362</Identifier><Identifier type="Organisational Study">MYT1DHERORCT</Identifier></Identifiers><Indications><Indication id="836">Insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>MyT1DHero app</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>T1D mobile app</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1038481" type="Company"><TargetEntity id="4297817326" type="organizationId">American Diabetes Association</TargetEntity></SourceEntity><SourceEntity id="1039353" type="Company"><TargetEntity id="5002308191" type="organizationId">Spectrum Health Hospitals</TargetEntity></SourceEntity><SourceEntity id="20624" type="Company"><TargetEntity id="4298219268" type="organizationId">Michigan State University</TargetEntity></SourceEntity><SourceEntity id="836" type="ciIndication"><TargetEntity id="E10" type="ICD10"></TargetEntity><TargetEntity id="10067584" type="MEDDRA"></TargetEntity><TargetEntity id="D003922" type="MeSH"></TargetEntity><TargetEntity id="-686743471" type="omicsDisease"></TargetEntity><TargetEntity id="507" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20624">Michigan State University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1038481">American Diabetes Association</Company><Company id="1039353">Spectrum Health Hospitals</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>330</PatientCountEnrollment><DateStart>2019-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2022-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T16:34:15Z</DateChangeLast><DateAdded>2018-05-14T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Michigan State University</Affiliation><Email>bholtz@msu.edu</Email><Name>Bree E Holtz, PhD</Name><Phone>5178844537</Phone></Contact><Contact type="Public contact"><Email>murra172@msu.edu</Email><Name>Katharine M Murray, MA</Name><Phone>2699860669</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;The adolescents must:&lt;ul&gt;&lt;li&gt;Have a T1D diagnosis according to the ADA practice guidelines&lt;/li&gt;&lt;li&gt;Be 10 to 15 years old&lt;/li&gt;&lt;li&gt;Have had a diagnosis of T1D for at least 6 months&lt;/li&gt;&lt;li&gt;Have an HbA1c&amp;gt; 7&lt;/li&gt;&lt;li&gt;Have had at least two outpatient visits in the past two years&lt;/li&gt;&lt;li&gt;Be treated at Spectrum for diabetes&lt;/li&gt;&lt;li&gt;Be fluent in English&lt;/li&gt;&lt;li&gt;Have a parent/guardian willing to participate&lt;/li&gt;&lt;li&gt;Have and be allowed to use a mobile phone for the study&lt;/li&gt;&lt;li&gt;Have permission from their care team to participate&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;The parent/guardian must:&lt;ul&gt;&lt;li&gt;Have an adolescent with T1D who is 10 to 15 years old&lt;/li&gt;&lt;li&gt;Be fluent in English&lt;/li&gt;&lt;li&gt;Have daily access to email and the Internet (for appointment reminders and technical support)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;For the adolescents include:&lt;ul&gt;&lt;li&gt;Significant medical conditions other than T1D&lt;/li&gt;&lt;li&gt;Being treated for thyroid disorders, celiac disease, or eating disorders&lt;/li&gt;&lt;li&gt;Being in foster care&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;For both the adolescents and parents/guardians include:&lt;ul&gt;&lt;li&gt;A diagnosis of a major psychiatric or neurocognitive disorder (eg, traumatic brain injury, dementia, schizophrenia, bipolar disorder, borderline personality disorder, and intellectual and developmental disabilities&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change from Baseline Diabetes Behavior Rating Scale at 12 months: a measure of diabetes adherence for both parent and child participants. Never (1) - Always(5) with a higher score indicating better adherence</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline HbA1c at 6 months and 12 months: a laboratory test that measures how high blood glucose has been on average over the last 8 to 12 weeks - for child participants only (Lower number is best)</Description><Timeframe>Baseline, 6, and 12 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change from Baseline Confidence in Diabetes Self-Care (Psychometric properties of a new measure of diabetes-specific self-efficacy in Dutch and U.S. patients with type 1 diabetes) at 12 months: a measure of diabetes-related self-efficacy for the child participants. Strongly disagree (1) - Strongly agree (5), with a higher score indicating more confidence in self-care ability</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline Diabetes Conflict Scale at 12 months: a measure of conflict for both the parent and child participants. Almost Always (1) - Never (3), with a higher score indicating less conflict</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline Diabetes Empowerment Scale Short Form at 12 months: a measure of diabetes-related self-efficacy for both parent and child participants. Strongly disagree (1) - Strongly agree (5), with a higher score indicating more empowerment</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline Diabetes Family Behavior Scale at 12 months: a measure of family characteristics for both the parent and child participants. All of the time (1) - Never (5), with a lower score indicating better family behavior</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline Family Functioning Scale at 12 months: a measure of family characteristics for both the parent and child participants. Totally disagree (1) - Totally agree (6). Responses are summed. Subscales include intimacy (items 1, 4, 6, 10, 13, 15, 18, 20, 23, 26, 27, 29), conflict (items 3, 5, 8, 9, 12, 14, 17, 19, 22, 24), and parenting style (items 2, 7, 11, 16, 21, 25, 28, 30)</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline Family Satisfaction (FSS) at 12 months: a measure of family characteristics for the parent participants. Very dissatisfied (1) - Extremely satisfied (5), with a higher score indicating more satisfaction</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline Impact on Family (Construct: Parental perceptions of the impact of a child's medical condition on the family) at 12 months: a measure of family characteristics for the parent participants. Strongly disagree (1) - Strongly agree (5), with a higher score indicating more impact (burden)</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline NIH Toolbox Emotional Support (Ages 8 to 17) at 12 months: a measure of social support for the child participants. Never (1) - Always (5), with a higher score indicating more support</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline NIH Toolbox Self-efficacy (ages 8 to 12) at 12 months: a measure of self-efficacy for the child participants. Never (1) - Very often (5), with a higher score indicating higher self-efficacy</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline Neuro-QOL Item Bank version 1.0 -Anxiety - Short Form at 12 months: a measure of anxiety for the parent participants. Never (1) - Always (5), with a higher score indicating more anxiety</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline Neuro-QOL Item Bank version 1.0 -Pediatric Anxiety - Short Form at 12 months: a measure of anxiety for the child participants. Never (1) - Almost always (5), with a higher score indicating more anxiety; Not at all (1) - Very much (5); with a higher score indicating more anxiety</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline Neuro-QOL Item Bank version 1.0 -Pediatric Stigma - Short Form at 12 months: a measure of stigma for the child participants. Never (1) - Always (5), with a higher score indicating more feelings of stigma</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline PROMIS Item Bank version 2.0 - Emotional Support - Short Form 8a at 12 months: a measure of social support for the parent participants. Never (1) - Always (5), with a higher score indicating more support</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline PROMIS Item Bank version 2.0 - Informational Support - Short Form 6a at 12 months: a measure of social support for the parent participants. Never (1) - Always (5), with a higher score indicating better support</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline PROMIS Item Bank version 1.0 - General Self-Efficacy at 12 months: a measure of self-efficacy for the parent participants. I am not at all confident (1) - I am very confident (5), with a higher score indicating higher self-efficacy</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline PROMIS Item Bank version 1.0 - General Life Satisfaction - Short Form 5a at 12 months: a measure of quality of life for the parent participants. Strongly disagree (1) - Strongly agree (7), with a higher score indicating more life satisfaction</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline PROMIS Parent Proxy Item Bank version 1.0 - Family Relationships - Short Form 8a at 12 months: a measure of family characteristics for both the parent and child participants. Never (1) - Always (4), with a higher score indicating better family relationships</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline PedsQL (Measurement Model for the Pediatric Quality of Life Inventory) at 12 months: a measure of quality of life for the child participants. Never (0) - Almost Always (4), with a lower score indicating better quality of life</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Change from Baseline Short-Form Outcome Expectations at 12 months: a measure of diabetes outcome expectancy for both the parent and child participants. Strongly disagree (1) - Strongly agree (5), with a higher score indicating more positive outcome expectations</Description><Timeframe>Baseline and 12 months</Timeframe></Measure><Measure><Description>Unified theory of acceptance and use of technology (UTAUT) Vantakesh, Morris, et al., 2003: a measure of technology usability and satisfaction for both the parent and child participants</Description><Timeframe>12 months</Timeframe></Measure><Measure><Description>Usability and Satisfaction Questionnaire: a measure of technology usability and satisfaction for both the parent and child participants</Description><Timeframe>12 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The overall objective of the proposed research is to improve HbA1c, adherence to treatment      plans, and family communication surrounding adolescents' self-management of T1D. The      investigators will test the efficacy of the MyT1DHero app against an attention control group.      This will allow investigators to better understand the health and psychosocial improvements      being made through the app.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This research seeks to realize the potential and test the efficacy of MyT1DHero to improve      adolescent users' glycemic control and adherence to blood glucose monitoring. The      investigators' goal is to help families receive more social support, and to improve diabetes      knowledge, self-efficacy, family communication, and quality of life. The investigators      further seek to decrease family conflict among children with T1D and their parents. In a      12-month RCT, investigators will randomize 166 adolescents and their parents to one of two      groups: (1) attention control, or (2) the MyT1DHero app. Adolescents enrolled in the study      will be 10 to 15 years old, and will have been living with T1D for &amp;lt; 1 year or &amp;gt; 5 years at the      start of the study.&lt;br/&gt;Participants in the MyT1DHero app group will receive use of the MyT1DHero app which will have two separate interfaces, one for the parent and one for the child, that work together to help them communicate about diabetes management. The child receives system reminders to enter their blood glucose numbers, and parents receive a notification about each blood glucose test their child enters. Parents will also be able to use the app to communicate with their child about their plan for care. The app has customizable blood glucose reminders and ranges, videos of support from other adolescents with T1D, snack lists, and other educational information on T1D.&lt;br/&gt;Participants in this control group will receive use of a different app with less capabilities. A mobile app will be used in this control/comparison group that only has blood sugar testing reminders and logging capabilities. There will be no other components of the app.&lt;/para&gt;&lt;para&gt;The primary outcome will be a change in the participants' HbA1C from      baseline levels at the start of the study, to levels measured after 12 months.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Michigan State University</Name><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="7603">Subjects with Specified Duration of Disease</PatientSegment><SubSegments><SubSegment id="7604">Subjects with more than 6 months of diabetes mellitus</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7644">Subjects with Poor/Inadequate Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7645">Subjects with Moderate Glycemic Control</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03521362</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Insulin dependent diabetes" id="18111"><Endpoint>Assessment of HbA1c Levels</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Insulin dependent diabetes" id="32006"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Insulin dependent diabetes" id="32006"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="32018">Neuropathic specific quality of life tool(NeuroQol)</SubEndpoint><SubEndpoint disease="Insulin dependent diabetes" id="32030">PedsQL questionnaires</SubEndpoint><SubEndpoint disease="Insulin dependent diabetes" id="32034">Diabetes empowerment questionnaire(DES-SF)</SubEndpoint><SubEndpoint disease="Insulin dependent diabetes" id="32066">Self-efficacy</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Insulin dependent diabetes" id="16308"><Criterion>Subjects with Specified Duration with Type 1 Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16309">Subjects with more than 6 months of diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="16356"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16361">Subjects able to communicate in the language specified in the protocol</SubCriterion><SubCriterion disease="Insulin dependent diabetes" id="16372">Outsubjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="35051"><Criterion>Subjects with specific level of glycemic control</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16354">Subjects with Poor/Inadequate Glycemic Control</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Insulin dependent diabetes" id="13773"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13838"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13886"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="25998"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="29272"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2022-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-04-18T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-05-14T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="340464"><TitleDisplay>Using MRI to predict the success of anticancer treatment before surgery to the esophagus (gullet) and the gastroesophageal junction (gullet-stomach junction)</TitleDisplay><TitleOfficial>PET-MRI for prediction of treatment response to neoadjuvant treatment of cancer in the esophagus and the gastroesophageal junction</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN35827514</Identifier><Identifier type="Trial Acronym">PREciSE II</Identifier></Identifiers><Indications><Indication id="1011">Esophagus tumor</Indication><Indication id="127">Stomach tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="1731" role="Therapeutic effect marker" type="Genomic;Proteomic">B-lymphocyte antigen CD20</BiomarkerName><BiomarkerName id="1857" role="Therapeutic effect marker" type="Genomic;Proteomic">T-cell surface glycoprotein CD4</BiomarkerName><BiomarkerName id="1880" role="Therapeutic effect marker" type="Cellular">T-Helper Lymphocytes</BiomarkerName><BiomarkerName id="1942" role="Therapeutic effect marker" type="Genomic;Proteomic">Leukocyte common antigen</BiomarkerName><BiomarkerName id="1977" role="Therapeutic effect marker" type="Genomic;Proteomic">Forkhead box protein P3</BiomarkerName><BiomarkerName id="3447" role="Therapeutic effect marker" type="Genomic;Proteomic">T-cell surface glycoprotein CD8 alpha chain</BiomarkerName><BiomarkerName id="6663" role="Therapeutic effect marker" type="Cellular">B-lymphocytes</BiomarkerName><BiomarkerName id="46187" role="Therapeutic effect marker" type="Cellular">Memory T-Lymphocytes</BiomarkerName><BiomarkerName id="46505" role="Therapeutic effect marker" type="Cellular">Cytotoxic T-Lymphocytes</BiomarkerName><BiomarkerName id="46731" role="Therapeutic effect marker" type="Structural (imaging)">Standardized uptake value</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>PET-MRI</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>neoadjuvant treatment</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1057365" type="Company"><TargetEntity id="5040043719" type="organizationId">Swedish Cancer Society</TargetEntity></SourceEntity><SourceEntity id="1165237" type="Company"><TargetEntity id="5064420129" type="organizationId">Lions Clubs International</TargetEntity></SourceEntity><SourceEntity id="22324" type="Company"><TargetEntity id="5001205357" type="organizationId">Uppsala University</TargetEntity></SourceEntity><SourceEntity id="1011" type="ciIndication"><TargetEntity id="C15" type="ICD10"></TargetEntity><TargetEntity id="150" type="ICD9"></TargetEntity><TargetEntity id="10061882" type="MEDDRA"></TargetEntity><TargetEntity id="D004938" type="MeSH"></TargetEntity><TargetEntity id="-1694229607" type="omicsDisease"></TargetEntity><TargetEntity id="598" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="127" type="ciIndication"><TargetEntity id="C16" type="ICD10"></TargetEntity><TargetEntity id="151" type="ICD9"></TargetEntity><TargetEntity id="10017758" type="MEDDRA"></TargetEntity><TargetEntity id="D013274" type="MeSH"></TargetEntity><TargetEntity id="-2031094615" type="omicsDisease"></TargetEntity><TargetEntity id="646" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="22324">Uppsala University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1057365">Cancerfonden</Company><Company id="1165237">Lions Foundation (Uppsla)</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Cross-sectional</Term><Term>Cohort</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2018-01-01T00:00:00Z</DateStart><DateEnd type="estimated">2025-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-07-20T04:38:41Z</DateChangeLast><DateAdded>2018-05-28T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Uppsala University Hospital</Affiliation><Email>jakob.hedberg@surgsci.uu.se</Email><Name>Dr Jakob Hedberg</Name><Phone>+46186116507</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Aged &gt; 18 years&lt;/li&gt;&lt;li&gt;Esophageal cancer or gastroesophageal junctional cancer Siewert I and II&lt;/li&gt;&lt;li&gt;Planned for neoadjuvant treatment and surgery&lt;/li&gt;&lt;li&gt;Clinical stage T1-4aN0-3M0&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Cannot undergo MRI due to claustrophobia&lt;/li&gt;&lt;li&gt;Implants contraindicating MRI fitted, including pacemaker, pacemaker electrodes, mechanical heart valve, CNS electrodes and cochlear implants&lt;/li&gt;&lt;li&gt;Language difficulties making informed consent impossible&lt;/li&gt;&lt;li&gt;Renal failure&lt;/li&gt;&lt;li&gt;Allergy to contrast medium&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The main outcome measure is specificity and sensitivity for prediction of complete pathological response to neoadjuvant treatment. The radiomic results will be calculated by an operated blinded for other clinical data and the score will be entered into a dataset. Other radiological markers (SUV-max etc) will be entered as well. The pathological examination will also be entered into a blinded dataset and correlation analysis will be performed</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Tumor immune cell population composition in relation to pathological clinical response. Plasma and tumor samples before and after neoadjuvant therapy are frozen and saved for future analysis. In circulating plasma, biomarker assays will be preformed before, during and after neoadjuvant treatment along with appropriate bioinformatic statistical interpretation (Oling, Immunooncology panel). In addition to this, immunohistochemical analyses of tumor material (CD4, FoxP3, CD8/CD45RO and En CD20), analysis for immunology gene-expression before and after neoadjuvant treatment (Nanostring, nCounter Immunology ans Inflammation panels) will be performed</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study hypothesize that PET-MRI can combine data from PET with radiomic characteristics of the tumor in order to improve the prediction of complete pathological response to neoadjuvant treatment in esophageal cancer and cancer in the gastroesophageal junction. &lt;/para&gt;&lt;para&gt;Investigators aims to evaluate PET-MRI in a cross-sectional, cohort of patients planned for neaodjuvant treatment followed by resectional surgery for esophageal cancer and cancer of the gastroesophageal junction.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The recruited patients will undergo PET-MRI at diagnosis and one before surgery. This will be a 60 to 90 min investigation. The surgical specimen will be investigated according to clinical routine for TNM (tumor, node metastasis) staging and tumor regression grade according to Becker. The follow-up will be performed in accordance with clinical routine. After that the patient will be followed in  national registries for registration of death and up to five-year survival rates can be included in future analysis.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Sweden"><Sites><Site><Name>Uppsala University Hospital</Name><Address1>Uppsala</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Esophagus tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="9476">Subjects with Early Stage/Localized Esophageal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9480">Subjects with Locally Advanced Esophageal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9486">Subjects with Gastro-esophageal Junction Cancer</PatientSegment><SubSegments><SubSegment id="9487">Subjects with Siewert type I adenocarcinoma of the GEJ</SubSegment><SubSegment id="9488">Subjects with Siewert type II adenocarcinoma of the GEJ</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="9490">Subjects with Resectable Esophageal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10854">Subjects with Stage I Esophageal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10855">Subjects with Stage II Esophageal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10856">Subjects with Stage III Esophageal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10857">Subjects with Stage IV Esophageal Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN35827514</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Esophagus tumor" id="11957"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Esophagus tumor" id="11960">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Esophagus tumor" id="11967">Assessment of histo-pathologic response</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Esophagus tumor" id="11970"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Esophagus tumor" id="12030"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Esophagus tumor" id="11957"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Esophagus tumor" id="11967">Assessment of histo-pathologic response</SubEndpoint><SubEndpoint disease="Esophagus tumor" id="11969">Assessment of immunological response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Esophagus tumor" id="11997"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Esophagus tumor" id="11999"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Esophagus tumor" id="11954"><Endpoint>Assessment of Survival</Endpoint></OtherEndpoint><OtherEndpoint disease="Esophagus tumor" id="12027"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Esophagus tumor" id="7750"><Criterion>Subjects with Early Stage/Localized Esophageal Cancer</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7751"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7753"><Criterion>Subjects with Stage I Esophageal Cancer</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7756"><Criterion>Subjects with Stage II Esophageal Cancer</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="7757">Subjects with stage IIA esophageal cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Esophagus tumor" id="7759"><Criterion>Subjects with Stage III Esophageal Cancer</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7763"><Criterion>Subjects with Stage IV Esophageal Cancer</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7764"><Criterion>Subjects with Gastro-esophageal Junction Cancer</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="7765">Subjects with Siewert type I adenocarcinoma of the GEJ</SubCriterion><SubCriterion disease="Esophagus tumor" id="7766">Subjects with Siewert type II adenocarcinoma of the GEJ</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Esophagus tumor" id="7768"><Criterion>Subjects with Resectable Esophageal Cancer</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7808"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="7810">Subjects able to communicate in the language specified in the protocol</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Esophagus tumor" id="9310"><Criterion>Subjects with Advanced/Metastatic Esophageal Cancer</Criterion></Exclusion><Exclusion disease="Esophagus tumor" id="9330"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Esophagus tumor" id="9369"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="9379">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Esophagus tumor" id="25494"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="9370">Subjects with inability/unwillingness to provide informed consent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Esophagus tumor" id="26149"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Esophagus tumor" id="26360"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="9342">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Esophagus tumor" id="27134"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Esophagus tumor" id="27819"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="9371">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Esophagus tumor" id="29277"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="estimated">2020-12-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>36.00 Months</EnrollmentPeriod><FundersType><Type>Academic</Type><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-05-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="341331"><TitleDisplay>A study to evaluate the association between glucose transporter type 1 (GLUT-1) expression and the therapeutic effect of chemoradiotherapy (CRT) in patients with pancreatic ductal adenocarcinoma (PDAC)</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="1507">Pancreatic ductal adenocarcinoma</Indication></Indications><BiomarkerNames><BiomarkerName id="744" role="Therapeutic effect marker" type="Genomic;Proteomic">Solute carrier family 2, facilitated glucose transporter member 1</BiomarkerName><BiomarkerName id="1289" role="Therapeutic effect marker" type="Structural (imaging)">Tumor mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>chemotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>radiotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>surgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1003755" type="Company"><TargetEntity id="5035531506" type="organizationId">Japan Society For The Promotion Of Science (Jsps)</TargetEntity></SourceEntity><SourceEntity id="1041701" type="Company"><TargetEntity id="5000044890" type="organizationId">Japan, Ministry Of Health Labour And Welfare(Government)</TargetEntity></SourceEntity><SourceEntity id="1507" type="ciIndication"><TargetEntity id="D021441" type="MeSH"></TargetEntity><TargetEntity id="1858" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1003755">Japan Society for the Promotion of Science (JSPS)</Company><Company id="1041701">Japanese Ministry of Health, Labor and Welfare</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Small molecule</Category><Category>Radiation therapy</Category></TrialCategories><PatientCountEnrollment>197</PatientCountEnrollment><PatientCountEvaluable>197</PatientCountEvaluable><DateChangeLast>2018-06-01T22:01:42Z</DateChangeLast><DateAdded>2018-06-02T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with pancreatic ductal adenocarcinoma (PDAC)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with distant metastases and those  who received only chemotherapy as treatmentÂ were excluded&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>To evaluate the association between glucose transporter type 1 (GLUT-1) expression and the therapeutic effect of chemoradiotherapy (CRT) in patients with pancreatic ductal adenocarcinoma (PDAC): specimens for immunohistochemical evaluations were obtained through surgical resection and endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of the primary tumor before any treatment</Description></Measure><Measure><Description>To evaluate the prognostic relevance ofÂ glucoseÂ transporterÂ typeÂ 1Â (GLUT-1) expression in therapeutic startegy for PDAC</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate the association between glucose transporter type 1 (GLUT-1) expression and the therapeutic effect of chemoradiotherapy (CRT) in patients with pancreatic ductal adenocarcinoma (PDAC). Also, to evaluate the prognostic relevance ofÂ glucoseÂ transporterÂ typeÂ 1Â (GLUT-1) expression in therapeutic startegy for PDAC  [&lt;ulink linkType="Reference" linkID="2040389"&gt;2040389&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In May 2018, results were published. Surgical resection was performed in 21 of 97 patients who received neoadjuvant CRT. In patients who underwent upfront surgery, lowÂ GLUT-1 expressionÂ was considered as an independent factor for a better prognosis. In patients who received neoadjuvant CRT, lowÂ GLUT-1 expressionÂ showed significant association with greater tumor size reduction, higher resection rate, and  better prognosis. Moreover,Â expression of GLUT-1 was prominently increased after neoadjuvant CRT   [&lt;ulink linkType="Reference" linkID="2040389"&gt;2040389&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who either underwent upfront surgery (n = 100) or received neoadjuvant chemoradiotherapy (CRT; n = 97) were included and analyzed  [&lt;ulink linkType="Reference" linkID="2040389"&gt;2040389&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Government</Type><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-06-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="344587"><TitleDisplay>A cohort study to evaluate the accuracy of [18F]-FDG PET/CT to predict early pathological response after neoadjuvant chemotherapy in patients with locally advanced gastric cancer</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="127">Stomach tumor</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>PET/CT</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>[18F]-FDG</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>chemotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1073491" type="Company"><TargetEntity id="4296681565" type="organizationId">Klinik Hirslanden AG</TargetEntity></SourceEntity><SourceEntity id="127" type="ciIndication"><TargetEntity id="C16" type="ICD10"></TargetEntity><TargetEntity id="151" type="ICD9"></TargetEntity><TargetEntity id="10017758" type="MEDDRA"></TargetEntity><TargetEntity id="D013274" type="MeSH"></TargetEntity><TargetEntity id="-2031094615" type="omicsDisease"></TargetEntity><TargetEntity id="646" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1073491">Hirslanden Private Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>30</PatientCountEnrollment><PatientCountEvaluable>30</PatientCountEvaluable><DateChangeLast>2018-07-31T22:03:06Z</DateChangeLast><DateAdded>2018-06-30T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with locally advanced gastric cancer&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>To evaluate the metabolic response defined as decrease of tumor standardized uptake value (SUV) by &gt;/= 35%</Description></Measure><Measure><Description>To evalute the accuracy of [18F]-FDG PET/CT in the prediction of histopathological response</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this cohort study was to evaluate the accuracy of [18F]-FDG PET/CT to predict early pathological response after neoadjuvant chemotherapy in patients with locally advanced gastric cancer [&lt;ulink linkType="Reference" linkID="2050124"&gt;2050124&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In May 2018, results were pubilshed. After neoadjuvant chemotherapy, metabolic response and non-response was detected in 66.7 and 33.3%, respectively. Major and minor pathological regression was demonstrated by 50 and 50% of patients, respectively, among metabolic responders. A sensitivity and specificity of 90.9 and 47.3%, were detected with positive predictive value and negative predictive value of 50% each and accuracy of 63.3% [&lt;ulink linkType="Reference" linkID="2050124"&gt;2050124&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who were treated with neoadjuvant chemotherapy and underwent [18F]-FDG PET/CT scan were included and evaluated [&lt;ulink linkType="Reference" linkID="2050124"&gt;2050124&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-06-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="347169"><TitleDisplay>A clinical trial of P-PSMA-101 for the treatment of prostate cancer</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="276">Prostate tumor</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>P-PSMA-101</Name><Drug id="104396">P-PSMA-101</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="104396">P-PSMA-101</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1109809">Poseida Therapeutics Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1109809" type="Company"><TargetEntity id="5048023521" type="organizationId">Poseida Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"></TargetEntity><TargetEntity id="10060862" type="MEDDRA"></TargetEntity><TargetEntity id="D011471" type="MeSH"></TargetEntity><TargetEntity id="-405461207" type="omicsDisease"></TargetEntity><TargetEntity id="5083" type="siCondition"></TargetEntity><TargetEntity id="637" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="15">Planned</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1109809">Poseida Therapeutics Inc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="9267">Glutamate carboxypeptidase II modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="393">Immunostimulant</Class><Class id="4790">Genetically engineered autologous cell therapy</Class><Class id="7761">T-lymphocyte stimulator</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="1247">Chimeric antigen receptor T cell therapy</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="84">Protein fusion</Technology><Technology id="345">Receptor chimeric</Technology><Technology id="135">T-lymphocyte</Technology></Technologies><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Gene therapy</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><DateChangeLast>2019-05-16T06:46:35Z</DateChangeLast><DateAdded>2018-07-25T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with prostate cancer&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This is a clinical trial of &lt;ulink linkType="Drug" linkID="104396"&gt;P-PSMA-101&lt;/ulink&gt; for the  treatment of prostate cancer [&lt;ulink linkType="Reference" linkID="2056158"&gt;2056158&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2151673"&gt;2151673&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2018, &lt;ulink linkType="Company" linkID="1109809"&gt;Poseida Therapeutics Inc&lt;/ulink&gt; planned to start this trial  in 2019 [&lt;ulink linkType="Reference" linkID="2056158"&gt;2056158&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-07-25T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-05-16T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="added"><Date>2019-05-16T00:00:00Z</Date><Reason id="313">Eligibility Criteria added</Reason></Change><Change type="added"><Date>2019-05-16T00:00:00Z</Date><Reason id="316">Trial Outcome Measure Added</Reason></Change></ChangeHistory></Trial><Trial id="364526"><TitleDisplay>Precise Percutaneous Coronary Intervention Plan (P3) Study</TitleDisplay><TitleOfficial>Prospective Evaluation of a Virtual Non-invasive Percutaneous Intervention Planner in Patients With Coronary Artery Disease</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03782688</Identifier><Identifier type="Organisational Study">CVBA-CRI_0001</Identifier><Identifier type="Trial Acronym">P3</Identifier></Identifiers><Indications><Indication id="80">Coronary artery disease</Indication></Indications><BiomarkerNames><BiomarkerName id="10487" role="Disease marker" type="Physiological">Fractional Flow Reserve</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>HeartFlow Planner</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1051603" type="Company"><TargetEntity id="5035548278" type="organizationId">Onze Lieve Vrouw Hospital</TargetEntity></SourceEntity><SourceEntity id="80" type="ciIndication"><TargetEntity id="10011078" type="MEDDRA"></TargetEntity><TargetEntity id="D003327" type="MeSH"></TargetEntity><TargetEntity id="-1572475765" type="omicsDisease"></TargetEntity><TargetEntity id="221" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1051603">Onze Lieve Vrouw Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>120</PatientCountEnrollment><DateStart>2019-02-01T00:00:00Z</DateStart><DateEnd type="estimated">2021-01-15T00:00:00Z</DateEnd><DateChangeLast>2019-02-14T05:57:16Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>jeroen.sonck@olvz-aalst.be</Email><Name>Jeroen CS Sonck, MD</Name><Phone>+32477181454</Phone></Contact><Contact type="Scientific contact"><Affiliation>OLV-Aalst</Affiliation><Name>Bernard De Bruyne, MD, PhD</Name></Contact><Contact type="Public contact"><Email>carlos.collet.bortone@olvz-aalst.be</Email><Name>Carlos A Collet, MD</Name><Phone>+3253724433</Phone></Contact><Contact type="Scientific contact"><Affiliation>Onze Lieve Vrouw Hospital</Affiliation><Name>Jeroen Sonck</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Coronary artery disease in a major epicardial vessel with an invasive fractional flow reserve (FFR)&amp;lt;/= 0.80&lt;/li&gt;&lt;li&gt;An indication to Percutaneous coronary intervention&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Angiographic exclusion criteria:&lt;ul&gt;&lt;li&gt;Severely calcified lesion/vessel&lt;/li&gt;&lt;li&gt;Bifurcation lesions&lt;/li&gt;&lt;li&gt;Ostial lesions&lt;/li&gt;&lt;li&gt;Left main disease&lt;/li&gt;&lt;li&gt;Severe vessel tortuosity&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Clinical exclusion criteria:&lt;ul&gt;&lt;li&gt;Chronic obstructive pulmonary disease&lt;/li&gt;&lt;li&gt;Contraindication to adenosine&lt;/li&gt;&lt;li&gt;NYHA class III or IV, or last known left ventricular ejection fraction&amp;lt; 30%&lt;/li&gt;&lt;li&gt;Uncontrolled or recurrent ventricular tachycardia&lt;/li&gt;&lt;li&gt;Atrial fibrillation, flutter or arrhythmia&lt;/li&gt;&lt;li&gt;History of recent stroke (&amp;lt;/= 90 days) &lt;/li&gt;&lt;li&gt;History of acute coronary syndrome (&amp;lt;/= 90 days) &lt;/li&gt;&lt;li&gt;Prior myocardial infarction&lt;/li&gt;&lt;li&gt;History of ischemic stroke (&amp;gt; 90 days) with modified RANKIN score &gt;/= 2 &lt;/li&gt;&lt;li&gt;History of any hemorrhagic stroke&lt;/li&gt;&lt;li&gt;Previous revascularization (PCI or Coronary artery bypass grafting)&lt;/li&gt;&lt;li&gt;Active liver disease or hepatic dysfunction, defined as AST or ALT&amp;gt; 3 times the ULN &lt;/li&gt;&lt;li&gt;Severe renal dysfunction, defined as an eGFR&amp;lt;30 mL/min/1.73 m2 &lt;/li&gt;&lt;li&gt;Body mass index&amp;gt; 35 kg/m2 &lt;/li&gt;&lt;li&gt;Nitrate intolerance&lt;/li&gt;&lt;li&gt;Contra-indication to heart rate lowering drugs Imaging-related&lt;/li&gt;&lt;li&gt;Insufficient coronary CT Angiography image quality&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Agreement on post-PCI fractional flow reserve between virtual treatment based on FFRct planner and measured invasive post-PCI fractional flow reserve: the agreement will be assessed by Cohen's Kappa coefficient</Description><Timeframe>The primary endpoint will be assessed immediately after the procedure (PCI)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The precise percutaneous coronary interventionÂ  (PCI) plan study is an investigator-initiated,      international and multicenter study of patients with an indication for PCI aiming at      assessing the agreement and accuracy of the HeartFlow Planner with invasive fractional flow      reserve (FFR) as a reference.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Multicenter study, including 120 patients at five centers in Europe and Asia. After identifying      the presence of significant coronary stenosis by means of coronary angiography and invasive      fractional flow reserve (FFR &amp;lt;/= 0.80) the patients will undergo the following procedures:      invasive FFR with intravenous adenosine (ie, pre- and post-PCI). Optical coherence      tomography-guided PCI (ie, pre- and post-procedural imaging). PCI with newer generation      drug-eluting stent.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Belgium"><Sites><Site><Name>OLV-Aalst</Name><Address1>Aalst</Address1><Address2>Oost-Vlaanderen</Address2><Address3>9300</Address3><CountrySubDivision>Oost-Vlaanderen</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>jeroen.sonck@olvz-aalst.be</Email><Name>Jeroen CS Sonck, MD</Name><Phone>003253724433</Phone></Contact><Contact type="Facility investigator"><Name>Carlos A Collet, MD</Name></Contact><Contact type="Facility investigator"><Name>Bernard De Bruyne, MD, PhD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="201">Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="243">Subjects with Abnormal Angiographic Findings</PatientSegment><SubSegments><SubSegment id="251">Stenosis/Narrowing of vessel</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="367">Subjects with Stable Coronary Artery Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03782688</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Coronary artery disease" id="2571"><Endpoint>Assessment of Vascular Indices or Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2672">Fractional flow reserve (FFR)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Coronary artery disease" id="43875"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="35243">Assessment by optical coherence tomography (OCT)</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1068"><Criterion>Subjects with Coronary Artery Disease (CAD)</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1069">Subejcts with coronary artery stenosis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1169"><Criterion>Subjects with History of /Scheduled for Coronary Revascularization Therapy</Criterion></Inclusion><Inclusion disease="Coronary artery disease" id="1201"><Criterion>Coronary Angiogram Findings Suggestive of/Confirmed CAD/CHD</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1223">Stenosis or lesion of one major epicardial artery</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1240"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="2057">Lab values meeting inclusion criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="34775"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Coronary artery disease" id="1602"><Criterion>Subjects with Myocardial Infarction (MI)</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1609"><Criterion>Subjects with Specific Coronary Angiographic Findings</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1614">Aorto-ostial location of lesion</SubCriterion><SubCriterion disease="Coronary artery disease" id="1616">Calcified lesions</SubCriterion><SubCriterion disease="Coronary artery disease" id="1620">Excessive tortuosity/angulation proximal to or within the lesion</SubCriterion><SubCriterion disease="Coronary artery disease" id="1622">Involves a bifurcation lesion</SubCriterion><SubCriterion disease="Coronary artery disease" id="1623">Left main artery location (protected /Unprotected)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1651"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1652">Subjects co-morbid with acute coronary syndrome</SubCriterion><SubCriterion disease="Coronary artery disease" id="1662">Subjects co-morbid with congestive heart failure (Killip class II-IV/NYHA Class II-IV)/Failure of the right ventricle/Decompensated heart failure</SubCriterion><SubCriterion disease="Coronary artery disease" id="1667">Severe left ventricular dysfunction /abnormal left ventricular ejection fraction</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1668"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1670">Subjects co-morbid with atrial fibrillation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1696"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1702">Subjects with renal failure/renal insufficiency</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1740"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1742">Subjects with bleeding disorders/bleeding diathesis/hemorrhagic diathesis /hematopoietic disease/coagulopathy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1760"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1764">Hepatic disease /hepatic insufficiency /jaundice</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1766"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1936">Subjects co-morbid with obesity</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1780"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="5588">Subjects co-morbid with cerebrovascular/CNS disorder</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1857"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1858">Subjects with abnormal renal function tests</SubCriterion><SubCriterion disease="Coronary artery disease" id="1861">Abnormal liver function test</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="23442"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="24889"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1881">Hypersensitivity/contraindication to adenosine</SubCriterion><SubCriterion disease="Coronary artery disease" id="1893">Hypersensitivity/Contraindication to cardiovascular medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="26090"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1846">Subjects with CABG (Coronary artery bypass graft) surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="26100"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="28412"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-01-15T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-12-12T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-02-14T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-02-14T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="364833"><TitleDisplay>Expresssion and significiance of P38MAPK and JNK pathways in lymphocytes of Schizophrenia patients</TitleDisplay><TitleOfficial>Expresssion and significiance of mitogen activated protein kinase pathways in lymphocytes of Schizophrenia patients</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1800020272</Identifier></Identifiers><Indications><Indication id="299">Schizophrenia</Indication></Indications><BiomarkerNames><BiomarkerName id="2584" role="Disease marker" type="Genomic;Proteomic">Mitogen-activated protein kinase 8</BiomarkerName><BiomarkerName id="11986" role="Disease marker" type="Genomic;Proteomic">p38 Mitogen-activated protein kinases</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1146618" type="Company"><TargetEntity id="5055467680" type="organizationId">Shandong Mental Health Center</TargetEntity></SourceEntity><SourceEntity id="299" type="ciIndication"><TargetEntity id="F20" type="ICD10"></TargetEntity><TargetEntity id="10039626" type="MEDDRA"></TargetEntity><TargetEntity id="D012559" type="MeSH"></TargetEntity><TargetEntity id="-729613619" type="omicsDisease"></TargetEntity><TargetEntity id="65" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1146618">Shandong Mental Health Center</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Case Control</Term><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2019-03-01T00:00:00Z</DateStart><DateEnd type="estimated">2019-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-12-31T08:25:23Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Shandong Mental Health Center</Affiliation><Email>121446885@qq.com</Email><Name>He Xiayue</Name><Phone>+86 18265318590</Phone></Contact><Contact type="Scientific contact"><Affiliation>Shandong Mental Health Center</Affiliation><Email>zengxunliu@126.com</Email><Name>Liu Zengxun</Name><Phone>+86 13583135343</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Aged 18 to 60 years, meet the standard of ICD - 10 in the diagnosis of schizophrenia&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Serious adverse events&lt;/li&gt;&lt;li&gt;Other mental illness&lt;/li&gt;&lt;li&gt;Substance abuse or dependence&lt;/li&gt;&lt;li&gt;An acute infection and autoimmune diseases&lt;/li&gt;&lt;li&gt;Nervous system disease or a history of trauma&lt;/li&gt;&lt;li&gt;Pregnant or lactating women&lt;/li&gt;&lt;li&gt;Schizophrenia with other serious mental disease&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>P38MAPK, P-P38MAPK, JNK, P-JNK</Description></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective is to study that whether P38MAPK and JNK expression level in peripheral blood lymphocytes in patients with schizophrenia is different with the healthy people, and to further study on if there is a correlation between cognitive symptoms of schizophrenia, negative and positive symptoms and P38MAPK and JNK protein expression level.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with schizophrenia will be observed for P38MAPK and JNK expression level in peripheral blood lymphocytes.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Shandong Mental Health Center</Name><Address1>Ji'nan</Address1><Address2>Shandong</Address2><CountrySubDivision>Shandong</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Schizophrenia</Disease><PatientSegments><PatientSegment><PatientSegment id="7179">Others</PatientSegment><SubSegments><SubSegment id="7180">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1800020272</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Schizophrenia" id="37187"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Schizophrenia" id="10062"><Endpoint>Assessment of Symptoms of Schizophrenia</Endpoint><SubEndpoints><SubEndpoint disease="Schizophrenia" id="10063">Assessment of positive symptoms</SubEndpoint><SubEndpoint disease="Schizophrenia" id="10064">Assessment of negative symptoms</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Schizophrenia" id="10075"><Endpoint>Cognitive, Global and Functional Assessments</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Schizophrenia" id="5456"><Criterion>Subjects with Clinical Disease Diagnosis</Criterion></Inclusion><Inclusion disease="Schizophrenia" id="33285"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion><SubCriteria><SubCriterion disease="Schizophrenia" id="5458">Diagnosed by ICD criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Schizophrenia" id="34525"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Schizophrenia" id="22505">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Schizophrenia" id="7033"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Schizophrenia" id="7034">Subjects with other neurological disorders/diseases</SubCriterion><SubCriterion disease="Schizophrenia" id="7042">Subjects with autoimmune diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Schizophrenia" id="7045"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Schizophrenia" id="7101"><Criterion>Subjects with Adverse Effects to Therapy</Criterion></Exclusion><Exclusion disease="Schizophrenia" id="7107"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Schizophrenia" id="7119">Subjects with protocol specified exclusion criteria for women</SubCriterion><SubCriterion disease="Schizophrenia" id="7125">History of trauma/injury</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Schizophrenia" id="25764"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Schizophrenia" id="23391">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Schizophrenia" id="25809"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Schizophrenia" id="7029">Subjects co-morbid with substance abuse disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="365362"><TitleDisplay>Pre-emptive Effect of Duloxetine in the Second Knee in Staged Total Knee Arthroplasty</TitleDisplay><TitleOfficial>Pre-emptive Effect of Duloxetine in the Second Knee in Staged Total Knee Arthroplasty: A Randomized Controlled Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03792828</Identifier><Identifier type="Organisational Study">SNUBMC_20181128</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames><BiomarkerName id="46522" role="Therapeutic effect marker" type="Physiological">Knee motion</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>duloxetine</Name><Drug id="5907">duloxetine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="5907">duloxetine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1003017">Seoul National University Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="5907" type="Drug"><TargetEntity id="142924" type="siDrug">Duloxetine hydrochloride</TargetEntity><TargetEntity id="142925" type="siDrug">LY-264452</TargetEntity><TargetEntity id="142926" type="siDrug">LY-227942</TargetEntity></SourceEntity><SourceEntity id="1003017" type="Company"><TargetEntity id="5035524531" type="organizationId">Seoul National University Hospital</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1003017">Seoul National University Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="285">Norepinephrine uptake inhibitor</Class><Class id="2941">Antidepressant</Class><Class id="2942">Anxiolytic</Class><Class id="2946">Analgesic</Class><Class id="3">5-HT uptake inhibitor</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="805">Daily dosing</Technology><Technology id="590">Enteric coated formulation</Technology><Technology id="559">Oral controlled release formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="742">Pellet</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>No Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>90</PatientCountEnrollment><DateStart>2019-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2019-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-01-08T12:22:09Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>SMG-SNU Boramae Medical Center</Affiliation><Email>ossbkang@gmail.com</Email><Name>Seung-Baik Kang, MD, PhD</Name><Phone>+82-870-3931</Phone></Contact><Contact type="Public contact"><Affiliation>Seoul National University Boramae Medical Center</Affiliation><Email>sjy820828@gmail.com</Email><Name>JoungYoup Shin, MD</Name><Phone>+82-10-5310-7133</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Candidate for staged bilateral total knee replacement arthroplasty due to osteoarthritis of the knee&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Known allergic reaction to duloxetine&lt;/li&gt;&lt;li&gt;Secondary arthritis (eg, rheumatic arthritis, traumatic arthritis, septic arthritis)&lt;/li&gt;&lt;li&gt;History of major operation(eg, arthroscopic knee arthroplasty, osteotomy, open reduction, and internal fixation)&lt;/li&gt;&lt;li&gt;History of manic or bipolar disorder, epilepsy, increased intraocular pressure or risk of acute angle-closure glaucoma, liver disease, moderate renal disease (CLcr&amp;lt; 30ml/min), severe heart disease, uncontrolled hypertension, unregulated narrow-angle glaucoma&lt;/li&gt;&lt;li&gt;Known congenital or acquired coagulopathy&lt;/li&gt;&lt;li&gt;Known genetic disorders such as fulminant intolerance / glucose-galactose uptake disorder/sucrose isoleucetase deficiency&lt;/li&gt;&lt;li&gt;Taken MAO inhibitor, anti-depressants, diuretics, duloxetine&lt;/li&gt;&lt;li&gt;Refuse to participate in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pain VAS: Pain VAS(11âpoint numeric scale: 0-11) at rest, maximal knee flexion and maximal knee extension</Description><Timeframe>Day 7 (inpatient)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Central censitization: DN4 (Douleur Neuropathique 4)</Description><Timeframe>Preop. days 1, 2, 7 (inpatient) , Postop. 6 weeks, 3 months</Timeframe></Measure><Measure><Description>Opioid consumption: Opioid conversion to Morphine IV</Description><Timeframe>Preop. days 1, 2, 7 (inpatient) , Postop. 6 weeks, 3 months</Timeframe></Measure><Measure><Description>Pain VAS: Pain VAS(11âpoint numeric scale: 0-11) at rest, maximal knee flexion and maximal knee extension</Description><Timeframe>Preop. days 1, 2, 7 (inpatient) , Postop. 6 weeks, 3 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this randomized, controlled study  is to assess the pre-emptive effect of &lt;ulink linkType="Drug" linkID="5907"&gt;duloxetine&lt;/ulink&gt; in the second knee in staged total knee arthroplasty.&lt;/para&gt;&lt;para&gt;The investigators aim to : &lt;br/&gt;Whether the pain is greater than the first operation      at the second operation in the control group. &lt;br/&gt;Whether the pre-operative and post-operative      duloxetine use causes the pre-analgesic effect on the second operation. &lt;br/&gt;Whether the      central sensitization, clinical score, and painkiller usage are different by comparing      duloxetine-treated group and control group.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomized to two groups. In the duloxetine group, one capsule of duloxetine HCl 30 mg  is taken orally and daily from the day before the first operation to 7 days after the second operation. In the control group, the patients can take painkillers except duloxetine.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="South Korea"><Sites><Site><Name>Seoul National University Boramae Medical Center</Name><Address1>Seoul</Address1><Address3>07061</Address3><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>ossbkang@gmail.com</Email><Name>Seung-Baik Kang, MD, PhD</Name><Phone>+82-2-870-3931</Phone></Contact><Contact type="Facility investigator"><Name>Seung-Baik Kang, MD, PhD</Name></Contact><Contact type="Facility investigator"><Name>Chong Bum Chang, MD, PhD</Name></Contact><Contact type="Facility investigator"><Name>Moon Jong Chang, MD, PhD</Name></Contact><Contact type="Facility investigator"><Name>Joung Youp Shin, MD</Name></Contact><Contact type="Facility investigator"><Name>Whang Kim, MD</Name></Contact><Contact type="Facility investigator"><Name>Dong Whan Suh, MD</Name></Contact><Contact type="Facility investigator"><Name>Jong Byung Oh, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8424">Subjects with Post-Operative Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03792828</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25871"><Endpoint>Assessment of Pain at Rest</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint><SubEndpoint disease="Pain" id="25875">Based on Numerical Rating Scale [NRS]</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="25959"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26000"><Endpoint>Assessment of Pain</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25871"><Endpoint>Assessment of Pain at Rest</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint><SubEndpoint disease="Pain" id="25875">Based on Numerical Rating Scale [NRS]</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25898"><Endpoint>Assessment of Neuropathic Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25902">Based on DN4 Neuropathic Pain Diagnosis scale</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25934"><Endpoint>Assessment of Post-operative Pain</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25959"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26007"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26044">Assessment of analgesic use/rescue medication</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="44807"><Endpoint>Neurological Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22142"><Criterion>Subjects with Peri-operative Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22143">Subjects with post operative pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22256">Subjects with history/scheduled for surgery for other indication</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20104"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20113">Subjects co-morbid with metabolic diseases/disorders</SubCriterion><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion><SubCriterion disease="Pain" id="20122">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Pain" id="20123">Subjects with infectious disorders/disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20115"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20117"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20137">Subjects with history/scheduled to receive anti-depressants</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20174">Subjects with history/scheduled to receive other drug therapies</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20129">Hypersensitivity/ contraindication to investigational drug/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="25794"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20154">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26044"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Pain" id="20116">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26300"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Pain" id="20106">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="27443"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Pain" id="27926"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="20184">Unwillingness to comply with protocol requirements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="29411"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-10-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-11-28T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="370414"><TitleDisplay>Exposure of Taxi Drivers to Ultrafine Particles and Black Carbon Within Their Vehicles</TitleDisplay><TitleOfficial>Exposure of Taxi Drivers to Ultrafine Particles and Black Carbon Within Their Vehicles: Determinants of In-Vehicle Exposure and Short Term Respiratory Impact</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03839537</Identifier><Identifier type="Organisational Study">K180303J</Identifier><Identifier type="Secondary Organisational">2018-A00811-54</Identifier><Identifier type="Trial Acronym">PUF-TAXI</Identifier></Identifiers><Indications><Indication id="711">Respiratory disease</Indication></Indications><BiomarkerNames><BiomarkerName id="1905" role="Disease marker" type="Physiological">Peak expiratory flow rate</BiomarkerName><BiomarkerName id="1912" role="Disease marker" type="Physiological">Forced Vital Capacity</BiomarkerName><BiomarkerName id="2029" role="Disease marker" type="Physiological">Forced expiratory flow </BiomarkerName><BiomarkerName id="2713" role="Disease marker" type="Physiological">Forced expiratory volume</BiomarkerName><BiomarkerName id="3050" role="Disease marker" type="Biochemical">Carbon monoxide</BiomarkerName><BiomarkerName id="3457" role="Disease marker" type="Biochemical">Carbon dioxide</BiomarkerName><BiomarkerName id="6033" role="Disease marker" type="Biochemical">Nitrite</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Exhaled carbon monoxide test</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Exposure measurement</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Fractional exhaled nNitric oxide testing</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Skin allergy test (Prick test)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Spirometry test (Spirobank II)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1181219" type="Company"><TargetEntity id="5040189358" type="organizationId">Agence de l'Environnement et de la Maitrise de l'Energie</TargetEntity></SourceEntity><SourceEntity id="15511" type="Company"><TargetEntity id="5001199274" type="organizationId">Ctre Nat De La Recherche Scientifique</TargetEntity></SourceEntity><SourceEntity id="23948" type="Company"><TargetEntity id="4296543185" type="organizationId">Assistance Publique Hopitaux de Paris</TargetEntity></SourceEntity><SourceEntity id="30170" type="Company"><TargetEntity id="5035524445" type="organizationId">Universite de Paris 5 Rene Descartes</TargetEntity></SourceEntity><SourceEntity id="711" type="ciIndication"><TargetEntity id="J98.9" type="ICD10"></TargetEntity><TargetEntity id="10038683" type="MEDDRA"></TargetEntity><TargetEntity id="D012140" type="MeSH"></TargetEntity><TargetEntity id="-2143937119" type="omicsDisease"></TargetEntity><TargetEntity id="269" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23948">Assistance Publique Hopitaux de Paris</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1181219">Agence de lâenvironnement et de la maÃ®trise de lâÃ©nergie (ADEME)</Company><Company id="15511">Centre National de la Recherche Scientifique (CNRS)</Company><Company id="30170">lâUniversite Paris Descartes</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Diagnosis</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2019-02-01T00:00:00Z</DateStart><DateEnd type="estimated">2022-01-31T00:00:00Z</DateEnd><DateChangeLast>2019-03-20T06:38:44Z</DateChangeLast><DateAdded>2019-02-19T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Assistance Publique Hopitaux de Paris</Affiliation><Email>melissa-hachem@hotmail.com</Email><Name>Melissa Hachem</Name><Phone>+ 33 6 52 95 24 25</Phone></Contact><Contact type="Scientific contact"><Affiliation>Assistance Publique Hopitaux de Paris</Affiliation><Name>Lynda Bensefa-Colas</Name></Contact><Contact type="Public contact"><Affiliation>Assistance Publique Hopitaux de Paris</Affiliation><Email>guillaume.masson@aphp.fr</Email><Name>Guillaume Masson</Name><Phone>+33 1 58 41 34 78</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;gt;18 years&lt;/li&gt;&lt;li&gt;Full time licensed taxi driver&lt;/li&gt;&lt;li&gt;Subjects with &gt;6 months of job tenure (as a taxi driver)&lt;/li&gt;&lt;li&gt;Subjects affiliated to a social security scheme&lt;/li&gt;&lt;li&gt;Subjects must have signed an informed consent and are willing to participate in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects having difficulty to understand the French language&lt;/li&gt;&lt;li&gt;Subjects with less than 6 months of job tenure (as a taxi driver)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mean number of ultrafine fraction of particles (UFP): per cm3 of air (from 1000 to 1000000 particles [pt]/cm3) - 8 to 11 h recording on 1 working day for each subject-repeated measurement in cold and warm seasons</Description><Timeframe>6 months apart</Timeframe></Measure><Measure><Description>Mean concentration of black carbon (BC): measurement of BC exposure concentrations per cubic meter (ng/m3) by the microAeth AE51 - 8 to 11 h recording on 1 working day for each subject-repeated measurement in cold and warm seasons</Description><Timeframe>6 months apart</Timeframe></Measure><Measure><Description>Difference between the values of the forced vital capacity (FVC) measured before and after work shift: measurement of FVC in liters by a portable spirometer before and after the work shift according to procedures described by the European Respiratory Society and the American Thoracic Society (2005) - 2 measurements per subject-before and after the work shift-one working day repeated measurement in cold and warm seasons (6 months apart) overall period: 2 working days (one in each season)-36 months</Description><Timeframe>36 months</Timeframe></Measure><Measure><Description>Difference between the values of the forced expiratory volume in one s (FEV1) measured before and after work shift: measurement of FEV1 in l by a portable spirometer before and after the work shift according to procedures described by the European Respiratory Society and the American Thoracic Society (2005) -2 measurements per subject - before and after the work shift - 1 working day Repeated measurement in cold and warm seasons (6 months apart) Overall period: 2 working days (one in each season)-36 months</Description><Timeframe>36 months</Timeframe></Measure><Measure><Description>Difference between the values of the forced expiratory flow between 25 and 75 % of FVC (FEF25 to 75) measured before and after work shift: measurement of FEF25 to 75 in l by a portable spirometer before and after the work shift according to procedures described by The European Respiratory Society and the American Thoracic Society (2005) -2 measurements per subject - before and after the work shift - 1 working day repeated measurement in cold and warm seasons (6 months apart) overall period: 2 working days (one in each season) - 36 months</Description><Timeframe>36 months</Timeframe></Measure><Measure><Description>Difference between the rates of the peak expiratory flow (PEF) measured before and after work shift: measurement of PEF in l/s by a portable spirometer before and after the work shift according to procedures described by The European Respiratory Society and the American Thoracic Society (2005)-2 measurements per subject - before and after the work shift - 1 working day repeated measurement in cold and warm seasons (6 months apart) overall period: 2 working days (one in each season) - 36 months</Description><Timeframe>36 months</Timeframe></Measure><Measure><Description>Acute respiratory symptoms through self-administered questionnaire: by means of a self-completion questionnaire, participants report their acute respiratory symptoms felt during the measurement day - reported before and after the work shift per subject - in cold and warm seasons (6 months apart)- overall period: reported during 2 working days (one in each season) - 36 months</Description><Timeframe>36 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Characteristics of the trips recorded by a self-administered questionnaire: speed, opened/closed windows, smoking, breaks, etc reported by a self-administered questionnaire - after the work shift per subject - in cold and warm seasons (6 months apart) overall period: reported during 2 working days (one in each season) - 36 months</Description><Timeframe>36 months</Timeframe></Measure><Measure><Description>Characteristics of vehicles recorded by a self-administered questionnaire: fuel, age and type of the vehicle, air conditioning, air cabin filter reported by a self-administered questionnaire - after the work shift per subject - in cold and warm seasons (6 months apart) overall period: reported during 2 working days (one in each season) - 36 months</Description><Timeframe>36 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The research aim of this study are to quantify the occupational exposure of      taxi drivers to ultrafine particles (UFP), black carbon (BC), oxides of carbon (CO, CO2) and to nitrogen dioxide (NO2), to identify spatio-temporal variability and patterns of exposure related to occupational tasks, and to study the impact of this occupational exposure to UFP and BC on ventilation performances      and respiratory symptoms.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study is based on a random sampling of 100 taxi drivers, working full-time day shift, in      Paris, members of three Trade Unions. It will be conducted over a period of two years in warm      and cold season. The research will begin with an inclusion clinical examination. It consists      on determining the overall health status of the participants by administering a standardized      questionnaire and performing spirometry test, prick test and FENO measurement. The exposure      assessment will be based on continuous measurement of UFP, BC, carbon monoxide (CO) and NO2,      by portable devices during a working day (+/- 11 h). Exposure measurement consists 2 measurements per subject (in warm season and in cold season). Devices will be placed inside taxi vehicles on the passenger seat in a sampling bag. On the same day, two spirometry tests      and two measurements of exhaled carbon monoxide will be performed at the beginning and at the      end of the shift, using handheld devices. Spirometry test (Spirobank II) consists of 2 measurements per subject-before and after the work shift-in warm and cold seasons. Subject will inhale and exhale in the device. Exhaled carbon monoxide test consists of 2 measurements per subject-before and after the work shift-in warm and cold seasons. Subject will exhale in the device. Skin allergy test (Prick test), spirometry test and fractional exhaled nitric oxide testing will be performed by a physician during the inclusion clinical examination. Multivariate analysis will provide spatio-temporal      distributions of individual exposures and their determinants. Generalized Estimating      Equations (GEE) multivariate models will be used to determine the relation between exposure      (UFP, BC) and respiratory symptoms, ventilation performances, adjusting for potential      confounding/modifying factors.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>Paris Descartes University</Name><Address1>Paris</Address1><Address3>75006</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>isabelle.momas@aphp.fr</Email><Name>Isabelle MOMAS, MD, PhD</Name><Phone>+33 1 53 73 97 28</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03839537</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><PrimaryCompletionDate type="Anticipated">2022-01-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2019-01-07T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-02-19T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-03-20T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="373770"><TitleDisplay>Influence of time of vaccination on Hepatitis B vaccine responses in health care students</TitleDisplay><TitleOfficial>A pilot study evaluating the influence of chronobiology on Hepatitis B responses in health-care students attending the University of Salford</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">2014-003756-32</Identifier><Identifier type="Secondary Organisational">HEP/UNI-001</Identifier></Identifiers><Indications><Indication id="152">Hepatitis B virus infection</Indication></Indications><BiomarkerNames><BiomarkerName id="11580" role="Therapeutic effect marker" type="Cellular">T-lymphocytes</BiomarkerName><BiomarkerName id="11956" role="Therapeutic effect marker" type="Proteomic">Anti-Hepatitis B virus antibodies</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Engerix B</Name><Drug id="3268">Engerix B</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3268">Engerix B</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="20613">University of Manchester</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="DOL28402">Central Manchester Healthcare NHS Trust</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3268" type="Drug"><TargetEntity id="137797" type="siDrug">Engerix B</TargetEntity></SourceEntity><SourceEntity id="20613" type="Company"><TargetEntity id="4297143274" type="organizationId">University Of Manchester</TargetEntity></SourceEntity><SourceEntity id="DOL28402" type="Company"><TargetEntity id="5035554475" type="organizationId">Central Manchester Healthcare Nhs Trust</TargetEntity></SourceEntity><SourceEntity id="152" type="ciIndication"><TargetEntity id="10019731" type="MEDDRA"></TargetEntity><TargetEntity id="D019694" type="MeSH"></TargetEntity><TargetEntity id="-1284790527" type="omicsDisease"></TargetEntity><TargetEntity id="429" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="DOL28402">Central Manchester Healthcare NHS Trust</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20613">University of Manchester</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="12372">Protein subunit vaccine</Class><Class id="12378">Prophylactic vaccine</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="745">Suspension</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Vaccine</Category><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Prevention</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2016-06-10T00:00:00Z</DateStart><DateEnd type="actual">2017-04-10T00:00:00Z</DateEnd><DateChangeLast>2019-03-22T08:34:42Z</DateChangeLast><DateAdded>2019-03-21T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Central Manchester University Hospitals NHS Foundation Trust</Affiliation><Email>lynne.webster@cmft.nhs.uk</Email><Name>Lynne Webster</Name><Phone>01612764125</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age more than or equal to16 years&lt;/li&gt;&lt;li&gt;University student in good health who consents to fill diary cards, provide saliva and blood samples and is able to attend a morning/afternoon/evening vaccination session&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;History of HepB infection or vaccination&lt;/li&gt;&lt;li&gt;Immunosuppression including HIV or chronic/current steroid use&lt;/li&gt;&lt;li&gt;Receipt of blood products or IgG within 3 months of enrolment&lt;/li&gt;&lt;li&gt;Any contraindication to Hepatitis B vaccination per Green Book&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>In this pilot study, Investigators objective is to establish the procedures we will use in a definitive study of circadian rhythm, the time of day and vaccine responses.To answer our research question, 'How does the time of day of first vaccination affect the immune response to Hepatitis B vaccine?' we will be using the anti Hepatitis B surface antigen antibody concentration after three doses of Hepatitis B vaccine as our primary outcome measure.To answer our research question, 'How does the time of day of first vaccination affect the immune response to Hepatitis B vaccine?' we will be using the anti Hepatitis B surface antigen antibody concentration after three doses of Hepatitis B vaccine as our primary outcome measure.</Description><Timeframe>The time point for the evaluation of the primary outcome will be after a blood sample has been collected 1 month after last vaccine dose</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Hepatitis B antibody levels after first and second HBV vaccinations</Description><Timeframe>Analysed from blood tests done at 1 and 2 months after first vaccination</Timeframe></Measure><Measure><Description>Quality of T-cell immune responses after first vaccination in relationship to time of day of vaccination, and to specific chronotypes (sleep/wake patterns)</Description><Timeframe>Part of the analysis will be done from blood tests one month after first vaccination. Final analysis will be performed one month after last vaccination</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The  principal research question was: 'How did the time of day of first vaccination affect the immune response to Hepatitis B vaccine?'&lt;br/&gt;The  primary objectives in the study are&lt;br/&gt;To establish the procedures for a definitive investigation into time of day and vaccine responses.&lt;br/&gt;To evaluate the difference in Hepatitis B antibody (Anti-HBs) titres of morning, afternoon and evening vaccination groups after 3 doses of Hepatitis B vaccination.&lt;/para&gt;&lt;para&gt;Exploratory objectives:&lt;br/&gt;To Evaluate differences between morning, afternoon and evening first vaccination groups for the following exploratory outcomes:&lt;br/&gt;Anti-HBs levels after 1st vaccination.&lt;br/&gt;Quality of T cell responses after primary vaccination.&lt;br/&gt;Explore specific chronotypes in relation to time of day of vaccination and vaccination outcomes.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Participants would receive &lt;ulink linkType="Drug" linkID="3268"&gt;Engerix B&lt;/ulink&gt; vaccine.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="UK"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Lynne Webster</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hepatitis B Vaccine</Disease><PatientSegments><PatientSegment><PatientSegment id="15278">Others</PatientSegment><SubSegments><SubSegment id="10042">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2014-003756-32</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hepatitis B Vaccine" id="19070"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Hepatitis B Vaccine" id="19041"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Hepatitis B Vaccine" id="19042">Anti-hepatitis B antibody titers</SubEndpoint><SubEndpoint disease="Hepatitis B Vaccine" id="19044">Cell mediated immunity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Hepatitis B Vaccine" id="19066"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hepatitis B Vaccine" id="19070"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hepatitis B Vaccine" id="17663"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Hepatitis B Vaccine" id="34724"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Hepatitis B Vaccine" id="17658">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hepatitis B Vaccine" id="15235"><Criterion>Subjects with Hepatitis B Infection</Criterion></Exclusion><Exclusion disease="Hepatitis B Vaccine" id="15257"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Hepatitis B Vaccine" id="15258">Subjects immunocompromized with HIV infection</SubCriterion><SubCriterion disease="Hepatitis B Vaccine" id="15260">Subjects on immunomodulators/corticosteroids/chemotherapeutic drugs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hepatitis B Vaccine" id="15270"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Hepatitis B Vaccine" id="15278"><Criterion>Subjects with Contraindications to Vaccines/Vaccine Ingredients</Criterion></Exclusion><Exclusion disease="Hepatitis B Vaccine" id="25531"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion><Exclusion disease="Hepatitis B Vaccine" id="26530"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Hepatitis B Vaccine" id="15273">Subjects with Prior Hepatitis B Vaccination</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-03-21T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="378828"><TitleDisplay>Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC)</TitleDisplay><TitleOfficial>MAESTRO: Molecular Stratification Profiling Protocol in Metastatic Castration Resistant Prostate Cancer (mCRPC)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03934164</Identifier><Identifier type="Organisational Study">ICR-CTSU/2016/10059</Identifier><Identifier type="Trial Acronym">MAESTRO</Identifier></Identifiers><Indications><Indication id="1069">Metastasis</Indication><Indication id="3246">Hormone refractory prostate cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="64" role="Disease marker" type="Cellular">Circulating Tumor Cells</BiomarkerName><BiomarkerName id="1827" role="Disease marker" type="Genomic">Cell-free DNA</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>bone marrow biopsy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>tumor biopsy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1081209" type="Company"><TargetEntity id="5001400500" type="organizationId">Prostate Cancer UK</TargetEntity></SourceEntity><SourceEntity id="21072" type="Company"><TargetEntity id="4297014876" type="organizationId">Institute of Cancer Research: Royal Cancer Hospital</TargetEntity></SourceEntity><SourceEntity id="1069" type="ciIndication"><TargetEntity id="10062194" type="MEDDRA"></TargetEntity><TargetEntity id="D009362" type="MeSH"></TargetEntity><TargetEntity id="-1423187778" type="omicsDisease"></TargetEntity><TargetEntity id="618" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21072">Institute of Cancer Research UK</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1081209">Prostate Cancer UK</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>600</PatientCountEnrollment><DateStart>2019-06-30T00:00:00Z</DateStart><DateEnd type="estimated">2025-03-31T00:00:00Z</DateEnd><DateChangeLast>2019-05-06T09:13:09Z</DateChangeLast><DateAdded>2019-05-03T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>maestro-icrctsu@icr.ac.uk</Email><Name>Stephanie Burnett, BSc</Name><Phone>02087224261</Phone></Contact><Contact type="Scientific contact"><Affiliation>The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust</Affiliation><Name>Johann de Bono</Name></Contact><Contact type="Public contact"><Email>maestro-icrctsu@icr.ac.uk</Email><Name>Ajit Sarvadikar</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male aged &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Histologically confirmed metastatic castrate resistant adenocarcinoma of the prostate&lt;/li&gt;&lt;li&gt;Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2&lt;/li&gt;&lt;li&gt;Surgically or medically castrated, with testosterone levels of&amp;lt; 50 ng/dl (&amp;lt; 2.0 nM)&lt;/li&gt;&lt;li&gt;Confirmed metastatic disease on imaging&lt;/li&gt;&lt;li&gt;Patients with tumor deemed by the designated investigator as safely suitable for fresh biopsy AND who are medically fit (according to local practice) to undergo a biopsy or procedure to acquire tumour tissue AND previously collected tumour specimens from prior surgery or biopsy available for analysis. An mCRPC biopsy collected within 6-months of trial entry can be used instead of this fresh biopsy if available and passes laboratory quality control requirements&lt;/li&gt;&lt;li&gt;Willing and able to comply with the requirements of the sample collection including fresh tumor biopsy&lt;/li&gt;&lt;li&gt;The subject is capable of understanding and complying with the protocol requirements and has given written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;The presence of any hematological disorders, including coagulation disorders, which would be a contraindication if patient were to undergo a biopsy&lt;/li&gt;&lt;li&gt;Any psychiatric illness/social situations that would limit compliance with study requirements&lt;/li&gt;&lt;li&gt;Presence of any concurrent condition or situation, which, in the investigators opinion, may put the patient at significant risk, may confound the study results or may interfere significantly with the patient's participation in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of molecular aberrations in diagnostic archive and fresh mCRPC tissue: the prevalence of molecular aberrations in diagnostic archive and fresh mCRPC will be calculated with 95% confidence intervals</Description><Timeframe>4 to 6 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Changes in molecular aberrations: changes in the molecular features of tumour biopsies acquired at diagnosis and fresh mCRPC will be quantified to demonstrate any differences in the molecular aberrations within the same patient's tumor</Description><Timeframe>4 to 6 weeks</Timeframe></Measure><Measure><Description>Overall Survival (OS): OS will be measured from the date of CRPC to the date of death (whatever the cause). Survival time of living patients will be censored on the last date a patient is known to be alive or lost to follow-up. Analyses will use the Kaplan Meier method and Cox proportional hazard models by molecular aberration. Multivariable Cox proportional hazard models will include established prognostic factors such as site of disease</Description><Timeframe>From the date of confirmed CRPC to the date of death from any cause, , through study completion, up to five years</Timeframe></Measure><Measure><Description>Quantify the association between molecular aberrations and baseline prognostic characteristics: the association between identified molecular aberrations and baseline characteristics, known to be prognostic factors, will be quantified. Associations will be determined using Fisher's exact test for categorical characteristics and for continuous characteristics either a Wilcoxon rank sum test or t test will be used depending on the results of normality testing</Description><Timeframe>4 to 6 weeks</Timeframe></Measure><Measure><Description>Safety - review of biopsy-related adverse events: occurrence of at least one grade 3 or 4 event: all events experienced by patients related to study procedures (collection of a fresh biopsy or blood samples) will be recorded and graded using CTCAE version 5 criteria and specifically the occurrence of at least one grade 3 or 4 event. Adverse events will be summarised by grade according to the worst grade experienced. In addition, the most frequently observed AEs will be summarised. The overall proportion of patients experiencing at least one grade 3 or 4 event will be presented by study procedure</Description><Timeframe>30 days after study biopsy/blood collection</Timeframe></Measure><Measure><Description>Time to development of CRPC: this is defined in whole days as the time from the date of diagnosis to the date of confirmed CRPC. The median time and interquartile range will be determined per molecular aberration. Analyses will be conducted per molecular aberration and will use the Kaplan-Meier method and Cox proportional hazard models. Analyses will adjust for known baseline characteristics and previous treatments received using multivariable Cox proportional hazard models</Description><Timeframe>From the date of diagnosis to the date of confirmed mCRPC, through study completion, up to five years</Timeframe></Measure><Measure><Description>Circulating free DNA: to evaluate the agreement between molecular aberrations found in cfDNA and tumour biopsies (fresh and archival) from primary (prostate) or metastatic site. Agreement will be determined per paired sample for each molecular aberration using Cohen's kappa coefficient</Description><Timeframe>4 to 6 weeks</Timeframe></Measure><Measure><Description>Circulating tumor cells: to acquire DNA from pure CTCs. To evaluate the agreement between molecular aberrations found in CTCs and tumour biopsies (fresh and archival) from primary (prostate) or metastatic site. Agreement will be determined per paired sample for each molecular aberration using Cohen's kappa coefficient</Description><Timeframe>4 to 6 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This  is a prospective, observational, study assess the molecular stratification profiling in metastatic castration resistant prostate cancer (mCRPC).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with mCRPC who have received at least one standard treatment for mCRPC will be      approached to participate in MAESTRO will be observed. Patients must have archival tumor available and be      willing to undergo a fresh tumor biopsy for molecular analysis. Tumor tissue (archival and      fresh), research blood samples and saliva will be sent to the central laboratory for analysis      to identify molecular aberrations through targeted or broader molecular analysis (eg, exome,      transcriptome) and orthogonal assays (eg, immunohistochemistry, digital droplet PCR). When      the results are available, depending on patients choice, the results will be discussed. If      significant results are indicated, patients will be recommended to have follow up with a      cancer geneticist to discuss the implications of these results for their personal and      family's health. &lt;/para&gt;&lt;para&gt;There is a safety follow up 30 days after collection of study biopsy or blood samples.      Patients will also be followed up for overall survival and subsequent anticancer treatment      every 6 monthly via medical notes or telephone calls.&lt;/para&gt;&lt;para&gt;The following research samples will be collected under as part of this study:&lt;br/&gt;Where available, excess archival tumor tissue from previous biopsies or routine           surgical procedures will be retrospectively collected.&lt;br/&gt;Fresh tissue specimens will be obtained for patients who are undergoing standard of care           interventions or patient will undergo a bone marrow biopsy or an ultrasound /CT guided           tumor biopsy of a safely accessible lesion. Fresh tumor specimens will be processed           and/or frozen.&lt;br/&gt;Sequencing analysis of tissues will be done and results will be made available in real           time. Clinically significant results will be disclosed to patients and their clinicians           as per patient consent.&lt;br/&gt;Research samples for blood, serum, plasma and saliva will be collected at the time of           the biopsy.&lt;/para&gt;&lt;para&gt;Patients who elected (optional consent) to receive sequencing results regarding incidental      clinically significant findings, will be referred for genetic counselling.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>The Royal Marsden NHSFT</Name><Address1>Sutton</Address1><Address2>Surrey</Address2><Address3>SM2 5PT</Address3><CountrySubDivision>Surrey</CountrySubDivision><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts><Contact type="Facility investigator"><Name>Johann de Bono</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Prostate tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3564">Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3565">Subjects with Stage IV Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3583">Subjects with Castrate Resistant Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12009">Subjects With Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12018">Subjects with adenocarcinoma of prostate</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="23604">Subjects with resectable Prostate Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03934164</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate tumor" id="7179"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Prostate tumor" id="7219"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Prostate tumor" id="7045"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7179"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7189"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7190">Assessment of adverse events/serious adverse events</SubEndpoint><SubEndpoint disease="Prostate tumor" id="7205">Assessment of grade 3 toxicity</SubEndpoint><SubEndpoint disease="Prostate tumor" id="7206">Assessment of grade 4 toxicity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7211"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7219"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="26571"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="31928">Assessment by CTCAE grading system</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Prostate tumor" id="7158"><Endpoint>Assessment of Markers of Tumor Growth and Progression</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="42024">Assessment of circulating tumor cells (CTC)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Prostate tumor" id="7179"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint><OtherEndpoint disease="Prostate tumor" id="7219"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Prostate tumor" id="3695"><Criterion>Subjects with Stage IV Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3714"><Criterion>Subjects with Histologically/Cytologically Confirmed Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3715">Subjects with adenocarcinoma of prostate</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3716"><Criterion>Subjects with Prostate Specific Laboratory Values</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3717">Subjects with castrate level of testosterone</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3737"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3738">Subjects with ECOG/WHO/Zubrod status 0-2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3755"><Criterion>Subjects with Castrate Resistant Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3771"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="7091"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="35968"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="35969">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="35974"><Criterion>Subjects with resectable Prostate Cancer</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Prostate tumor" id="4918"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4921">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4920"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="5004"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="5015">Subjects unsuitable to participate as per investigator</SubCriterion><SubCriterion disease="Prostate tumor" id="14249">Subjects with medical condition interfering with the study protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="27139"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="27938"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="5010">Subjects unable to comply with study requirements</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2024-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-12-21T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-05-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="43127"><TitleDisplay>Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer</TitleDisplay><TitleOfficial>A Partially-Blind, Phase III, Randomized Trial of Fulvestrant (Faslodex) With or Without Concomitant Anastrozole (Arimidex) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-Steroidal Aromatase Inhibitors</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">CRUK/09/007</Identifier><Identifier type="Other">10.1186/ISRCTN44195747</Identifier><Identifier type="Organisational Study">CDR0000448616</Identifier><Identifier type="NCT">NCT00253422</Identifier><Identifier type="Secondary Organisational">ICR-CTSU-SOFEA</Identifier><Identifier type="Secondary Organisational">EU-20531</Identifier><Identifier type="Secondary Organisational">SSA-04Q200635</Identifier><Identifier type="Secondary Organisational">ISRCTN44195747</Identifier><Identifier type="Secondary Organisational">MREC-03677</Identifier><Identifier type="Secondary Organisational">EUDRACT-2004-000093-30</Identifier><Identifier type="Trial Acronym">SoFEA</Identifier></Identifiers><Indications><Indication id="3657">Metastatic breast cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="5" role="Disease marker" type="Genomic;Proteomic">Estrogen receptor</BiomarkerName><BiomarkerName id="6" role="Disease marker" type="Genomic;Proteomic">Progesterone receptor</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>exemestane</Name><Drug id="3081">exemestane</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>fulvestrant</Name><Drug id="3313">fulvestrant</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>anastrozole</Name><Drug id="3321">anastrozole</Drug></Intervention><Intervention type="InterventionPrimary"><Name>fulvestrant</Name><Drug id="3313">fulvestrant</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3081">exemestane</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21072">Institute of Cancer Research UK</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3313">fulvestrant</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21072">Institute of Cancer Research UK</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3313">fulvestrant</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21072">Institute of Cancer Research UK</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3321">anastrozole</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21072">Institute of Cancer Research UK</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3081" type="Drug"><TargetEntity id="129640" type="siDrug">Exemestane</TargetEntity></SourceEntity><SourceEntity id="3321" type="Drug"><TargetEntity id="147754" type="siDrug">Anastrozole</TargetEntity></SourceEntity><SourceEntity id="3313" type="Drug"><TargetEntity id="177872" type="siDrug">Fulvestrant</TargetEntity><TargetEntity id="177872" type="siDrug">Fulvestrant</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="21072" type="Company"><TargetEntity id="4297014876" type="organizationId">Institute of Cancer Research: Royal Cancer Hospital</TargetEntity></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"></TargetEntity><TargetEntity id="589" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="286" type="Action"><TargetEntity id="1284" type="Mechanism">Estrogen Receptor (ER) Antagonists</TargetEntity><TargetEntity id="3050" type="Mechanism">Selective Estrogen Receptor Destabilizers (SERD)</TargetEntity><TargetEntity id="3127" type="Mechanism">Estrogen Receptor (ER) Zinc Finger Inhibitors</TargetEntity></SourceEntity><SourceEntity id="76" type="Action"><TargetEntity id="393" type="Mechanism">Aromatase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="21072">Institute of Cancer Research UK</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20519">National Cancer Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="286">Estrogen receptor antagonist</Action><Action id="76">Aromatase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1129">Non-steroid hormone receptor antagonist</Class><Class id="1545">Anticancer</Class><Class id="62254">Anticancer hormone antagonist</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="90">Steroid</Technology><Technology id="589">Sustained release formulation</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>750</PatientCountEnrollment><PatientCountEvaluable>63</PatientCountEvaluable><DateStart>2004-03-31T00:00:00Z</DateStart><DateEnd type="actual">2006-01-01T00:00:00Z</DateEnd><DateChangeLast>2019-02-15T10:52:58Z</DateChangeLast><DateAdded>2009-02-05T04:40:19Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Royal Marsden - London</Affiliation><Name>Stephen Johnston</Name></Contact><Contact type="Scientific contact"><Affiliation>Royal Marsden NHS Foundation Trust</Affiliation><Name>Stephen R. D. Johnston, MD, PhD, FRCP</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Disease characteristics:&lt;ul&gt;&lt;li&gt;Histologically or cytologically confirmed adenocarcinoma of the breast&lt;ul&gt;&lt;li&gt;Locally advanced or metastatic disease&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Metastatic disease must be measurable or evaluable&lt;ul&gt;&lt;li&gt;Patients with bone only metastases are eligible provided there is an evaluable site of bone metastasis that can be followed by X-ray, MRI, or CT scan&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Relapsed or progressed during prior treatment with single-agent nonsteroidal aromatase inhibitor (NSAI), meeting either of the following criteria:&lt;ul&gt;&lt;li&gt;NSAI given as adjuvant therapy that lasted &gt;/= 12 months&lt;/li&gt;&lt;li&gt;Achieved an objective complete response, partial response, or stable disease that lasted &gt;/= 6 months after prior first-line therapy with NSAI for locally advanced or metastatic disease: chemotherapy as part of the first-line therapy given before initiation of NSAI allowed. Note: patients are required to continue to take NSAI until beginning of study treatment.&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;No rapidly progressive visceral disease (ie, lymphangitis carcinomatosa or diffuse hepatic involvement)&lt;/li&gt;&lt;li&gt;Hormone receptor status:&lt;ul&gt;&lt;li&gt;Estrogen receptor (ER) and/or progesterone receptor positive tumor&lt;/li&gt;&lt;li&gt;No ER-unknown disease&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patient characteristics:&lt;ul&gt;&lt;li&gt;Sex: female&lt;/li&gt;&lt;li&gt;Menopausal status:&lt;ul&gt;&lt;li&gt;Postmenopausal, as defined by one of the following criteria: age 60 years and over, age 45 years to 59 years and &gt;/= 12 months since last menstrual period with no prior hysterectomy, any age with prior bilateral oophorectomy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Performance status: WHO 0 to 2&lt;/li&gt;&lt;li&gt;Life expectancy: more than 3 months&lt;/li&gt;&lt;li&gt;Hematopoietic:&lt;ul&gt;&lt;li&gt;Neutrophil count &gt;/= 1500/mm(3)&lt;/li&gt;&lt;li&gt;Platelet count &gt;/= 100,000/mm(3): no thrombocytopenia&lt;/li&gt;&lt;li&gt;Hemoglobin &gt;/= 10 g/dl&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Hepatic:&lt;ul&gt;&lt;li&gt;AST and ALT&amp;lt;/= 2.5 times upper limit of normal (ULN) &lt;/li&gt;&lt;li&gt;Alkaline phosphatase&amp;lt;/= 5 times ULN (unless due to bone metastases) &lt;/li&gt;&lt;li&gt;No liver disease&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Renal: creatinine&amp;lt; 1.97 mg/dl&lt;/li&gt;&lt;li&gt;Other: no other malignancy within the past five years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Prior concurrent therapy:&lt;ul&gt;&lt;li&gt;Chemotherapy:&lt;ul&gt;&lt;li&gt;See disease characteristics&lt;/li&gt;&lt;li&gt;Prior neoadjuvant or adjuvant chemotherapy allowed&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Endocrine therapy:&lt;ul&gt;&lt;li&gt;See disease characteristics&lt;/li&gt;&lt;li&gt;Prior tamoxifen as neoadjuvant or adjuvant therapy allowed&lt;/li&gt;&lt;li&gt;No systemic corticosteroids that lasted &gt; 15 days within the past 4 weeks&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Other:&lt;ul&gt;&lt;li&gt;More than 4 weeks since prior investigational drugs&lt;/li&gt;&lt;li&gt;Concurrent bisphosphonates for bone metastases allowed provided bisphosphonate therapy has been established for &gt;/= 6 months: concurrent initiation of bisphosphonate allowed provided patient has soft tissue or visceral metastases as the measurable or evaluable target lesion&lt;/li&gt;&lt;li&gt;No concurrent anticoagulant therapy&lt;/li&gt;&lt;li&gt;No concurrent unlicensed noncancer investigational agents&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Progression-free survival</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Objective complete response (CR) and partial response (PR) rate</Description></Measure><Measure><Description>Duration of response</Description></Measure><Measure><Description>Clinical benefit (ie, 6-month CR, PR, and stable disease) rate</Description></Measure><Measure><Description>Duration of clinical benefit</Description></Measure><Measure><Description>Time to treatment failure</Description></Measure><Measure><Description>Overall survival</Description></Measure><Measure><Description>Tolerability</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In February 2018, pooled results were published from ten clinical trials (&lt;ulink linkType="Protocol" linkID="49221"&gt;NCT00863655&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="157088"&gt;NCT01958021&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="181037"&gt;NCT02107703&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="43619"&gt;NCT00721409&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="100505"&gt;NCT01740427&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="154529"&gt;NCT01942135&lt;/ulink&gt;, NCT00253422, &lt;ulink linkType="Protocol" linkID="78739"&gt;NCT01381874&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="41833"&gt;NCT00075764&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="28665"&gt;NCT00083993&lt;/ulink&gt;) which evaluated the efficacy and safety of endocrine monotherapy (ET) versus combination therapy (ET +/- targeted therapies) in age-stratified cohorts of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. In age-stratified subsets, rates of adverse events were found to be similar. Although treatment discontinuation for patients aged &gt;/= 70 y who were receiving everolimusÂ +Â exemestane were higher, there were no-age related differences in discontinuations observed for CDK4/6 inhibitors. Tolerability of combination therapy were found to be worse compared to monotherapy [&lt;ulink linkType="Reference" linkID="2027855"&gt;2027855&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, phase III trial was to study &lt;ulink linkType="Drug" linkID="3313"&gt;fulvestrant&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3321"&gt;anastrozole&lt;/ulink&gt; to see how well they work compared to &lt;ulink linkType="Drug" linkID="3313"&gt;fulvestrant&lt;/ulink&gt; and a placebo or &lt;ulink linkType="Drug" linkID="3081"&gt;exemestane&lt;/ulink&gt; alone in treating postmenopausal women with locally advanced or metastatic breast cancer.&lt;br/&gt;&lt;br/&gt;The primary
objective of the study was to compare progression-free survival of postmenopausal women with estrogen receptor- and/or progesterone receptor-positive, locally advanced or metastatic breast cancer that relapsed or progressed during prior treatment with nonsteroidal aromatase inhibitors treated with &lt;ulink linkType="Drug" linkID="3313"&gt;fulvestrant&lt;/ulink&gt; with versus without &lt;ulink linkType="Drug" linkID="3321"&gt;anastrozole&lt;/ulink&gt; versus &lt;ulink linkType="Drug" linkID="3081"&gt;exemestane&lt;/ulink&gt; alone.
&lt;/para&gt;&lt;para&gt;The secondary
objectives of the study were to:&lt;br/&gt;Compare the objective complete response (CR) and partial response (PR) rate and duration of response in patients treated with these regimens.
&lt;br/&gt;Compare the clinical benefit (ie, 6-month CR, PR, and stable disease) rate and duration of clinical benefit in patients treated with these regimens.
&lt;br/&gt;Compare time to treatment failure in patients treated with these regimens.&lt;br/&gt;Compare the overall survival of patients treated with these regimens.&lt;br/&gt;Compare the tolerability of these regimens in these patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 2012, results from a meta-analysis of &lt;ulink linkType="Protocol" linkID="27115"&gt;EFECT&lt;/ulink&gt; and SoFEA studies were presented. The treatments were found to be well-tolerated and serious adverse events occurred were rare [&lt;ulink linkType="Reference" linkID="1352527"&gt;1352527&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2016, results were published which assessed the impact of ESR1 mutations on sensitivity to therapy representing the development of the current standard therapy for estrogen receptor-positive advanced breast cancer. ESR1 mutations were found in 39.1% (62/161) of patients of whom 49.1% (27/55) were polyclonal. Treatment with fulvestrant (n = 45) compared with exemestane (n = 18) showed improved progression free survival (PFS) in patients with ESR1 mutation (p = 0.02), whereas for either treatment groups similar PFS was seen in patients with wild-type ESR1 (p = 0.77) [&lt;ulink linkType="Reference" linkID="1798867"&gt;1798867&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2018, pooled results were published from ten clinical trials (&lt;ulink linkType="Protocol" linkID="49221"&gt;NCT00863655&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="157088"&gt;NCT01958021&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="181037"&gt;NCT02107703&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="43619"&gt;NCT00721409&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="100505"&gt;NCT01740427&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="154529"&gt;NCT01942135&lt;/ulink&gt;, NCT00253422, &lt;ulink linkType="Protocol" linkID="78739"&gt;NCT01381874&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="41833"&gt;NCT00075764&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="28665"&gt;NCT00083993&lt;/ulink&gt;) which evaluated the efficacy and safety of endocrine monotherapy (ET) versus combination therapy (ET +/- targeted therapies) in age-stratified cohorts of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. In age-stratified subsets, efficacy were found to be similar. Compared to ET alone, a reduced disease progression risk was found for ET + everolimus, palbociclib, or ribociclib. In the patients treated with letrozole + temsirolimus, palbociclib, and ribociclib, median progression-free survival (mPFS) in the first-line setting for older patients was 8.5, 26.2 months, and not reached, respectively; and in younger patients was 9.0, 18.8Â months, and not reached, respectively. Simlarly in the patients treated with everolimus + exemestane and palbociclib + fulvestrant, mPFS in older patients was 6.8 and 9.9 months, respectively; and in younger patients was 8.1 and 9.5 months, respectively [&lt;ulink linkType="Reference" linkID="2027855"&gt;2027855&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2018, pooled results of SoFEA and &lt;ulink linkType="Protocol" linkID="27115"&gt;EFECT&lt;/ulink&gt; study evaluating the interaction between ESR1 mutation status and relative benefit from aromatase inhibitors (fulvestrant or exemestane) and the impact of mutation status on overall survival (OS) in patients with advanced hormone receptor-positive breast cancer, were presented. Patients who received fulvestrant 250 mg (n = 116) or exemestane (n = 106) had baseline serum samples for analysis for ESR1 mutations. ESR1 mutations were detected in 23.4% of samples. Detection of ESR1 mutations at baseline was associated with shorter progression-free survival (PFS; 3.5 and 3.7 months versus 2 and 4.5 months for ESR1 mutant and ESR1 wild type, respectively, in fulvestrant versus exemestane arms) in EFECT study. In SoFEA and EFECT meta-analysis, patients with ESR1 mutation detected on fulvestrant showed improved PFS (3.9 versus 2.4 months, respectively) relative to exemestane (p = 0.01); while no difference was noted for patients with ESR1 wild type (p = 0.69). Patients with ESR1 mutation on fulvestrant showed an improved overall survival (68.87 versus 45.75%) relative to exemestane (mean difference = -3.3; p = 0.04), while no difference was noted for patients with ESR1 wild type (mean difference = -2.5; p = 0.69) [&lt;ulink linkType="Reference" linkID="2104001"&gt;2104001&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This was a randomized, partially double-blind and placebo-controlled, multicenter study. Patients were stratified according to the setting in which prior nonsteroidal aromatase-inhibitor therapy was given (adjuvant therapy versus first-line therapy) and participating center. Patients were randomized to one of three treatment arms.
&lt;/para&gt;&lt;para&gt;Arm I (&lt;ulink linkType="Drug" linkID="3313"&gt;fulvestrant&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3321"&gt;anastrozole&lt;/ulink&gt;): patients would receive &lt;ulink linkType="Drug" linkID="3313"&gt;fulvestrant&lt;/ulink&gt; intramuscularly (im) on days 1, 15, and 29 and then once-monthly. Patients would receive &lt;ulink linkType="Drug" linkID="3321"&gt;anastrozole&lt;/ulink&gt; orally, once-daily.
&lt;br/&gt;Arm II (&lt;ulink linkType="Drug" linkID="3313"&gt;fulvestrant&lt;/ulink&gt; and placebo): patients would receive &lt;ulink linkType="Drug" linkID="3313"&gt;fulvestrant&lt;/ulink&gt; as in arm I and placebo orally, once-daily.
&lt;br/&gt;Arm III (&lt;ulink linkType="Drug" linkID="3081"&gt;exemestane&lt;/ulink&gt; alone): patients would receive &lt;ulink linkType="Drug" linkID="3081"&gt;exemestane&lt;/ulink&gt; orally, once-daily. In all arms, treatment would repeat every month in the absence of disease progression or unacceptable toxicity.
&lt;br/&gt;After completion of study treatment, patients would be  followed periodically for survival.
A total of 750 patients (250 per treatment arm) would be accrued for this study.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized to receive &lt;ulink linkType="Drug" linkID="3313"&gt;fulvestrant&lt;/ulink&gt; (250 mg, im, monthly after 500 mg loading dose) + &lt;ulink linkType="Drug" linkID="3321"&gt;anastrozole&lt;/ulink&gt; (1 mg, daily) (n = 243), &lt;ulink linkType="Drug" linkID="3313"&gt;fulvestrant&lt;/ulink&gt; (250 mg, im, monthly after 500 mg loading dose) + placebo (n = 231) or &lt;ulink linkType="Drug" linkID="3081"&gt;exemestane&lt;/ulink&gt; (25 mg, daily) alone (n = 249) [&lt;ulink linkType="Reference" linkID="1352527"&gt;1352527&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1798867"&gt;1798867&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="93047">anastrozole</Intervention><Treatments><Treatment><Dose>1 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="93048">exemestane</Intervention><Treatments><Treatment><Dose>25 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="93197">fulvestrant</Intervention><Treatments><Treatment><Dose>250 milligram</Dose><Route>Intramuscular</Route></Treatment><Treatment><Dose>500 milligram</Dose><Route>Intramuscular</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>Institute of Cancer Research - Sutton</Name><Address1>Sutton</Address1><Address2>England</Address2><Address3>SM2 5NG</Address3><CountrySubDivision>England</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Royal Marsden - London</Name><Address1>London</Address1><Address2>England</Address2><Address3>SW3 6JJ</Address3><CountrySubDivision>England</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Breast tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3930">Subjects with Hormone Receptor Positive Breast Cancer</PatientSegment><SubSegments><SubSegment id="3931">Estrogen receptor positive (ER+) breast cancer</SubSegment><SubSegment id="3932">Progesterone receptor positive (PR+) breast cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3945">Subjects with Stage III Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3952">Subjects with Locally Advanced Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3954">Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3965">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3966">Subjects with Relapsed/Recurrent Breast cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8027">Breast Cancer Subjects with Bone Metastasis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12020">Subjects with Adenocarcinoma of the Breast</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00253422</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">EUDRACT-2004-000093-30</Identifier></Identifiers></Registry><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="Secondary Organisational">ISRCTN44195747</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Breast tumor" id="8713"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Breast tumor" id="8712"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="8726"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8719">Assessment of Overall/Objective Response Rate (ORR)</SubEndpoint><SubEndpoint disease="Breast tumor" id="8720">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Breast tumor" id="8721">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Breast tumor" id="8722">Assessment of Clinical Benefit Rate (CBR)</SubEndpoint><SubEndpoint disease="Breast tumor" id="8725">Assessment of Stable Disease</SubEndpoint><SubEndpoint disease="Breast tumor" id="8738">Assessment of duration of tumor response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="8976"><Endpoint>Assessment of Clinical Response</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8977">Assessment of time to treatment failure (TTF)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Breast tumor" id="8996"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Breast tumor" id="4807"><Criterion>Subjects with Hormone Receptor Positive Breast Cancer</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4808">Estrogen receptor positive (ER+) breast cancer</SubCriterion><SubCriterion disease="Breast tumor" id="4809">Progesterone receptor positive (PR+) breast cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4817"><Criterion>Postmenopausal Breast Cancer Women</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4827"><Criterion>TNM Stage III Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4840"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4833">Subjects with bone metastases</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4856"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4863"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4864">Subjects with acceptable hematological test values</SubCriterion><SubCriterion disease="Breast tumor" id="4865">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4877"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4878"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4879">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Breast tumor" id="4880">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Breast tumor" id="4881">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4893"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4895">Subjects with history of anti-cancer hormonal therapy</SubCriterion><SubCriterion disease="Breast tumor" id="22394">Subjects with history of anti-cancer biological therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4906"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4903">Subjects with history of bisphosphonates therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4922"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4917">Disease progression after chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4923"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22413"><Criterion>Subjects with Adenocarcinoma of Breast</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22417"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Breast tumor" id="34046"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4866">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Breast tumor" id="6252"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6261">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion><SubCriterion disease="Breast tumor" id="6265">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6294"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6393"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2016-05-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2005-11-11T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-02-05T04:40:19Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-09-18T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-02-15T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="45173"><TitleDisplay>Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients</TitleDisplay><TitleOfficial>A Phase II, Randomized, Multicenter Compare Epirubicine and Cyclophosphamide Treatment Plus Docetaxel and Trastuzumab Versus Epirubicine and Cyclophosphamide Treatment Plus Docetaxel and Lapatinib in Women With Primary Resectable Breast Cancer or Locally Advanced Breast Cancer Positive Her 2</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Other">EudraCT: 2007-007031-13</Identifier><Identifier type="Organisational Study">GEICAM/2006-14</Identifier><Identifier type="NCT">NCT00841828</Identifier><Identifier type="Secondary Organisational">NÂº EudraCT 2007-007031-13</Identifier></Identifiers><Indications><Indication id="49">Breast tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="3" role="Disease marker" type="Genomic;Proteomic">HER2</BiomarkerName><BiomarkerName id="5" role="Disease marker" type="Genomic;Proteomic">Estrogen receptor</BiomarkerName><BiomarkerName id="7" role="Disease marker" type="Genomic;Proteomic">Antigen KI-67</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>cyclophosphamide</Name></Intervention><Intervention type="InterventionPrimary"><Name>docetaxel</Name><Drug id="2953">docetaxel</Drug></Intervention><Intervention type="InterventionPrimary"><Name>epirubicin</Name><Drug id="13022">epirubicin</Drug></Intervention><Intervention type="InterventionPrimary"><Name>lapatinib</Name><Drug id="33591">lapatinib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="combo"><Interventions><Intervention type="InterventionControl"><Name>cyclophosphamide</Name></Intervention><Intervention type="InterventionControl"><Name>docetaxel</Name><Drug id="2953">docetaxel</Drug></Intervention><Intervention type="InterventionControl"><Name>epirubicin</Name><Drug id="13022">epirubicin</Drug></Intervention><Intervention type="InterventionControl"><Name>trastuzumab</Name><Drug id="6386">trastuzumab</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="13022">epirubicin</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1042061">Spanish Breast Cancer Research Group</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1064355">Grupo Espanol de Investigacion del Cancer de Mama</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2953">docetaxel</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1042061">Spanish Breast Cancer Research Group</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1064355">Grupo Espanol de Investigacion del Cancer de Mama</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="33591">lapatinib</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1042061">Spanish Breast Cancer Research Group</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1064355">Grupo Espanol de Investigacion del Cancer de Mama</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2953" type="Drug"><TargetEntity id="140605" type="siDrug">Docetaxel</TargetEntity></SourceEntity><SourceEntity id="33591" type="Drug"><TargetEntity id="301036" type="siDrug">Lapatinib ditosylate</TargetEntity><TargetEntity id="648545" type="siDrug">Lapatinib dimesylate hydrate</TargetEntity></SourceEntity><SourceEntity id="13022" type="Drug"><TargetEntity id="91069" type="siDrug">Epirubicin hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1042061" type="Company"><TargetEntity id="5037040312" type="organizationId">Spanish Breast Cancer Research Group</TargetEntity></SourceEntity><SourceEntity id="1064355" type="Company"><TargetEntity id="5036351969" type="organizationId">Grupo Espanol de Investigacion en Cancer de Mama</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"></TargetEntity><TargetEntity id="10006279" type="MEDDRA"></TargetEntity><TargetEntity id="D001943" type="MeSH"></TargetEntity><TargetEntity id="-436099203" type="omicsDisease"></TargetEntity><TargetEntity id="588" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="142" type="Action"><TargetEntity id="419" type="Mechanism">DNA Topoisomerase II Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3756" type="Action"><TargetEntity id="1223" type="Mechanism">HER2 (erbB2) Inhibitors</TargetEntity><TargetEntity id="1820" type="Mechanism">Anti-HER2/neu/ErbB2</TargetEntity></SourceEntity><SourceEntity id="740" type="Action"><TargetEntity id="1071" type="Mechanism">EGFR (HER1; erbB1) Inhibitors</TargetEntity><TargetEntity id="1613" type="Mechanism">Anti-EGFR</TargetEntity><TargetEntity id="4344" type="Mechanism">EGFR (HER1; erbB1) (Mutant) Inhibitors</TargetEntity><TargetEntity id="4345" type="Mechanism">EGFR (Thr790Met Mutant) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>27</NumberOfSites><CompaniesSponsor><Company id="1042061">Spanish Breast Cancer Research Group</Company><Company id="1064355">Grupo Espanol de Investigacion del Cancer de Mama</Company></CompaniesSponsor><CompaniesCollaborator><Company id="28355">GlaxoSmithKline plc</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="142">Topoisomerase II inhibitor</Action><Action id="3756">Erbb2 tyrosine kinase receptor inhibitor</Action><Action id="740">Epidermal growth factor receptor antagonist</Action><Action id="82444">DNA helicase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2575">Microtubule inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="750">DNA intercalator</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="66">Antibiotic</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="751">Film coating</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="1647">Natural product</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>102</PatientCountEnrollment><PatientCountEvaluable>102</PatientCountEvaluable><DateStart>2009-02-28T00:00:00Z</DateStart><DateEnd type="estimated">2013-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-05-26T09:48:40Z</DateChangeLast><DateAdded>2009-02-12T11:18:31Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Hospital ClÃ­nico de Valencia. Av. Blasco IbÃ¡Ã±ez, 17. 46010 Valencia.</Affiliation><Name>Ana Lluch, PhD., MD.</Name></Contact><Contact type="Scientific contact"><Affiliation>Hospital Virgen de la Victoria. Campus de Teatinos, s/n. 29010 MÃ¡laga</Affiliation><Name>Emilio Alba, PhD., MD.</Name></Contact><Contact type="Scientific contact"><Affiliation>Hospital del Mar. Paseo MarÃ­timo, 25-29. 08003 Barcelona</Affiliation><Name>Joan Albanell, PhD., MD.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Signature of the written informed consent&lt;/li&gt;&lt;li&gt;Histological documentation of breast cancer&lt;/li&gt;&lt;li&gt;Stage I (T1, N0M0), IIA (T2N0M0); IIB (T2N1M0, T3N0M0), IIIA (TXN2M0) and IIIB (T3N1M0, T4NXM0)
             primary resectable breast cancer or locally advanced breast cancer&lt;/li&gt;&lt;li&gt;T &gt;/= 2 cm&lt;/li&gt;&lt;li&gt;HER2-positive breast cancer, defined as immunohistochemistry (IHC) 3+ or positive fluorescence in situ hybridization (FISH). When IHC 2+ HER2
             status must be assessed by FISH&lt;/li&gt;&lt;li&gt;The patient  granted her consent  for taking a biopsy before treatment&lt;/li&gt;&lt;li&gt;The patient granted her consent for sending two tumor samples to central laboratory
             for molecular sub study&lt;/li&gt;&lt;li&gt;Pregnancy test negative for women of childbearing
             potential at 2 weeks prior randomization&lt;/li&gt;&lt;li&gt;Women of childbearing potential must use adequate contraceptive measures during
             participation into study. Oral, injectable or implant hormonal contraceptives measure
             are not permitted&lt;/li&gt;&lt;li&gt;A WHO performance status of 0 or 1 (Karnofsky &gt; 80)&lt;/li&gt;&lt;li&gt;Age&amp;gt; 18 years&lt;/li&gt;&lt;li&gt;Absence of metastases disease&lt;/li&gt;&lt;li&gt;Baseline EKG 12 weeks  prior to randomization. Baseline left ventricular oncology group (LVEF) value within limit of
             normal value for the institution or&amp;gt; 50% of basal value
&lt;/li&gt;&lt;li&gt;Normal laboratory test 2 weeks prior to randomization:&lt;ul&gt;&lt;li&gt;Hematology values: neutrophil
             count &gt;/= 1.5 x 10(9)/l; platelets &gt;/= 100 x             10(9)/l; hemoglobine &gt;/= 10 mg/dl&lt;/li&gt;&lt;li&gt;Biochemistry values: serum total bilirubin  1 x upper limit of normal (ULN); aspartate aminotransferase (ASAT) (serum glutamic oxaloacetic transaminase [SGOT]); alanine    aminotransferase (ALAT) (serum glutamic pyruvic transaminase [SGPT])  &amp;lt; 2.5 x
             ULN; alkaline phosphatase  &amp;lt; 5 x ULN. The patients which ASAT and/or ALAT value are &amp;gt; 1.5
             x ULN along with alkaline phosphatase value &amp;gt; 2.5 ULN will be not included into the
             study&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Renal function: serum creatinine&amp;lt; 175 micromol/l (2 mg/dl). If the value are borderline,
             clearance creatinine must be &gt;/= 60 ml/min&lt;/li&gt;&lt;li&gt;The following assessments and procedures must be
             fulfilled at 12 weeks prior to randomization:&lt;ul&gt;&lt;li&gt;Bilateral mammography&lt;/li&gt;&lt;li&gt;MRI Breast and axillary&lt;/li&gt;&lt;li&gt;Chest X-ray (PA and
             lateral)&lt;/li&gt;&lt;li&gt;Abdominal ultrasound&lt;/li&gt;&lt;li&gt;Chest CT-Scan&lt;/li&gt;&lt;li&gt;Abdominal CT-Scan. Bone scan (if
             applicable)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients must be accessible for treatment and follow up&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with lumpectomy, partial mastectomy, modified radical mastectomy are not
             allowed to include into study&lt;/li&gt;&lt;li&gt;Prior Immunotherapy, hormonal therapy and chemotherapy for breast cancer is not
             allowed&lt;/li&gt;&lt;li&gt;Prior therapy with anthracycline and taxanes (paclitaxel and&lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt;) is not
             permitted for any neoplasia&lt;/li&gt;&lt;li&gt;Prior radiotherapy for breast cancer&lt;/li&gt;&lt;li&gt;Bilateral invasive breast carcinoma&lt;/li&gt;&lt;li&gt;Pregnant or nursing patients. Negative pregnant test (serum or urine) 14 days prior
             to randomization&lt;/li&gt;&lt;li&gt;HER 2 negative breast cancer&lt;/li&gt;&lt;li&gt;Patients of childbearing potential must be use adequate contraceptive measures during
             study treatment. No hormonal contraceptive measure is permitted&lt;/li&gt;&lt;li&gt;Any M1 breast cancer&lt;/li&gt;&lt;li&gt;Any motor or sensorial neurotoxicity  grade &gt;/= 2 according to common toxicity criteria (CTC) criteria version 3&lt;/li&gt;&lt;li&gt;Serious cardiac illness or medical conditions: congestive heart failure, angina
             pectoris requiring specific treatment, myocardial infarction one year prior to enroll in
             the study; poorly controlled hypertension or high-risk uncontrolled arrhythmias&lt;/li&gt;&lt;li&gt;History of significative neurological or psychiatric disease (psychotic, dementia or
             attack) what is unable to patient to grant her informed consent&lt;/li&gt;&lt;li&gt;Uncontrolled severe Infection&lt;/li&gt;&lt;li&gt;Uncontrolled diabetes mellitus, active peptic ulcer&lt;/li&gt;&lt;li&gt;Current malignancy or previous malignancy other that breast cancer. Exception  cell
             carcinoma of the skin no melanoma, carcinoma in situ of the cervix or any other cancer
             in the past ten years&lt;/li&gt;&lt;li&gt;Long term treatment with corticoids except 6 months prior to inclusion in the study
             and low doses (&amp;lt; 20 mg metilprednisolone or equivalent )&lt;/li&gt;&lt;li&gt;Corticoid use contraindication&lt;/li&gt;&lt;li&gt;Concomitant hormonal replacement therapy. Previous treatment should be interrupted
             before inclusion into study&lt;/li&gt;&lt;li&gt;Cardiopathy what stops patient taking&lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; and herceptin: myocardial infarction
             recorded; angina pectoris requiring specific treatment; any congestive heart failure
             recorded; arrhythmia grade 3 or 4 according to CTC version 3; any relevant valvular
             disease; chest X-ray which shows cardiomegaly or EKG which shows ventricular
             hypertrophy unless forced expiratory volume in 1 s (FEVI) value has been upper URL in the last 3 months&lt;/li&gt;&lt;li&gt;Poorly controlled hypertension (systolic&amp;gt; 180 mmHg or diastolic &amp;gt; 100 mmHg). The
             patients with controlled hypertension under treatment can be included into study&lt;/li&gt;&lt;li&gt;Patients under treatment of arrhythmia, angina or congestive heart failure with drug
             which modifies cardiac conduction (after digital, beta blocker or inhibitors calcium
             channel) are excluded. However if these drugs are took for arterial tension the
             patient can be included into study&lt;/li&gt;&lt;li&gt;The patient must interrupt concomitant treatment with hormonal therapy eg, raloxifen,
             tamoxifen and selective estrogen receptor modulators (SERM) prior to randomization&lt;/li&gt;&lt;li&gt;Concomitant use of inhibitors and inductors of enzyme CYP3A4 complex (ketoconazol,
             itraconazol or grape juice; rifampicin, carbamazepin or fenitoin) are not permitted.
             Also, drug are substrate of enzyme CYP2C8 complex is not permitted along with
             &lt;ulink linkType="Drug" linkID="33591"&gt;lapatinib&lt;/ulink&gt; treatment&lt;/li&gt;&lt;li&gt;Concurrent treatment with an investigational agent or participation in another
             therapeutic clinical trial within 30 days prior to randomization into study&lt;/li&gt;&lt;li&gt;Concomitant treatment with other anticancer therapy&lt;/li&gt;&lt;li&gt;Hypersensitivity reaction to drugs herceptin,&lt;ulink linkType="Drug" linkID="33591"&gt;lapatinib&lt;/ulink&gt; or their excipients&lt;/li&gt;&lt;li&gt;Male&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Complete pathological response Rate</Description><Timeframe>Within 3 to 4 weeks after last docetaxel dose, surgery will be performed to evaluate pathological response</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Toxicity assessment</Description><Timeframe>After each treatment cycle</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In January 2014, results were published. Grade 3 to 4 toxicity did not differ across treatments, except for diarrhea (2% in EC-DT versus 13.5% in EC-DL, p = 0.030) [&lt;ulink linkType="Reference" linkID="1518860"&gt;1518860&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a phase II, randomized, multicenter trial to compare &lt;ulink linkType="Drug" linkID="13022"&gt;epirubicin&lt;/ulink&gt; and cyclophosphamide plus
      &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6386"&gt;trastuzumab&lt;/ulink&gt; with &lt;ulink linkType="Drug" linkID="13022"&gt;epirubicin&lt;/ulink&gt; and cyclophosphamide plus &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="33591"&gt;lapatinib&lt;/ulink&gt;
      for patients with positive HER2 neu and resectable breast cancer or locally advanced breast
      cancer.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In January 2014, results were published. Pathological complete response in breast was 52.1  and 25.5% for  EC-DT  and EC-DL, respectively (p = 0.0065). Pathological complete response in breast and axilla was 47.9 and 23.5% for EC-DT and for EC-DL, respectively (p = 0.011). Multivariate analyses showed that treatment (p = 0.036) and ER (p = 0.014) were the only predictors of pCR in both groups [&lt;ulink linkType="Reference" linkID="1518860"&gt;1518860&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2016, pooled results were published from four GEICAM (Spanish Breast Cancer Group) clinical trials (&lt;ulink linkType="Protocol" linkID="48320"&gt;NCT00129896&lt;/ulink&gt;, NCT00841828, &lt;ulink linkType="Protocol" linkID="55769"&gt;NCT00432172&lt;/ulink&gt;, and &lt;ulink linkType="Protocol" linkID="27451"&gt;NCT00128856&lt;/ulink&gt;) which evaluated the optimal threshold for Ki67 using the receiver-operating characteristic curve method to maximize its predictive value for chemotherapy benefit and predictive role of the defined Ki67 cutoffs for molecular subtypes defined by estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2). Pathological complete response (pCR) was predicted with a basal Ki67 cutpoint of 50%. A pCR rate of 40 versus 19% was observed in patients with Ki67 &amp;gt; 50 and Ki67 &amp;lt;/= 50% (p = 0.0004), respectively. Relevant Ki67 predictive value was observed in ER-HER2- and ER-HER2+ patients (with pCR rates of 42 and 64%, respectively, in patients with Ki67 &amp;amp;gt; 50 versus 15 and 45%, respectively, and in patients with Ki67 &amp;lt;/= 50%; p = 0.0337 and 0.3238, respectively). The independent predictive value of the Ki67 cutpoint of 50% was found to be confirmed by both multivariate analyses [&lt;ulink linkType="Reference" linkID="1747028"&gt;1747028&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive &lt;ulink linkType="Drug" linkID="13022"&gt;epirubicin&lt;/ulink&gt; and cyclophosphamide (each 21 days for four cycles) followed by  &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="33591"&gt;lapatinib&lt;/ulink&gt; (each 21 days for 4 cycles) or &lt;ulink linkType="Drug" linkID="13022"&gt;epirubicin&lt;/ulink&gt; and cyclophosphamide (each 21 days for four cycles) followed by &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt;  + &lt;ulink linkType="Drug" linkID="6386"&gt;herceptin&lt;/ulink&gt; (each 21 days for four cycles).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were  randomized to receive &lt;ulink linkType="Drug" linkID="13022"&gt;epirubicin&lt;/ulink&gt;  plus cyclophosphamide x four cycles followed by &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; plus either &lt;ulink linkType="Drug" linkID="6386"&gt;trastuzumab&lt;/ulink&gt; (EC-DT) or &lt;ulink linkType="Drug" linkID="33591"&gt;lapatinib&lt;/ulink&gt; (EC-DL) [&lt;ulink linkType="Reference" linkID="1518860"&gt;1518860&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Spain"><Sites><Site><Name>Hospital Germans Trias i Pujol</Name><Address1>Badalona</Address1><Address2>Badalona/Barcelona</Address2><Address3>08916</Address3><CountrySubDivision>Badalona/Barcelona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Xarxa Asistencial de Manresa</Name><Address1>Manresa</Address1><Address2>Barcelona</Address2><Address3>08243</Address3><CountrySubDivision>Barcelona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>CorporaciÃ³n Sanitaria Parc TaulÃ­</Name><Address1>Sabadell</Address1><Address2>Barcelona</Address2><Address3>08208</Address3><CountrySubDivision>Barcelona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Hospital Xeral CÃ­es</Name><Address1>Vigo</Address1><Address2>Pontevedra</Address2><Address3>36204</Address3><CountrySubDivision>Pontevedra</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Complejo Hospitalario Universitario A CoruÃ±a</Name><Address1>A CoruÃ±a</Address1><Address3>15006</Address3><Contacts></Contacts></Site><Site><Name>Centro OncolÃ³gico de Galicia</Name><Address1>A CoruÃ±a</Address1><Address3>15009</Address3><Contacts></Contacts></Site><Site><Name>Hospital Clinic i Provincial</Name><Address1>Barcelona</Address1><Address3>08036</Address3><Contacts></Contacts></Site><Site><Name>Hospital de la Santa Creu i Sant Pau</Name><Address1>Barcelona</Address1><Address3>08041</Address3><Contacts></Contacts></Site><Site><Name>Hospital del Mar</Name><Address1>Barcelona</Address1><Address3>08003</Address3><Contacts></Contacts></Site><Site><Name>Complejo Hospitalario San Pedro de AlcÃ¡ntara</Name><Address1>CÃ¡ceres</Address1><Address3>10003</Address3><Contacts></Contacts></Site><Site><Name>Hospital de la Princesa</Name><Address1>Madrid</Address1><Address3>28006</Address3><Contacts></Contacts></Site><Site><Name>Instituto OncolÃ³gico de GuipÃºzcoa</Name><Address1>San SebastiÃ¡n</Address1><Address3>20012</Address3><Contacts></Contacts></Site><Site><Name>Hospital Virgen de la Salud</Name><Address1>Toledo</Address1><Address3>45004</Address3><Contacts></Contacts></Site><Site><Name>Hospital Clinico de Valencia</Name><Address1>Valencia</Address1><Address3>46010</Address3><Contacts></Contacts></Site><Site><Name>Instituto Valenciano de OncologÃ­a</Name><Address1>Valencia</Address1><Address3>46009</Address3><Contacts></Contacts></Site><Site><Name>Hospital Miguel Servet</Name><Address1>Zaragoza</Address1><Address3>50009</Address3><Contacts></Contacts></Site><Site><Name>Hospital Universitario Virgen de la Victoria</Name><Address1>MÃ¡laga</Address1><Address3>29010</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital Provincial de CÃ³rdoba</Name><Address1>CÃ³rdoba</Address1><Address3>14004</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Complejo Hospitalario de JaÃ©n</Name><Address1>JaÃ©n</Address1><Address3>23007</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital Universitario La Fe</Name><Address1>Valencia</Address1><Address3>46009</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital Central de Asturias</Name><Address1>Oviedo</Address1><Address3>33006</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital General YagÃ¼e</Name><Address1>Burgos</Address1><Address3>09005</Address3><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Consorci Sanitari de Terrasa</Name><Address1>Tarrasa</Address1><Address2>Barcelona</Address2><Address3>08221</Address3><CountrySubDivision>Barcelona</CountrySubDivision><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital General de Granollers</Name><Address1>Granollers</Address1><Address2>Barcelona</Address2><Address3>08400</Address3><CountrySubDivision>Barcelona</CountrySubDivision><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital Mutua de Terrasa</Name><Address1>Tarrasa</Address1><Address2>Barcelona</Address2><Address3>08221</Address3><CountrySubDivision>Barcelona</CountrySubDivision><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital del EspÃ­ritu Santo</Name><Address1>Santa Coloma de Gramanet</Address1><Address2>Barcelona</Address2><Address3>08923</Address3><CountrySubDivision>Barcelona</CountrySubDivision><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site><Site><Name>Hospital Universitario de Canarias</Name><Address1>La Laguna</Address1><Address2>Santa Cruz de Tenerife</Address2><Address3>38320</Address3><CountrySubDivision>Santa Cruz de Tenerife</CountrySubDivision><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Breast tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3936">Subjects with HER-2 Positive Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3943">Subjects with Stage I Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3944">Subjects with Stage II Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3945">Subjects with Stage III Breast Cancer</PatientSegment><SubSegments><SubSegment id="3946">TNM stage IIIA Breast cancer</SubSegment><SubSegment id="3947">TNM stage IIIB Breast cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3950">Subjects with Early Stage Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3952">Subjects with Locally Advanced Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3955">Subjects with Resectable/Operable Breast Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3968">Subjects with non-metastatic breast cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12844">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-2029263702" id="12845">ERBB2_HUMAN_Amplification</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00841828</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>EudraCT: 2007-007031-13</Identifier><Identifier type="Secondary Organisational">NÂº EudraCT 2007-007031-13</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Breast tumor" id="8726"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="8730">Assessment of histo-pathologic response</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Breast tumor" id="8996"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Breast tumor" id="9012">Assessment of treatment induced toxicity</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Breast tumor" id="4813"><Criterion>Subjects with HER-2 Positive Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4823"><Criterion>TNM Stage I Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="4824"><Criterion>TNM Stage II Breast Cancer</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4825">TNM stage IIA Breast Cancer</SubCriterion><SubCriterion disease="Breast tumor" id="4826">TNM stage IIB Breast Cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4827"><Criterion>TNM Stage III Breast Cancer</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4828">TNM stage IIIA Breast Cancer</SubCriterion><SubCriterion disease="Breast tumor" id="4829">TNM stage IIIB Breast Cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="4878"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="4879">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Breast tumor" id="4880">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Breast tumor" id="4885">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Breast tumor" id="5383"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22398"><Criterion>Subjects with Resectable Tumor</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22417"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22418"><Criterion>Subjects with Early Breast Cancer</Criterion></Inclusion><Inclusion disease="Breast tumor" id="22517"><Criterion>Subjects with History of/Scheduled for Diagnostic Procedures</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="22521">Subjects scheduled for biopsy</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Breast tumor" id="6215"><Criterion>Subjects with Other forms of Breast Cancer</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6217">Subjects with bilateral breast cancer</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6252"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6253">Subjects with central nervous system diseases</SubCriterion><SubCriterion disease="Breast tumor" id="6261">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6257"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6258"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6260"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6272"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6294"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6301"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6302">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion><SubCriterion disease="Breast tumor" id="6317">Subjects with hypersensitivity/contraindications to immunomodulators</SubCriterion><SubCriterion disease="Breast tumor" id="20288">Subjects contraindicated to targeted therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6328"><Criterion>Subjects with History of/Scheduled for Anti-neoplastic Therapy</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6348">Subjects with history of/scheduled for Selective Estrogen Receptor Modulators (SERMs)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="6377"><Criterion>Subjects with history of/planned radiotherapy</Criterion></Exclusion><Exclusion disease="Breast tumor" id="6393"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6331">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="26375"><Criterion>Subjects by disease severity</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6246">Metastatic/TNM Stage IV Breast Cancer</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="26402"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="6911">Subjects with HER-2 negative breast cancer</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="26805"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="20289">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Breast tumor" id="26891"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Breast tumor" id="20290">Subjects with history of/scheduled for surgery</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2011-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2011-02-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>24.13 Months</EnrollmentPeriod><EnrollmentRate>4.23 Patients/Month</EnrollmentRate><DateFirstReceived>2009-02-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-02-12T11:18:31Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-01-28T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="57060"><TitleDisplay>Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes</TitleDisplay><TitleOfficial>A 26-week, Randomized, Multinational, Open-labeled, Two-armed, Parallel-group, Treat-to-target, Once-Daily Treatment Trial With Insulin Detemir Versus Insulin Glargine, Both in Combination With Metformin in Subjects With Type 2 Diabetes</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">NN304-1768</Identifier><Identifier type="NCT">NCT00909480</Identifier><Identifier type="Other">CTRI/2009/091/000161</Identifier><Identifier type="Other">TEMP UTRN 011740523-02042009581207</Identifier><Identifier type="Trial Acronym">EFFICACY</Identifier></Identifiers><Indications><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>insulin detemir</Name><Drug id="17426">insulin detemir</Drug></Intervention><Intervention type="InterventionPrimary"><Name>insulin glargine</Name><Drug id="10252">insulin glargine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>metformin hydrochloride</Name><Drug id="6050">metformin hydrochloride</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="10252">insulin glargine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="18614">Novo Nordisk A/S</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="17426">insulin detemir</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="18614">Novo Nordisk A/S</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="6050">metformin hydrochloride</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="18614">Novo Nordisk A/S</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="10252" type="Drug"><TargetEntity id="215931" type="siDrug">Insulin glargine</TargetEntity></SourceEntity><SourceEntity id="6050" type="Drug"><TargetEntity id="220882" type="siDrug">Metformin hydrochloride</TargetEntity></SourceEntity><SourceEntity id="17426" type="Drug"><TargetEntity id="239855" type="siDrug">Insulin detemir</TargetEntity></SourceEntity><SourceEntity id="18614" type="Company"><TargetEntity id="4295865996" type="organizationId">Novo Nordisk A/S</TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="400" type="Action"><TargetEntity id="609" type="Mechanism">Insulin Secretagogues</TargetEntity><TargetEntity id="1034" type="Mechanism">Insulin Receptor Agonists</TargetEntity></SourceEntity><SourceEntity id="8805" type="Action"><TargetEntity id="2375" type="Mechanism">AMP-Activated Protein Kinase (AMPK) Activators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>95</NumberOfSites><CompaniesSponsor><Company id="18614">Novo Nordisk A/S</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="23014">Insulin ligand</Action><Action id="400">Insulin receptor agonist</Action><Action id="8805">AMP activated protein kinase stimulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="38206">Biguanide antidiabetic product</Class><Class id="38212">Human insulin intermediate acting product</Class><Class id="38215">Human insulin long acting product</Class><Class id="399">Hypoglycemic agent</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="805">Daily dosing</Technology><Technology id="751">Film coating</Technology><Technology id="1646">Injectable controlled release formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="80">Peptide</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>457</PatientCountEnrollment><PatientCountEvaluable>457</PatientCountEvaluable><DateStart>2009-05-31T00:00:00Z</DateStart><DateEnd type="actual">2010-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-11-27T04:40:22Z</DateChangeLast><DateAdded>2009-06-02T12:03:46Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Novo Nordisk India Private Limited</Affiliation><Email>avkg@novonordisk.com</Email><Name>AvikÂ Ghosh</Name><Phone>918030713446</Phone></Contact><Contact type="Public contact"><Affiliation>Novo Nordisk India Private Limited</Affiliation><Email>rasy@novonordisk.com</Email><Name>RamanÂ Shetty</Name><Phone>918030713358</Phone></Contact><Contact type="Public contact"><Affiliation>Swamy Diabetes Centre</Affiliation><Email>swamydiabetes@gmail.com</Email><Name>Nallaperumal</Name><Phone>04424615115</Phone></Contact><Contact type="Scientific contact"><Affiliation>Novo Nordisk A/S</Affiliation><Name>Global Clinical Registry (GCR, 1452)</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosed with type 2 diabetes for at least 6 months&lt;/li&gt;&lt;li&gt;Stable treatment with a total daily dose of at least 1500 mg&lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt; or maximum
             tolerated dose (minimum 1000 mg) with or without one other OAD (sulphonylureas,
             meglitinides, thiazolidinediones or DPP-4 inhibitors) for at least 3 months
&lt;/li&gt;&lt;li&gt;Subject is insulin-naive (short-term insulin treatment of up to 14 days is allowed)&lt;/li&gt;&lt;li&gt;HbA1c 7.0 to 9.0 % (both inclusive) by central laboratory analysis (one re-test within
             1 week is allowed)&lt;/li&gt;&lt;li&gt;Body Mass Index (BMI)&amp;lt;/= 35.0 kg/m2
&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any contraindication to&lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt; according to the local
             labelling&lt;/li&gt;&lt;li&gt;Receipt of any investigational product within 4 weeks&lt;/li&gt;&lt;li&gt;Anticipated change of dose of any systemic treatment with products, which in the
             Investigator's opinion could interfere with glucose metabolism (eg, systemic
             corticosteroids)
&lt;/li&gt;&lt;li&gt;Clinically significant diseases which, in the investigator's opinion may confound the
             results of the trial or pose additional risk in administering trial product&lt;/li&gt;&lt;li&gt;Any other condition that the Investigator feels would interfere with trial
             participation or evaluation of results&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in HbA1C from baseline</Description><Timeframe>Week 0, and 26</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Percentage of subjects achieving HbA1c &lt;/= 7.0%: the percentage of subjects - overall and by previous OAD treatment - meeting the HbA1c &lt;/= 7%</Description><Timeframe>Week 26</Timeframe></Measure><Measure><Description>Percentage of subjects achieving HbA1c &lt;/= 6.5%:  the percentage of subjects - overall and by previous OAD treatment - meeting the HbA1c &lt;/= 6.5%</Description><Timeframe>Week 26</Timeframe></Measure><Measure><Description>Within-subject variation of self measured plasma glucose (SMPG) before breakfast. The median values of the sample standard variation (the within subject variation) within the insulin detemir or insulin glargine arms were plotted against time</Description><Timeframe>Week 26</Timeframe></Measure><Measure><Description>Glycemic control as measured by plasma glucose (9-point self-measured profiles). Plasma glucose measured: before breakfast, 2 h after breakfast, before lunch, 2 h after lunch, before dinner, 2 h after dinner, bedtime and at 3 am</Description><Timeframe>Week 26</Timeframe></Measure><Measure><Description>Incidence of hypoglycemic episodes during the trial: number of hypoglycaemic episodes from week 0 to 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose &lt; 3.1 mmol/l. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose &gt;/= 3.1 mmol/l</Description><Timeframe>Weeks 0 to 26</Timeframe></Measure><Measure><Description>Change in body weight from baseline</Description><Timeframe>Week 0, and 26</Timeframe></Measure><Measure><Description>Percentage of subjects achieving HbA1c of &lt;/= 7%  with no hypoglycemia. The subjects must have reached target and not have experienced any confirmed symptomatic hypoglycaemia or any confirmed major hypoglycaemia within the last 30 days of treatment</Description><Timeframe>Week 26</Timeframe></Measure><Measure><Description>Percentage of subjects achieving HbA1c of &lt;/= 6.5% or less with no hypoglycemia. The subjects must have reached target and not have experienced any confirmed symptomatic hypoglycaemia or any confirmed major hypoglycaemia within the last 30 days of treatment</Description><Timeframe>Week 26</Timeframe></Measure><Measure><Description>Fasting plasma glucose</Description><Timeframe>Week 26</Timeframe></Measure><Measure><Description>Hypoglycemic episodes, diurnal: number of hypoglyaemic episodes from week 0 to 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose &lt; 3.1 mmol/l. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose &gt;/= 3.1 mmol/l</Description><Timeframe>Weeks 0 to 26</Timeframe></Measure><Measure><Description>Hypoglycemic episodes, nocturnal: number of hypoglycemic episodes from week 0 to 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose &lt; 3.1 mmol/l. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose &gt;/= 3.1 mmol/l</Description><Timeframe>Weeks 0 to 26</Timeframe></Measure><Measure><Description>Hypoglycemic episodes, unclassifiable: number of hypoglycemic episodes from week 0 to 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose &lt; 3.1 mmol/l. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose &gt;/= 3.1 mmol/l</Description><Timeframe>Weeks 0 to 26</Timeframe></Measure><Measure><Description>Number of subjects having the adverse event 'incorrect dose administered'. Number of subjects having the adverse event 'incorrect dose administered' within the system organ class 'injury, poisoning and procedural complications'</Description><Timeframe>Weeks 0 to 26</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In August 2013, results were published. Decrease in weight was observed with &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; (-0.49 [3.3] kg) whereas increase was observed in &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt; (+1.0 [3.1] kg) [&lt;ulink linkType="Reference" linkID="1471119"&gt;1471119&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this clinical trial was to determine whether two insulin treatments &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt; given once-daily are equally effective with respect to the blood glucose lowering effect in subjects with type 2 diabetes inadequately controlled on &lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt; treatment with or without an additional
      anti-diabetic drug (OAD). &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In August 2013, results were published. &lt;ulink linkType="Drug" linkID="17426"&gt;Insulin detemir&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt; decreased mean HbA1c by 0.48 and 0.74% points, respectively, to 7.48% Â (0.91%) and 7.13% (0.72%). At the a priori level of 0.4% points, non-inferiority for &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; was not established. At 26âweeks, HbA1c &amp;lt;/=â7% was reached by 38 and 53% patients (pâ=â0.026) taking detemir and glargine, respectively. In both groups, FPG decreased approximately 43.2âmg/dl. Good treatment satisfaction was found with both insulins. Hypoglycemia was observed less with detemir than glargine (rate ratio, 0.73). In the &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt; groups, the proportions of patients reaching HbA1câ&amp;lt;/= â7% without hypoglycemia were 32 and 38% respectively [&lt;ulink linkType="Reference" linkID="1471119"&gt;1471119&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would be randomized to receive individually adjusted subcutaneous injection of either   &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="10252"&gt;insulin glargine&lt;/ulink&gt; once daily in addition to  pre-trial &lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt; dose (at least 1500 mg/day).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="17426"&gt;Insulin detemir&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="10252"&gt;Insulin glargine&lt;/ulink&gt; was added to current &lt;ulink linkType="Drug" linkID="6050"&gt;metformin&lt;/ulink&gt; therapy  and titrated to a target fasting plasma glucose (FPG) &amp;lt;/= 90â mg/dl (&amp;lt;/= 5.0â mmol/l) [&lt;ulink linkType="Reference" linkID="1471119"&gt;1471119&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>insulin detemir</Name><Drug id="17426">insulin detemir</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="2955">Weight loss</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>insulin glargine</Name><Drug id="10252">insulin glargine</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="2954">Weight gain</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Argentina"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Buenos Aires</Address1><Address3>B1704ETD</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Capital Federal</Address1><Address3>1405</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Capital Federal</Address1><Address3>1429</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Mar del Plata</Address1><Address3>B7600FZN</Address3><Contacts></Contacts></Site><Site><Address1>Buenos Aires</Address1><Address3> B1704ETD</Address3><Contacts></Contacts></Site><Site><Address1>Capital Federal</Address1><Address3> 1405</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="India"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Bangalore</Address1><Address2>Karnataka</Address2><Address3>560 017</Address3><CountrySubDivision>Karnataka</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Chennai</Address1><Address2>Tamil Nadu</Address2><Address3>600028</Address3><CountrySubDivision>Tamil Nadu</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Thriruvananthapuram</Address1><Address3>695 032</Address3><Contacts></Contacts></Site><Site><Address1>Bangalore</Address1><Address3> 560 017</Address3><Contacts></Contacts></Site><Site><Address1>Chennai</Address1><Address3> 600028</Address3><Contacts></Contacts></Site><Site><Name>Jothydev Diabetes and Research Centre</Name><Address3> 695032</Address3><Contacts></Contacts></Site><Site><Name>Swamy Diabetes Centre</Name><Address1>Chennai</Address1><Address3>600028</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="South Korea"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Seoul</Address1><Address3>110-746</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Seoul</Address1><Address3>130-701</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Seoul</Address1><Address3>138-736</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Seoul</Address1><Address3>139-707</Address3><Contacts></Contacts></Site><Site><Address1>Seoul</Address1><Address3> 110746</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Puerto Rico"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Manati</Address1><Address3>00674</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Trujillo Alto</Address1><Address3>00976</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Manati</Address1><Address3> 674</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Trujillo Alto</Address1><Address3> 976</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Thailand"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Bangkok</Address1><Address3>10110</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Bangkok</Address1><Address3>10330</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Bangkok</Address1><Address3>10400</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Pathumthani</Address1><Address3>12120</Address3><Contacts></Contacts></Site><Site><Address1>Bangkok</Address1><Address3> 10330</Address3><Contacts></Contacts></Site><Site><Address1>Pathumthani</Address1><Address3> 12120</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Altoona</Address1><Address2>Pennsylvania</Address2><Address3>16602</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Anaheim</Address1><Address2>California</Address2><Address3>92801</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Aurora</Address1><Address2>Colorado</Address2><Address3>80045</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Buckley</Address1><Address2>Michigan</Address2><Address3>49620</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Butte</Address1><Address2>Montana</Address2><Address3>59701</Address3><CountrySubDivision code="MT">Montana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Cayahoga Falls</Address1><Address2>Ohio</Address2><Address3>44223</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Charlotte</Address1><Address2>North Carolina</Address2><Address3>28277</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Chattanooga</Address1><Address2>Tennessee</Address2><Address3>37404</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Chattanooga</Address1><Address2>Tennessee</Address2><Address3>37411</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Chesterfield</Address1><Address2>Missouri</Address2><Address3>63017</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Cincinnati</Address1><Address2>Ohio</Address2><Address3>45245</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Clarion</Address1><Address2>Pennsylvania</Address2><Address3>16214</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Clilfton</Address1><Address2>New Jersey</Address2><Address3>07011</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Concord</Address1><Address2>California</Address2><Address3>94520</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Corpus Christi</Address1><Address2>Texas</Address2><Address3>78404</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75230</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75246</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Dayton</Address1><Address2>Ohio</Address2><Address3>45406</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Escondido</Address1><Address2>California</Address2><Address3>92025</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Fresno</Address1><Address2>California</Address2><Address3>93720</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Gallipolis</Address1><Address2>Ohio</Address2><Address3>45631-1560</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Greensboro</Address1><Address2>North Carolina</Address2><Address3>27408</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Greer</Address1><Address2>South Carolina</Address2><Address3>29651</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Hollywood</Address1><Address2>Florida</Address2><Address3>33021</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77025</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Hurst</Address1><Address2>Texas</Address2><Address3>76054</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Idaho Falls</Address1><Address2>Idaho</Address2><Address3>83404-7596</Address3><CountrySubDivision code="ID">Idaho</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Independence</Address1><Address2>Kansas</Address2><Address3>67301-3263</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Jacksonville</Address1><Address2>Florida</Address2><Address3>32204</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Jacksonville</Address1><Address2>Florida</Address2><Address3>32207</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Jefferson City</Address1><Address2>Missouri</Address2><Address3>65109</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Lancaster</Address1><Address2>Pennsylvania</Address2><Address3>17601</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Litchfield Park</Address1><Address2>Arizona</Address2><Address3>85340</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Long Beach</Address1><Address2>California</Address2><Address3>90822</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3>90057</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Martinsburg</Address1><Address2>West Virginia</Address2><Address3>25401</Address3><CountrySubDivision code="WV">West Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3>33136</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3>33143</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Milwaukee</Address1><Address2>Wisconsin</Address2><Address3>53209</Address3><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Norristown</Address1><Address2>Pennsylvania</Address2><Address3>19401</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Northport</Address1><Address2>New York</Address2><Address3>11768</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Norwalk</Address1><Address2>Connecticut</Address2><Address3>06851</Address3><CountrySubDivision code="CT">Connecticut</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Ocala</Address1><Address2>Florida</Address2><Address3>34471</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Odessa</Address1><Address2>Texas</Address2><Address3>79761</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Orlando</Address1><Address2>Florida</Address2><Address3>32804</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3>19104</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3>19107</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Plantation</Address1><Address2>Florida</Address2><Address3>33324</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Ponte Vedra</Address1><Address2>Florida</Address2><Address3>32081</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Portland</Address1><Address2>Maine</Address2><Address3>04101</Address3><CountrySubDivision code="ME">Maine</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Powder Springs</Address1><Address2>Georgia</Address2><Address3>30127</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Redlands</Address1><Address2>California</Address2><Address3>92374</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Renton</Address1><Address2>Washington</Address2><Address3>98057</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Rockville</Address1><Address2>Maryland</Address2><Address3>20852</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Roswell</Address1><Address2>Georgia</Address2><Address3>30076</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78209</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Santa Ana</Address1><Address2>California</Address2><Address3>92705</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Searcy</Address1><Address2>Arkansas</Address2><Address3>72143</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Shawnee Mission</Address1><Address2>Kansas</Address2><Address3>66204</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Spartanburg</Address1><Address2>South Carolina</Address2><Address3>29303</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Spring Valley</Address1><Address2>California</Address2><Address3>91978</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>St. George</Address1><Address2>Utah</Address2><Address3>84790</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>St. Louis</Address1><Address2>Missouri</Address2><Address3>63141</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Staten Island</Address1><Address2>New York</Address2><Address3>10301</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Syracuse</Address1><Address2>New York</Address2><Address3>13210</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Taylors</Address1><Address2>South Carolina</Address2><Address3>29687</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Tulsa</Address1><Address2>Oklahoma</Address2><Address3>74104</Address3><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Virginia Beach</Address1><Address2>Virginia</Address2><Address3>23462</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Waltham</Address1><Address2>Massachusetts</Address2><Address3>02453</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Winston Salem</Address1><Address2>North Carolina</Address2><Address3>27103</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Winter Haven</Address1><Address2>Florida</Address2><Address3>33880</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Altoona</Address1><Address2>Pennsylvania</Address2><Address3> 16602-2415</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Anaheim</Address1><Address2>California</Address2><Address3> 92801</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Aurora</Address1><Address2>Colorado</Address2><Address3> 80045</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Buckley</Address1><Address2>Michigan</Address2><Address3> 49620</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Butte</Address1><Address2>Montana</Address2><Address3> 59701</Address3><CountrySubDivision code="MT">Montana</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Cayahoga Falls</Address1><Address2>Ohio</Address2><Address3> 44223</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Charlotte</Address1><Address2>North Carolina</Address2><Address3> 28277</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Chattanooga</Address1><Address2>Tennessee</Address2><Address3> 37403</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Chattanooga</Address1><Address2>Tennessee</Address2><Address3> 37404</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Chattanooga</Address1><Address2>Tennessee</Address2><Address3> 37411</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Chesterfield</Address1><Address2>Missouri</Address2><Address3> 63017</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Cincinnati</Address1><Address2>Ohio</Address2><Address3> 45245</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Clarion</Address1><Address2>Pennsylvania</Address2><Address3> 16214</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Clilfton</Address1><Address2>New Jersey</Address2><Address3> 7011</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Concord</Address1><Address2>California</Address2><Address3> 94520</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Corpus Christi</Address1><Address2>Texas</Address2><Address3> 78404</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3> 75230</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3> 75231</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3> 75246</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Dayton</Address1><Address2>Ohio</Address2><Address3> 45406</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Escondido</Address1><Address2>California</Address2><Address3> 92026</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Fresno</Address1><Address2>California</Address2><Address3> 93720</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Galesburg</Address1><Address2>Illinois</Address2><Address3> 61401</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Gallipolis</Address1><Address2>Ohio</Address2><Address3> 45631-1560</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Goodyear</Address1><Address2>Arizona</Address2><Address3> 85395</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Greensboro</Address1><Address2>North Carolina</Address2><Address3> 27408</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Greer</Address1><Address2>South Carolina</Address2><Address3> 29651</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Hollywood</Address1><Address2>Florida</Address2><Address3> 33021</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3> 77025</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Hurst</Address1><Address2>Texas</Address2><Address3> 76054</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Idaho Falls</Address1><Address2>Idaho</Address2><Address3> 83404-7542</Address3><CountrySubDivision code="ID">Idaho</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Independence</Address1><Address2>Kansas</Address2><Address3> 67301-3263</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Jacksonville</Address1><Address2>Florida</Address2><Address3> 32204</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Jacksonville</Address1><Address2>Florida</Address2><Address3> 32207</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Jefferson City</Address1><Address2>Missouri</Address2><Address3> 65109</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Lancaster</Address1><Address2>Pennsylvania</Address2><Address3> 17601</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Litchfield Park</Address1><Address2>Arizona</Address2><Address3> 85340</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Long Beach</Address1><Address2>California</Address2><Address3> 90822</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3> 90057</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Martinsburg</Address1><Address2>West Virginia</Address2><Address3> 25401</Address3><CountrySubDivision code="WV">West Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3> 33136</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3> 33143</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Milwaukee</Address1><Address2>Wisconsin</Address2><Address3> 53209</Address3><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Norristown</Address1><Address2>Pennsylvania</Address2><Address3> 19401</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Northport</Address1><Address2>New York</Address2><Address3> 11768</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Norwalk</Address1><Address2>Connecticut</Address2><Address3> 06851-4697</Address3><CountrySubDivision code="CT">Connecticut</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Ocala</Address1><Address2>Florida</Address2><Address3> 34471</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Odessa</Address1><Address2>Texas</Address2><Address3> 79761-5100</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Orlando</Address1><Address2>Florida</Address2><Address3> 32804</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3> 19104</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3> 19107</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Plantation</Address1><Address2>Florida</Address2><Address3> 33324</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Ponte Vedra</Address1><Address2>Florida</Address2><Address3> 32081</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Portland</Address1><Address2>Maine</Address2><Address3> 4101</Address3><CountrySubDivision code="ME">Maine</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Powder Springs</Address1><Address2>Georgia</Address2><Address3> 30127</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Redlands</Address1><Address2>California</Address2><Address3> 92374</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Renton</Address1><Address2>Washington</Address2><Address3> 98057</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Rockville</Address1><Address2>Maryland</Address2><Address3> 20852</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Roswell</Address1><Address2>Georgia</Address2><Address3> 30076</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3> 78209</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Santa Ana</Address1><Address2>California</Address2><Address3> 92705</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Searcy</Address1><Address2>Arkansas</Address2><Address3> 72143</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Shawnee Mission</Address1><Address2>Kansas</Address2><Address3> 66204</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Spartanburg</Address1><Address2>South Carolina</Address2><Address3> 29303</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Spring Valley</Address1><Address2>California</Address2><Address3> 91978</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>St. George</Address1><Address2>Utah</Address2><Address3> 84790</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>St. Louis</Address1><Address2>Missouri</Address2><Address3> 63141</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Staten Island</Address1><Address2>New York</Address2><Address3> 10301</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Syracuse</Address1><Address2>New York</Address2><Address3> 13210</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Taylors</Address1><Address2>South Carolina</Address2><Address3> 29687</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Tulsa</Address1><Address2>Oklahoma</Address2><Address3> 74104</Address3><CountrySubDivision code="OK">Oklahoma</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Virginia Beach</Address1><Address2>Virginia</Address2><Address3> 23462</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Waltham</Address1><Address2>Massachusetts</Address2><Address3> 2453</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Winston Salem</Address1><Address2>North Carolina</Address2><Address3> 27103</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Winter Haven</Address1><Address2>Florida</Address2><Address3> 33880</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Novo Nordisk Clinical Trial Call Center</Name><Address1>Winter Park</Address1><Address2>Florida</Address2><Address3> 32789</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="100">Subjects on Treatment/Requiring &gt;1  Antidiabetic Agent</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="102">Subjects with Good Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="103">Subjects with Poor/Inadequate Glycemic Control</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="104">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="108">Subjects with obesity</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="172">Insulin Naive Type 2 Diabetes Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00909480</Identifier></Identifiers></Registry><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier>CTRI/2009/091/000161</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1358"><Endpoint>Assessment of Hemoglobin A1c (HbA1c) Levels</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1359">Change in HbA1c</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1344"><Endpoint>Assessment of Blood Glucose Levels</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1350">Self monitoring of blood glucose (SMBG)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1358"><Endpoint>Assessment of Hemoglobin A1c (HbA1c) Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1514"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1345">Assessment of fasting blood glucose</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1521">Nocturnal hypoglycemia</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Non-insulin dependent diabetes" id="6727"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1503">Assessment of body weight</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="608"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="610">Obese subjects (Grade 2 obesity, BMI= 30 to 39.9)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="670"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="672">Subjects on/treated with biguanides</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="674">Subjects on/treated with dipeptidyl peptidase-4 inhibitors</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="675">Subjects on/treated with sulphonylureas</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="676">Subjects on/treated with thiazolidinediones</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="678">Subjects on/treated with any other oral anti-diabetic agents</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="905">Subjects on/agreeing to maintain stable dose of oral hypoglycemic agents</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="1047"><Criterion>Treatment Naive Subjects</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1048">Insulin naÃ¯ve subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="33510"><Criterion>Subjects with specific level of glycemic control</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="606">Subjects with Good Glycemic Control</SubCriterion><SubCriterion disease="Non-insulin dependent diabetes" id="901">Subjects with Moderate Glycemic Control</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="959"><Criterion>Conditions Altering Blood Glucose Levels</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="5060">Use of drugs which interferes with the plasma glucose level</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="983"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="990">Hypersensitivity/contraindications to study medication/device</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-06-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2009-12-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>7.03 Months</EnrollmentPeriod><EnrollmentRate>65.01 Patients/Month</EnrollmentRate><DateFirstReceived>2009-05-27T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-06-02T12:03:46Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="60748"><TitleDisplay>Sandostatine LP and Hyperinsulinism</TitleDisplay><TitleOfficial>Replace Sandostatine in Three Daily Subcutaneous Injections by a Single Intramuscular Injection of Sandostatine LP Per Month in Patients With a Diffuse Form of Hyperinsulinism</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CRC 07024</Identifier><Identifier type="NCT">NCT00987168</Identifier></Identifiers><Indications><Indication id="441">Hyperinsulinemia</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Sandostatin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="23948" type="Company"><TargetEntity id="4296543185" type="organizationId">Assistance Publique Hopitaux de Paris</TargetEntity></SourceEntity><SourceEntity id="441" type="ciIndication"><TargetEntity id="10060378" type="MEDDRA"></TargetEntity><TargetEntity id="D006946" type="MeSH"></TargetEntity><TargetEntity id="-1990377991" type="omicsDisease"></TargetEntity><TargetEntity id="511" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23948">Assistance Publique Hopitaux de Paris</Company></CompaniesSponsor><CompaniesCollaborator><Company id="23137">Novartis AG</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>10</PatientCountEnrollment><DateStart>2009-05-31T00:00:00Z</DateStart><DateEnd type="actual">2011-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-07-09T06:39:41Z</DateChangeLast><DateAdded>2009-10-09T06:22:36Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Assistance Publique - HÃ´pitaux de Paris</Affiliation><Name>Pascale De Lonlay, PUPH</Name></Contact><Contact type="Public contact"><Affiliation>Necker Hospital; paris; 75015; France</Affiliation><Email>pascale.delonlay@nck.aphp.fr</Email><Name>Pascale De  Lonlay, PUPH</Name><Phone>(0)1 44 49 26 94</Phone></Contact><Contact type="Public contact"><Affiliation>Necker Hospital; paris; 75015; France</Affiliation><Email>kh.lequansang@nck.aphp.fr</Email><Name>Kim-hanhÂ Sang</Name><Phone>1 44 49 59 51</Phone></Contact><Contact type="Scientific contact"><Affiliation>Assistance Publique - HÃ´pitaux de Paris</Affiliation><Email>pascale.delonlay@nck.aphp.fr</Email><Name>Pascale De  Lonlay, PUPH</Name><Phone>(0)1 44 49 26 94</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Congenital hyperinsulinism patients&lt;/li&gt;&lt;li&gt;Age of patients : 6 months to 16 years&lt;/li&gt;&lt;li&gt;Normoglycemia under sandostatine subcutaneous&lt;/li&gt;&lt;li&gt;Contraception efficiency&lt;/li&gt;&lt;li&gt;Signed informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Refusal from parents&lt;/li&gt;&lt;li&gt;Vesicular lithiasis&lt;/li&gt;&lt;li&gt;Absence of social security&lt;/li&gt;&lt;li&gt;Hypersensitivity to&lt;ulink linkType="Drug" linkID="3735"&gt;Sandostatine LP&lt;/ulink&gt; or excipients
&lt;/li&gt;&lt;li&gt;Pregnancy or nursing mother&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Glycemia &gt;/= 3 mmol/l, before and after 4 meals + Midnight + 4 am</Description><Timeframe>6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Abdominal ultra echography, before and after 6 month treatment</Description><Timeframe>6 months</Timeframe></Measure><Measure><Description>Life quality</Description><Timeframe>6 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to replace Sandostatine in three daily sc injections by a single im
      injection of &lt;ulink linkType="Drug" linkID="3735"&gt;Sandostatine LP&lt;/ulink&gt; per month in patients with a diffuse form of hyperinsulinism.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would  receive im injection of 10, 20, 30 mg of &lt;ulink linkType="Drug" linkID="3735"&gt;Sandostatine LP&lt;/ulink&gt;, qm.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>Necker Hospital</Name><Address1>Paris</Address1><Address3>75015</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hyperinsulinemia</Disease><PatientSegments><PatientSegment><PatientSegment id="10993">Subjects with Neonatal Hyperinsulinism</PatientSegment><SubSegments><SubSegment id="10994">Subjects with congenital hyperinsulinism</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00987168</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Insulin resistance" id="23275"><Endpoint>Glycemic Control Analysis</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Hyperinsulinemia" id="24493"><Endpoint>Glycemic Control Analysis</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Insulin resistance" id="23310"><Endpoint>Assessment of Abdominal Obesity</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hyperinsulinemia" id="24521"><Endpoint>Assessment of Abdominal Obesity</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Hyperinsulinemia" id="30978"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Hyperinsulinemia" id="30983">Quality of life(Non-specific)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Insulin resistance" id="33217"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Insulin resistance" id="33260">Quality of life(Non-specific)</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Insulin resistance" id="20225"><Criterion>Subjects with Acceptable Glycemic Levels</Criterion></Inclusion><Inclusion disease="Hyperinsulinemia" id="21217"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Hyperinsulinemia" id="21218">Subjects with abdominal obesity</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hyperinsulinemia" id="21237"><Criterion>Subjects with Acceptable Liver Functions</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Insulin resistance" id="18043"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Insulin resistance" id="18050"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Hyperinsulinemia" id="19023"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Hyperinsulinemia" id="19030"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2011-04-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2010-10-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>17.03 Months</EnrollmentPeriod><EnrollmentRate>0.59 Patients/Month</EnrollmentRate><DateFirstReceived>2009-09-29T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-10-09T06:22:36Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="74692"><TitleDisplay>A phase II trial to assess the safety and efficacy of temozolomide and whole brain irradiation in patients with melanoma metastatic to brain</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="205">Melanoma</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>temozolomide</Name><Drug id="4529">temozolomide</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4529">temozolomide</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1051922">City of Hope Medical Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4529" type="Drug"><TargetEntity id="108485" type="siDrug">Temozolomide</TargetEntity></SourceEntity><SourceEntity id="1051922" type="Company"><TargetEntity id="5009617951" type="organizationId">City of Hope Medical Center</TargetEntity></SourceEntity><SourceEntity id="205" type="ciIndication"><TargetEntity id="C43" type="ICD10"></TargetEntity><TargetEntity id="10025650" type="MEDDRA"></TargetEntity><TargetEntity id="D008545" type="MeSH"></TargetEntity><TargetEntity id="-361092282" type="omicsDisease"></TargetEntity><TargetEntity id="705" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1051922">City of Hope Medical Center</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="50">Anticancer alkylating agent</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>31</PatientCountEnrollment><PatientCountEvaluable>31</PatientCountEvaluable><DateStart>1999-08-31T00:00:00Z</DateStart><DateChangeLast>2011-02-23T06:36:05Z</DateChangeLast><DateAdded>2011-02-23T06:36:05Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Adult patients with histologically-proven metastatic melanoma with involvement of the CNS&lt;/li&gt;&lt;li&gt;Radiographical documentation of bidimensionally-measurable brain metastasis that was not amenable to curative therapy&lt;/li&gt;&lt;li&gt;Prior surgery and/or stereotactic radio surgery was allowed&lt;/li&gt;&lt;li&gt;Biological therapies were limited to at most one agent adjuvantly and no more than one agent for advanced disease&lt;/li&gt;&lt;li&gt;World Health Organization performance status 0 to 1&lt;/li&gt;&lt;li&gt;Adequate organ function:&lt;ul&gt;&lt;li&gt;Hemoglobin &gt; 10 g/dl&lt;/li&gt;&lt;li&gt;Absolute neutrophil count &gt; 1500/microl&lt;/li&gt;&lt;li&gt;Platelets &gt; 100,000/microl&lt;/li&gt;&lt;li&gt;Serum creatinine&amp;lt;/=  2.5 mg/dl or clearance &gt;/=  50 ml/min&lt;/li&gt;&lt;li&gt;Serum bilirubin less than or equal to institutional normal limit or isolated unconjugated bilirubin elevation&amp;lt;/=  3 mg/dl consistent with Gilbert's disease, serum transaminases &amp;lt;/= 2.5 x institutional upper limit), and stable glucocorticosteroid dose for at least 7 days or off steroid &lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Stable glucocorticosteroid dose for at least 7 days or off steroid&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Prior systemic chemotherapy&lt;/li&gt;&lt;li&gt;Patients with known human immunodeficiency virus, pregnancy or carcinomatous meningitis&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Toxicities assessed by National Cancer Institute Common Toxicity Grading Criteria, version 2.0</Description></Measure><Measure><Description>Efficacy (complete and partial response, progression free survival)</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;The toxicities observed were mild to moderate in severity which included fatigue, anorexia and nausea. There was serum alanine aminotransaminase elevation (grade 3) observed in one patient. Neutropenia associated with the treatment was complex with fatal sepsis (grade 5) in one patient and in the other it was of grade 3 in severity [&lt;ulink linkType="Reference" linkID="1138480"&gt;1138480&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this phase II trial was to assess the safety and efficacy of &lt;ulink linkType="Drug" linkID="4529"&gt;temozolomide&lt;/ulink&gt; and whole brain irradiation (WBI) in patients with melanoma metastatic to brain [&lt;ulink linkType="Reference" linkID="1138480"&gt;1138480&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In April 2002, results were published. A total of three patients  had objective  response. Complete response was observed in one patient with duration of 4.5 months. There were two CNS partial responses  of 2 and 7 months duration, a 4-month complete remission was also observed in the latter patient. The median progression free survival and median survival was  2 and 6 months, respectively [&lt;ulink linkType="Reference" linkID="1138480"&gt;1138480&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients were irradiated with WBI over ten  fractions (30 Gy) on days 1 to 5 and 8 to 12. &lt;ulink linkType="Drug" linkID="4529"&gt;Temozolomide&lt;/ulink&gt; (75 mg/m2, po) was administered    on day 1 and was given daily for 6 weeks followed by off treatment for a period of 4 weeks. The dose was repeated every 10 weeks [&lt;ulink linkType="Reference" linkID="1138480"&gt;1138480&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>temozolomide</Name><Drug id="4529">temozolomide</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="1991">Neutropenia</Indication><CountPatientsTotal>31</CountPatientsTotal><CountPatientsAffected>2</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication></AdverseEvent><AdverseEvent><Indication id="3038">Appetite loss</Indication></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="182188">temozolomide</Intervention><Treatments><Treatment><Dose>75 milligram/m2</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-02-23T06:36:05Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="80884"><TitleDisplay>Pilot Study of Varenicline to Treat Opioid Dependence</TitleDisplay><TitleOfficial>The Role of Varenicline in Treating Opioid Dependence: A Pilot Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">11-002062</Identifier><Identifier type="NCT">NCT01436474</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication><Indication id="243">Opiate dependence</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>varenicline</Name><Drug id="31977">varenicline</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="31977">varenicline</Drug><IndicationsPioneer><Indication id="20">Pain</Indication><Indication id="243">Opiate dependence</Indication></IndicationsPioneer><Companies><Company><Company id="21111">Mayo Clinic Foundation</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="31977" type="Drug"><TargetEntity id="301545" type="siDrug">Varenicline</TargetEntity><TargetEntity id="330290" type="siDrug">Varenicline tartrate</TargetEntity></SourceEntity><SourceEntity id="21111" type="Company"><TargetEntity id="5035523907" type="organizationId">Mayo Foundation</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="243" type="ciIndication"><TargetEntity id="F11.2" type="ICD10"></TargetEntity><TargetEntity id="D009293" type="MeSH"></TargetEntity><TargetEntity id="-1731206897" type="omicsDisease"></TargetEntity><TargetEntity id="1154" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1166" type="Action"><TargetEntity id="15" type="Mechanism">Drugs Acting on Acetylcholine Receptors (Nicotinic)</TargetEntity><TargetEntity id="4996" type="Mechanism">Nicotinic alpha9alpha10 Receptor Ligands</TargetEntity><TargetEntity id="5001" type="Mechanism">Nicotinic alpha4beta2alpha5 Receptor Ligands</TargetEntity><TargetEntity id="5004" type="Mechanism">Nicotinic alpha6beta2alpha4beta2beta3 Receptor Ligands</TargetEntity><TargetEntity id="5075" type="Mechanism">Nicotinic alpha3beta2 Receptor Ligands</TargetEntity><TargetEntity id="5147" type="Mechanism">Nicotinic alpha6beta2beta3 Receptor Ligands</TargetEntity><TargetEntity id="6568" type="Mechanism">Nicotinic Receptor Ligands</TargetEntity></SourceEntity><SourceEntity id="16661" type="Action"><TargetEntity id="2558" type="Mechanism">Nicotinic Receptor Partial Agonists</TargetEntity><TargetEntity id="5002" type="Mechanism">Nicotinic alpha4beta2alpha5 Partial Agonists</TargetEntity><TargetEntity id="5005" type="Mechanism">Nicotinic alpha6beta2alpha4beta2beta3 Partial Agonists</TargetEntity><TargetEntity id="5120" type="Mechanism">Nicotinic alpha6beta2beta3 Partial Agonists</TargetEntity><TargetEntity id="5277" type="Mechanism">Anti-Bone Morphogenetic Protein 6 (BMP6)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21111">Mayo Clinic Foundation</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="1166">Nicotinic acetylcholine receptor modulator</Action><Action id="16386">Nicotinic ACh receptor alpha 4 subunit modulator</Action><Action id="16413">Nicotinic ACh receptor beta 2 subunit modulator</Action><Action id="16661">Nicotinic acetylcholine receptor partial agonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>21</PatientCountEnrollment><DateStart>2011-06-30T00:00:00Z</DateStart><DateEnd type="actual">2012-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-07-24T06:34:40Z</DateChangeLast><DateAdded>2011-09-20T07:51:28Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Mayo Clinic</Affiliation><Name>William Hooten, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;gt;/= 21 years
&lt;/li&gt;&lt;li&gt;Use of opioids at admission to PRC (pain rehabilitation center), with daily morphine equivalent dose&amp;gt;/= 60 mg
&lt;/li&gt;&lt;li&gt;Be able and willing to participate fully in all aspects of the study including 1
             month follow-up after completion of PRC&lt;/li&gt;&lt;li&gt;Ability to provide informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Currently using&lt;ulink linkType="Drug" linkID="31977"&gt;varenicline&lt;/ulink&gt; or other pharmacotherapy for nicotine dependence
&lt;/li&gt;&lt;li&gt;Currently pregnant, lactating, or likely to become pregnant during the trial and not
             willing to use an acceptable form of contraception&lt;/li&gt;&lt;li&gt;History of a major cardiovascular event in the past 6 months including unstable
             angina, acute myocardial infarction, stroke, or coronary angioplasty&lt;/li&gt;&lt;li&gt;Known&lt;ulink linkType="Drug" linkID="31977"&gt;varenicline&lt;/ulink&gt; allergy
&lt;/li&gt;&lt;li&gt;Use of any medication (eg, methadone, Suboxone) as maintenance therapy for opiate
             addiction&lt;/li&gt;&lt;li&gt;Identification of illicit drugs (eg, marijuana, cocaine) on the baseline urine
             toxicology screen&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Assessment of opioid withdrawal symptoms: during their treatment, patients are closely monitored by a multidisciplinary team, and there are regular assessments of pain, depression, substance use, and pain-related physical and emotional functioning</Description><Timeframe>45 days</Timeframe></Measure><Measure><Description>Assessment of cravings at 1 month following opioid tapering: during their treatment, patients are closely monitored by a multidisciplinary team, and there are regular assessments of pain, depression, substance use, and pain-related physical and emotional functioning</Description><Timeframe>45 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this proposal is to explore the potential of &lt;ulink linkType="Drug" linkID="31977"&gt;varenicline&lt;/ulink&gt; as a
      pharmacotherapeutic agent for opioid dependence and addiction.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomly assigned to receive either &lt;ulink linkType="Drug" linkID="31977"&gt;varenicline&lt;/ulink&gt; or placebo for 45 days. Patients assigned to &lt;ulink linkType="Drug" linkID="31977"&gt;varenicline&lt;/ulink&gt; and are current smokers will receive 0.5 mg po qd  for 3 days, followed by 0.5 mg bid  for 4 days. After the first week, the dose will be increased to 1 mg bid for the remainder of the active treatment period of the study. Patients assigned to &lt;ulink linkType="Drug" linkID="31977"&gt;varenicline&lt;/ulink&gt; and are non-smokers will receive 0.5 mg po qd  for 6 days, followed by 0.5 mg bid for 6 days. After the first 12 days, the dose will be increased to 1 mg bid  for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to &lt;ulink linkType="Drug" linkID="31977"&gt;varenicline&lt;/ulink&gt;.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Mayo Clinic in Rochester</Name><Address1>Rochester</Address1><Address2>Minnesota</Address2><Address3>55905</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8428">Subjects with Psychogenic Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01436474</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25959"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26013">Assessment of physical activity</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26000"><Endpoint>Assessment of Pain</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26042">Assessment of drop-out rate/withdrawal rate</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="35230">Assessment of psychological symptoms</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Pain" id="34061"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="22211">Subjects with history/scheduled to receive opioids</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pain" id="20115"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20125"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20174">Subjects with history/scheduled to receive other drug therapies</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-09-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2011-06-03T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-09-20T07:51:28Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="85013"><TitleDisplay>A pilot, phase III, double-blind, randomized, placebo-controlled study to determine the safety and efficacy of topical 2% viscous lidocaine (Xylocaine) for the treatment of children with painful infectious mouth conditions</TitleDisplay><TitleOfficial>For children with painful infectious mouth conditions and poor oral intake, does topical 2% viscous lignocaine improve oral intake?</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">ACTRN12609000566235</Identifier><Identifier type="Other">ANZCTR308194</Identifier><Identifier type="Other">29070 C</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lidocaine</Name><Drug id="44403">lidocaine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44403">lidocaine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="22894">Royal Childrens Hospital Research Foundation</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="28891">Murdoch Childrens Research Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44403" type="Drug"><TargetEntity id="91302" type="siDrug">Lidocaine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="22894" type="Company"><TargetEntity id="5035528806" type="organizationId">Children's Health Foundation Queensland</TargetEntity></SourceEntity><SourceEntity id="28891" type="Company"><TargetEntity id="5035485652" type="organizationId">Murdoch Childrens Research Institute</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="22894">Royal Childrens Hospital Research Foundation</Company></CompaniesSponsor><CompaniesCollaborator><Company id="28891">Murdoch Childrens Research Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="1669">Local anesthetic</Class><Class id="59620">Unspecified drug target</Class></Class><Technologies><Technology id="615">Aerosol formulation dermatological</Technology><Technology id="611">Dermatological formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="776">Oral gel formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="745">Suspension</Technology><Technology id="558">Transdermal formulation</Technology></Technologies><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2009-11-09T00:00:00Z</DateStart><DateChangeLast>2018-06-13T10:55:33Z</DateChangeLast><DateAdded>2012-02-20T11:47:37Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Emergency DepartmentRoyal Children s HospitalFlemington RDParkville, 3052VIC, Australia</Affiliation><Email>sandy.hopper@rch.org.au</Email><Name>Sandy Hopper</Name><Phone>61393456592</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects with gingivostomatitis (herpetic or non herpetic), ulcerative pharyngitis, herpangina and hand foot and mouth disease as assessed by the treating clinician&lt;/li&gt;&lt;li&gt;History of poor oral fluid intake (as assessed by parent and defined as oral fluid intake of&amp;lt; 10 ml/kg of fluid in the preceding 2 h)&lt;/li&gt;&lt;li&gt;Age 6 months to 8 years&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Presence of &gt; 2  vomits in the preceding 24 h&lt;/li&gt;&lt;li&gt;Presence of active painful dental disease (caries, dental abscess) or painful recent mouth trauma, mouth burn, or post-operative state (minimum of 5 days)&lt;/li&gt;&lt;li&gt;Systemic toxicity related to infection&lt;/li&gt;&lt;li&gt;Severe dehydration requiring immediate therapy&lt;/li&gt;&lt;li&gt;Pre-existing significant upper airway obstruction and swallowing difficulties&lt;/li&gt;&lt;li&gt;Known allergy to local anesthetic, gelatine, methylcellulose, cherry flavouring, paracetamol or ibuprofen&lt;/li&gt;&lt;li&gt;Chronic renal or liver impairment&lt;/li&gt;&lt;li&gt;History of epilepsy or cardiac disease&lt;/li&gt;&lt;li&gt;Presence of acute porphyria&lt;/li&gt;&lt;li&gt;Presence of malignancy&lt;/li&gt;&lt;li&gt;Current use of anti-arrhythmic drugs,&lt;ulink linkType="Drug" linkID="44403"&gt;lidocaine&lt;/ulink&gt;, phenytoin, cimetidine or beta-blockers, warfarin, lithium, angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics, frusemide, aspirin, salicylates, probenecid, anti-diabetic medications, zidovudine, cardiac glycosides or methotrexate&lt;/li&gt;&lt;li&gt;Analgesia taken 1 h preceding enrollment to study&lt;/li&gt;&lt;li&gt;More than one dose of&lt;ulink linkType="Drug" linkID="44403"&gt;lidocaine&lt;/ulink&gt; viscous and/or other medications containing &lt;ulink linkType="Drug" linkID="44403"&gt;lidocaine&lt;/ulink&gt; as an active ingredient given in this episode of illness&lt;/li&gt;&lt;li&gt;Non- English speaking parents/guardians&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Amount of fluid ingested by each child, expressed in ml/kg, as recorded by the treating nurses on a standard fluid balance chart</Description><Timeframe>60 min after administration of the treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The proportion of subjects in each arm to have ingested &gt; 10 ml/kg of fluid</Description><Timeframe>30 and 60 min after administration of the study solution</Timeframe></Measure><Measure><Description>Incidence of adverse effects (seizures, cardiac arrhythmia, aspiration as defined by presence of cough and increased respiratory rate or decreased saturation or onset of new adventitial breath sounds)</Description><Timeframe>90 min after administration of the treatment</Timeframe></Measure><Measure><Description>The proportion of subjects who undergo involuntary fluid administration via intravenous or nasogastic routes</Description><Timeframe>90 min after administration of the treatment</Timeframe></Measure><Measure><Description>The proportion of subjects in each arm to have ingested &gt; 20 ml/kg of fluid</Description><Timeframe>30 and 60 min from the time of administration of the study mixture</Timeframe></Measure><Measure><Description>The proportion of subjects who experience vomiting</Description><Timeframe>90 min after administration of the study solution</Timeframe></Measure><Measure><Description>The proportion of subjects who are admitted to hospital (both to the hospital and to the emergency department short stay unit)</Description><Timeframe>Discharge or admission to hospital</Timeframe></Measure><Measure><Description>Length of stay in the emergency department (ED)</Description><Timeframe>Discharge or transfer to the ward</Timeframe></Measure><Measure><Description>The proportion of subjects in each arm to have ingested &gt; 5 ml/kg of fluid</Description><Timeframe>30 and 60 min from the time of administration of the study mixture</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this  pilot, phase III, double-blind, randomized, placebo-controlled study was to determine the safety and efficacy  of topical 2% viscous &lt;ulink linkType="Drug" linkID="44403"&gt;lidocaine&lt;/ulink&gt; (Xylocaine) for the treatment of   children with painful infectious mouth conditions  [&lt;ulink linkType="Reference" linkID="1262525"&gt;1262525&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1264211"&gt;1264211&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2011, 20 patients were already   randomized to receive 2% &lt;ulink linkType="Drug" linkID="44403"&gt;lidocaine&lt;/ulink&gt; or placebo. A further 80 patients would be randomized to receive either 2% &lt;ulink linkType="Drug" linkID="44403"&gt;lidocaine&lt;/ulink&gt; or placebo    [&lt;ulink linkType="Reference" linkID="1262525"&gt;1262525&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects received either placebo or    0.15 ml/kg of 2% viscous &lt;ulink linkType="Drug" linkID="44403"&gt;lidocaine&lt;/ulink&gt;, topically to the oral cavity once only   [&lt;ulink linkType="Reference" linkID="1262525"&gt;1262525&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1264211"&gt;1264211&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Australia"><Sites><Site><Name>Royal Children's Hospital</Name><Address1>Melbourne</Address1><Contacts></Contacts></Site><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8431">Subjects with Other Types of Pain</PatientSegment><SubSegments><SubSegment id="8434">Subjects with pain associated with infections</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Enterovirus 71 infection</Disease><PatientSegments><PatientSegment><PatientSegment id="11820">Subjects with Enterovirus 71 Infection</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11824">Subjects with Hand, Foot and Mouth Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1011">Australian New Zealand Clinical Trials Registry (ANZCTR)</Name><Identifiers><Identifier type="Organisational Study">ACTRN12609000566235</Identifier><Identifier>ANZCTR308194</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25988"><Endpoint>Assessment of Underlying Conditions</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Enterovirus 71 infection" id="25847"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Enterovirus 71 infection" id="25848">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25988"><Endpoint>Assessment of Underlying Conditions</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26033"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26039">Assessment of efficacy</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Enterovirus 71 infection" id="22071"><Criterion>Subjects with Enterovirus 71 Infection</Criterion></Inclusion><Inclusion disease="Enterovirus 71 infection" id="22075"><Criterion>Subjects with Hand, Foot and Mouth Disease</Criterion></Inclusion><Inclusion disease="Enterovirus 71 infection" id="22086"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="Pain" id="22189"><Criterion>Conditions Associated with Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22203">Subjects with oro-facial disorder/disease associated pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22210"><Criterion>Subjects with History/Scheduled for Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="22220">Subjects with history/scheduled to receive local anaesthetics</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Enterovirus 71 infection" id="19989"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Enterovirus 71 infection" id="19990"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Enterovirus 71 infection" id="19991"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="Enterovirus 71 infection" id="19993"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Enterovirus 71 infection" id="19994"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Enterovirus 71 infection" id="19995"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Enterovirus 71 infection" id="20001"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Enterovirus 71 infection" id="20006"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Enterovirus 71 infection" id="20009"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Pain" id="20052"><Criterion>Subjects with Somatic Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="20058">Subjects with trauma related pain</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20113">Subjects co-morbid with metabolic diseases/disorders</SubCriterion><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion><SubCriterion disease="Pain" id="20123">Subjects with infectious disorders/disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20115"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Pain" id="20117"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Pain" id="20125"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20127">Hypersensitivity/ contraindication to local anaesthesia/ blocks</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20132">Subjects with history/scheduled to receive opioids</SubCriterion><SubCriterion disease="Pain" id="20133">Subjects with history of NSAIDs</SubCriterion><SubCriterion disease="Pain" id="20134">Subjects with history/scheduled to receive acetaminophen</SubCriterion><SubCriterion disease="Pain" id="20140">Subjects with history/scheduled to receive anti-arrhythmics</SubCriterion><SubCriterion disease="Pain" id="20141">Subjects with history/scheduled to receive local anaesthetics</SubCriterion><SubCriterion disease="Pain" id="20144">Subjects with history/scheduled to receive beta blockers</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20173"><Criterion>Subjects with History/ Scheduled to Undergo Other Therapy/Procedures</Criterion><SubCriteria><SubCriterion disease="Pain" id="20174">Subjects with history/scheduled to receive other drug therapies</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20129">Hypersensitivity/ contraindication to investigational drug/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="25893"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Pain" id="20124">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="26044"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Pain" id="20116">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2012-11-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>36.74 Months</EnrollmentPeriod><EnrollmentRate>2.72 Patients/Month</EnrollmentRate><FundersType><Type>Company</Type><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-02-20T11:47:37Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2016-08-08T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="88373"><TitleDisplay>PK Study of Oral and Intravenous Clofarabine in High Risk Myelodysplasia + Acute Leukemias</TitleDisplay><TitleOfficial>A Pharmacokinetic Study of Oral and Intravenous Clofarabine in Patients With High Risk Myelodysplasia and Acute Leukemias - Determination of Oral Bioavailability and the Effect of Cimetidine on Clofarabine Clearance</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">LCCC 0909</Identifier><Identifier type="NCT">NCT01169012</Identifier><Identifier type="Secondary Organisational">10-0256</Identifier></Identifiers><Indications><Indication id="1272">Myelodysplastic syndrome</Indication><Indication id="1728">Acute lymphoblastic leukemia</Indication><Indication id="1731">Acute myelogenous leukemia</Indication><Indication id="306">Spina bifida</Indication><Indication id="6833">Chronic myelomonocytic leukemia</Indication></Indications><BiomarkerNames><BiomarkerName id="118" role="Toxic effect marker" type="Genomic;Proteomic">Albumin</BiomarkerName><BiomarkerName id="126" role="Disease marker" type="Genomic;Proteomic">BCR-ABL1 fusion protein</BiomarkerName><BiomarkerName id="213" role="Toxic effect marker" type="Biochemical">Creatinine</BiomarkerName><BiomarkerName id="340" role="Therapeutic effect marker" type="Proteomic">POU domain, class 2, transcription factor 2</BiomarkerName><BiomarkerName id="1925" role="Therapeutic effect marker" type="Cellular">Neutrophils</BiomarkerName><BiomarkerName id="2054" role="Therapeutic effect marker" type="Cellular">Blood platelets</BiomarkerName><BiomarkerName id="12955" role="Toxic effect marker" type="Genomic;Proteomic">gamma-Glutamyltranspeptidase 2</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>cimetidine</Name><Drug id="44398">cimetidine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>clofarabine (oral), Genzyme</Name><Drug id="47924">clofarabine (oral), Genzyme</Drug></Intervention><Intervention type="InterventionPrimary"><Name>clofarabine (oral), Genzyme</Name><Drug id="47924">clofarabine (oral), Genzyme</Drug></Intervention><Intervention type="InterventionPrimary"><Name>clofarabine + Clolar + cimetidine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44398">cimetidine</Drug><IndicationsPioneer><Indication id="1272">Myelodysplastic syndrome</Indication><Indication id="1728">Acute lymphoblastic leukemia</Indication><Indication id="1731">Acute myelogenous leukemia</Indication><Indication id="306">Spina bifida</Indication><Indication id="6833">Chronic myelomonocytic leukemia</Indication></IndicationsPioneer><Companies><Company><Company id="1041077">UNC Lineberger Comprehensive Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="16299">Sanofi Genzyme</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="47924">clofarabine (oral), Genzyme</Drug><IndicationsPioneer><Indication id="1728">Acute lymphoblastic leukemia</Indication><Indication id="1731">Acute myelogenous leukemia</Indication><Indication id="306">Spina bifida</Indication><Indication id="6833">Chronic myelomonocytic leukemia</Indication></IndicationsPioneer><Companies><Company><Company id="1041077">UNC Lineberger Comprehensive Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="16299">Sanofi Genzyme</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="47924">clofarabine (oral), Genzyme</Drug><IndicationsPioneer><Indication id="1728">Acute lymphoblastic leukemia</Indication><Indication id="1731">Acute myelogenous leukemia</Indication><Indication id="306">Spina bifida</Indication><Indication id="6833">Chronic myelomonocytic leukemia</Indication></IndicationsPioneer><Companies><Company><Company id="1041077">UNC Lineberger Comprehensive Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="16299">Sanofi Genzyme</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44398" type="Drug"><TargetEntity id="91556" type="siDrug">Cimetidine</TargetEntity></SourceEntity><SourceEntity id="1041077" type="Company"><TargetEntity id="5035543653" type="organizationId">Unc Lineberger Comprehensive Cancer Center</TargetEntity></SourceEntity><SourceEntity id="16299" type="Company"><TargetEntity id="4295906583" type="organizationId">Genzyme Corp</TargetEntity></SourceEntity><SourceEntity id="1272" type="ciIndication"><TargetEntity id="D46" type="ICD10"></TargetEntity><TargetEntity id="10028533" type="MEDDRA"></TargetEntity><TargetEntity id="D011289" type="MeSH"></TargetEntity><TargetEntity id="-376765165" type="omicsDisease"></TargetEntity><TargetEntity id="711" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1728" type="ciIndication"><TargetEntity id="C91.0" type="ICD10"></TargetEntity><TargetEntity id="204" type="ICD9"></TargetEntity><TargetEntity id="513" type="ORPHANET"></TargetEntity><TargetEntity id="685" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1731" type="ciIndication"><TargetEntity id="D015470" type="MeSH"></TargetEntity><TargetEntity id="519" type="ORPHANET"></TargetEntity><TargetEntity id="-1550871001" type="omicsDisease"></TargetEntity><TargetEntity id="686" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="306" type="ciIndication"><TargetEntity id="Q05" type="ICD10"></TargetEntity><TargetEntity id="10041524" type="MEDDRA"></TargetEntity><TargetEntity id="D016135" type="MeSH"></TargetEntity><TargetEntity id="-1512706724" type="omicsDisease"></TargetEntity><TargetEntity id="2568" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="6833" type="ciIndication"><TargetEntity id="10009018" type="MEDDRA"></TargetEntity><TargetEntity id="D015477" type="MeSH"></TargetEntity><TargetEntity id="98823" type="ORPHANET"></TargetEntity><TargetEntity id="-1293987798" type="omicsDisease"></TargetEntity><TargetEntity id="692" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="201" type="Action"><TargetEntity id="197" type="Mechanism">Histamine H2 Receptor Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1041077">UNC Lineberger Comprehensive Cancer Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="16299">Sanofi Genzyme</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="201">Histamine H2 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="182">Gastric secretion inhibitor</Class><Class id="38199">Histamine H2 antagonist antiulcerant product</Class><Class id="59620">Unspecified drug target</Class></Class><Technologies><Technology id="596">Injectable formulation</Technology><Technology id="102">Nucleotide and derivatives</Technology><Technology id="585">Oral formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioavailability</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>13</PatientCountEnrollment><PatientCountEvaluable>10</PatientCountEvaluable><DateStart>2010-09-30T00:00:00Z</DateStart><DateEnd type="actual">2013-01-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T22:50:01Z</DateChangeLast><DateAdded>2012-06-15T12:05:40Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of North Carolina, Chapel Hill</Affiliation><Name>Matthew Foster, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;MDS patients age &gt;/= 18 years with International Prostate Symptom Score (IPSS) risk of intermediate-2 who have failed &gt;/= 1
             prior regimen with a DNA methyltransferase inhibitor, or have &gt;/= 10% bone marrow
             myeloblasts&lt;/li&gt;&lt;li&gt;MDS patients age &gt;/= 18 years with IPSS high risk&lt;/li&gt;&lt;li&gt;Patients with CMML (chronic myelomonocytic leukemia) age &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Untreated AML or Philadelphia (Ph)-negative ALL patients age &gt;/= 60 years who are deemed not to be
             candidates for intensive anthracycline based induction therapies based on age, organ
             function or co-morbidities&lt;/li&gt;&lt;li&gt;AML or Ph-negative ALL patients age &gt;/= 60 years who have failed or relapsed following
             initial induction therapy&lt;/li&gt;&lt;li&gt;Provide signed written informed consent&lt;/li&gt;&lt;li&gt;Capable of understanding the investigational nature, potential risks and benefits of
             the study, and able to provide valid informed consent&lt;/li&gt;&lt;li&gt;Have adequate renal and hepatic functions as indicated by the following laboratory
             values:&lt;ul&gt;&lt;li&gt;Serum creatinine&amp;lt;/= 1.0 mg/dl; if serum creatinine &amp;gt; 1.0 mg/dl, then the
                  estimated glomerular filtration rate (GFR) must be &amp;gt; 60 ml/min as calculated
                  by the Cockcroft-Gault equation: GFR (ml/min) = (140 - age) x (weight in kg) x (0.85 if female)/72 x serum creatinine in
        mg/ml&lt;/li&gt;&lt;li&gt;Serum bilirubin&amp;lt;/= 1.5 mg/dl x upper limit of normal (ULN)&lt;/li&gt;&lt;li&gt;Aspartate transaminase (AST)/alanine transaminase (ALT)&amp;lt;/= 2.5 x ULN&lt;/li&gt;&lt;li&gt;Alkaline phosphatase  2.5 x ULN&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Female patients of childbearing potential must have a negative serum pregnancy
                  test within 1 week prior to enrollment&lt;/li&gt;&lt;li&gt;Male and female patients must use an effective contraceptive method during the
                  study and for a minimum of 6 months after study treatment&lt;/li&gt;&lt;li&gt;International normalized ratio (INR)&amp;lt;/= 1.5 and activated partial thromboplastin time (APTT) within the upper limits of normal (patients on therapeutic
                  anticoagulation will be allowed to participate if anticoagulation can be changed
                  to parenteral medication or discontinued when platelet count is &amp;lt; 50 x 10(9)/l&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as
             specified in the protocol&lt;/li&gt;&lt;li&gt;Use of investigational agents within 30 days or any anticancer therapy within 2 weeks
             before study entry with the exception of hydroxyurea.  The patient must have
             recovered from all acute toxicities from any previous therapy&lt;/li&gt;&lt;li&gt;Have any other severe concurrent disease, or have a history of serious organ
             dysfunction or disease involving the heart, kidney, liver, or other organ system that
             may place the patient at undue risk to undergo treatment&lt;/li&gt;&lt;li&gt;Patients with a systemic fungal, bacterial, viral, or other infection not controlled
             (defined as exhibiting ongoing signs/symptoms related to the infection and without
             improvement, despite appropriate antibiotics or other treatment)&lt;/li&gt;&lt;li&gt;Pregnant or lactating patients&lt;/li&gt;&lt;li&gt;Any significant concurrent disease, illness, or psychiatric disorder that would
             compromise patient safety or compliance, interfere with consent, study participation,
             follow up, or interpretation of study results&lt;/li&gt;&lt;li&gt;Abnormal organ function as defined by ALT, AST or total bilirubin&amp;gt; 1.5 x ULN, GFR&amp;lt;
             60 ml/min by Modification of Diet in Renal Disease (MDRD) equation&lt;/li&gt;&lt;li&gt;Active cardiac disease as manifest by:&amp;gt; class II New York Heart Association (NYHA) congestive heart failure,
             unstable angina or myocardial infarction within the last 6 months&lt;/li&gt;&lt;li&gt;Hemorrhage or bleeding&amp;gt;/= common toxicity criteria for adverse events (CTCAE) grade 3 within 4 weeks of enrollment
&lt;/li&gt;&lt;li&gt;Pulmonary hemorrhage&amp;gt;/= CTCAE grade 2 within 4 weeks of enrollment&lt;/li&gt;&lt;li&gt;HIV infection&lt;/li&gt;&lt;li&gt;Active hepatitis B or hepatitis C infection (defined as measurable viral load by PCR,
             or liver function abnormalities attributed to viral hepatitis)&lt;/li&gt;&lt;li&gt;Cerebrovascular accident or transient ischemic attack within 6 months of study
             enrollment&lt;/li&gt;&lt;li&gt;Non-healing wound or ulcer, or major surgery or trauma within 4 weeks of study
             enrollment&lt;/li&gt;&lt;li&gt;Active graft versus host disease of any grade&lt;/li&gt;&lt;li&gt;Active CNS disease that will require radiation therapy&lt;/li&gt;&lt;li&gt;Suspected or confirmed hypersensitivity to cimetidine or other histamine H2
             antagonists&lt;/li&gt;&lt;li&gt;Have currently active gastrointestinal disease, or prior surgery that may affect the
             ability of the patient to absorb oral&lt;ulink linkType="Drug" linkID="47924"&gt;clofarabine&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Have had a diagnosis of another malignancy, unless the patient has been disease-free
             for at least three years following the completion of curative intent therapy, with the
             following exceptions:
&lt;ul&gt;&lt;li&gt;Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical
                  intraepithelial neoplasia, regardless of the disease-free duration, are eligible
                  for this study if definitive treatment for the condition has been completed&lt;/li&gt;&lt;li&gt;Patients with organ-confined prostate cancer with no evidence of recurrent or
                  progressive disease based on prostate-specific antigen (PSA) values are also
                  eligible for this study if hormonal therapy has been initiated or a radical
                  prostatectomy has been performed&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Medical indication for therapy with one of the previously-documented human organic cation transporter 2 (OCT2)
             inhibitors, for which cessation of the OCT2 inhibitor or conversion to an
             alternate agent would pose unacceptable risk to the patient&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Define human intra-patient bioavailability of clofarabine; compare the pharmacokinetics of iv-administered clofarabine when administered alone, with the pharmacokinetics of clofarabine when co-administered with cimetidine, an OCT2 inhibitor: regarding primary endpoints, each patient will generate pharmacokinetic data sufficient to compute area under the concentration versus time curve (AUC) and clearance (Cl) for each of the initial three clofarabine doses (iv, oral and iv administered after cimetidine) for each patient. These values will be used to compute the human oral bioavailability of clofarabine and compare AUC and Cl of clofarabine when given after cimetidine with AUC and Cl of clofarabine when administered alone</Description><Timeframe>Four years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Examine safety of orally-administered clofarabine; examine the safety of a combined iv and oral clofarabine regimen: regarding secondary objectives, safety will be evaluated by grading and reporting all adverse experiences during protocol therapy. The dose-limiting toxicity (DLT) rate of &lt;/= 20% is considered to be acceptable</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>Examine efficacy of orally-administered clofarabine: response to therapy will be determined at the time of hematological reconstitution (platelets &gt; 50 x 10[9]/l, ANC &gt; 1.0 x 10[9]/l for MDS patients or platelets &gt; 100 x 10[9]/l, ANC &gt; 1.0 x 10[9]/l for leukemia patients) or day 28, whichever is sooner by complete blood count with differential and bone marrow aspirate, biopsy and cytogenetics</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>Explore the influence of OCT2-encoding single nucleotide polymorphisms on clofarabine pharmacokinetics and pharmacodynamics: the effect of previously-described OCT2 polymorphisms on clofarabine pharmacokinetics will be investigated in an exploratory study. If specific OCT2-encoding single nucleotide polymorphisms are detected in study patients, the geometric mean AUC and Cl of clofarabine in such patients will be compared with the geometric mean AUC and Cl in patients with wild-type OCT2</Description><Timeframe>Five years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Myelosuppression and infection were the expected most common adverse events, with drug-related grades 3 to 4 neutropenia and thrombocytopenia, respectively reported in responding patients lasting a median of 32 and 14 days. The most commonly reported grades 3 to 4 non-hematological toxicities were gout (10%), atrial flutter (10%), tumor lysis (20%), elevated gamma-glutamyl transpeptidase (GGT) (10%), elevated creatinine (10%), hypokalemia (80%), low albumin (20%), hemorrhagic stroke (10%), and hypomagnesemia (10%). At 30 days post-dose, mortality was 0% [&lt;ulink linkType="Reference" linkID="1274945"&gt;1274945&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a non-blinded, non-randomized, pharmacokinetic study to determine the oral
      bioavailability of clofarabine, and the effect of &lt;ulink linkType="Drug" linkID="44398"&gt;cimetidine&lt;/ulink&gt; on clofarabine pharmacokinetics (PK)
      in patients with poor-risk acute leukemias and myelodysplastic syndrome (MDS).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In April 2012, results were presented. Complete remission (CR) was reported in two patients, with incomplete count recovery (CRi) in one patient, which led to an overall response rate of 30%. Hematological improvement in neutrophils was observed in one patient with relapsed AML and became newly platelet transfusion independent; in this patient clinical improvement lasted for 4 months, however remission was not attained. The AUC (0 to infinity) for iv &lt;ulink linkType="Drug" linkID="23624"&gt;clofarabine&lt;/ulink&gt; was greater after &lt;ulink linkType="Drug" linkID="44398"&gt;cimetidine&lt;/ulink&gt; than without (1211 versus 998 ng.h/ml, respectively). Geometric mean clearance for iv &lt;ulink linkType="Drug" linkID="23624"&gt;clofarabine&lt;/ulink&gt; was lower after &lt;ulink linkType="Drug" linkID="44398"&gt;cimetidine&lt;/ulink&gt; than without (24.5 versus 29.7 l/h, respectively). The 95% CI for geometric mean oral bioavailability was 0.67, which represented a 37% greater drug exposure than previously estimated [&lt;ulink linkType="Reference" linkID="1274945"&gt;1274945&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012, interim results from first ten treated patients were presented. The mean AUC (0 to infinity) value for &lt;ulink linkType="Drug" linkID="23624"&gt;clofarabine&lt;/ulink&gt; (15 mg/m2, iv) without &lt;ulink linkType="Drug" linkID="44398"&gt;cimetidine&lt;/ulink&gt; (reference), &lt;ulink linkType="Drug" linkID="23624"&gt;clofarabine&lt;/ulink&gt; (15 mg/m2, iv) with &lt;ulink linkType="Drug" linkID="44398"&gt;cimetidine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="47924"&gt;clofarabine&lt;/ulink&gt; (30 mg/m2, po) without &lt;ulink linkType="Drug" linkID="44398"&gt;cimetidine&lt;/ulink&gt; were 998, 1211 (p = 0.04) and 1333 (p = -0.06) ng.h/ml, respectively; the mean clearance values in the &lt;ulink linkType="Drug" linkID="23624"&gt;clofarabine&lt;/ulink&gt; (15 mg/m2, iv) without &lt;ulink linkType="Drug" linkID="44398"&gt;cimetidine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="23624"&gt;clofarabine&lt;/ulink&gt; (15 mg/m2, iv) with &lt;ulink linkType="Drug" linkID="44398"&gt;cimetidine&lt;/ulink&gt; groups were 29.7 and 24.5 l/h (p = 0.04), respectively. The absolute bioavailability value of &lt;ulink linkType="Drug" linkID="47924"&gt;clofarabine&lt;/ulink&gt; (30 mg/m2 po) without &lt;ulink linkType="Drug" linkID="44398"&gt;cimetidine&lt;/ulink&gt; was 0.67. In the presence of &lt;ulink linkType="Drug" linkID="44398"&gt;cimetidine&lt;/ulink&gt;, the AUC value of clofarabine was increased but its clearance values were reduced [&lt;ulink linkType="Reference" linkID="1296191"&gt;1296191&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive clofarabine as induction therapy in five doses.  Initially, and unless
      dose-escalation or de-escalation criteria were met, patients would be assigned to dose level 0
      (iv &lt;ulink linkType="Drug" linkID="23624"&gt;clofarabine&lt;/ulink&gt; [15 mg/m2]; po &lt;ulink linkType="Drug" linkID="47924"&gt;clofarabine&lt;/ulink&gt; [30 mg/m2]).  The first three doses (on days 1, 3 and
      5) would be administered followed by washout periods that extend until the next clofarabine
      dose would be administered.  Patients would also receive &lt;ulink linkType="Drug" linkID="44398"&gt;cimetidine&lt;/ulink&gt; (800 mg). During the washout periods, frequent phlebotomy for PK sampling would
      be performed in an outpatient setting at the UNC Clinical Translational Research Center
      (CTRC).  The duration of the induction period would be determined by time to recovery of
      hematological toxicity (platelets &amp;gt; 50 x 10[9]/l, ANC &amp;gt; 1.0 x 10[9]/l).&lt;/para&gt;&lt;para&gt;Acute myelogenous leukemia (AML) patients achieving complete remission (CR), and myelodysplastic syndrome (MDS) patients achieving CR, partial remission (PR) or hematological improvement would
      receive additional consolidation cycles of oral &lt;ulink linkType="Drug" linkID="47924"&gt;clofarabine&lt;/ulink&gt; daily on days 1 to 5 of
      each subsequent cycle, with clofarabine dose according to assigned dose level (0: 30 mg/m2,
      -1: 20 mg/m2, +1: 40 mg/m2).  Consolidation cycles would begin no sooner than 28 days after
      the first day of the previous clofarabine cycle.  Patients would be evaluated for response
      after each cycle, and would be continued on trial for up to six total cycles of therapy as long
      as a response or lack of progression would be maintained and no grades 3 to 4 non-hematological
      toxicities would have been observed in that patient.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received &lt;ulink linkType="Drug" linkID="23624"&gt;clofarabine&lt;/ulink&gt; (15 mg/m2, iv on days 1 and 5), and &lt;ulink linkType="Drug" linkID="47924"&gt;clofarabine&lt;/ulink&gt; (30 mg/m2, po on day 3) preceded by two doses of &lt;ulink linkType="Drug" linkID="44398"&gt;cimetidine&lt;/ulink&gt; (800 mg, po 8 to 10 h apart), and &lt;ulink linkType="Drug" linkID="47924"&gt;clofarabine&lt;/ulink&gt; (30 mg/m2, po on days 6 and 7). Patient (n = 1) received &lt;ulink linkType="Drug" linkID="23624"&gt;clofarabine&lt;/ulink&gt; (10 mg/m2, iv on days 1 and 5), &lt;ulink linkType="Drug" linkID="47924"&gt;clofarabine&lt;/ulink&gt; (20 mg/m2, po on day 3) preceded by two doses of &lt;ulink linkType="Drug" linkID="44398"&gt;cimetidine&lt;/ulink&gt; (800 mg, po 8 to 10 h apart), and &lt;ulink linkType="Drug" linkID="47924"&gt;clofarabine&lt;/ulink&gt; (20 mg/m2, po on days 6 and 7). Additionally, patients (n = 2) received second cycles of &lt;ulink linkType="Drug" linkID="47924"&gt;clofarabine&lt;/ulink&gt; (30 mg/m2/day, po) on days 1 to 5 [&lt;ulink linkType="Reference" linkID="1274945"&gt;1274945&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1296191"&gt;1296191&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;This trial was terminated as the drug supply was discontinued by collaborator.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>clofarabine + Clolar + cimetidine</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="136">Gout</Indication><CountPatientsAffectedPercentage>10.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1543">Atrial flutter</Indication><CountPatientsAffectedPercentage>10.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="181">Hypokalemia</Indication><CountPatientsAffectedPercentage>80.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1991">Neutropenia</Indication></AdverseEvent><AdverseEvent><Indication id="2733">Hypomagnesemia</Indication><CountPatientsAffectedPercentage>10.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2948">Tumor lysis syndrome</Indication></AdverseEvent><AdverseEvent><Indication id="324">Thrombocytopenia</Indication></AdverseEvent><AdverseEvent><Indication id="3677">Hemorrhagic stroke</Indication><CountPatientsAffectedPercentage>10.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3826">Bone marrow depression</Indication></AdverseEvent><AdverseEvent><Indication id="746">Infectious disease</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="219962">cimetidine</Intervention><Treatments><Treatment><Dose>800 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="219949">clofarabine (oral), Genzyme</Intervention><Treatments><Treatment><Dose>10 milligram/m2</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>15 milligram/m2</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="219961">clofarabine (oral), Genzyme</Intervention><Treatments><Treatment><Dose>20 milligram/m2</Dose><Route>Oral</Route></Treatment><Treatment><Dose>30 milligram/m2</Dose><Route>Oral</Route></Treatment><Treatment><Dose>40 milligram/m2</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>University of North Carolina at Chapel Hill</Name><Address1>Chapel Hill</Address1><Address2>North Carolina</Address2><Address3>27599</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Leukemia</Disease><PatientSegments><PatientSegment><PatientSegment id="3973">Subjects at risk of developing disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3975">Subjects with Acute Leukemia Unspecified Type</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3977">Subjects with Acute Myeloid Leukemia (AML)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3979">Subjects with Acute Lymphocytic Leukemia (ALL)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="4003">Subjects with Relapsed/Recurrent Leukemia</PatientSegment><SubSegments><SubSegment id="4004">Subjects with relapsed/recurrent leukemia after chemotherapy</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Myelodysplastic syndrome</Disease><PatientSegments><PatientSegment><PatientSegment id="8708">Subjects at Risk of Developing Myelodysplastic Syndrome</PatientSegment><SubSegments><SubSegment id="8727">Subjects with Intermediate Risk-2 Myelodysplastic Syndrome</SubSegment><SubSegment id="8728">Subjects with High Risk Myelodysplastic Syndrome</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Myeloproliferative disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="8754">Subjects with Chronic Myelogenous Leukemia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01169012</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Leukemia" id="7981"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8077"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8090">Assessment of dose limiting toxicity</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Myelodysplastic syndrome" id="11882"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Myelodysplastic syndrome" id="11929"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Myeloproliferative disorder" id="14254"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Leukemia" id="7906"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7916">Assessment of hematologic/bone marrow response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7981"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7988"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8015"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8071"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8075">Assessment of genetic polymorphisms</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8077"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8078"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myelodysplastic syndrome" id="11882"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myelodysplastic syndrome" id="11912"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myelodysplastic syndrome" id="11937"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Myelodysplastic syndrome" id="11938">Assessment of Efficacy</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Myeloproliferative disorder" id="14254"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myeloproliferative disorder" id="14280"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Leukemia" id="4961"><Criterion>Subjects at Risk of Developing Disease</Criterion></Inclusion><Inclusion disease="Leukemia" id="4973"><Criterion>Subjects with Acute Leukemia Unspecified Type</Criterion></Inclusion><Inclusion disease="Leukemia" id="4979"><Criterion>Subjects with BCR-ABL Negative/Philadelphia Negative Leukemia</Criterion></Inclusion><Inclusion disease="Leukemia" id="4981"><Criterion>Subjects with Acute Myeloid Leukemia (AML)</Criterion></Inclusion><Inclusion disease="Leukemia" id="4985"><Criterion>Subjects with Acute Lymphocytic Leukemia (ALL)</Criterion></Inclusion><Inclusion disease="Leukemia" id="5031"><Criterion>Subjects with Other Bone Marrow Disorders</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5032">Subjects with myelodysplastic syndromes</SubCriterion><SubCriterion disease="Leukemia" id="5033">Subjects co-morbid with myeloproliferative disorders</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5071"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5073">Subjects with normal/adequate liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5173"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5184">Subjects with relapsed/recurrent disease after chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7597"><Criterion>Subjects with Intermediate Risk-2 Myelodysplastic Syndrome</Criterion></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7605"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7608">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7631"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7632">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="7633">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="7635">Subjects with normal/acceptable cardiac function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myeloproliferative disorder" id="8741"><Criterion>Subjects with Chronic Myelogenous Leukemia</Criterion></Inclusion><Inclusion disease="Myeloproliferative disorder" id="8750"><Criterion>Subjects co-morbid with malignancy/tumor</Criterion></Inclusion><Inclusion disease="Leukemia" id="22405"><Criterion>Treatment Naive Subjects</Criterion></Inclusion><Inclusion disease="Myeloproliferative disorder" id="33320"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="8776">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="8778">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="33739"><Criterion>Subjects with risk of disease recurrence</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7598">Subjects with High Risk Myelodysplastic Syndrome</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myeloproliferative disorder" id="33998"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="8777">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34013"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5074">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="34033"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7634">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Leukemia" id="6527"><Criterion>Leukemia Subjects with Advanced Disease</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6530">Subjects with central nervous system involvement of leukemia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="6534"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Leukemia" id="6554"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Leukemia" id="8709"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6618">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Leukemia" id="6645">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9160"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9161"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9171"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="9175">Subjects with abnormal pulmonary functions</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="9176">Subjects with abnormal hematological status</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9180"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9188"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="9189">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="9193">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="9194">Subjects with history of surgical interventions/procedure</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="9195">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10302"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="10303">Subjects with central nervous system diseases/disorders</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="10310">Subjects with premalignant/malignant condition</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="10312">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10304"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10306"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10308"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10311"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10328"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10335"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="10336">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="10340">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="10341">Subjects with history of surgical interventions/procedure</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="10342">Subjects with history of/scheduled to receive an investigational drug</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="10945">Patient with history of immunotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myeloproliferative disorder" id="10344"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Myeloproliferative disorder" id="26056"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="10307">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myeloproliferative disorder" id="26326"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="10324">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Myeloproliferative disorder" id="10325">Subjects with abnormal/unacceptable renal function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="26354"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="9172">Subjects with abnormal/unacceptable liver function</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="9173">Subjects with abnormal/unacceptable renal function</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="9174">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="26833"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="9191">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="26844"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6639">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myeloproliferative disorder" id="27083"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Myeloproliferative disorder" id="10305">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-04-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2012-07-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>22.06 Months</EnrollmentPeriod><EnrollmentRate>0.59 Patients/Month</EnrollmentRate><DateFirstReceived>2010-07-22T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-06-15T12:05:40Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2016-08-31T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-08-23T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="91245"><TitleDisplay>A Phase II, Non-Controlled Study To Evaluate The Efficacy Of Umbilical Cord Mesenchymal Stem Cells Transplantation In The Treatment Of Brainstem Chronic Disease Patients</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">ChiCTR-TNC-11001486</Identifier></Identifiers><Indications><Indication id="1631">Brain stem infarction</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Mesenchymal stem cells transplantation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1060889" type="Company"><TargetEntity id="5035552949" type="organizationId">General Hospital of Armed Police Forces</TargetEntity></SourceEntity><SourceEntity id="1631" type="ciIndication"><TargetEntity id="10006147" type="MEDDRA"></TargetEntity><TargetEntity id="D020526" type="MeSH"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1060889">General Hospital of Chinese Armed Police Forces</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2011-09-01T00:00:00Z</DateStart><DateChangeLast>2012-09-13T04:58:19Z</DateChangeLast><DateAdded>2012-09-13T04:58:19Z</DateAdded><Contacts><Contact type="Public contact"><Email>riveran@163.com</Email><Name>Yihua An</Name><Phone>+86 10 57976848</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Brainstem chronic diseases: including the brainstem hemorrhage, brainstem infarct and brain stem injury and other causes leading to the formation of malacia of the brainstem&lt;/li&gt;&lt;li&gt;Clearly diagnosis on CT or MRI&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Acute cerebrovascular disease&lt;/li&gt;&lt;li&gt;Severe cardiovascular disease&lt;/li&gt;&lt;li&gt;Imunocompromised or using immunosuppressive agents&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Electricity physical check</Description></Measure><Measure><Description>FIM score</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate the efficacy of umbilical cord mesenchymal stem cells transplantation in the treatment of brainstem chronic disease patients [&lt;ulink linkType="Reference" linkID="1322795"&gt;1322795&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive mesenchymal stem cells transplantation [&lt;ulink linkType="Reference" linkID="1322795"&gt;1322795&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>General Hospital of Chinese People's Armed Police Forces</Name><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier type="Secondary Organisational">ChiCTR-TNC-11001486</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-09-13T04:58:19Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput>